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Summary 
A persistent goal of industrial biotechnology is to produce recombinant protein at reduced costs, while 
maintaining high product quality and yield. A high proportion of production costs are incurred due to 
downstream processing. One route to reduce these processing costs is to achieve secretion of proteins by 
the expression organism, an objective that has also been shown to increase product yield and quality. 
One route to achieve this is to re-engineer the bacterial flagella type III secretion system (FT3SS). This 
organelle provides motility to the cell through motor and filament structures -however in the context of 
biotechnology, the FT3SS provides a high capacity one step route for protein export from the cytoplasm 
to the extracellular space –exporting approximately 1000 protein subunits per minute- a rate which rivals 
other extracellular secretion systems in a range of biotechnologically relevant organisms. 
This project aimed to optimise an E. coli strain for directed secretion of proteins from the cytoplasm 
directly to the extracellular environment, through a modified FT3SS. The flagella secretion system served 
as a platform technology for the secretion of a range of proteins. Initially native protein secretion through 
the modified secretion apparatus was investigated, using a flagellin monomer variant. Once established, 
directed recombinant protein secretion of an antibody fragment (CH2) through the modified FT3SS 
secretion apparatus was achieved with the aid of a secretion construct, which harboured recombinant 
cargo protein and was also comprised of elements of the native flagellin to aid secretion (the 
untranslated regions and secretion signal) and tags for purification. The secretion construct is modular 
and therefore amenable to alteration of the cargo protein –and also modification of the secretion 
construct for improved secretion. Strain optimisation for improved secretion was also implemented. With 
the generation of a wealth of strain improvements and secretion construct variants, a high-throughput 
assay was required to quantify secretion output of combinations of these secretion tools. An enzyme 
based secretion assay was developed to screen the multitude of strains and secretion plasmids in an 
efficient and accurate manner. This resulted in identification of a secretion strain and construct which 
resulted in high capacity secretion. When utilised together a 25 fold increase in the secretion capacity 
was observed. Finally expression of a 45kDa human collagen I α chain was investigated as extrusion of 
collagen from the FT3SS was an attractive possibility, while secretion was not achieved, strain 
improvements resulted in an increase in intracellular concentration of this large therapeutically relevant 
protein. 
The yield of secreted protein was measured throughout and it is possible that with further improvements 
to strains and fermentation procedures that the FT3SS platform could be competitive in the field of 
industrial biotechnology 
2 
 
Acknowledgements 
Firstly I would like to extend my thanks to The University of Sheffield for providing me with the 
opportunity and funding to carry out this PhD.  
I would like to thank my supervisor Dr. Graham Stafford for his invaluable guidance and advice 
throughout my project.  He has also provided me with the support, motivation and confidence to 
develop into the scientist I am today -your love of science is truly inspiring! I would also like to thank 
my secondary supervisor Prof. Phillip Wright, for his support and ‘helicopter vision’ throughout the 
project. 
To Jason Heath and Brenka McCabe, the labs would be shambolic without you and I can’t thank you 
enough for the continuous effort you both go to, to make things run smoothly. On top of this, the 
wealth of knowledge you both have had been a great help. You both also made the labs a genuinely 
great place to work -I’ve really valued your company over the past few years. 
To my colleagues over the years -in the Stafford lab group, the Dental School and Chemical and 
Biological Engineering and the Synthetic Biology Network- on an academic level, thank you for your 
input and support, but I also greatly value the friendships I have made. A special mention goes to 
Andy Frey and Genevieve Melling –we’ve shared some excellent times and I’m certain I’ve gained 
some lifelong friends. 
Kate and Liz. You are the most incredible beings and also excellent scientists. We’ve shared some 
amazing times over the past few years.  You both bring out the best in me and it’s been a privilege to 
go through this PhD experience together. I couldn’t have done this without you, whether it’s been 
rallying me along or celebrating my achievements, you’ve both always been there.  
To Jack and Liz my eternal gratitude goes out to you for putting a roof over my head (and an airbed 
under my head!) for the past 9 months.  I am incredibly grateful for you generosity and excellent 
company - it was also an honour to be so welcome in your house.  
To my fellow Tamworth Tossers, your unique mix of love and support, with a good dose of mockery 
has made my PhD life a whole lot easier. Thank you! 
Finally to Mum and Dad and Jackson -the love and support you give me has given me the confidence 
to excel throughout my academic career. You’re all great inspirations to me and I’m glad I can do the 
Green family proud! All my love. 
3 
 
Table of contents 
Summary ................................................................................................................................................. 1 
Acknowledgements ................................................................................................................................. 2 
Table of contents .................................................................................................................................... 3 
List of Figures ........................................................................................................................................ 14 
List of Tables ......................................................................................................................................... 22 
1. Introduction ...................................................................................................................................... 23 
1.1. Synthetic Biology ................................................................................................................... 24 
1.1.1. Standardisation ............................................................................................................. 24 
1.1.2. Decoupling .................................................................................................................... 25 
1.1.3. Abstraction .................................................................................................................... 26 
1.1.4. The reality of synthetic biology ..................................................................................... 27 
1.1.5. Synthetic biology approaches: top down and bottom up ............................................ 29 
1.1.6. Progressive synthetic biology ....................................................................................... 29 
1.1.7. The salvation narrative of synthetic biology ................................................................. 30 
1.2. Industrial Biotechnology ....................................................................................................... 31 
1.2.1. Industrial biotechnology expression chassis (organisms) ............................................. 32 
1.3. E. coli as a chassis for synthetic biology and biotechnology ................................................. 33 
1.3.1. Enabling technologies ................................................................................................... 34 
1.3.2. Cellular location and its effect of the protein product ................................................. 37 
1.3.3. Post translational modifications ................................................................................... 38 
1.3.4. Immunogenicity ............................................................................................................ 39 
1.3.5. E. coli protein secretion systems................................................................................... 40 
1.3.5.1. Type I secretion system............................................................................................. 41 
1.3.5.2. Type II secretion system............................................................................................ 41 
1.3.5.3. Type III secretion system........................................................................................... 43 
4 
 
1.3.5.3.1. Injectisome .................................................................................................................... 43 
1.3.5.3.2. Flagella .......................................................................................................................... 44 
1.3.5.4. Type IV secretion system ................................................................................................. 45 
1.3.5.5. Type V secretion system ........................................................................................... 45 
1.3.5.6. Type VI secretion system .......................................................................................... 46 
1.3.6. Secretion of recombinant proteins ............................................................................... 46 
1.4. The bacterial flagellum.......................................................................................................... 50 
1.4.1. Structure and assembly ................................................................................................ 51 
1.4.2. Comparison to injectisome T3SS ................................................................................... 56 
1.4.3. Flagella gene hierarchy ................................................................................................. 57 
1.4.4 Previous FT3SS gene deletions that result in secretion of monomeric flagella subunits .... 60 
1.4.5. FT3SS recombinant protein secretion ................................................................................. 61 
1.4.6. Master regulator effects of FT3SS expression .................................................................... 63 
1.5. Collagen ................................................................................................................................. 66 
1.5.1. Basic structure............................................................................................................... 67 
1.5.2. Collagen biosynthesis .................................................................................................... 67 
1.5.3. Therapeutic uses of collagen ........................................................................................ 70 
1.5.4. Sources of therapeutic collagen .................................................................................... 71 
1.5.4.1. Animal Sources .......................................................................................................... 71 
1.5.4.2. Recombinant sources of human collagen ................................................................. 72 
1.5.5. Recombinant collagen production in E. coli ........................................................................ 76 
1.5.5.1. Posttranslational modifications ....................................................................................... 76 
1.5.5.2. Proline metabolism .......................................................................................................... 77 
Chapter 2. Materials and methods ....................................................................................................... 78 
2.1. Strains ........................................................................................................................................ 78 
2.2. Plasmids ..................................................................................................................................... 80 
2.3. Chemicals, reagents and buffers ................................................................................................ 85 
5 
 
2.4. Microbiological culture methods ............................................................................................... 86 
2.4.1. Bacterial culture .................................................................................................................. 86 
2.4.2. Transformation by heat shock ............................................................................................ 87 
2.4.3. Transformation by electroporation .................................................................................... 87 
2.4.4. Chromosomal mutagenesis by Lambda Red recombination. ............................................. 88 
2.4.5. Chromosomal mutagenesis by P1 phage transduction ...................................................... 89 
2.4.5.1. Lysate preparation ........................................................................................................... 89 
2.4.5.2. Transduction .................................................................................................................... 89 
2.4.6. Strain storage ...................................................................................................................... 90 
2.4.7. Plate reader growth curve .................................................................................................. 90 
2.4.8. Gram Staining ...................................................................................................................... 90 
2.5. Molecular biology methods ....................................................................................................... 91 
2.5.1. DNA methods ...................................................................................................................... 91 
2.5.1.1. Buffers and reagents ........................................................................................................ 91 
2.5.1.2. DNA agarose gel electrophoresis ..................................................................................... 91 
2.5.1.3. Bacterial plasmid DNA extraction .................................................................................... 92 
2.5.1.4. Bacterial chromosomal DNA extraction........................................................................... 92 
2.5.1.5. Quantification of DNA concentration .............................................................................. 92 
2.5.1.6. Polymerase chain reaction ............................................................................................... 92 
2.5.1.6.1. High-fidelity PCR ........................................................................................................... 93 
2.5.1.6.2. Overlap PCR .................................................................................................................. 94 
2.5.1.6.3. Colony PCR .................................................................................................................... 94 
2.5.1.7. Blunt end cloning ............................................................................................................. 96 
2.5.1.8. DNA ligation ..................................................................................................................... 96 
2.5.1.9. DNA sequencing ............................................................................................................... 98 
2.5.1.10. Gene synthesis ............................................................................................................... 98 
2.5.2. Protein methods ................................................................................................................. 99 
6 
 
2.5.2.1. Buffers and reagents ........................................................................................................ 99 
2.5.2.2. Bacterial protein precipitation ....................................................................................... 100 
2.5.2.3. SDS-PAGE ....................................................................................................................... 100 
2.5.2.4. Western blot .................................................................................................................. 101 
2.5.2.5. Cell lysis .......................................................................................................................... 102 
2.5.2.6. Concentration of protein ............................................................................................... 102 
2.5.2.7. Protein purification ........................................................................................................ 103 
2.5.2.8. Quantification of protein concentration ........................................................................ 103 
2.5.2.9. TEV cleavage .................................................................................................................. 103 
2.6. Assays to quantify type III secretion system capacity for protein secretion. .......................... 104 
2.6.1. Gene expression assay ...................................................................................................... 104 
2.6.2. Protein secretion assay ..................................................................................................... 105 
2.6.3. Flagellin standard to quantify secretion ........................................................................... 105 
2.6.4. Motility assay .................................................................................................................... 106 
2.6.5. Flagella expression assay .................................................................................................. 106 
2.6.6. MUB assay for cutinase activity ........................................................................................ 107 
Chapter 3. Strain improvements for increased secretion capacity of native substrates through the 
T3SS ..................................................................................................................................................... 108 
3.1. Secretion platform for secretion of native protein .................................................................. 109 
3.1.1. Construct for flagellin secretion ........................................................................................ 109 
3.1.2 Platform strain for flagellin secretion: HAP-less and CAP-less flagella .............................. 110 
3.1.2.1 PCR product generation for mutagenesis: MC1000 ΔfliCD ............................................. 112 
3.1.2.2. MC1000 ΔfliCD mutant generation via Lambda Red recombinase method .................. 113 
3.1.2.3. MC1000 ΔfliCD mutant conformation by PCR ............................................................... 114 
3.2. Development of a standardised protein secretion assay to quantify flagellin secretion ........ 116 
3.2.1. Isolating monomeric flagellin to quantify secretion capacity ........................................... 116 
3.2.2. Development of a secretion assay to quantify platform strain suitability ....................... 117 
7 
 
3.2.3. Growth phenotype of secretion platform strains ............................................................. 122 
3.2.4. Selection of secretion platform strain .............................................................................. 125 
3.3. Optimisation of a standardised protein secretion assay to quantify flagellin secretion ......... 125 
3.3.1. Refining induction of expression vector ........................................................................... 126 
3.4. Improved secretion: master regulator repressor mutants ...................................................... 128 
3.4.1. Rationale for mutant generation: lrhA, dksA, clpX ........................................................... 128 
3.4.1.1. lrhA ................................................................................................................................. 129 
3.4.1.2. dksA ................................................................................................................................ 129 
3.4.1.3. clpX ................................................................................................................................. 129 
3.4.2. Mutant generation: lrhA, dksA, clpX ................................................................................. 130 
3.4.2.1. Knockout mutagenesis via the Lambda Red recombinase method: lrhA and dksA ...... 130 
3.4.2.2. PCR conformation of knockout mutagenesis: lrhA and dksA ........................................ 131 
3.4.2.3. Knockout mutagenesis via phage transduction: clpX .................................................... 132 
3.4.3. Mutant characterisation: lrhA ........................................................................................... 133 
3.4.3.1. Effects of deletion of lrhA on FT3SS secretion ............................................................... 133 
3.4.3.2. Effect of deletion of lrhA on flagella gene expression ................................................... 137 
3.4.4. Presence of insertion sequence 5 in the flhDC promoter region ..................................... 140 
3.4.4.1. Testing for the presence of insertion sequence 5 in the flhDC promoter region .......... 141 
3.4.5. Mutant characterisation: dksA.......................................................................................... 144 
3.4.5.1. Effects of deletion of dksA on FT3SS secretion .............................................................. 145 
3.4.5.2. Effects of deletion of dksA on flagella gene expression ................................................ 148 
3.4.6. Mutant characterisation: clpX........................................................................................... 149 
3.4.6.1. Effects of deletion of clpX on the abundance of filament protein ................................ 150 
3.4.6.2. Effects of deletion of clpX on motility ............................................................................ 152 
3.4.6.3. Effects of deletion of clpX on FT3SS secretion ............................................................... 154 
3.4.6.4. Effects of deletion of clpX on growth phenotype .......................................................... 161 
3.4.6.5. Effects of deletion of clpX on cell morphology .............................................................. 162 
8 
 
3.5. Negative control of FT3SS secretion ........................................................................................ 164 
3.5.1. Rationale for mutagenesis: negative control of protein secretion through the FT3SS .... 165 
3.5.1.1. flhDC ............................................................................................................................... 165 
3.5.1.2. flgDE ............................................................................................................................... 165 
3.5.2. Mutant generation: flhDC and flgDE ................................................................................. 166 
3.5.2.1. Knockout mutagenesis via phage transduction: flhDC .................................................. 166 
3.5.2.2. Knockout mutagenesis via the Lambda Red recombinase method: flgDE .................... 166 
3.5.2.3. PCR conformation of knockout mutagenesis: flgDE, ..................................................... 167 
3.5.3. Mutant characterisation: Further optimisation of the secretion assay ............................ 168 
3.5.4. Negative control mutant characterisation: Effects of deletion of flhDC and flgDE on FT3SS 
secretion ..................................................................................................................................... 169 
3.6. Improved FT3SS secretion: reduced metabolic burden and negative feedback ..................... 175 
3.6.1. Rationale for mutants: reduced metabolic burden and feedback mutants ..................... 175 
3.6.1.1. motAB ............................................................................................................................ 175 
3.6.1.2. flgMN ............................................................................................................................. 176 
3.6.1.3. fliDST .............................................................................................................................. 177 
3.6.2. Mutant generation: fliDST, motAB, flgMN ........................................................................ 178 
3.6.2.1. Knockout mutagenesis via the Lambda Red recombinase method: fliDST, motAB, flgMN
 .................................................................................................................................................... 178 
3.6.2.2. PCR conformation of knockout mutagenesis: fliDST, motAB, flgMN ............................ 180 
3.6.3. Reduced metabolic burden and feedback mutants: Effects of deletion of motAB, flgMN 
and fliDST on FT3SS secretion ..................................................................................................... 181 
3.7. Discussion: a prototype secretion platform for secretion of native protein ........................... 187 
3.7.1. Protein secretion assay development ............................................................................... 187 
3.7.2. A modified FT3SS platform secretion strain ..................................................................... 188 
3.7.3. Negative control of FT3SS secretion ................................................................................. 189 
3.7.4. Strain improvements: reduced negative regulation of the master regulator .................. 190 
9 
 
3.7.4.1. Effects of deletion of lrhA on FT3SS secretion ............................................................... 190 
3.7.4.2. Effects of deletion of dksA on FT3SS secretion .............................................................. 191 
3.7.4.3. Effects of deletion of clpX on FT3SS secretion ............................................................... 192 
3.7.4.4. Promoter replacement or promoter region modification for increased transcription of 
the master regulator ................................................................................................................... 194 
3.7.5. Strain improvements: reduced metabolic burden and negative feedback ...................... 195 
3.7.5.1. Effects of deletion of motAB on FT3SS secretion .......................................................... 195 
3.7.5.2. Effects of deletion of flgMN on FT3SS secretion ........................................................... 196 
3.7.5.3. Effects of deletion of fliDST on FT3SS secretion ............................................................ 196 
3.7.6. Limitations of the E2 protein secretion assay ................................................................... 198 
3.7.6.1. Variation in results ......................................................................................................... 198 
3.7.6.2. E2 as a substrate ............................................................................................................ 200 
3.7.7. Outcomes of strain improvements to the FT3SS platform secretion strain ..................... 201 
Chapter 4. Further development and testing of the engineered FT3SS system: non-native protein 
secretion and assay development ...................................................................................................... 203 
4.1. Design of a synthetic modular secretion construct for FT3SS secretion ................................. 203 
4.2. Antibody fragment within the synthetic modular secretion construct ................................... 206 
4.3. Investigation of the performance of the synthetic modular secretion construct ................... 206 
4.3.1. Protein purification of the CH2 harbouring secretion construct ...................................... 206 
4.3.2. Antibody detection of CH2 protein in the secretion construct ........................................ 209 
4.3.3. CH2 protein isolation from the secretion construct ......................................................... 210 
4.3.4. CH2 protein structural properties ..................................................................................... 213 
4.4. Investigation of secretion of the synthetic modular secretion construct through the FT3SS. 215 
4.4.1. Secretion of the CH2 harbouring synthetic modular secretion construct through the 
modified FT3SS ............................................................................................................................ 215 
4.4.2. Optimisation of a standardised protein secretion assay to quantify secretion of CH2 
through the modified FT3SS: induction ...................................................................................... 216 
4.4.3. Isolating monomeric CH2 to quantify secretion capacity ................................................. 219 
10 
 
4.5. Improved secretion of recombinant protein through the FT3SS ............................................. 220 
4.5.1. Establishing that secretion in engineered strains is truly FT3SS dependent .................... 220 
4.5.2. Secretion construct modification for negative control of FT3SS secretion ...................... 226 
4.5.2.1. Production of the modified secretion construct ............................................................ 227 
4.5.2.2. Testing the modified secretion construct ...................................................................... 231 
4.5.3. Reduced metabolic burden and negative regulation mutants: Effects of deletion of 
motAB, flgMN, fliDST and clpX on FT3SS secretion of CH2......................................................... 233 
4.5.4. Reduced metabolic burden: Effects of deletion of motAB, flgMN, fliDST and clpX on 
growth phenotype ...................................................................................................................... 238 
4.6. Discussion: Secretion of a non-native antibody fragment through the FT3SS ........................ 243 
4.6.1. Performance of the synthetic modular secretion construct ............................................. 243 
4.6.2. Secretion of CH2 through the modified FT3SS ................................................................. 245 
4.6.3. Secretion of CH2 through the modified FT3SS: strain mediated negative control ........... 245 
4.6.4. Effects of reduced metabolic burden and negative regulation mutants on FT3SS secretion 
of CH2 .......................................................................................................................................... 247 
Chapter 5: Development of a high-throughput assay for FT3SS secretion to screen a multitude of 
secretion strains and plasmids ............................................................................................................ 253 
5.1. An enzyme based FT3SS secretion assay ................................................................................. 253 
5.2. Choice of enzyme for production within the synthetic modular secretion construct ............. 254 
5.2.1. Cloning cutinase into the synthetic modular secretion construct .................................... 255 
5.2.1.1. Design of synthetic cutinase gene ................................................................................. 255 
5.2.1.2. Production of the cutinase harbouring secretion construct .......................................... 256 
5.2.2. Secretion of the cutinase harbouring synthetic modular secretion construct through the 
modified FT3SS ............................................................................................................................ 258 
5.3. Development of a standardised protein secretion assay to quantify cutinase secretion ....... 259 
5.3.1. Trail development of a tributyrin and pNPB protein secretion assay .............................. 259 
5.3.2. Development of a MUB based cutinase protein secretion assay ..................................... 260 
5.3.3. Preliminary MUB assay: active secreted cutinase ............................................................ 261 
11 
 
5.3.4. Development of the MUB assay: early considerations ..................................................... 262 
5.3.5. Development of the MUB assay: buffer pH ...................................................................... 262 
5.3.6. Development of the MUB assay: substrate concentration .............................................. 263 
5.3.7. Development of the MUB assay: time and sensitivity to a range of concentrations of 
cutinase ....................................................................................................................................... 265 
5.3.8. Development of the MUB assay: excitation in the UV region of the spectrum ............... 269 
5.4. Combination of strain improvement strategies for increased FT3SS capacity ........................ 274 
5.4.1. Mutant generation: multiple gene knockout strain improvements ................................. 275 
5.4.1.1. Knockout mutagenesis via the Lambda Red recombinase method............................... 275 
5.4.1.2. Knockout mutagenesis via the P1 phage transduction method: ................................... 277 
5.4.2. Combined strategies for improved FT3SS secretion: Effects of multiple gene deletions on 
growth phenotype ...................................................................................................................... 281 
5.4.3. Combining strategies for improved FT3SS secretion: Effects of multiple gene deletions on 
FT3SS secretion of cutinase ........................................................................................................ 285 
5.4.4. Candidate high capacity secretion strains: E2 and CH2 secretion .................................... 297 
5.4.4.1. Secretion of E2 through the modified FT3SS of the best candidate secretion strains .. 297 
5.4.4.2. Secretion of CH2 through the modified FT3SS of the best candidate secretion strains 300 
5.5. Modification of the synthetic modular secretion construct for increased secretion through the 
FT3SS ............................................................................................................................................... 303 
5.5.1. Production of variants of the modified secretion construct ............................................. 304 
5.5.2. Production of variants of the modified secretion construct ............................................. 309 
5.6. Investigation of secretion through the FT3SS following both strain and secretion construct 
improvements ................................................................................................................................. 314 
5.7. Discussion: Development of a high-throughput assay for FT3SS secretion to screen a 
multitude of secretion strains and plasmids................................................................................... 321 
5.7.1. Secretion of active cutinase through the modified FT3SS ................................................ 321 
5.7.2. Combination of strain improvement strategies for increased FT3SS capacity ................. 324 
12 
 
5.7.3. Modification of the synthetic modular secretion construct for increased FT3SS secretion
 .................................................................................................................................................... 328 
5.7.4. Combination of strain and secretion construct based strategies for improved FT3SS 
secretion ..................................................................................................................................... 330 
5.7.5. Future utilisation of the MUB secretion assay .................................................................. 331 
Chapter 6: 45kDa human collagen expression for FT3SS secretion.................................................... 335 
6.1. Production of collagen within the synthetic modular secretion construct ............................. 336 
6.1.1. A synthetic collagen gene in the synthetic modular secretion construct ......................... 336 
6.1.2. Expression of the COL1A1 harbouring synthetic modular secretion construct: 
hyperosmotic shock .................................................................................................................... 337 
6.2. Strain improvements for increased intracellular proline ......................................................... 341 
6.2.1. Removal of feedback inhibition of proline accumulation: ProB ....................................... 342 
6.2.2. Removal of proline catabolism: PutA ................................................................................ 343 
6.2.3. Removal of proline catabolism for other metabolic processes: GdhA ............................. 343 
6.2.4. Mutagenesis for increased intracellular proline: proB, putA, gdhA ................................. 344 
6.2.4.1. Knockout mutagenesis via the Lambda Red recombinase method: proB, putA, gdhA . 344 
6.2.4.2. PCR conformation of knockout mutagenesis: proB, putA, gdhA ................................... 346 
6.2.4.3. Knockout mutagenesis via the P1 phage transduction method .................................... 347 
6.2.4.4. Site directed mutagenesis .............................................................................................. 348 
6.3. Collagen expression in strains with proline metabolism based improvements for increased 
intracellular proline ......................................................................................................................... 354 
6.4. Secretion of a bacterial collagen like protein in the FT3SS secretion strain ............................ 357 
6.5. Discussion: Collagen expression for FT3SS .............................................................................. 360 
6.5.1. Expression of human COL1A1 in the FT3SS secretion strain ............................................ 360 
6.5.2. Proline metabolism strain improvements ........................................................................ 361 
6.5.3. Secretion of a collagen-like protein through the FT3SS.................................................... 363 
6.5.4. Further improvements for collagen secretion through the FT3SS ................................... 363 
Chapter Seven: Discussion and future prospects ............................................................................... 366 
13 
 
7.1. Summary of major findings ...................................................................................................... 366 
7.1.1. Chapter Three: Strain improvements for increased secretion capacity of native substrates 
through the T3SS ......................................................................................................................... 367 
7.1.2. Chapter Four: Further development and testing of the engineered FT3SS system: non-
native protein secretion and assay development ....................................................................... 369 
7.1.3: Chapter Five: Development of a high-throughput assay for FT3SS secretion to screen a 
multitude of secretion strains and plasmids ............................................................................... 370 
7.1.4. Chapter Six: 45kDa human collagen expression for FT3SS secretion ............................... 371 
7.2. Improved secretion capacity of the FT3SS ............................................................................... 372 
7.3. The modified FT3SS as a tool ................................................................................................... 375 
7.4. The role of the modified FT3SS in industrial biotechnology .................................................... 375 
7.5. Conclusion ................................................................................................................................ 379 
References .......................................................................................................................................... 380 
Appendix ............................................................................................................................................. 415 
 
 
 
 
 
 
 
 
 
14 
 
List of Figures 
Figure 1.1: The abstraction hierarchy exemplified by a formula one car and E. coli as chassis. .......... 26 
Figure 1.2: Schematic of a section of a metabolic reconstruction. ...................................................... 28 
Figure 1.3: Secretion systems of E. coli and the proteins involved. ..................................................... 40 
Figure 1.4: The distribution of proteins in the flagella type II secretion system. ................................. 51 
Figure 1.5: The switch from class II to class III flagella gene expression. ............................................. 53 
Figure 1.6: Flagella genes organised into operons within flagella regulatory classes. ......................... 59 
Figure 1.7: Collagen (fibril) biosynthesis in eukaryotic cells. ................................................................ 69 
Figure 3.1: Schematic of the native E. coli fliC gene and the E2 variant…………………………………….……114 
Figure 3.2. The structural differences in wild type flagella type III secretion system and the CAPless 
and HAPless (secretor strain) mutants. .............................................................................................. 110 
Figure 3.3: Lambda Red recombinase knock out mutagenesis. ......................................................... 112 
Figure 3.4: DNA gel of fliCD gene knockout construct PCR product. .................................................. 113 
Figure 3.5: PCR verification of gene knockouts. ................................................................................. 115 
Figure 3.6: DNA gel to confirm successful gene knockout mutagenesis of the fliCD genes in MC1000 
through homologous recombination. ................................................................................................. 115 
Figure 3.7: SDS-PAGE protein gel of isolated momomeric E2 ............................................................ 117 
Figure 3.8: Intracellular and secreted fractions of MC1000 ∆fliC ∆flgKL and ∆fliCD. ......................... 119 
Figure 3.9: Worked example of densitometry analysis of secreted E2 from a Coomassie stained SDS-
PAGE (Figure 3.8B). ............................................................................................................................. 120 
Figure 3.10: Results following densitometry analysis of the supernatant samples of the Coomassie 
stained SDS-PAGE seen in Figure 3.9. ................................................................................................. 121 
Figure 3.11: Results following densitometry analysis of the intracellular samples of Western blot 
seen in Figure 3.9. ............................................................................................................................... 122 
Figure 3.12: Growth of candidate platform strains for flagella mediated protein secretion over time 
in a 96 well plate. Calibrated to LB media. ......................................................................................... 123 
Figure 3.13: Growth of candidate platform strains for flagella mediated protein secretion over time 
in a 96 well plate. Calibrated to LB media and OD600 adjusted for path length. ................................. 124 
Figure 3.14: Intracellular and secreted fractions of MC1000 ∆fliC ∆flgKL supplemented with different 
concentrations of IPTG........................................................................................................................ 126 
Figure 3.15: Agarose DNA gels showing PCR products to initiate gene knock out mutagenesis for (A) 
dksA and (B) lrhA ................................................................................................................................. 130 
15 
 
Figure 3.16: Agarose DNA gels showing PCR products to confirm gene knock out mutagenesis for (A) 
dksA and (B) lrhA ................................................................................................................................. 131 
Figure 3.17: Secretion of E2 from the secretor strain and ΔlrhA mutant during the growth curve. .. 133 
Figure 3.18: Secretion of E2 from the secretor strain and ΔlrhA mutant during the growth curve ... 135 
Figure 3.19: Secretion of E2 from the secretor strain and ΔlrhA mutant during the growth curve per 
hour ..................................................................................................................................................... 136 
Figure 3.20: Schematic of the gene expression assay. ....................................................................... 138 
Figure 3.21: Flagella gene expression throughout the growth curve. ................................................ 139 
Figure 3.22: Schematic of the genetic region upstream of the flhD operon with and without the IS5 
element. .............................................................................................................................................. 141 
Figure 3.23: Annotated nucleotide sequence of the genetic region upstream of the flhD operon with 
and without the IS5 element. ............................................................................................................. 143 
Figure 3.24: Secretion of E2 from the secretor strain and ΔdksA mutant during the growth curve. . 145 
Figure 3.25: Secretion of E2 from the secretor strain and ΔdksA mutant during the growth curve .. 146 
Figure 3.26: Secretion of E2 from the secretor strain and ΔdksA mutant during the growth curve per 
hour ..................................................................................................................................................... 147 
Figure 3.27: Flagella gene expression throughout the growth curve. ................................................ 148 
Figure 3.28: Concentration of sheared flagella filaments from WT MC1000 and MC1000 ΔclpX...... 150 
Figure 3.29: Relative concentration of sheared flagella filaments from WT MC1000 and MC1000 
ΔclpX. .................................................................................................................................................. 151 
Figure 3.30: The effect of clpX on the swimming motility of MC1000 and MC1000 ∆flgKL ∆fliC strains.
 ............................................................................................................................................................ 152 
Figure 3.31: The effect of clpX on swimming rate of MC1000 and MC1000 ∆flgKL ∆fliC strains. ...... 153 
Figure 3.32: Intracellular and secreted E2 from the secretor strain and ΔclpX mutant during the 
growth curve. ...................................................................................................................................... 154 
Figure 3.33: Intracellular and secreted E2 from the secretor strain and ΔclpX mutant during the 
growth curve ....................................................................................................................................... 156 
Figure 3.34: Secretion of E2 from the secretor strain and ΔclpX mutant during the growth curve per 
hour ..................................................................................................................................................... 157 
Figure 3.35: The proportion of E2 secreted from the secretor strain and ΔclpX mutant during the 
growth curve ....................................................................................................................................... 158 
Figure 3.36: Abundance of GroEL in the supernatant of ΔCKL and the ΔclpX mutant through the 
growth curve ....................................................................................................................................... 159 
16 
 
Figure 3.37: Growth of the secretor strain and the ∆clpX mutant with pTrc or pTrc E2 plasmid in LB 
media over time in a 96 well plate. Calibrated to LB media. .............................................................. 162 
Figure 3.38: Microscope images of Gram stained ∆CKL and ∆CKL ∆clpX cells. .................................. 163 
Figure 3.39: Length of Gram stained ∆CKL and ∆CKL ∆clpX cells and histogram following bin sorting 
for length............................................................................................................................................. 164 
Figure 3.40: DNA gel of gene knockout construct PCR products. ....................................................... 167 
Figure 3.41: Agarose DNA gel of PCR product to confirm successful knockout mutagenesis of flgDE.
 ............................................................................................................................................................ 168 
Figure 3.42: Intracellular and secreted E2 from the secretor strain, ΔflhDC, ΔflgDE and ΔclpX 
mutants. .............................................................................................................................................. 171 
Figure 3.43: Intracellular and secreted E2 from the secretor strain, ΔflhDC, ΔflgDE and ΔclpX 
mutants. .............................................................................................................................................. 172 
Figure 3.44: Abundance of GroEL in the intracellular and supernatant fractions of ΔCKL and the 
ΔflhDC, ΔflgDE and ΔclpX mutants, following expression and secretion of E2 protein through the 
FT3SS. .................................................................................................................................................. 173 
Figure 3.45: Densitometry analysis of the abundance of GroEL in the intracellular and supernatant 
fractions of ΔCKL and the ΔflhDC, ΔflgDE and ΔclpX mutants, following expression and secretion of 
E2 protein through the FT3SS. ............................................................................................................ 174 
Figure 3.46: Schematic of the gene regulatory network of the FlgMN proteins ................................ 177 
Figure 3.47: Schematic of the gene regulatory network of fliDST ...................................................... 178 
Figure 3.48: DNA gels of gene knockout construct PCR products. ..................................................... 179 
Figure 3.49: Agarose DNA gels of PCR products to confirm successful knockout mutagenesis. ........ 181 
Figure 3.50: Intracellular and secreted E2 from the ∆CKL strain, ΔmotAB, ΔflgMN and ΔclpX mutants.
 ............................................................................................................................................................ 183 
Figure 3.51: Intracellular and secreted E2 from the secretor strain, ΔfliDST and ΔmotAB mutants. . 184 
Figure 3.52: Intracellular and secreted E2 from the secretor strain, ΔfliDST and ΔmotAB mutants. . 185 
Figure 3.53: The proportion of secreted E2 as a percentage of total E2 expressed and secreted  by 
the secretor strain, ΔfliDST and ΔmotAB mutants, following expression and secretion of E2 protein 
through the FT3SS. .............................................................................................................................. 186 
Figure 3.54: Combined results from E2 secretion assays in this chapter. .......................................... 200 
Figure 4.1: Schematic of (A) the prototype synthetic modular secretion construct inserted into an 
IPTG inducible plasmid and (B) the resulting peptide. ....................................................................... 204 
17 
 
Figure 4.2: Protein fractions following overexpression and purification of Strep tagged CH2 protein.
 ............................................................................................................................................................ 207 
Figure 4.3: CH2 containing protein fractions following purification and dialysis. .............................. 209 
Figure 4.4: Detection of the FLAG-tag in CH2 containing protein fractions following purification and 
dialysis. ................................................................................................................................................ 210 
Figure 4.5: Protein fractions following overexpression and purification and TEV cleavage of CH2. .. 212 
Figure 4.6: CH2 protein following overexpression and purification prepared for SDS-PAGE followed 
by Coomassie stain or Western blotting in both the presence and absence of DTT. ......................... 214 
Figure 4.7: CH2 protein in the secreted and intracellular fractions of ∆CKL secretor strain cell culture.
 ............................................................................................................................................................ 216 
Figure 4.8: Intracellular and secreted fractions of MC1000 ∆fliC ∆flgKL supplemented with different 
concentrations of IPTG........................................................................................................................ 217 
Figure 4.9: Expression and secretion capacities of MC1000 ∆fliC ∆flgKL supplemented with different 
concentrations of IPTG........................................................................................................................ 218 
Figure 4.10: Intracellular and secreted CH2 from the ∆CKL, ΔflhDC and ∆CKL ΔflgMN and ∆CKL ΔflgDE 
mutants. .............................................................................................................................................. 221 
Figure 4.11: Abundance of GroEL in the intracellular and supernatant fractions of the secretor strain, 
ΔflhDC, ΔflgMN and ΔflgDE mutants, following expression and secretion of CH2 protein through the 
FT3SS. .................................................................................................................................................. 222 
Figure 4.12: Intracellular and secreted CH2 from the secretor strain and the ΔflhDC and ΔflgDE 
mutants when supplemented with increasing concentrations of IPTG ............................................. 224 
Figure 4.13: Quantitative measurement of intracellular CH2 from the secretor strain, ΔflhDC and 
ΔflgDE mutants following the addition of various concentrations of IPTG. ....................................... 225 
Figure 4.14: GroEL in the supernatant fraction of the CH2 expressing secretor strain and the ΔflhDC 
and ΔflgDE mutants with the addition of IPTG. .................................................................................. 226 
Figure 4.15: Schematic of the existing prototype secretion construct harbouring CH2 and the 
alternative secretion constructs (SCA and SCB) following the removal of the 5’ UTR or 47 amino acid 
secretion peptide. ............................................................................................................................... 228 
Figure 4.16: Agarose DNA gels showing SCA and SCB PCR products for ligation into NdeI and BamHI 
cut pJexpress-FliC-empty-FLAG-Strep ................................................................................................. 229 
Figure 4.17: Agarose DNA gel showing uncut and NdeI and BamHI cut pJexpress-FliC-empty-FLAG-
Strep .................................................................................................................................................... 230 
18 
 
Figure 4.18: Intracellular and secreted CH2 from the secretor strain and ∆CKL ΔflgDE mutant with 
variable FliC 5’ UTR and FliC secretion signal peptide sequences ...................................................... 232 
Figure 4.19: Intracellular and secreted CH2 from the secretor strain and ΔmotAB, ΔflgMN, ΔfliDST 
and ΔclpX and mutants. ...................................................................................................................... 234 
Figure 4.20: Western blot densitometry analysis of intracellular and secreted protein fractions of 
CH2 expressing secretor strain and ΔmotAB, ΔflgMN, ΔfliDST and ΔclpX and mutants. ................... 236 
Figure 4.21: CH2 yield in the intracellular and secreted protein fractions of the secretor strain and 
ΔmotAB, ΔflgMN, ΔfliDST and ΔclpX mutants. ................................................................................... 237 
Figure 4.22: Growth of the ΔCKL strain and (ΔCKL) ΔmotAB, ΔflgMN, ΔfliDST and ΔclpX mutant strains 
expressing empty or CH2 harbouring secretion construct over time in a 96 well plate. Calibrated to 
LB media. ............................................................................................................................................. 239 
Figure 4.23: Growth of ΔCKL and ΔmotAB, ΔflgMN, ΔfliDST and ΔclpX mutant strains expressing 
empty or CH2 harbouring secretion construct over time in a 96 well plate. Calibrated to LB media.
 ............................................................................................................................................................ 242 
Figure 5.1: Agarose DNA gel showing a PCR product following colony PCR of cells to confirm blunt 
end cloning of the synthesised cutinase gene into the storage vector. ............................................. 256 
Figure 5.2: Genetic and protein schematic of the secretion construct harbouring cutinase ............. 256 
Figure 5.3: Agarose DNA gel showing plasmid from colonies DNA digested with EcoRI and PstI. ..... 257 
Figure 5.4: Cutinase protein in the secreted and intracellular fractions of ∆CKL secretor strain cell 
culture. ................................................................................................................................................ 259 
Figure 5.5: Fluorescence emission of reaction mixtures containing MUB and either LB media or cell 
culture supernatant. ........................................................................................................................... 261 
Figure 5.6: Emission spectra for pH 5 buffered 50µM and 100µM MUB with LB media or cell culture 
supernatant from cells expressing cutinase or empty FT3SS signal peptide tagged secretion 
constructs. ........................................................................................................................................... 265 
Figure 5.7: Fluorescence output (AU) of reaction mixtures over time. .............................................. 266 
Figure 5.8: Fluorescence output (AU) of reaction mixtures following incubation of MUB with the 
secreted fraction of ΔCKL, ΔflhDC, ΔCKL ΔflgDE, ΔCKL ΔflgMN or ΔCKL ΔclpX cells secreting empty or 
cutinase harbouring secretion construct. Excitation 365nm, Emission 446nm. ................................ 268 
Figure 5.9: Emission spectra for different concentration solutions of pH 5 buffered MUB with LB 
media or cell culture supernatant from cells expressing cutinase or empty FT3SS signal peptide 
tagged secretion constructs- excitation at 302nm. ............................................................................ 270 
19 
 
Figure 5.10: Intracellular and secreted cutinase from the secretor strain and ΔflhDC, ΔflgDE, ΔflgMN 
and ΔclpX and mutants. ...................................................................................................................... 271 
Figure 5.11: Fluorescence output (AU) of reaction mixtures following incubation of MUB with the 
secreted fraction of ΔCKL, ΔflhDC, ΔCKL ΔflgDE, ΔCKL ΔflgMN or ΔCKL ΔclpX cells secreting empty or 
cutinase harbouring secretion construct. Excitation 302nm, Emission 446nm. ................................ 273 
Figure 5.12: Agarose DNA gels of PCR products to confirm successful knockout mutagenesis. ........ 277 
Figure 5.13: Growth of ∆CKL and (∆CKL) ∆MN ∆DST, ∆M ∆MN, ∆M ∆DST, ∆X ∆M, ∆X ∆MN, ∆X ∆DST, 
∆X ∆M ∆MN and ∆X ∆M ∆DST mutant strains expressing either empty or cutinase harbouring 
secretion construct over time in a 96 well plate. Calibrated to LB media. ......................................... 282 
Figure 5.14: Growth of ∆CKL and (∆CKL) ∆MN ∆DST, ∆M ∆MN, ∆M ∆DST, ∆X ∆M, ∆X ∆MN, ∆X ∆DST, 
∆X ∆M ∆MN and ∆X ∆M ∆DST mutant strains expressing either empty (no fill) or cutinase (black) 
harbouring secretion construct over time in a 96 well plate. Calibrated to LB media. ...................... 285 
Figure 5.15: Intracellular cutinase from ∆CKL and all additional mutant strains. .............................. 287 
Figure 5.16: Western blot densitometry analysis of intracellular protein fractions of cutinase 
expressing ΔCKL, ΔflhDC and ΔCKL strains with additional mutations ............................................... 289 
Figure 5.17: Fluorescence output (AU) of reaction mixtures following incubation of MUB with the 
secreted fraction of ∆CKL and all ∆CKL background mutant strains secreting empty (-) or cutinase (+) 
harbouring secretion construct. ......................................................................................................... 292 
Figure 5.18: Intracellular and secreted cutinase from ∆CKL and the ΔclpX ΔmotAB and ΔmotAB 
ΔfliDST mutants................................................................................................................................... 294 
Figure 5.19: Abundance of GroEL in the intracellular and supernatant fractions of ∆CKL and the ΔclpX 
ΔmotAB and ΔmotAB ΔfliDST mutants, following expression and secretion of cutinase protein 
through the FT3SS. .............................................................................................................................. 295 
Figure 5.20: Relative fluorescence output (AU) of reaction mixtures following incubation of MUB 
with the secreted fraction of ∆CKL, ∆flhDC, ΔclpX ΔmotAB or ΔCKL ΔmotAB ΔfliDST secreting empty  
(-) or cutinase (+) harbouring secretion construct. ............................................................................. 296 
Figure 5.21: Intracellular and secreted E2 from ΔCKL, ΔclpX ΔmotAB and ΔmotAB ΔfliDST. ............. 298 
Figure 5.22: Western blot densitometry analysis of intracellular and secreted protein fractions of E2 
expressing ΔCKL, ΔclpX ΔmotAB and ΔmotAB ΔfliDST. ....................................................................... 299 
Figure 5.23: Intracellular and secreted CH2 from ΔCKL, ΔclpX ΔmotAB and ΔmotAB ΔfliDST ........... 301 
Figure 5.24: Western blot densitometry analysis of intracellular and secreted protein fractions of 
CH2 expressing ΔCKL, ΔclpX ΔmotAB and ΔmotAB ΔfliDST. ............................................................... 302 
20 
 
Figure 5.25: Schematic of the existing secretion construct harbouring cutinase and the primers used 
to generate alternative secretion constructs following the removal or modification of the 5’ or 3’ UTR 
regions or the 47 amino acid secretion peptide. ................................................................................ 306 
Figure 5.26: Agarose DNA gels showing PCR products for ligation into NdeI and BamHI digested 
pJexpress-FliC-empty-FLAG-Strep ....................................................................................................... 307 
Figure 5.27: Agarose DNA gel showing uncut and NdeI and BamHI cut pJexpress-FliC-empty-FLAG-
Strep .................................................................................................................................................... 308 
Figure 5.28: Intracellular cutinase in original prototype cutinase-secretion construct expressing 
ΔflhDC and ΔCKL ΔclpX and ΔCKL expressing the prototype secretion construct and nine candidate 
secretion constructs ............................................................................................................................ 310 
Figure 5.29: Western blot densitometry analysis of intracellular protein fractions of prototype 
cutinase-secretion construct expressing ΔflhDC and ΔCKL ΔclpX and ΔCKL expressing the prototype 
secretion construct and nine candidate variant secretion constructs. .............................................. 311 
Figure 5.30: Relative fluorescence output (AU) of reaction mixtures following incubation of MUB 
with the secreted fraction of prototype secretion construct expressing ∆flhDC and ΔCKL ΔclpX  and 
∆CKL expressing the prototype secretion construct and nine candidate variant secretion constructs.
 ............................................................................................................................................................ 313 
Figure 5.31: Intracellular and secreted cutinase from ∆CKL and the ΔclpX ΔmotAB and ΔmotAB 
ΔfliDST mutants expressing either cutinase harboured in either the prototype (P) secretion construct 
or SC1 (1). ............................................................................................................................................ 316 
Figure 5.32: Western blot densitometry analysis of intracellular and secreted protein fractions of 
∆CKL and the ΔclpX ΔmotAB and ΔmotAB ΔfliDST mutants expressing cutinase harboured in either 
the prototype secretion construct or SC1. ......................................................................................... 317 
Figure 5.33: Abundance of GroEL in the intracellular and supernatant fractions of ∆CKL and the ΔclpX 
ΔmotAB and ΔmotAB ΔfliDST mutants, following expression and secretion of cutinase protein either 
in the prototype secretion construct or SC1 through the FT3SS. ....................................................... 318 
Figure 5.34: Relative fluorescence output (AU) of reaction mixtures following incubation of MUB 
with the secreted fraction of ∆CKL and the ΔclpX ΔmotAB and ΔmotAB ΔfliDST mutants, following 
expression and secretion of either the empty secretion construct or cutinase protein either in the 
prototype secretion construct or SC1. ................................................................................................ 320 
Figure 6.1: Genetic and protein schematic of the secretion construct harbouring COL1A1 .............. 337 
Figure 6.2: Intracellular and secreted fractions of ∆CKL expressing either empty (-) or COL1A1 (C) 
harbouring secretion construct following osmotic shock................................................................... 339 
21 
 
Figure 6.3: Results following densitometry analysis of the intracellular samples of anti-FLAG-HRP 
probed Western blots of the intracellular fractions of COL1A1 expressing cells following cell culture 
with or without osmotic shock. .......................................................................................................... 340 
Figure 6.4: The proline metabolism network in E. coli ....................................................................... 342 
Figure 6.5: DNA gels of gene knockout construct PCR products. ....................................................... 345 
Figure 6.6: Agarose DNA gels of PCR products to confirm successful knockout mutagenesis. .......... 347 
Figure 6.7: Strategy to implement proB substitutions by overlap PCR. ............................................. 350 
Figure 6.8: DNA gels of DNA template PCR products for overlap PCR to implement single nucleotide 
substitutions. ...................................................................................................................................... 352 
Figure 6.9: Chromosomal DNA amplified from the chromosome of proB D107N and proB E153A... 353 
Figure 6.10: Intracellular and secreted fractions of ∆CKL expressing either empty (-) or COL1A1 (C) 
harbouring secretion construct and proline metabolism mutant strains: ∆proB, proB E153A, ∆putA, 
∆gdhA, ∆putA ∆gdhA and ∆proB ∆putA .............................................................................................. 355 
Figure 6.11: Results following densitometry analysis of the intracellular samples of anti-FLAG-HRP 
and anti-COL1A1 probed Western blots of ∆CKL, ∆proB, ∆gdhA, ∆putA ∆gdhA and ∆proB ∆putA 
COL1A1 expressing cells following cell culture ................................................................................... 356 
Figure 6.12: Intracellular and secreted fractions of ∆CKL or ∆CKL ∆clpX ∆motAB expressing Scl2. ... 358 
Figure 6.13: Results following densitometry analysis of the intracellular samples of anti-FLAG-HRP 
probed Western blots of ∆CKL (C) and ∆CKL ∆clpX ∆motAB (XM) Scl2 expressing cells following cell 
culture ................................................................................................................................................. 359 
 
 
 
 
 
 
 
22 
 
List of Tables 
Table 1.1: Gene knockouts and reported flagella gene and phenotypic effects ……………………………...64 
Table 1.2: Recombinant human collagen production ………………………………………………………………………73 
Table 2.1: E. coli strains used in the study. ........................................................................................... 78 
Table 2. 2: Plasmids used in this study. ................................................................................................ 80 
Table 2.3: Manufacturers and suppliers of chemicals, reagents, kits and equipment. ........................ 85 
Table 2.4: Reagents and quantities for PCR with Phusion® High-Fidelity DNA Polymerase ................. 93 
Table 2.5: Settings for PCR with Phusion® High-Fidelity DNA Polymerase. .......................................... 94 
Table2.6: Reagents and quantities for PCR with DreamTaq DNA Polymerase. .................................... 95 
Table 2.7: Settings for PCR with DreamTaq DNA Polymerase. ............................................................. 95 
Table 2.8: Reagents and quantities to restriction enzyme digest......................................................... 97 
Table 2.9: Reagents and quantities for DNA ligation. ........................................................................... 97 
Table 2.10: Reagents and quantities for polyacrylamide resolving gels. ............................................ 101 
Table 2.11: Antibodies for probing nitrocellulose membranes for Western blotting. ....................... 102 
Table 3.1: PCR products for gene knockouts ...................................................................................... 178 
Table 3.2: PCR products for confirmation of knockout mutagenesis in the secretor strain. ............. 180 
Table 5.1: Parent strain and the additional gene knockout targets, with PCR products for 
confirmation of knockout mutagenesis in the various parent strains. ............................................... 276 
Table 5.2: Parent strain and associated knockout mutations implemented by P1 phage transduction 
with chromosomal DNA packaged from donor strains. ..................................................................... 278 
Table 5.3: Chromosomal location (bp) of genes which underwent knockout mutagenesis and existing 
gene knockouts. .................................................................................................................................. 279 
Table 5.4: Strains tested for expression and secretion of cutinase through the modified FT3SS. ..... 280 
Table 5.5: Guide to the production of variations of the pJexpress-FliC-cutinase-FLAG-Strep plasmid.
 ............................................................................................................................................................ 305 
Table 6.1: PCR products for gene knockouts ...................................................................................... 344 
Table 6.2: PCR products for confirmation of knockout mutagenesis in ∆CKL. ................................... 346 
Table 6.3: Chromosomal location (bp) of genes which underwent knockout mutagenesis and existing 
gene knockouts. .................................................................................................................................. 348 
Table 6.4: Size of PCR products in overlap PCR to generate D107N and E143A proB substitutions .. 351 
 
23 
 
1. Introduction 
 
Recombinant therapeutic protein production is a common application of industrial biotechnology. 
Recombinant therapeutics are of high economic value, however a persistent aim of the 
biotechnology industry is to increase product yields and reduce production costs. A high proportion 
of production costs are incurred due to downstream processing of recombinant proteins, i.e. 
separation from undesirable cellular contaminants (Lowe et al., 2001). One route to reduce these 
processing costs is to achieve secretion of proteins by the expression organism, an objective that has 
also been shown to increase product yield and quality (Georgiou & Segatori, 2005; Ni & Chen, 2009).  
One possible solution is the high throughput one-step directed secretion of proteins from bacteria 
from the cell cytoplasm into the surrounding media from where it can then be harvested in a 
simplified manner. This also opens up the possibility of stable cell cultures that secrete protein 
continuously without the need for sacrifice of the seed culture during the process. Secretion into the 
media by Gram-negative bacteria is a major challenge in biotechnology and while it would be 
beneficial it is low yielding.  
One route to achieving such an aim would be the re-engineering of an existing biological protein 
secretion system to reach this end.  This thesis will outline work aimed at this end focussing on re-
engineering of the common biotechnology employed bacterium, Escherichia coli, to directly secrete 
proteins in to growth medium using the flagella type III secretion system (FT3SS).  This aim was 
addressed using a combination of traditional biological modification methods and emerging 
methodology associated with synthetic biology and certainly considers the ethos of directed 
engineering with a defined goal in mind.  As a grand challenge for this secretion system and as an 
aim in itself, I set the objective of collagen production and secretion as an exemplar for this system, 
because it is an important therapeutic protein, there are challenges in its current production and the 
FT3SS has potential capacity to secrete it. Recombinant collagen production in E. coli requires 
additional metabolic pathway modifications. Routes for these improvements are identified and 
implemented through a combination of molecular and metabolic modelling techniques.  
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1.1. Synthetic Biology 
 
Synthetic biology aims to design and construct novel biological parts, devices and systems and also 
redesign existing biological systems for useful purposes. In conjunction with these aims, synthetic 
biology aims to change the process and strategies previously employed in existing biological fields -
such as genetic engineering- by drawing on elements of the design process synonymous to 
engineering. Biological work can be a time consuming process of trial and error. Whereas previously 
it was accepted that engineering biology could be cumbersome, synthetic biology aims to eliminate 
the uncertainty and lack of transferability of such work. The challenges associated with engineering 
biology are four-fold: (1) managing biology is difficult as it is unavoidably complex, (2) constructing 
and characterising biological systems is tedious and unreliable, (3) there is spontaneous variation in 
a biological system and (4) evolution is continuous (Endy, 2005). With these challenges in mind three 
principles, routed in engineering are applied to synthetic biology work: standardisation, decoupling 
and abstraction. The three ideas listed above are conceptual; however they provide a framework for 
implementation.  
 
1.1.1. Standardisation 
 
Standardisation is central to engineering; examples include screw threads and internet web 
addresses. If design and construction frameworks (standards) can be developed for biological 
systems then it would be possible to routinely assemble multi component genetic systems or 
‘circuits’. To allow this a universal standard must be abided to for the characterisation of all 
biological components. The universal nature of standard parts means that components are both 
consistent and compatible. Compatibility allows parts to be assembled and integrated into 
functional systems with other parts. Consistency means that biological parts function as expected in 
different circuits, organisms and laboratories. To achieve standardisation of biology, specifications 
must be developed which characterise biological parts quantitatively. Once a consensus on 
characterisation methods is agreed on it must be adhered to for all biological parts -although 
consideration can always be made to improvements or additions to characterisation requirements. 
The output of this work is datasheets, which can be arranged into a catalogue. Datasheets are 
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commonplace in engineering and concisely state the behaviour, requirements and compatibility of 
parts. In synthetic biology these components are biological parts, which are defined as genetically 
encoded components which confer a biological function (Canton et al., 2008). The behaviours of 
biological parts can be summarised by inputs and outputs. The parts are designed so that they 
possess certain properties which allow compatibility with other parts. One example of a biological 
standard is the BioBrick, which are catalogued in The Registry of Standard Biological Parts 
(http://parts.igem.org/Main_Page). Parts in the BioBricks repository are designed so that they are 
easily integrated into circuits due by ‘prefix’ and ‘suffix’ restriction enzyme sites on each part. The 
catalogue is easily navigable; parts are organised into components, such as promoters or ribosome 
binding sites -allowing circuits to be designed easily. Standard measurements such as reliability or 
‘polymerases per second (PoPS)’ mean that the performance and suitability of each part can be 
evaluated. There are however difficulties associated with standardisation, for example there is a 
tendency for BioBricks to behave differently in different circuits, strains, or even laboratories (Kelly 
et al., 2009; Zucca et al., 2013).  
 
1.1.2. Decoupling 
 
Decoupling describes the separation of the design process and the actual fabrication of a system 
(Heinemann & Panke, 2006). Successful decoupling would allow design engineers with little 
biological knowledge to create functional biological circuits and likewise biologists to implement a 
blueprint. Furthermore it allows the separation of a large problem into many simple problems. Each 
problem can be solved independently, solutions can then be combined (Endy, 2005). This is 
exemplified by the building process, where architects, project managers, engineers, inspectors and 
builders all work on specialist areas to produce a final product. Decoupling relies on both abstraction 
and standardisation to deconstruct a problem and combine solutions respectively. While the 
combination of the two aids the design process through decoupling, this reliance results in the 
limitations of the two being relayed to the decoupling process, therefore this strategy is often 
ineffective.  
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1.1.3. Abstraction 
 
Abstraction is a method that aims to reduce the complexity of biology, easing the process of design 
and analysis. It also describes the fact that a cell or organism can be deconstructed to increasingly 
simpler constituents. This allows the formation of abstraction hierarchies, where constituent parts 
are embedded in a more complex system, which confers context. At the top of the hierarchy is the 
chassis, (much like car) components can be loaded onto the chassis to change overall performance. 
Different chassis (bacterial, fungal, mammalian cell line) have different merits (growth, cost, yield, 
ease of scaling up) and can be selected according to purpose. At the bottom of the hierarchy are 
parts, which are assembled into devices, which combine to form systems which are loaded onto a 
chassis (Arkin, 2008). A part can be relevant in a number of devices and therefore systems. This 
hierarchy is applicable to any machine, whether it be a car or a bacteria (Figure 1.1). The use of 
hierarchical structure means that biology can be viewed at the lowest level of complexity possible 
for a task to be carried out. For example, while the design process can be viewed at the top of the 
hierarchy it is implemented from the bottom, at a DNA level (Andrianantoandro et al., 2006).   
 
Figure 1.1: The abstraction hierarchy exemplified by a formula one car and E. coli as chassis. 
Respective hierarchal components are the steering and motility system as systems, the wheel and 
bacterial flagella as devices and wheel nut and a flagellin subunit as parts. 
Chassis System Device Part 
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Abstraction takes a reductionist perspective on biology. While this is convenient, it is not necessarily 
an accurate representation of biological systems. Reductionism versus a system wide view (holism) is 
a recurring debate in molecular biology (Gatherer, 2010). Holism is the basis of the rationale for 
systems biology, which involves observing a biological system as a whole (Mazzocchi, 2012). 
Application of systems biology to synthetic biology may aid integration of the two approaches.  
 
1.1.4. The reality of synthetic biology 
 
There are many problems associated with the synthetic biology vision of the future of biological 
engineering. Incomplete knowledge of biological systems contributes to much of this – something 
that the biological community are constantly striving to improve. Biological systems are not stable. 
Fluctuations in gene expression are common and strains accumulate mutations over generations, 
resulting in a change in phenotype (Kwok, 2010). Chassis organisms often have short generation 
times; therefore the rate at which mutations accumulate is amplified. In addition the rate at which 
mutations occur is increased in response to evolutionary pressures caused by the environment 
(Lenski & Travisano, 1994) and has been shown to increase with increased protein expression 
(Sleight et al., 2010).  Genetic variation results in reduced predictability of phenotype and may 
amount to complete loss of function. Many issues stem from the lack of modularity within biological 
systems. While a circuit can be designed, it is not insulated from other cell processes. This impacts 
on the reliability and predictability of systems. Various methods can be employed to aid circuit 
insulation, these include deleting competing reactions, aiding protein interaction by protein fusion 
or rational engineering or localising components on a scaffold (Agapakis et al., 2010). An alternative 
solution to the variability seen is to complete tasks through a population of cells rather that single 
cells, thus decreasing overall variation (Andrianantoandro et al., 2006). Other steps, which are being 
taken to improve predictability, concern computational tools such as modelling. This involves 
genomic scale metabolic reconstructions, which are based on biological data. All known cell 
processes are annotated as a series of reactions which occur between metabolites 
(Andrianantoandro et al., 2006). Metabolic reconstructions include reaction inputs, outputs, rate 
constants and stoichiometry for each reaction, again based on experimental evidence. Reactions can 
be modified to account for change in culture media, gene knockouts or upregulation. Modelling 
methodologies can be applied to the reconstruction to simulate metabolic processes within the cell. 
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Modelling can be applied to many research questions, providing a dry-lab route of calculating the 
feasibility of systems, identifying routes for system improvement and also troubleshooting designs 
which do not perform as predicted. A common form of metabolic network simulation analysis is flux 
balance analysis (FBA), where the simulated flow of metabolites through a network is measured in 
response to an objective function (Reed et al., 2003; Orth et al., 2010). The system is subject to 
constraints therefore the flux of metabolites is limited to a solution space. Linear optimisation will 
produce a solution with a mini- or maximised objective function. The objective function may relate 
to biomass or be metabolite specific. Comparisons of solutions to different objective functions or 
alternatively the same objective function on different metabolic networks (Figure 1.2) are used to 
validate predictions, search for solutions or identify bottlenecks, therefore revealing targets for 
modification. Models do not always represent the biology well. In a bid to improve this, extensions 
of FBA have been developed, for example models such as ‘FlexFlux’ which involves regulatory 
metabolic network reconstruction (Marmiesse et al., 2015). This accounts for variable gene 
expression in a system in along with metabolic flux. Regulatory network construction based on 
knowledge of gene expression makes it possible to constrain a reaction to a certain percentage of its 
maximal flux value. This percentage corresponds to the estimated probability of activation of the 
gene associated to the reaction. Implementation of this allows more accurate models and for more 
complex phenotypes to be studied. 
 
Figure 1.2: Schematic of a section of a metabolic reconstruction.  
Flux balance analysis can be applied to measure the flux of metabolites through the metabolic 
reconstruction to maximise an objective function. In this schematic the objective function is to 
produce more ‘P’. 1) In the model 9/10 metabolite flux goes through reaction B to C. 2) If the B to C 
reaction is knocked out of the model flux balance analysis shows that all metabolic flux will travel 
through the B to P reaction and more P is made. 
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1.1.5. Synthetic biology approaches: top down and bottom up 
 
There are two approaches which can be taken within synthetic biology, top down and bottom up. 
Bottom up is currently far rarer and involves building an organism from scratch. Synthia is a rare 
example of this approach. Synthia was the product of the transplantation of a chemically derived 
minimal genome of Mycoplasm mycodes into a M. capricolum recipient cell, resulting in a cell which 
was self-replicating (Gibson et al. 2010). The Mycoplasm genus harbour the smallest complement of 
genes in any genus, furthermore the M. mycodes genome had previously been modified to remove 
all dispensable genomic material. Since this breakthrough there have been two iterations of removal 
of non-essential ‘pseudogenes’ from this chassis, resulting in the 531kbp, 473 gene Syn3.0. However 
it is noted that establishing a minimal genome relies on the top down approach; in fact the 
production of Syn3.0, was solely top down, relying on transposon mutagenesis of the existing Syn2.0 
and strain characterisation (Hutchison et al., 2016). Work on minimal genomes is important to 
synthetic biology and much work is focusing on this in a variety of organisms (Juhas et al., 2011). The 
top down approach draws on the aforementioned points much more, repurposing existing biological 
function in an organism. In this approach, biological parts, devices or systems can be re-assembled, 
removed or added to those which exist in the chassis, to perform a specific task (Roberts et al., 
2013). There is much confusion between the two approaches and the terms are often used 
interchangeably (Bedau et al. 2009; Purnick & Weiss, 2009).  
 
1.1.6. Progressive synthetic biology 
 
Synthetic biology is still very much emerging and evolving, but has matured over the past 15 years -
improving on some of these ‘hard truths’. For example stability of genetic circuits by implementing 
bidirectional promoters, where an essential gene (i.e. antibiotic resistance), protects a non-essential 
gene. Progression in the field has produced complex circuitry including, riboswitches, oscillating 
circuits, multiple input logic gates and impressive multicellular cross talk patterning systems 
(Cameron et al., 2008; Barcena Menendez et al., 2015). An area of research concerning 
posttranslational circuits is also emerging. The complexity of synthetic biology is increasing, for 
example a system based on inducible recombinases was able to implement a 16 gate Boolean logic 
device (Siuti et al., 2013). The integration of computational and systems biology has allowed much 
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progress in the field, for both designing and predicting biology in a ‘top down’ approach and also in 
analysing complex experimental outputs (Church et al. 2014; Takors & de Lorenzo, 2016). With a 
wealth of information being produced computationally, more efficient gene editing methods such as 
CRISPR/Cas allows the implementation of the ideas these generate (Jinek et al., 2012) .  The field is 
still very collaborative for example the Sc 2.0’ project, set out to design a minimal Saccharomyces 
cerevisiae genome from the ‘bottom up’, each of the 16 chromosomes is being worked on my a 
different institution (Callaway, 2014). Finally real world examples of synthetic biology are emerging, 
for example the chemical industry has been aided by synthetic biology in the incorporation of 
biosynthetic building blocks to produce small chemicals –this involves the combination or redesign 
of naturally occurring metabolic pathway (often from multiple species) to produce diverse 
metabolites or compounds which are made in a more cost effective manner to alternatives or 
otherwise inaccessible using naturally occurring enzymes of chemical processes, examples of this 
include food flavourings, biofuels and therapeutics (Szczebara et al. 2003; Winter & Tang, 2012; 
Breitling & Takano, 2015; Jullesson et al. 2015). 
 
1.1.7. The salvation narrative of synthetic biology 
 
It is envisioned that the field of synthetic biology will not only change the approach taken when 
working in biology, chemical engineering and manufacturing, but also provide solutions to some of 
the world’s biggest problems. The synthetic biology community aim to positively contribute to a 
huge range of areas such as food production, renewable fuels, healthcare, computing and 
electronics – often with an emphasis on sustainability and a not-for-profit onus. While the 
philosophy of synthetic biology is to make a great difference to global society, it often falls short of 
this. Products of synthetic biology are often showpieces, which although demonstrate progress in 
science and are excellent tools for gaining interest in the field, do little to add to the revolutionary 
aims of synthetic biology. In addition many successful not-for-profit projects have spin out 
companies which do make profit. However there are some positive and successful examples of 
synthetic biology. Arguably the most impressive example was the large scale production of the anti-
malarial plant derived drug artemisinin in yeast. This was scaled up by Sanofi-Aventis in a business 
model designed to stabilise world anti-malarial drug production, improve treatment and reduce 
mortality worldwide (Paddon et al., 2013). While this will improve healthcare worldwide, artemisinin 
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is a classic example of unequal distribution of technology. Synthetic biology derived artemisinin was 
created and produced in more developed countries and will compete with naturally derived 
artemisinin which is extracted from plants cultivated by farmers in less developed countries. While 
the producers of synthetic artemisinin set out on a not for profit business model (Peplow, 2013), the 
reality was that artemisinin crops were very successful during the years of synthetic biology and  
reduced artemisinin production (2014-2016), with the price of a kg of artemisinin reaching $250, 
much lower than the $350 ‘no profit-no less’ margin of production and the factory has now ceased 
operations (Peplow, 2016). This is evidence of the sad reality of the combination of business and 
philanthropy. Perhaps less marketable in terms of salvation narrative, but still a solution to a global 
problem is the production of biofuels. While there is much debate about the true carbon footprint of 
‘green’ fuel, the field of synthetic biology has excelled in producing renewable fuel. For example 
Solazyme recently produced 250,000 gallons of microalgae derived biodiesel for the US Navy 
(Mayfield, 2013). 
 
1.2. Industrial Biotechnology 
 
Industrial biotechnology represents the worldwide sector of utilising microorganisms or cell 
expression systems to produce a range of biological products ranging from therapeutics and biofuels 
to industrial enzymes and small chemicals (McCormick & Kautto, 2013). It also encompasses the 
production of chemicals and enzymes to treat textiles and paper. A large sector within industrial 
biotechnology involves the production of therapeutic biologics, in the USA alone this contributes $91 
billion to the economy, which continues to rise (Carlson, 2016). Biologics accounted for five of the 
top ten prescribed drugs in the world in 2014 and included the largest selling drug, the monoclonal 
antibody Humira, which achieved $11.8 billion in sales for use in treatment of rheumatoid arthritis –
amongst other conditions (Lindsley, 2015). While Humira is produced in Chinese Hamster Ovary 
(CHO) cells, the second biggest seller in this market is the synthetic long-acting insulin substitute 
Lantus, which is produced in E. coli. A staggering number of biologics are approved for therapeutic 
use, for E. coli alone this includes many hormones (largely insulin and human growth hormone), 
antibody fragments, interferons for cancer treatment, colony stimulating factors (which stimulate 
white blood cell production) and vaccines and this is set to grow over coming years (Walsh, 2014).  
 
32 
 
1.2.1. Industrial biotechnology expression chassis (organisms) 
 
A range of chassis options are available for recombinant protein production in industry, all with 
differing advantages and disadvantages. The type of chassis depends on the nature of the 
recombinant protein and the specifications of the product. Commonly used expression systems are 
laid out below; as the focus of this project is to secrete protein, various secreted yields of protein 
product are also given. Many eukaryotic cells can be utilised for recombinant therapeutic protein 
production, these may include plants, microalgae, insect cells, fungus (often yeast) and animal cells, 
which are usually in the form of a cell line rather than a whole organism (spider silk (and other 
recombinant proteins) from goat milk, is one example of an exception to this (Clark, 1998; Service, 
2002)). In general they are better at carrying out PTMs than prokaryotic cells. Mammalian cells are 
favoured because they are able to carry out PTMs and produce biologics with the correct glycoforms 
to be compatible in humans. They have been utilised to produce many antibodies and hormones at 
yields of up to 10g per Litre (Kim et al., 2012) with CHO cells being able to secrete recombinant 
protein, however yields for CHO are much lower -0.8g per Litre (Le Fourn et al., 2014). Pichia pastoris 
is another commonly used eukaryotic organism; it is also able to carry out PTMs and 
glycoengineering allows more human like glycosylation of protein, it also has cheaper growth 
requirements than CHO cells and is able to secrete protein into media efficiently –for example 1.5g 
secreted insulin per litre of cell culture following 80 hours growth (Weinacker et al., 2013; Fidan et 
al., 2015; Gurramkonda et al., 2010), although the maximum secreted yield in Pichia  is around 15g L-
1 21kDa chains of rodent collagen (Werten et al., 1999). Saccharomyces is also used but has lower 
yields, for example 2.5mg L-1 secreted amylase after 96 hours (Rodríguez-Limas et al., 2015). 
Microalgae are also a desirable expression organism because they capture carbon dioxide and also 
utilise sunlight to acquire energy. Yields of 11.8g milk amyloid were achieved per kg dry weight total 
of Chlamydomonas reinhardtii –this was not secreted (Gimpel et al., 2015). 
 
Prokaryotes are often favoured in biotechnology for a variety of reasons. Prokaryotes can be grown 
quickly and to high cell density on cheap carbon sources and secretion is possible (Ferrer-Miralles & 
Villaverde, 2013). Furthermore scale up of growth conditions is simple. Examples include Bacillus, 
which is widely reported to be proficient in recombinant protein secretion of certain enzymes 
achieving yields of up to 25g L-1, following cell culture for 72 hours of more (Liu et al., 2013) –
however it yields reported explicitly in the literature are much less impressive than this for example 
1g L-1 proinsulin and up to 1g L-1 amylase (Heng et al. 2005; Olmos-Soto & Contreras-Flores, 2003). 
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Another candidate is Pseudomonas which can secrete up to 1g L-1, of various proteins (Retallack et 
al., 2012). However when it comes to recombinant protein production E. coli is often seen as a 
‘workhorse’ organism and is often favoured in biotechnology, and certainly by the often 
conservative contract manufacturing community, who develop expression (and secretion) platforms 
for a range of products. Reasons for this will be documented below. 
 
1.3. E. coli as a chassis for synthetic biology and 
biotechnology 
 
The use of E. coli is common in biotechnology. It has fast generation times and low growth 
requirements, therefore a large number of cells can be grown in a matter of hours. Alternatively, it is 
relatively cheap to make rich media, which allows cells to be grown to OD600 in excess of 100, for 
high protein expression in a small culture volume. Along with favourable growth requirements they 
are also well studied and there are a large number of tools available to both understand and alter E. 
coli gene and protein expression; these will be discussed in the next section. The first example of 
clinically available recombinant protein was human insulin from an E. coli host. This was followed by 
bovine growth hormone, again in E. coli (Swartz, 2001). Following years of optimisation, intracellular 
yields of up to 4.34g L-1 have been reported for human insulin, however the highest extracellular 
secreted is just 7mg L-1, this was achieved through fusion to Staphylococcal protein A, which has 
been shown to result in the presence of extracellular protein in E. coli, although lysis is never 
excluded (Baeshen et al. 2014; Mergulhão et al. 2004). Secretion is documented in E.coli; however it 
is not as effective at secreting protein as other expression chassis, such as Pichia or Bacillus (Rosano 
& Ceccarelli, 2014). Furthermore the majority of secretion reported in biotechnology is for 
periplasmic secretion, not secretion in the media. E. coli do not naturally carry out PTMs and 
harbour endotoxins, however as stated above, a huge range of E. coli derived recombinant proteins 
are now licensed for use in humans and are produced on an industrial scale (Walsh, 2014). These 
examples demonstrate the amenability of E. coli to recombinant protein expression; it’s suitability to 
industrial scale up and cost effectiveness as a chassis organism. Furthermore the fact that E. coli 
derived therapeutic products are licensed, highlights that products are effective without adverse 
characteristics and well viewed by regulatory authorities.  
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1.3.1. Enabling technologies 
  
E. coli are particularly suitable for use in synthetic biology and biomanufacturing for a number of 
reasons. This includes intrinsic properties, such as good recombinant protein expression rate with 
low growth requirements and  a high rate of cell growth up to optical densities in excess of OD600 
100 (Soini et al., 2008). Historical use of E. coli in industrial biotechnology is also beneficial as it is 
acceptable to stakeholders and companies and contract manufacturing organisations are equipped 
with expertise and machinery to grow E. coli. In terms of making improvements to the chassis, the 
genome, transcriptional regulation and metabolic pathways of E. coli are well characterised and 
available in easily accessible formats, for example the online database EcoCyc 
(http://www.ecocyc.org/). Furthermore there are online tools for visualisation of pathways such as 
Reactome (http://www.reactome.org/).  
 
Molecular enabling technologies have contributed much to the amenability of E. coli to 
biotechnological applications. There are a large number of tools available for molecular 
manipulation of genomic and plasmid DNA (Sørensen & Mortensen, 2005; Rosano & Ceccarelli, 
2014). The toolset available is also well tailored for achieving protein overexpression and 
technologies may be implemented for a range of tasks which include cloning, (recombinant) protein 
expression and protein purification and isolation.  Many of these technologies are aided by the post 
genomic revolution, which has resulted in fast, cheap gene sequencing and synthesis. For example it 
was possible to sequence the genome of the parent strain which formed the basis of this study for 
£50, by Microbes NG (https://microbesng.uk/). In terms of recombinant protein expression, 
commercial cloning systems are widely available, common examples include blunt end vector 
cloning and gateway cloning (both Invitrogen). Genes for insertion can be assembled by PCR or 
synthesised de novo by services such as GeneArt® (Invitrogen) and GenScript. The costs of these 
commercial systems are continually decreasing, gene synthesis can cost from £0.23/bp (GenScript, 
2016). Gene synthesis companies also offer codon optimisation for E. coli, this technology takes 
advantage of the fact that multiple codons encode the same amino acids and often realises higher 
expression levels- though this is not always a guarantee of functionality or solubility. The prevalence 
of tRNAs for each codon varies between organisms, therefore optimising codons to reflect this 
results in more efficient translation (Ikemura, 1981; Rosano & Ceccarelli, 2014). 
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Development in molecular methods has also greatly increased the ease of modifying chromosomal 
DNA of strains, allowing generation of knock out mutations or insertion of recombinant DNA. 
Traditionally a combination of restriction enzymes and ligase were used to generate mutations, 
however these methods can be considered cumbersome and inefficient (Warming et al., 2005). 
Recombineering techniques are ideal for removal or addition of genetic material into the E. coli 
chromosome. E. coli are not readily transformable with the presence of linear DNA alone. This is 
largely due to the presence of exonucleases (namely the RecBCD encoded exonuclease V) which 
digest linear DNA (Datsenko & Wanner, 2000). RecBCD deficient strains allow recombination, but 
with low efficiency. A RecD mutant was shown to be exonuclease V deficient, but still displayed high 
recombination efficiency (Biek & Cohen, 1986). Alternatively phage based recombineering methods 
provide simple, efficient means of introducing mutations. Lambda-Red plasmid based technology is 
widely used; the Red recombinase containing plasmid encodes proteins which inhibit RecCBD 
activity, separate linear DNA into single strands and anneal complementary single stranded DNA to 
chromosomal DNA. The plasmid is inducible, allowing control of recombination events (Murphy, 
1998). One of the most commonly used versions of this protocol is the one generated by Datsenko & 
Wanner (2000) and will be discussed later in this thesis (Chapter 3) –although other methods are 
available which may result in more efficient or scarless mutagenesis, for example making use of the 
I-SceI meganuclease  (Kim et al. 2014; Lee et al. 2009; Stringer et al. 2012). An alternative historical 
method for mutagenesis is phage transduction where bacteriophages transfer gene deletions from a 
donor bacteria to a host- usually P1 for E.coli (Donath et al., 2011), although this relies on the 
occurrence of a strain which already harbours the desired gene mutation, it is very efficient.  
 
These tools can be utilised to overcome the challenges associated with protein production in E. coli. 
Protein overexpression often results in aggregates which form insoluble inclusion bodies rendering 
protein inactive. There are benefits to inclusion body formation, as it does hinder proteolysis, 
therefore product is not degraded (Sørensen & Mortensen, 2005; Rudolph & Lilie, 1996), however 
protein must be resolubilised to be functional and this complicates downstream processing. In 
addition, prokaryotic cells lack eukaryotic post translational machinery for glycosylation, 
phosphorylation, acylation and methylation, therefore recombinantly expressed proteins are often 
not correctly modified (Wacker et al., 2002; Yue et al., 2000; Sahdev et al., 2008). However steps 
have been made to implement and improve PTM capacity of E. coli which will be discussed later. A 
reduction in the rate of cell growth can arise when producing heterologous proteins; this is referred 
to as the metabolic burden and describes the amount of resources (both raw material and energy) 
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which are withheld from the host metabolism in order to express recombinant genes (Sørensen & 
Mortensen, 2005; Glick, 1995). Metabolic burden can be decreased by deleting unnecessary genes 
(including those for antibiotic resistance) or incorporating exogenous plasmid harboured DNA into 
the chromosome (Lee et al. 2009; Jones et al. 2000; Glick, 1995). Often, plasmid expression system 
characteristics allow controlled protein expression to overcome these challenges. Plasmids have 
different copy numbers and induction characteristics, allowing control of the timing and strength of 
protein expression; these can be tailored to promote the formation of high quality protein products 
without the formation of inclusion bodies or high metabolic burden (Rosano & Ceccarelli, 2014). 
Alternatively biological circuits can be designed to promote optimum protein expression by 
modifying promoters and ribosome binding sites (Young & Alper, 2010). The availability of 
catalogued and characterised promoters, ribosome binding sites and terminators in the BioBricks 
parts registry and on ribosome databases (for example http://rdp.cme.msu.edu/) means that 
designing circuits has, in theory been simplified over recent years.  Co-expression of enzymes which 
aid correct folding (chaperones, hydrophilic proteins) and PTMs (N-linked glycosylation system 
of Campylobacter jejuni or prolyl-4-hydroxylase for proline hydroxylation) can also be incorporated 
into expression systems (Baneyx, 1999; Khokhlatchev et al. 1997; Wacker et al. 2002; Ikeno et al. 
2013; Kranen et al. 2014; Pinkas et al. 2011). The combination of a large range of protein purification 
tags, all with different binding properties and choice of cleavage sites means that protein 
purification can be optimised for each expression system (Hunt, 2005). Protein tags or fusions can 
also aid protein folding and direct protein for secretion (Makrides, 1996; Rosano & Ceccarelli, 2014).  
 
In addition to molecular tools, commercial strains have been optimised to aid the yield and quality of 
recombinant protein expression. These strains improvements are commonly concerned with 
posttranslational modifications. Mutant commercial strains such as Origami™ (Novagen) express 
thioredoxin reductase and glutathione reductase, which enhance disulphide bond formation in the 
cytoplasm, achieving correctly folded proteins (Prinz et al., 1997). Likewise the SHuffle® (NEB) 
expression system has enhanced cytoplasmic disulphide bond formation by expressing a disulphide 
bond isomerase, which aids production (Lobstein et al., 2012). BL21-CodonPlus (Agilent 
Technologies) and Rosetta™ (Novagen) enhance expression of proteins with rare E. coli codon 
sequences (Hunt, 2005; Sahdev et al. 2008).  Combined, these enabling technologies allow 
controlled expression of recombinant proteins and effective protein purification in E. coli –
reinforcing that this organism is an excellent chassis. 
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1.3.2. Cellular location and its effect of the protein product 
   
Expressed protein can be directed to the periplasm, cytoplasm or secreted to the media (Cornelis, 
2000). The preferred site of export is specific to the recombinant protein product. The cytoplasm is 
often favoured as it tends to result in a higher production yield, however there are also 
disadvantages to cytoplasmic location (Sahdev et al., 2008). Disulphide bond formation usually 
occurs in the periplasm. Therefore the formation of inclusion bodies is common if protein remains in 
the cytoplasm, as periplasmic molecular chaperones and folding enzymes are absent and incorrect 
folding and aggregation occur (Sørensen & Mortensen, 2005; Baeshen et al. 2015). Although it 
should be noted that some folding chaperones are present in the cytoplasm (Berlec & Štrukelj, 
2013). The periplasm is also a reducing environment, which can aid protein folding (Eser et al., 
2009). As discussed previously inclusion body formation can be beneficial; initial purification is 
simpler, N-terminal authenticity is greater and the protein is protected from proteolysis (Hannig & 
Makrides, 1998). However it also inhibits protein functionality, therefore inclusion bodies must be 
unfolded and refolded correctly, this is often complicated, time consuming, hard to predict and 
therefore costly (Singh & Panda, 2005). There are strategies to overcome protein aggregation, which 
include optimising protein expression with low copy number and promoter strength, growing culture 
at a low temperature and using strains that are designed to (over)express certain molecular 
chaperones, which reduce protein aggregation. These can be split into folding chaperones (such as 
ATP dependent Dnak and GroEL), holding chaperones (which hold unfolded proteins until 
chaperones are available) and disaggregating chaperones (such as ClpB, which solubilises aggregated 
protein (Mergulhão et al. 2005; Gupta et al. 2009; Berlec & Štrukelj, 2013). With the correct 
secretion signal protein can be secreted into the periplasm. This can be desirable as around 4% total 
cell protein is located here, thus downstream processing is simplified. Proteolysis is also reduced and 
the non-reducing environment allows formation of disulphide bonds (Berlec & Štrukelj, 2013; Yoon 
et al. 2010). Extracellular secretion would reduce the incidence of inclusion bodies, but also confer 
all of the positive attributes of inclusion body formation (Choi & Lee, 2004). Purification would be 
simpler; proteolysis less common and N-terminal authenticity would be maintained. Much is known 
about secretion signal peptides which direct proteins for export by secretion (Nielsen et al., 1997; 
Dyrløv Bendtsen et al., 2004) and these can be exploited to allow directed secretion of tagged 
proteins, through a secretion system of choice into the periplasm of E.coli with great efficiency. 
Additionally purification of extracellular protein, eliminates the steps usually implemented to first 
lyse cells and second remove cellular contaminants (van der Wal et al., 1998). Profit would be 
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increased due to the reduction in downstream processing costs and increase in product yield, as 
proteins are less likely to undergo proteolysis and more likely to be correctly folded (Choi & Lee, 
2004). In summary secretion of protein into the extracellular media would be of great benefit in 
industrial biotechnology. 
 
1.3.3. Post translational modifications 
 
Problems at a post-translational level are rife when expressing recombinant protein in E. coli, as 
much of the post translational machinery required is absent. To circumvent this, machinery can be 
introduced on plasmid vectors. This technique is common, for example although E. coli is 
occasionally able to phosphorylate recombinant proteins using native kinases (Mijakovic et al., 
2006), the co-expression of recombinant protein kinase (often fused to the target protein) confers 
reliable phosphorylation of proteins (Sahdev et al., 2008; Murata et al., 2008). This strategy has also 
been used for protein methylases and acetylases and their substrates (Yue et al., 2000; Acharya et 
al., 2005). Glycosylation is a complex PTM, which while common in eukaryotes is rarer in 
prokaryotes. There are two forms, N- and O-linked. The process of N-linked glycosylation in 
eukaryotes involves the oligosaccharyl intermediate (Glc3Man9GlcNAc2) being attached to an 
asparagine residue through the action of the enzyme oligosaccharyltransferase. The resulting 
structure is then trimmed by α-glucosidase I and II for quality control and can then be trimmed 
further or decorated with monosaccharides. O-linked glycosylation is much simpler and involves the 
attachment of a single GalNAc monosaccharide to a serine or threonine of the polypeptide backbone 
-next there is either the addition of a SA residue, which terminates the chain, or the addition of 
further monosaccharides to form a longer linear or branched chain (Brooks, 2004). While new 
examples of bacterial protein glycosylation are discovered all the time, their characteristics are 
significantly different from the common core and terminal glycans present in eukaryotic proteins- 
both therapeutic and non-therapeutic.  This is problematic when producing heterologous proteins 
where glycosylation status is key to efficacy or function -effecting protein half-life, stability, solubility 
and immunogenicity (Baker et al., 2013); for example, N- linked glycosylation has also been shown to 
improve pharmacokinetic and biophysical properties of proteins. In addition recognition of N- 
glycans by carbohydrate binding proteins and lectins allows tissue and cell specific targeting of 
proteins (Lizak et al., 2011). O-linked glycosylation also aids protein stability and recognition, 
including the immune response (Steen et al., 2008). For these reasons correct glycosylation of 
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therapeutic products is advantageous as protein will be more characteristic of the native protein in 
structure and function and is more likely to interact with other proteins and less likely to elicit an 
immune response. Some non-enzymatic N- glycosylation of recombinant human interferon γ has 
been observed in E. coli (Mironova et al., 2005), however it is not a common feature. The discovery 
of an N-linked glycosylation system in Campylobacter jejuni which is transferable to E. coli has added 
to the possibility of bacteria derived glycoproteins (Wacker et al., 2002). While this research was 
central to enabling PTM’s in E. coli, the efficiency of N-linked glycosylation was poor and occurs only 
in the periplasmic space. However additional work has demonstrated that this can be improved by 
codon optimisation of the oligosaccharyltransferase PglB, which transfers the C. jejuni 
heptasaccaride to asparagine (N) residues and by increasing expression of the glycosyltransferase 
WecA (Pandhal et al., 2012). E. coli can also be engineered to confer O-linked glycosylation with the 
expression of recombinant enzymes (Lubas, 2000; Henderson et al. 2011).  
 
1.3.4. Immunogenicity 
 
It is imperative that proteins derived for therapeutic uses have low or at least predictable 
immunogenicity. Differences in the 3D structure of proteins to those in humans are detected by 
antibodies, eliciting an immune response. The use of non-human expression systems can increase 
the immunogenic properties of therapeutic proteins. As explained previously, a recombinant human 
protein may not harbour all of the human PTMs; therefore an immunogenic response is likely. 
Additionally if the whole protein is not expressed or correctly folded it may result in exposure of new 
antigenic sites (Schellekens, 2002). While there are developments to reduce immunogenicity by 
implementing correct PTMs, as stated in the previous section, the production of small therapeutics 
which do not require PTMs such as glycosylation are advancing to clinical trials (Frenzel et al., 2013). 
Furthermore the storage of recombinant proteins may result in oxidation or aggregation which may 
elicit an immune response. The covalent attachment of polyethylene glycol (PEGylation) to 
recombinant therapeutic proteins can aid evasion of the immune system, as it shields sites of 
antigenicity (DeFrees et al., 2006). Furthermore PEGylation of protein can increase circulatory half-
life, and protect the protein from enzyme degradation. It is also important to eliminate any E. coli 
derived contaminants which may induce an immune response (Schädlich et al., 2009). A common 
contaminant is endotoxin (often in the form of lipopolysaccharide chains in the case of E.coli) which 
is present on the E. coli outer membrane. Even minute amounts of endotoxins can have a large 
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effect in humans. Steps in the protein purification methods must ensure that such contaminants are 
removed (Petsch & Anspach, 2000). A widely used example of this is the use of polymyxin B which 
has a high binding affinity for the lipid A moiety of most endotoxins. 
 
1.3.5. E. coli protein secretion systems 
 
As stated, secretion of recombinant protein is desirable in industrial biotechnology, as product yield 
may be higher in concentration and quality and downstream processing simplified. Protein secretion 
in widespread in E. coli and can be active or inactive. For example periplasmic translocation without 
the release of cytoplasmic contaminants is observed when cells undergo osmotic shock (Jonasson et 
al., 2002). This section will focus on active routes of protein secretion to various cellular locations 
through a range of secretion systems (Figure 1.3). Together, these secretion systems allow protein 
secretion from the cytoplasm into the periplasm or extracellular space, in a one or two step 
secretion pathway. 
 
 
 
Figure 1.3: Secretion systems of E. coli and the proteins involved.   
Showing the RND pump, type I, type II, injectisome type III, type IV and type VI secretion systems 
and their localisation in the inner membrane (IM), outer membrane (OM) and host cell membrane 
(CM). NOTE: Only the type III injectisome system is shown, not the flagella type III secretion system. 
Taken from (Costa et al., 2015) 
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1.3.5.1. Type I secretion system 
 
Type I secretion in E.coli exports protein directly from the cytoplasm to the environment in one step. 
A number of substrates are secreted which are often associated with nutrient acquisition or 
virulence.  In terms of their architecture they are also closely related to the resistance–nodulation–
division (RND) family of multidrug efflux pumps (Costa et al., 2015). Both systems form a three 
component double-membrane-spanning channel with an ATP-binding cassette transporter (ABC) or 
RND efflux transporter which spans the inner membrane, a TolC membrane protein which is 
embedded in the outer membrane and an inner membrane anchored membrane fusion protein 
(MFP)  which forms a tunnel like structure with TolC in its open form which spans the periplasm -
linking the other two components (Tseng et al., 2009). TolC is a trimer that forms a β-barrel channel 
in the OM and a periplasmic α-helical barrel that associates with the MFP from multiple secretion 
pathways including the hemolysin (HylA), colicin V and RND (Delepelaire, 2004). Opening of the 
channel occurs at the periplasmic end of the α-barrel and is triggered by a twisting motion of the α-
helix (Koronakis et al., 2004). Secretion is ATP facilitated by the inner membrane ABC. Both ABC and 
MFP carry out substrate recognition prior to secretion, whereas TolC can associate with multiple 
MFP complexes. Protein is directed for export by a non-cleavable C-terminal signal sequence, which 
binds to the ABC (Zhang et al., 1995). Secretion into the periplasmic cavity of the MFP is energized by 
the hydrolysis of ATP, which is mediated by the C terminus of the ATP-binding cassette complex 
(Thomas et al., 2014; Kanonenberg et al., 2013) –RND pumps also use a proton gradient to aid 
substrate secretion.  This enables the ABC-MFP complex to associate with TolC. This triggers the 
opening of TolC and the subsequent release of the substrate into the extracellular space (Costa et 
al., 2015).  
 
1.3.5.2. Type II secretion system 
 
Secretion through the type II secretion system is a two-step process and machinery spans from the 
inner to outer membranes. T2SS are comprised of a channel like outer membrane complex (often 
referred to as the secretin), a periplasmic pseudopilus, which is anchored to an inner membrane 
platform -and is tightly associated with a cytoplasmic ATPase (Korotkov et al., 2012).  First protein is 
exported through the Tat or Sec pathway from the cytoplasm to the periplasm, then protein is 
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exported to the environment (Mergulhão et al., 2005). T2SS substrates are transported to the 
periplasm as unfolded polypeptides by the Sec translocon or as folded proteins by the Tat 
transporter; protein is exported through the secretin in a folded state (Nivaskumar & Francetic, 
2014). N-terminal secretion peptides direct protein for export to the periplasm through both the Sec 
and Tat pathways, which are cleaved following secretion into the periplasm (Choi et al., 2006; Patel 
et al., 2014). The secretion peptides of these two pathways are similar in structure; both harbour 
Ala-X-Ala motifs and hydrophobic and hydrophilic regions; however the Tat signal is less 
hydrophobic and also contains the twin arginine SRRxFLK sequence. Furthermore basic residues in 
the Tat signal, which are not present in the Sec signal, are thought to hinder interaction with Sec 
secretion apparatus. Substrates are recognised by TatC and assemble at the TatBC complex receptor 
where TatA is recruited and facilitates transport of folded protein across the inner membrane, this 
complex binding and possible translocation are driven by proton motive force (Alcock et al., 2013). 
The signal peptide is cleaved in the periplasm and following folding and PTM’s may be directed for 
export through the secretin to the extracellular membrane by the chaperone AB5 which is thought to 
recognise the tertiary or quaternary structure of folded proteins (Sandkvist, 2001). There are two 
targeting pathways for delivering protein to the Sec translocon, the SecA pathway is mainly used for 
periplasmic or outer membrane proteins and recognises proteins, which have a cleavable 
hydrophobic N-terminal Ala-X-Ala motive signal sequences. These proteins are transferred to SecA, 
which drives translocation through the SecYEG translocon channel by ATP hydrolysis (Denks et al., 
2014). The SRP pathway mainly secretes inner membrane proteins; here ribosome bound SRP-signal 
nascent protein is directed to the membrane where it is recognised by the SRP membrane receptor: 
FtsY. FtsY binds to SecY and upon GTP hydrolysis promotes the dissociation of the SRP–FtsY complex 
delivering the protein cargo to the SecY channel (Chatzi et al., 2013). Once in the periplasm, N-
terminal signal peptides are cleaved -at this stage proteins reside in the periplasm. Current 
understanding of how protein reaches the extracellular space is limited. The prevalent idea is that 
protein binds to the periplasmic domains of secretin and the tip of the pseudopilus, stimulating 
ATPase activity, subunits are added to the pseudopilus, and the growing pseudopilus functions as a 
piston, pushing substrates through secretin channel, however knowledge of how proteins are 
targeted to this complex is lacking (Nivaskumar et al., 2007; Korotkov et al., 2012). 
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1.3.5.3. Type III secretion system 
 
The type III secretion system (T3SS) describes two distinct systems, the flagella and injectisome T3SS. 
The flagella T3SS shares many components with the injectisome T3SS and many of the proteins are 
homologous in structure and function (Erhardt et al. 2010). There is much discussion around the 
evolutionary divergence of the two T3SSs. With evidence that each diversified from the other or that 
they share a common ancestor (Abby & Rocha, 2012; Macnab, 2004; Gophna et al. 2003). Both 
systems span all of the cellular membranes and have the capacity to secrete a large number of 
protein subunits from the cytoplasm, direct to the supernatant or into host cells in one step. 
 
1.3.5.3.1. Injectisome 
 
The T3SS injectisome is present in several pathogenic bacteria (including enteropathogenic E. coli 
(Jarvis et al., 1995), much of the literature concerns Salmonella or Yersinia. The secretion system 
allows the bacteria to inject toxic proteins through the host eukaryotic cell membrane and is 
essential for infection, survival and pathogenicity (Cornelis & Van Gijsegem, 2000). The injectisome is 
comprised of around 25 proteins, which assemble in a highly regulated, ordered fashion. The central 
component is the needle complex, which spans both the inner and outer membranes and allows the 
translocation of secreted effector proteins from the cytoplasm to the extracellular environment 
(host cell) in one step (Diepold & Wagner, 2014). Other than the basal needle structure the 
injectisome is comprised of rings, export apparatus and cytostolic proteins (Galán & Wolf-Watz, 
2006).  
 
The basal structure is formed of an OM and IM ring which encompass the inner rod -the T3SS export 
apparatus is situated within the IM ring and is composed of two proteins (PrgK and PrgH) which form 
concentric rings. The secretion apparatus resides in the IM and forms a sorting platform for 
substrates and an ATPase complex mediates interaction with the export apparatus, which exhibits 
substrate recognition and unfolds substrates prior to export (Lara-Tejero et al., 2011). The export 
apparatus is thought to recognise a common N-terminal signal sequence, which is also the location 
of binding of T3SS chaperones for certain effector proteins (SopB and SigE for example (Roblin et al., 
2015)), although in the case of some proteins a 5’ UTR is thought to play a role, although this is 
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under debate (Munera et al., 2010; Lloyd et al., 2001; Anderson et al., 2002). The rod (PrgJ) 
assembles on the IM ring and finally the OM ring is made of InvG proteins from the secretin family, 
which are moved to the outer membrane with the aid of pilotins (InvH) (Koster et al. 1997; Crago & 
Koronakis, 1998). A neck region spans the periplasm and links the OM ring to the IM ring. The needle 
structure is then assembled on to the rod structure. This is comprised of around 100 <10kDa 
polymerised hair-pin like proteins called PrgI. Chaperones generally bind within the first 160 residues 
of the N-terminal of substrates. The ATPase complex (InvC ATPase) couples ATP hydrolysis to the 
unfolding and release of needle and effector proteins from their chaperones prior to secretion 
through the T3SS (Akeda & Galán, 2005); proton motive force may also aid secretion (Kosarewicz et 
al., 2012).  The needle complex is traversed by a 28 Å diameter channel, through which substrates 
travel before assembly at the tip. At the tip of the needle assembles the translocon platform, upon 
contact with the host, two transmembrane proteins (IpaB and SipB) locate here to form the 
transposon and toxic proteins or ‘effectors’ are delivered from the bacterial cytoplasm to eukaryotic 
cells through this channel (Costa et al., 2015).   These are analogous to the late (filament type) 
subunits of the flagella system these proteins are often chaperoned by specific chaperone proteins 
that bind in the N-terminal secretion signal region and are involved in docking at the export 
apparatus. 
 
1.3.5.3.2. Flagella 
 
The flagella T3SS is ultimately present to build a functional flagellum and provide motility to the cell, 
through motor and filament structures. The FT3SS shares morphology and mechanisms of assembly 
with the bacterial injectisome, with both assembling in a similar ordered fashion from the base 
upwards in steps which are controlled by checkpoints and a defined regulatory pathway, alongside 
several conserved proteins in the secretion apparatus- as outlined in Section 1.4.2 (Chilcott & 
Hughes, 2000). The structure consists of a basal body and cylindrical proteins which extend from the 
cytoplasm and protrude from the bacterial cell. These structures assemble at the distal end following 
secretion through the T3SS (Macnab, 2004).  The FT3SS forms the basis of the next section of this 
introduction and will discussed in detail in Section 1.4 
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1.3.5.4. Type IV secretion system 
 
The type IV secretion system is the most ubiquitous secretion system in nature and is able to 
transport both toxins, effector proteins and nucleic acid from bacteria to host cells. The T4SS spans 
both membranes of gram negative bacteria and transport is ATP dependent (Zechner et al., 2012). 
Subunits of six proteins form the scaffold and translocation apparatus is formed. Two types of 
subunit form the pilus that extends into the extracellular space and VirB1 is a periplasmic lytic 
transglycosylase that degrades the peptidoglycan layer and is required for pilus biogenesis. The 
system is powered by three ATPases located in the IM, which serve to provide energy for pilus 
biogenesis and substrate translocation (Costa et al. 2015; Fronzes et al. 2009; Cascales & Christie, 
2004). The pili extend into the extracellular space and it is proposed that when they contact a host 
cell, the T4SS secretion switches to substrate translocation. C-terminal signal sequences which are 
comprised of unstructured clusters of positively charged or hydrophobic residues or internal signals, 
direct protein for export while nucleic acid export is thought to be contact-dependent initiated upon 
binding to a DNA dependent ATPase coupling protein (VirD4) –which favours GGGG nucleotide 
structures. This is directed for export through the T4SS (Darbari & Waksman, 2015). Much like other 
systems, proteins often require chaperones and adapter proteins for efficient secretion (Zechner et 
al., 2012; Christie et al., 2014).  This general requirement for chaperones in protein secretion is both 
intriguing and seems to be a solution to prevent mis-folding and aggregation in these pathways since 
many of the proteins are destined for polymerisation. 
 
1.3.5.5. Type V secretion system 
 
There are now 5 classes of type V secretion systems types (a-e), however the best characterised are 
a and b (van Ulsen et al., 2014). The autotransporter (Va) and the two partner secretion pathway 
(Vb). Proteins secreted through the type V secretion pathway are comprised of passenger domains, 
signal sequences and β-domain regions (Henderson et al., 2004). Proteins are recognised by N-
terminal signal sequences and directed into the periplasm by the Sec machinery and occasionally the 
SRP pathway. In the autotransporter system, once in the periplasm the signal sequences are cleaved 
and the β-domains assemble into β-barrel structures in the cell membrane. The passenger domain is 
then translocated across the membrane where it is released or remains anchored in the cell 
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envelope for surface display. In the Vb system the β-domain and passenger domain are translated as 
two peptides, as opposed to one in the autotransporter. 
 
1.3.5.6. Type VI secretion system 
 
The type VI secretion system is also an injectisome and analogous both structurally and 
mechanistically to an intracellular membrane-attached contractile T4 bacteriophage tail. It is 
comprised a tail complex which consists of structural elements that are equivalent to the contractile 
phage tail: a tail sheath, an inner tube which assemble on a baseplate (Ho et al., 2014). This is 
anchored to the cell by the membrane complex which extends from the inner to outer membrane. 
Extracellular signals cause a conformational change in the baseplate, which drives contraction of the 
sheath. The inner tube is transported out of the cell and effectors are recruited to the N- or C-
terminals of the two proteins which form the spike domain at the tip (Costa et al., 2015). The T6SS 
therefore spans both of the bacterial membranes, transferring toxic effectors from the cytoplasm to 
eukaryotic cells in one step by propelling the structure along with effectors into mammalian or 
bacterial host cells; retraction of this requires ATP (Wandersman & Coulthurst, 2013). A single T6SS 
contraction event might translocate multiple effectors into a target cell (Shneider et al., 2013). The 
system appears to be a hybrid system, with components derived from the bacteriophage and type IV 
secretion systems.  Its discovery and mechanism of action was a real surprise to the protein 
secretion field and is a wonderful example of biological evolution at work- though whether this 
comes from hijacking of a viral system by bacteria or vice versa is an open question. 
1.3.6. Secretion of recombinant proteins  
 
On average downstream processing can be said to account for 80% costs of biomanufacturing 
(Hellwig et al. 2004; Walsh, 2014). If recombinant proteins are secreted then downstream processing 
is simpler and therefore cheaper, furthermore cells can remain in culture without being disrupted 
and therefore continue to function.  As discussed in section 1.3.2, following (or in the absence of) 
protein secretion, protein can be localised to the cytoplasm, periplasm or extracellular space. The 
properties of these environments affect protein quality and concentration. Secretion may aid correct 
protein folding, inhibit the formation of inclusion bodies and reduce product degradation 
(Mergulhão et al., 2005). Enhanced correct protein folding and lack of proteases also means that the 
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product is structurally robust and therefore biologically active. Secreted protein has better N-
terminal authenticity, as cleavage of the secretion signal often occurs at the N-terminal following 
secretion, thus reducing the presence of  N-terminal methionine residues at the N-terminus which 
can effect biological properties of the protein, including immunogenicity (Baneyx, 1999). Secretion of 
recombinant protein into the periplasm is commonly carried out in industry. This is because of the 
benefits which arise from non-cytoplasmic protein expression. Protein is harboured in a small and 
contained area, which aids initial isolation of protein, however periplasmic extraction must then be 
utilised to retrieve protein, followed by purification of the product from the remaining protein.  As 
previously stated, secretion into the extracellular environment would be beneficial for both cost 
effectiveness of downstream processing and improved product quality. Much work on extracellular 
secreted protein relies more on the presence of secreted protein, without knowledge of the route by 
which it was localised there (Ni & Chen, 2009). This section of the review will focus on secretion of 
protein through known secretion pathways. 
 
Protein secretion in E. coli is a complex process, therefore there are many issues surrounding the 
secretion of recombinant proteins. These include incompatibility for secretion, incomplete secretion, 
low capacity of secretion and proteolysis (Huang et al. 2001; Baneyx, 1999). For example the 
secretion of some large proteins may be impossible, as this is limited by secretion system capacity. 
When protein secretion demand exceeds the capabilities of the cell, intracellular accumulation 
occurs, leading to the formation of inclusion bodies, therefore the two must be evenly matched 
(Schlegel et al., 2013). To date recombinant products have been secreted through the type I, II, III 
and V secretion systems in E. coli, all with limited success.  
 
Recombinant proteins have been secreted via the 3.5nm diameter type I secretion system by fusing 
them to the HlyA secretion signal (Blight & Holland, 1994). As protein transits in an unfolded state, 
the secretion system is capable of secreting large proteins. The T1SS is commonly used due to its 
simplicity; a range of proteins (including ScFvs) have been secreted through the system with 
secretion efficiencies into the extracellular space varying from 1% to 90%, with yields of around 2mg 
L-1 reported (Fernández, 2004; Fernandez & de Lorenzo, 2001). As lipases are a natural substrate of 
the type I secretion system, particular success has arisen when expressing recombinant lipases 
(Chung et al., 2009). As there are so many proteins which rely on the T1SS for secretion and its use 
as a means to efflux toxic compounds, limited recombinant protein secretion can occur due to 
competitive exclusion –this is also true of TolC in the T2SS. Other negatives of this expression system 
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include the common occurrence of cytoplasmic accumulation of recombinant protein and the 
dependence of the T1SS on the growth phase and oxygen availability (Hahn & Specht, 2003).  
 
The type II secretion system is also capable of secreting recombinant proteins. Secretion is directed 
by N-terminal signal peptides, which can be fused to recombinant proteins, as a range of native 
substrates exist a number of secretion signals can be utilised (Berlec & Štrukelj, 2013). Following 
secretion they are cleaved which is a benefit of the system when expressing recombinant protein. As 
explained previously the T2SS is a two stage secretion system, with different secretion steps for each 
membrane. Folded protein is secreted through the TAT and secreton secretion systems, but not the 
Sec or SRP systems. Many recombinant proteins will fold in the cytoplasm, therefore the only route 
for the export of these proteins by the T2SS is the TAT system which is slow and easily saturated 
(Georgiou & Segatori, 2005). However many recombinant proteins have been successfully secreted 
through the TAT system by fusion to the twin-arginine signal peptide, including ScFv (up to 4.4mg L-1 
following periplasmic extraction), GFP (up to 1g L-1 following periplasmic extraction),   human growth 
hormone and interleukin (Choi & Lee, 2004; Matos et al. 2014; Matos et al. 2012). The Sec and SRP 
systems are ineffective if protein folding occurs in the cytoplasm. The SRP pathway has been utilised 
to secrete human growth hormone and thioredoxin into the periplasm, by fusion with a DsbA signal 
peptide, with yields of 4mg L-1 observed following periplasmic extraction (Soares et al., 2003). A yield 
of 60 mg L-1 was achieved for GFP in small batch culture or 1g L-1 following fed batch fermentation to 
optical densities upwards of OD600150 (Matos et al., 2012). Transport from the periplasm through 
the outer membrane via TolC is easily saturated; low recombinant protein translation rates must be 
used to overcome this, therefore yield is low (Mergulhão et al., 2005). However the majority of uses 
of the T2SS for recombinant protein secretion concern secretion to the periplasm, as explained 
previously this enables advantageous qualities such as correct protein folding and lack of proteolysis, 
however the cells must be lysed to obtain protein. If yield and protein quality are high this method if 
favourable in industry, however there is a clear case for extracellular protein secretion. 
  
However the research in this thesis focuses on the FT3SS. The FT3SS has previously been modified 
for protein secretion with limited success -but great promise.  A 35 kDa recombinant lipase PalB was 
secreted in small amounts in by a from a flagella CAPless (∆fliCD) E. coli MKS12 mutant after 32 
hours, however the paper does not eliminate cell lysis as the reason for the occurrence of PalB in the 
media or show that the protein was secreted by the modified FT3SS specifically (Narayanan et al., 
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2010). A selection of recombinant amino acid motifs and genes were fused to the a secretion signal 
and terminator sequence and secreted from the same mutant strain (Majander et al., 2005). The 
largest secreted protein was a 43 kDa enolase and the highest yield was 12mg L-1 of 28 kDa Peb1. 
Another study showed that sea snail venom (25 amino acids long) could be secreted by the 
Salmonella enterica FT3SS when fused to a protein which is natively secreted by the FT3SS (Singer et 
al., 2012). Spider silk has also been secreted from the Salmonella injectisome T3SS. Three different 
spider silk proteins were fused to an N-terminal secretion tag and a chaperone (Widmaier et al., 
2009). The largest protein secreted was 75kDa at a yield of 6.9 nmol-1 L-1 Hour.  The highest yield of 
recombinant protein secretion achieved was 1.8 mg L-1 Hour-1. A range of proteins (GFP, human 
complement protein) have also been successfully secreted in Salmonella with the partial protein 
secretion tag (Végh et al., 2006; Dobó et al., 2010). The intricacies of these modes of recombinant 
FT3SS in terms of modifications to the FT3SS and use of secretion signals will be discussed in a later 
section, once the FT3SS has been introduced more thoroughly.   
 
The autotransporter type V secretion system has potential for recombinant protein secretion 
applications; although this is more commonly related to cell surface expression of protein, rather 
than full secretion into the media. For example replacing the passenger domain of the 
autotransporter protein can result in surface display on the outside of the bacteria –this has value in 
vaccine development (Jong et al., 2012).  Recombinant ScFv, lipase and toxins have all been 
displayed on the surface of E. coli following secretion through the TVSS (van Ulsen et al., 2014).  
 
In this thesis the secretion of recombinant proteins via a modified FT3SS will be investigated. As 
described above, secretion of recombinant proteins has been achieved previously in a number of 
other secretion systems in addition to the FT3SS. However this secretion system was selected due to 
various regulatory and structural characteristics of the FT3SS. In the next section the secretion 
system will be detailed and reference will be given to why this secretion system was selected to 
form the basis of the secretion platform. A strategy for modification of this protein secretion system 
to generate a secretion apparatus for protein expression will also be given. 
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1.4. The bacterial flagellum 
 
 
The bacterial flagella is an organelle which allows cell motility in many Gram negative bacteria 
(Wang et al., 2012). Each flagella is a helical filament which is driven by an ion flux powered rotary 
motor (Berg, 2003). On average E. coli have 4-10 flagellum –which can be around 20µm in length 
(Lino, 1974). Movement is directional and driven by a sensory system which dictates whether the 
motor spins clockwise or anticlockwise. With clockwise flagella rotation, E. coli conduct tumble or a 
random search moving 30 diameters per second in one direction – then the other (Adler, 1975). 
Receptors on the cell surface detect chemical stimulants, such as sugars and amino acids –and 
chemical deterrents. In this event the motor will switch to anticlockwise rotation and steady one-
directional movement known as a run is achieved, this causes the individual flagella to assemble into 
a bundle and allows the bacteria to move to a more beneficial environment. The bacterial flagella is 
the product of billions of years of evolution – it is comprised of over 50 proteins, which assemble in 
an orderly fashion, controlled by checkpoints (Chilcott & Hughes, 2000). Proteins assemble initially 
at the inner membrane and proceed to assemble to the cell exterior in a distal to proximal fashion. 
The majority of flagella proteins are secreted as unfolded subunits through the existing central 
channel and proceed to the distal end of the existing flagella structure for assembly beneath various 
FT3SS cap foldases.  
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1.4.1. Structure and assembly  
 
Figure 1.4: The distribution of proteins in the flagella type II secretion system.  
Adapted from (Liu & Ochman, 2007) 
 
 
This section will give an overview of the mechanism of assembly and structure of the FT3SS (Figure 
1.4), for specific protein name and function see Appendix 1. The basic structure of the flagella is of a 
basal body, hook and filament. The basal body acts as the motor and the secretion apparatus, the 
hook as a universal joint and the filament as a propeller. Flagella assembly initiates at the MS ring, 
Hook 
Filament 
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which is comprised of FliF subunits. The MS ring is a component of the basal body which houses the 
T3SS element of the bacterial flagella. FlhB, FliO, FliP, FlhA, FliQ, and FliR are integral membrane 
proteins which assemble in the vicinity of the MS ring and either directly or indirectly all six interact 
with each other, forming the export gate. The latter three associate with the MS ring directly, 
anchoring the export gate in the central pore of the MS ring (Minamino, 2014). Once assembled 
these form a pore of about 2.0nm diameter, through which the majority of the remaining flagella 
proteins are exported (Yonekura et al., 2003). Once in situ the C ring proteins FliG, FliM and FliN then 
attach to the MS ring and cytoplasmic domain of FlhA protrudes into this cavity formed within the C 
ring (Kawamoto et al. 2013). The cytoplasmic domain of FlhA forms the binding site for ATPase, 
chaperones and export substrates. FlhB is also located in the export apparatus and has a membrane 
and cytoplasmic domain connected by a flexible linker. The C ring proteins form the rotor/switch 
complex, which contribute to control of rotation direction. Next the motor proteins MotA and MotB, 
which form the MotA4MotB2 complex attach to the C ring via MotA. This complex forms the stator 
and also the proton channel. Prior to assembly unbound MotB blocks proton flow through the 
proton channel, however when MotA collides with the basal body motor (FliG), a conformational 
change removes the block and proton flow is initiated (Hosking et al. 2006). This allows proton 
transport down their electrochemical potential gradient through the cell membrane, providing 
energy (known as proton motive force) which drives both secretion of flagella substrates and 
rotation of the flagella motor (Hosking et al. 2006) Recently sodium motive force was also shown to 
drive secretion (Minamino et al. 2016). T3SS of the rod, hook and filament proteins occurs through 
the six protein export gate described above, with the aid of the soluble FliH, FliI and FliJ proteins, 
which form the ATPase complex and at least partially unfold substrates prior to secretion. The 
proximal and distal rod proteins (FliE, FlgB, FlgC, FlgF, FlgG) are secreted through the T3SS in 
succession and assemble to span the peptidoglycan and outer membrane. Rod proteins assemble 
under the rod cap foldase FlgJ which and has dual function as it is also a β-N-acetylglucosaminidase, 
which degrades the peptidoglycan layer, to allow export of the rod proteins into the periplasmic 
space (Nambu et al., 1999; Herlihey et al., 2014).  Formation of the P and L ring proteins which 
assemble in the peptidoglycan and outer membrane respectively, are dependent on the rod proteins 
being in place beforehand. The P and L rings surround the other T3SS transmembrane proteins, 
providing a channel for both assembly and rotation (Chaban et al., 2015). 
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Figure 1.5: The switch from class II to class III flagella gene expression. 
The hook grows under the FlhD cap. FlgM binds to σ28, inhibiting it from initiating transcription of 
class III genes 2) Following completion of the hook, the hook cap is ejected 3) FlgM is secreted, σ28 is 
uninhibited and class III gene transcription is initiated  
 
The hook is then assembled under the FlgD cap, from FlgE subunits to a length of 55nm, under the 
control of the hook length regulator protein FliK to form the universal joint (Erhardt et al. 2010). 
Following the completion of the hook, a signal is sent from the hook length control protein FliK to 
the membrane export component FlhB, which results in a conformational change -switching export 
substrate specificity from early to late substrate, allowing secretion of the hook-junction and 
filament proteins (Williams et al., 1996; Evans et al., 2014). This change is brought about because 
following FlhB auto cleavage a region is opened which is comprised of a basic patch formed by the α- 
helix and β-sheets which is adjacent to the NPTH loop. It is thought that an acidic loop of FliK is able 
to ‘wedge’ into the cleft formed by the basic patch -this drives the substrate specificity switch  
(Mizuno et al., 2011). This is critical for the secretion of late substrates, as prevention of auto 
cleavage maintains the secretion apparatus early locked (Fraser et al., 2003), suggesting that FlhB is 
essential for recognition of export substrates. Current theory suggests that FliK is intermittently 
secreted through the hook structure, immediately triggering the switch from early substrate (FlgE 
included) secretion to late when the hook reaches its physiological length of 55nm. While the hook 
extends at a constant rate, secretion of FliK is inversely proportional to this and it is thought that this 
low rate of secretion towards the end of hook extension, results in the substrate specificity switch as 
FliK is more likely to interact with FlhB (Erhardt et al., 2011). In synchrony following completion of 
the hook, secretion of the hook filament junction protein, FlgK displaces the FlgD cap from the hook 
tip (Ohnishi et al., 1994). This permits secretion of the anti σ28 factor FlgM, resulting in uninhibited 
intracellular FliA (Hughes et al., 1993). Prior to this FlgM binds σ28 factor –FliA (Figure 1.5), inhibiting 
Export apparatus :
Rod/ hook type
FlgM-28 
complexes
No class III 
transcription
FlgM-28 
complexes
No class III 
transcription
FlgD ejection Export apparatus:
Switches to 
Filament type
Export apparatus:
Switches to 
Filament type
class III gene 
transcription
active 28
FlgM secretion
1. 2. 3.
54 
 
class III gene expression (and also protecting in FliA from proteolysis) (Barembruch & Hengge, 2007). 
FliA initiates class III based transcription of proteins including the hook associated proteins (HAPs) 
FlgK, FlgL and FliD and the 52kDa flagellin protein FliC (Daniell et al., 2003). Secretion of the late 
subunits is dependent on chaperones FlgN (for FlgK and FlgL), FliT (for FliD) and FliS (for FliC). The 
hook-filament junction proteins (FlgK and FlgL) assemble on the hook and finally the filament grows 
as flagellin monomers are transported from the cytoplasm through the central channel and then to 
the distal end (Yonekura et al., 2000). Flagellin monomers assemble under the FliD cap which rotates 
as flagellin units assemble and aids polymerisation of the flagellin units. 20,000-30,000 flagellin 
monomers self-assemble in one flagella at a rate up to 1000 per minute to form a filament 10-20µm 
long, with a diameter of 120-240nm (Erhardt et al. 2010).  
 
Efficient secretion through the FT3SS is accomplished by the presence of chaperones, secretion 
signals, ATPases, proton and sodium motive force and subunit interaction. Together the export gate 
including the protruding FlhA cytoplasmic domain -which binds secretion substrates, chaperones and 
ATPase- form the ‘export cage'. (Evans et al., 2014). FlhB is also located in the export apparatus and 
has a membrane and cytoplasmic domain connected by a flexible linker. FlhB auto cleavage occurs at 
the NPTH loop the cytoplasmic domain. The cytoplasmic domain remains associated with the 
membrane domain and this flexibility between the two substrates allows secretion to occur 
(Minamino & Macnab, 2000). Situated below the export cage is the ATPase complex (comprised of 
FliI, FliH and FliJ). The ATPase regulator FliH interacts with the ATPase FliI; anchoring it to the C-ring 
and preventing ATPase activity and interaction with the export cage until the secretion structure is 
constituted (Minamino & Macnab, 2000). To initiate subunit export, FliJ is required to span the gap 
between FliH-FliI and FlhA (Abrusci et al., 2013).   
 
As described, the flagella assembles in a sequential manner; during secretion in the early phase, 
unchaperoned early substrates interact with the ATPase FliI and its regulator FliH (Auvray et al. 2002; 
Thomas et al. 2004). Following docking at FliI, substrates are sorted for early or late export by the N-
terminal secretion signal residues of substrates (Stafford et al. 2007). FliI is also thought to mediate 
partial unfolding of the substrate (Akeda & Galán, 2005). Along with FlhA, early substrates also 
interact with FlhB prior to export. Autocleaved FlhB has a hydrophobic pocket in the cytoplasmic 
region; the presence of this is essential for the secretion of rod and hook proteins. It is though that 
this is a binding site for N-terminal gate recognition motifs (GRM) of early secretion substrates 
(Evans et al., 2013).  
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Late substrate soluble components are pre-bound to their respective chaperones at the C-terminus 
(Bennett & Hughes, 2000). Chaperone binding prevents polymerisation of monomeric substrates 
prior to export and degradation by proteolytic enzymes (Fraser et al., 1999). The chaperones target 
chaperone-substrate complexes towards the export machinery, where the chaperone N-terminals 
associate with the ATPase (FliI), which is present as a FliI-FliH complex, this complex directs the N-
terminal of the substrate to FlhA, in unison the FliJ drives the N-terminal of chaperones to interact 
with the cytoplasmic domain of FlhA (Thomas et al. 2004; Kinoshita et al. 2013; Minamino & Namba, 
2008). FliJ interacts with FlhA and has affinity for the FlgKL and FliD chaperones FlgN and FliT, but 
not the FliC chaperone FliS suggesting that FliJ enables efficient export of the hook associated 
proteins prior to the secretion of FliC (Evans et al. 2006). It is thought that rotation of FliJ may drive 
conformational change in FlhA, which results in release of the subunit by its cognate chaperone and 
further unfolding (Abrusci et al., 2013).  
 
The chaperones direct late substrates for export, prior to release, but they do not serve as signals for 
secretion. Disordered N-terminus domains serve as secretion signals for protein export (Kuwajima et 
al., 1989). No defined cleavable signal peptide sequence is conserved in T3SS export proteins, 
therefore it is thought that a recognition is achieved at a higher level in the disordered N-terminus 
domains (Homma et al., 1990; Vonderviszt et al., 1992). Despite this, studies have previously 
identified the peptide regions responsible for directed secretion by investigating the secretion of 
protein with N-terminal residue deletion mutants. For example it was found that only residues 26-47 
of FliC were required for secretion, furthermore fusing these residues to a homologous protein 
directed it for FT3SS (Végh et al., 2006). There is also much debate over whether the 5’ untranslated 
region of secretion substrate mRNA is required as a secretion signal, while it is certainly capable of 
driving secretion it is not essential (Cheng & Schneewind, 2000; Majander et al. 2005; Dobó et al. 
2010). As previously explained early subunits harbour GRMs which have affinity for the export gate 
protein FlhB (Evans et al., 2013).  
 
Secretion through the FT3SS and torque generation of the flagella is powered by ATP and proton and 
sodium motive force. This is under tight regulation as it is costly. As described the FliH inhibits 
premature ATP expenditure by the ATPase complex and MotB blocks proton flow through the 
proton channel (Minamino & Macnab, 2000; Hosking et al. 2006). The ATPase complex facilitates 
substrate association with the export gate, however the ATPase is not essential for protein export, 
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although it is thought that following interaction with the substrate-chaperone complex, ATP energy 
is required to release the substrate (Minamino & Namba, 2008). It is now known that the PMF also 
provides energy for secretion through the FT3SS; this is comprised of two components: the 
electrochemical potential difference (∆Ѱ) and the proton gradient (∆pH) (Galperin et al. 1982). It 
was shown that in the absence of the ATPase complex, low efficiency ∆pH transport occurs, however 
when the FliJ component of the ATPase complex interacts with FlhA high capacity ∆Ѱ and ∆pH 
driven secretion is enabled (Erhardt et al., 2014). There is also evidence that FlhA acts as a channel 
for sodium, thus facilitating a sodium motive force. While this is usually inactive, in the absence of 
the ATPase complex it is activated –this suggests a dual powered system, which is effective in the 
absence or presence of ATPase (Minamino et al. 2016). Once subunits are secreted they must move 
through the existing structure before they are crystallised at the tip, as the filament can reach 
lengths of 20µm –as the structure elongates the rate of protein secretion remains constant (Turner 
et al., 2012). This constant rate of secretion is driven by head to tail linkage of both FliC and FlgE 
protein subunits, which results in a chain (Evans et al., 2013). This chain is formed by linkage of the 
N- and C-terminals of adjacent subunits; this enables subunit transit through the existing flagella 
structure by a pulling force which is generated as the N-terminus of the foremost subunit shortens 
during crystallisation at the tip -this results in subunits being pulled from the export apparatus into 
the existing flagella structure. 
 
As stated previously, with modifications there is scope to secrete recombinant proteins through a 
modified structure of the FT3SS. Not only would this enable one step secretion of protein from the 
cytoplasm to the extracellular space, but if the secretion capacity could be fully harnessed, then the 
yield of secreted recombinant proteins could be of industrial biotechnological relevance. If this were 
achieved this work would serve as a pertinent example of a top down synthetic biology approach to 
achieving recombinant protein secretion in an E. coli chassis. To enable this, knowledge was drawn 
on from the literature of the genetic regulation of FT3SS structure and previous flagella mutants 
which enabled monomeric secretion of subunits through the FT3SS and into the media.   
 
1.4.2. Comparison to injectisome T3SS 
 
There are many similarities between the Injectisome and flagella T3SS. There are many homologous 
proteins and both assemble from the base to the tip (Erhardt et al. 2010). The majority of major 
structures are in place in both, however there are some differences. In the IT3SS the MS ring is 
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comprised of secretins -it is also void of a motor. The export apparatus is situated within the MS ring 
of both structures however the injectisome lacks a robust C-ring –although a homologue SpaO is 
present and this forms the sorting platform along with OrgA and OrgB (Lara-Tejero et al., 2011). 
Injectisome gene expression is less stepwise in regulation, as all components are transcribed from 
class II operons. However there are still checkpoints in terms of assembly, due to the affinity of 
substrates and chaperones for the secretion apparatus. Chaperones protect substrates from 
premature polymerisation and degradation and direct substrates for export at the export apparatus 
in both systems and this is facilitated by the ATPase and proton motive force. The IT3SS ATPase InvC 
is analogous to FliI and also unfolds protein before transit which is aided by OrgA and OrgB, the 
former is homologous to FliH, however the latter has no known homologue in the FT3SS (Akeda & 
Galán, 2005). However while FT3SS chaperones bind to the C-terminal of substrates, IT3SS 
chaperones bind to the N-terminal, however N-terminal signal peptides are present in both systems 
(Kosarewicz et al., 2012). If injectisome chaperones are removed this can lead to IT3SS substrates 
being exported through the FT3SS, suggesting homology of the N-terminal secretion signal and T3SS 
and also demonstrating the importance of chaperones (Lee & Galán, 2004). The main differences 
arise in terms of the extracellular structure and function, however subunits are still analogous. The 
needle (PrgI) and hook proteins are analogous and the length of both are controlled by an accessory 
protein (InvJ in the injectisome), resulting in either an 80nm needle or 55nm hook. InvJ also drives a 
substrate specific switch following hook completion and late substrates are exported (Kawamoto et 
al. 2013; Wee & Hughes, 2015). Rather than the hook filament junction, a translocon platform is 
then assembled on the tip of the needle and upon contact with a host cell, this results in the 
secretion of two translocon proteins, followed by the secretion of effector proteins through the 
lumen of the existing structure into a host cell (Galán & Wolf-Watz, 2006). Whereas the hook-
filament junction proteins assemble on the hook tip and filament proteins are secreted through the 
existing structure –rather than be released into the environment, they are polymerised under a cap 
protein. Both are high capacity secretion systems. 
 
1.4.3. Flagella gene hierarchy  
 
As production of flagella is an energetically expensive process it is under tight regulatory control. 
Flagella genes are assembled into a transcriptional hierarchy (Chilcott & Hughes, 2000). Three 
classes exist within the hierarchy; the class I operon flhDC is at the top of the hierarchy (Figure 1.6). 
The class I operon product is the FlhD4C2 complex which activates the class II genes which encode 
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the flagella hook basal body (HBB) proteins and some regulatory proteins, including sigma factor σ28 
(FliA) and anti-sigma factor σ28 FlgM. FlgM suppresses FliA during hook basal body formation, upon 
completion FlgM is secreted into the media, allowing FliA to promote the transcription of the class III 
genes which encode the filament, motor and chemotaxis proteins (Kutsukake, 1994).  flhDC 
expression is regulated by various proteins which are expressed in response to environmental cues 
including pH, temperature, nutrient availability and osmotic pressure (Soutourina & Bertin, 2003). 
These proteins may either directly or indirectly result in up- or down- transcriptional regulation of 
flhDC or act on the FlhD4C2 complex to either block it from activating gene expression of class II 
promoters or actively degrade the complex. Transcriptional regulation is mediated through multiple 
sites in the large upstream region of the flhDC promoter (Fahrner & Berg, 2015). Additionally 
feedback expression loops of flagella genes occur; where protein produced as a result of flhDC 
expression go on to repress or activate master regulator or class II or III protein expression (see 
Figure 1.6). These proteins are the protein chaperones FlgN, FliS and FliT. FlgN regulates FlgM, 
therefore affecting class III gene expression  (Karlinsey et al. 2000). FliS negatively regulates the 
export of FlgM (Yokoseki et al., 1996).  FliT negatively regulates class II gene expression by binding to 
FlhD4C2 (Yamamoto and Kutsukake, 2006). Alternatively proteins can directly digest the FlhD4C2 
complex.  The effects of these proteins on flagella gene expression are outlined in detail in Table 1.1 
with reference to the phenotype of strains following mutagenesis. Along with flagella biogenesis 
FlhD4C2 also regulates promoters in a wider regulon. While it binds to a multitude of promoter 
regions it does not cause a large transcriptional effect (Stafford et al., 2005), nether-the-less it has 
been shown to repress cell division, upregulate galactose transport, downregulate aerobic 
respiration (Prüß et al. 2001; Prüss & Matsumura, 1996).  
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Figure 1.6: Flagella genes organised into operons within flagella regulatory classes.  
Feedback inhibition is denoted with blunt ended arrows. Adapted from Claret & Hughes, 2002; 
Karlinsey et al. 2000. 
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The master regulator forms a point of fulcrum control over the FT3SS; therefore it is a prime point 
investigation into improved FT3SS performance with regards to protein secretion, whether this 
concerns transcriptional regulators and proteases which respond to environmental cues or negative 
feedback from within the flagella regulatory hierarchy. Previous experimental work will now be 
summarised which has 1) modified the FT3SS to initiate the secretion of recombinant proteins and 2) 
reported gene modifications which have resulted in increased master regulator activity. This will 
form the basis of experimental work in the next chapter, as combined it will aid the production of a 
strain which is capable of high capacity secretion of recombinant proteins through the FT3SS.  
 
1.4.4 Previous FT3SS gene deletions that result in secretion of monomeric 
flagella subunits 
 
Various gene deletions are outlined in the literature, which result in the secretion of monomeric 
flagellin into the extracellular media. This will be exploited for the development of a modified FT3SS 
which is able to secrete recombinant proteins into the media. As stated previously, bacterial FT3SS 
genes and function are highly conserved among gram negative bacteria, therefore deletions 
reported in the literature regarding various bacterial species are also applicable to E. coli. Deletions 
of the flagella, cap and hook-filament junction proteins produce immotile mutants as the flagella fail 
to polymerise, these are outlined below –with additional reference made to beneficial knockout 
mutations in terms of increasing FT3SS secretion. 
 
As discussed the tip of the flagella is formed of the cap protein FliD. Flagellin subunits assemble 
under the cap. In FliD mutants the hook assembles, however polymerised FliC filaments do not form, 
instead FliC is secreted into the culture media as monomers (Yokoseki et al., 1995). FliD mutants are 
mainly immotile, however it has been shown that when supplemented with exogenous flagellin, 
filaments will polymerise on the hook and some motility is restored. E. coli which lack FliC, do not 
have filaments and are essentially immotile (Li et al., 1993). Class II promoter activity is seen to 
increase in ΔfliD (Brown et al., 2008). This is thought to be because fliD is in the same operon as fliT, 
which represses master regulator gene expression. Furthermore an increased number of flagella 
basal bodies were observed following the deletion of fliCD, this is thought to be due to the removal 
of secretion competitors to FlgM (Singer et al. 2012). 
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The hook-filament junction is absent in ΔflgKL bacteria. These mutants produce FliC however it does 
not form a filament, instead the unpolymerised FliC monomers are secreted into the culture media 
(Homma, 1984). Increased extracellular homologous protein (FlgM, FliD) has been observed in cells 
with flgKL deletions in comparison to wild type, suggesting that secretion of some protein subunits is 
higher in ΔflgKL (Brown et al., 2008).  
 
1.4.5. FT3SS recombinant protein secretion  
 
As described, the FT3SS provides a high capacity route of protein export from the cytoplasm to the 
extracellular space – the filament is comprised of up to 30,000 flagellin monomers (Erhardt et al. 
2010). If generation time is assumed to be 30 minutes, this amounts to an export rate of 
approximately 1000 subunits per minute, which equates to approximately 0.5g L-1 Hour-1 -a rate 
which rivals that achieved by secretion efficient yeast strains such as Pichia Pastoris or secretion 
competent Bacilus genus (Love et al., 2012; Chen et al., 2012; Liu et al., 2013) However it has since 
been demonstrated experimentally that the rate of secretion is one monomer every two seconds, 
equating to 15 mg-1 Hour-1 (Turner et al. 2012)–while this is less impressive than the previous 
estimation, it is still an remarkable rate. This capacity can be exploited for high throughput secretion 
of recombinant proteins. In addition, well understood natural regulatory systems are in place for 
flagella gene expression control and lend themselves to manipulation and control. Specifically, they 
are under direct or indirect control of the master regulator complex FlhD4C2, which itself is 
transcriptionally regulated by proteins in response to environmental cues. Various attempts have 
been made to convert the FT3SS into a high capacity secretion system. These efforts mostly rely on 
the fact that removal of filament and cap proteins results in a modified FT3SS that is capable of 
secreting both native and recombinant proteins (Majander et al. 2005; Narayanan et al. 2010; Singer 
et al. 2012). 
This project aims to optimise an E. coli strain for directed secretion of proteins from the cytoplasm 
directly to the extracellular environment, through a modified FT3SS. The flagella secretion system 
will serve as a platform technology for the secretion of a range of proteins. Strain optimisation by 
knockout mutagenesis aims to improve secretion output by altering regulatory gene expression and 
also removing superfluous genes to reduce metabolic burden. Assays will be developed to quantify 
secretion output of strains; this will be coupled with an assay to measure flagella gene expression. 
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Initially native protein secretion through the modified secretion apparatus will be investigated and 
an SDS-PAGE based protein secretion assay will be developed. Once this is established directed 
recombinant protein secretion will be implemented with the aid of a secretion construct, which will 
harbour recombinant cargo protein and is also comprised of a secretion signal and tags for 
purification. The secretion construct will be modular and therefore allow alteration of the cargo 
protein –and later modification of the secretion construct for improved secretion. This will be 
employed to secrete a recombinant enzyme which will enable a high throughput enzyme based 
secretion assay to be developed. This assay will allow efficient and accurate screening of a multitude 
of strains and secretion plasmids to identify the most productive combination in terms of secretion. 
 
This work is in the context of previous attempts to modify the FT3SS to secrete recombinant protein. 
In section 1.3.6 yields of secreted recombinant protein through the FT3SS were reported; here I will 
outline how they were implemented, along with additional examples.  
∆fliCD mutants were successfully utilised to secrete a number or recombinant proteins (including 
enolase, GFP, the Peb1 adhesin, and PalB lipase) through the FT3SS into the media. This was enabled 
by fusing recombinant protein to the 5’ and 3’ untranslated regions of the FliC gene (Majander et al., 
2005; Narayanan et al., 2010). This background was also used to secrete FlgM secretion signal 
tagged recombinant toxin proteins; while secretion was achieved without this mutation, it was 
greatly improved with it (Singer et al., 2012). 
∆fliC mutants were utilised to investigate secretion of FliC 47 amino acid secretion signal peptide 
fused recombinant proteins in the absence of the UTRs. Here it was concluded that the 5’ UTR was 
not necessary to secrete protein through the FT3SS. In addition to this it was established that only    
of residues 26-47 of the secretion signal were required to incur secretion (Dobó et al., 2010; Végh et 
al., 2006).  
The literature here has focused on secretion of late secretion substrates in mutants with intact 
hooks, however it is also possible to bypass this and secrete protein linked to early secretion 
substrates in a hook mutant, this forgoes the control of FlgM on protein secretion. This has been 
achieved by fusing recombinant protein to either FlgD or FlgE secretion signals or the FlgD 5’ UTR in 
a ∆flgD or ∆flgE background (Singer et al., 2014) 
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1.4.6. Master regulator effects of FT3SS expression 
 
Once the FT3SS has been successfully modified to allow recombinant protein secretion, increasing 
the number of basal flagella systems in the organism will allow more secretion into the culture 
media. Some gene deletions may increase the number of flagella present. The main route to 
enabling this is to reduce the prevalence of negative regulators of the master regulator and increase 
activators. An alternative is to remove proteins which actively degrade the FlhD4C2 complex or 
inhibit the complex from inducing class II gene expression. If this is achieved the increased 
abundance of FlhD4C2 will directly or indirectly promote expression of all remaining flagella genes in 
the hierarchy. Motility of cells is commonly used to ascertain flagella gene expression, as the output 
of increased flagella gene expression in cells which produce full length filaments is generally an 
increase in motility. Previous gene deletions which resulted in increased flagella expression (or 
motility) as a result of either increased flhDC expression or decreased FlhD4C2 complex proteolysis or 
binding are compiled in Table 1.1. It is hoped that these can be later implemented to improve 
secretion capacity of the modified FT3SS. Likewise gene deletions which resulted in reduced flagella 
gene expression are also included, to give a more complete picture of regulation and because these 
could also be utilised later -in promoter replacement strategies for example. This table only concerns 
flagella synthesis and does not account for the wider regulatory effects which FlhD4C2 initiates 
transcription throughout the genome –which included protein folding machinery, polysaccharide 
synthesis, membrane transport (Stafford et al., 2005; Fitzgerald et al., 2014). It should be noted that 
whereas previously literature describing assembly and regulation of the FT3SS was drawn on for 
both Salmonella and E. coli due to similarities, environmental cue determinants of flhDC expression 
vary in the two species. This is because in low nutrient availability E. coli flagella gene expression is 
upregulated, whereas in Salmonella it is down regulated, therefore care must be taken when 
interpreting data, depending on which species was investigated and whether nutrient availability 
impacted on results (Wada et al., 2012). For example in Salmonella YdiV inhibits FlhD4C2 class II gene 
expression in low nutrient concentrations. This can be reversed by upregulating the flagella protein 
FliZ, as it represses ydiV. However the E. coli ydiV is non-functional, therefore neither of these 
effects are observed in E. coli (Wada et al., 2012) –that aside FliZ does negatively regulate flhDC 
expression directly in E. coli (Pesavento & Hengge, 2012). Literature referring to environmental 
regulators of Salmonella was excluded for this summary (for example RflM and EcnR (Wozniak et al., 
2009; Singer et al., 2013)), with the exception of information relating to FliT and Dnak as they do not 
concern environmental regulation of flhDC.  ………………………………………………………………. 
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Table 1.1: Gene knockouts and reported flagella gene and phenotypic effects  
Gene 
 
Organism  Function in WT Reported gene and phenotypic effects in 
mutant 
Reference  
A. Knockout mutations result in increased flagella gene expression or motility 
fliT Salmonella 
enterica  
Prevents  FlhD4C2 from binding to class II 
promoters, also releases DNA-bound FlhD4C2 which 
results in increased ClpXP proteolysis 
 
Higher class II gene expression and increased 
motility, despite less FlhD4C2 
Yamamoto & 
Kutsukake, 2006 
 
fliZ E. coli Binds to the flhDC promotor region Increased flhDC expression in the fliZ knockout 
mutant 
 
Pesavento & 
Hengge, 2012 
lrhA E. coli Binds to flhD 3.5 reduction in FlhDC expression and 
hypermotile cells 
 
Lehnen et al. 2002 
 
dksA E. coli Enhances activity of ribosome synthesis molecules 
pppGpp and ppGpp, which reduce flagella gene 
expression 
Increased flhDC expression (Lemke et al., 2009), 
hyperflagelated and hypermotile cells (Aberg et 
al., 2009) OR less motile  cells (Magnusson et al., 
2007) 
 
(Lemke et al., 2009; 
Aberg et al., 2009; 
Magnusson et al., 
2007) 
clpXP E. coli Degrades  FlhD4C2 protein (is a protease) Hyperflagellated  Kitagawa et al. 
2011; Tomoyasu et 
al. 2002 
 
matA E. coli Represses flhDC transcription Mutants were slightly more motile Lehti et al. 2012 
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rscB E. coli and 
S.enterica 
Binds to the flhDC regulon and negatively regulates 
flhDC, positively regulates fliPQR 
 
Decreased flhDC gene expression when over 
expressed in E. coli, increased motility in 
Salmonella knockout mutant 
Wang et al. 2007; 
Francez-Charlot et 
al. 2004 
 
hdfR E. coli Binds  FlhD4C2 In H-NS deficient mutants. HdfR is negatively 
controlled by H-NS. Therefore H-NS mutants have 
more active HdfR  and mutants are nonflagellated  
Ko & Park, 2000 
B. Knockout mutations result in decreased flagella gene expression or motility 
sirA, 
csrB & 
csrC 
E. coli csrA stabilises FlhD4C2 and increases its expression, 
csrB and csrC are antagonists of csrA. sirA activates 
csrBC translation 
Reduced flhDC gene expression and motility and 
less flhDC mRNA in late exponential phase 
Wei et al. 2001  
DnaK Salmonella 
enterica 
This chaperone aids correct assembly of  FlhD4C2 
allowing it to interact with promoters 
 
Lack flagella and class II and III gene expression Takaya et al. 2006 
CRP E. coli Increases flhD operon transcription in the absence 
of glucose 
crp mutant was non-motile  Soutourina et al. 
1999; Zhao et al. 
2007 
QseB E. coli Increases  flhD operon transcription in the 
presence of FliA 
 
Less flagellin and less transcription of flhD, fliA, 
motA and fliC 
Sperandio et al. 
2002 
H-NS E. coli Increases flhD operon transcription when all H-NS 
binding sites are bound by H-NS  
hns mutant was non-motile Soutourina et al. 
1999 
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With this information in mind it seems that there is great potential to modify the FT3SS into a 
secretion apparatus, for the secretion of recombinant protein. Secretion occurs from the cytoplasm 
directly to the extracellular environment, the system is high throughput and there is good control of 
secretion with the use of protein secretion signals. There is a good understanding of structure and 
genetic regulation of the FT3SS and the regulatory network is well suited for genetic manipulation. In 
addition, there are previous examples of recombinant protein secretion by this route, demonstrating 
that manipulations can result in positive results. Once an optimised protein secretion system has 
been produced, strain improvements and plasmid based improvements for increased secretion will 
be investigated and recombinant proteins will be expressed for directed secretion through the 
modified FT3SS.  
 
1.5. Collagen 
 
This project had the main aim of improving the flagella type III secretion system (FT3SS) for 
recombinant protein secretion, however the crowning aim was to secrete human collagen as an 
exemplar of this secretion platform. Collagen is the most abundant and widely distributed class of 
mammalian proteins, comprising of around one third of all protein, it constitutes three-quarters of 
dry skin weight and is the most abundant component of the extracellular matrix (Shoulders & 
Raines, 2009). Collagen describes a class of proteins which form supercoiled triple α helical 
supramolecular structures. Collagen proteins are comprised of a combination of 46 distinct 
polypeptide chains which trimerise homo- or hetero-trimerically to form the 28 distinct collagen 
types, all of which vary in size, function and distribution. While the different collagen types have 
different structures and properties all are structural fibrous proteins which are usually located in the 
extracellular matrix.  Collagen most commonly serves as a biomechanical scaffold, giving tensile 
strength, allowing cell attachment and macromolecule anchorage, therefore defining the form of 
associated tissues (Kadler et al., 1996). Collagen is also involved in cell migration, cancer, 
angiogenesis and tissue morphogenesis and repair (Kadler et al., 2007). As different collagen types 
have different properties, tissue types have different collagen type compositions. Type I collagen is 
the most abundant collagen and is found in all tissues except cartilage. For this reason it will be the 
focus of the work carried out in this thesis. As described below Type I collagen is extremely useful, 
however there are issues with deriving it from animal sources, therefore recombinant sources would 
be favourable.  
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1.5.1. Basic structure 
 
The three polypeptide α chains which form a collagen triple helix molecule are about 1000 amino 
acids long and all conform to a strict repeating amino acid motif of (Gly-X-Y)n (Brodsky & Persikov, 
2005). Most commonly the motif repeated is Gly-Pro-Hyp (Ramshaw et al., 1998). Each α chain has a 
pitch of 18 amino acids per turn, these assemble trimerically and are staggered relative to each 
other by one amino acid (Schulz & Bader, 2007). Collagens are not consistently triple helical 
molecules – all collagens have non-helical domains at the N- and C- termini. Furthermore only type I 
collagen is in absence of any imperfections in the triple helix. Other collagens have interruptions in 
the triple helix, this is more common in non-fibril forming collagens (Kadler et al., 2007).  
 
1.5.2. Collagen biosynthesis  
 
I will focus on fibril forming collagen formation – primarily of type I collagen, as they are the most 
abundant and the majority of literature also focuses on them. However it is likely that the basic 
mechanism of triple helix formation applies to all collagen types (Gelse et al., 2003).  
 
Collagens are mainly produced in cells of connective tissues and secreted into the extracellular 
space, where they assemble into collagen fibrils. The steps of collagen biosynthesis are summarised 
in Figure 1.7. Collagen mRNA is transcribed in the nucleus, capping at the 5’ end and polyadenylation 
at the 3’ end occurs as may alternative splicing. mRNA is then transported to the cytoplasm and 
translated at the rough endoplasmic reticulum (RER) (Gelse et al., 2003). Prior to trimerisation 
extensive post-translational modifications occur in the endoplasmic reticulum. Single chain 
preprocollagen projects from the RER, following the removal of signal peptides for RER protrusion 
the molecule is known as procollagen. Some proline and lysine residues are hydroxylated in the 
presence of cofactors by prolyl 3-hydroxylase (P3H) and prolyl 4-hydroxylase (P4H) or lysyl 3-
hydroxylase respectively (LH3). The hydroxylation of proline residues is essential to collagen 
thermostability. Around 100 proline residues are converted to hydroxyproline in each collagen α  
chain (Olsen, 2003). Some hydroxylysines are also O-linked glycosylated (Perdivara et al., 2013). The 
terminal pro-peptides have a single N-linked oligosaccharide, which is added by  oligosaccharide 
transfer complex (Clark, 1979). The aforementioned PTMs are essential for the formation of 
intermolecular hydrogen bonds between α chains and later for intermolecular crosslinking and 
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carbohydrate attachment. The propeptide chains are flanked by N- and C- terminus telopeptide 
regions. Three procollagen α chains align at the C-terminal and aided by enzymes (peptidyl-prolyl cis-
trans-isomerase, protein disulphide isomerase) and molecular chaperones (heat shock protein 47), 
trimerise and fold, progressing to the N terminal to form an α triple helix. These triple helical 
procollagen molecules are now packaged into secretory vesicles in the Golgi apparatus and secreted 
into the extracellular space.  N- and C-metalloproteinases then cleave the procollagen molecule 
forming tropocollagen. Lysyl oxidase catalyses the formation of aldehydes from lysine and 
hydroxylysine residues of telopeptides.  
 
Collagen fibril formation is largely a self-assembly process, driven by entropy (much like flagella). As 
described previously type I collagen is comprised of uninterrupted triple helical collagens, with non-
helical flanking N- and C- terminus regions -which are on average 300nm length and 1.5nm in 
diameter. The fibrils orientate differently depending on the tissue, but type I tropocollagens align in 
parallel and display D periodicity of 67nm. As the length of tropocollagen monomers is not a multiple 
of D this suggests a regular pattern of gaps and overlaps in the collagen fibril (Shoulders & Raines, 
2009). Once assembled fibrils may crosslink with other fibrils of the same or different collagen types 
or be decorated with fibril associated collagens. 
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Figure 1.7: Collagen (fibril) biosynthesis in eukaryotic cells.  
Including transcription, translation, post translational modifications, secretion and fibril formation. 
SP: signal peptidase, LH3: lysyl hydroxylase, P4H: prolyl 4-hydroxylase, OTC: oligosaccharyl 
transferase complex, PDI: protein disulphide isomerase, PPI: peptidyl-prolyl cis-trans-isomerase, NP : 
procollagen N-proteinase, CP: procollagen C-proteinase, LO: lysyl oxidase, HSP47: heat shock protein 
47. Adapted from Gelse et al., 2003. 
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1.5.3. Therapeutic uses of collagen  
 
Collagen is widely used as a medical material, due to good biocompatibility, biodegradability and low 
antigenicity. In addition the nature of collagen to form strongly associated fibres by self-aggregation 
and crosslinking, means that collagen has excellent strength. It also controls fluid loss and provides 
thermoregulation (Patino et al., 2002). Therapeutic collagen promotes cell integration; on 
administration exogenous collagen activates a cellular response, this is product specific but can 
involve the penetration of a range of cells including fibroblasts, macrophages and neutrophils. The 
degradation time of collagen products can be altered by crosslinking and pre-treatment  procedures 
(Friess, 1998). These characteristics lend collagen for use in a large number of medical applications. 
Most commonly collagen is used as a drug delivery system, however collagen is increasingly being 
used as a biomaterial for tissue therapy (Lee et al. 2001). Collagen can be manipulated into many 
physical states including solutions gels, fibres, membranes, sponges and tubing for a range of 
medical procedures including dressing for burns and wounds following injury or surgery, as fillers 
and haemostatic agents. Collagen has also been used as a dressing for vascular prostheses, as a 
guide for peripheral nerve generation and in various ophthalmology applications (Patino et al., 2002; 
Bushnell et al., 2008). Additionally collagen can be used for the delivery of a range of drugs (Friess, 
1998). For example collagen microspheres and gels have been utilised for the delivery of 
chemotherapy drugs (Panduranga Rao, 1996; Kojima et al. 2013). Type I collagen is useful as a 
scaffold for tissue engineering as it is biocompatible and also abundant and ubiquitous –therefore 
obtainable on a large scale and suitable for widespread use. In tissue engineering collagen is used as 
a scaffold in the form of a hydrogel or lattice. Although it can be used intact, removing the N- and C- 
telopeptides can reduce antigenicity (Glowacki & Mizuno, 2008). Additional crosslinking and 
copolymerisation of molecules such as chondroitin 6-sulphate may be favoured prior to use of 
collagen in tissue engineering, as this has been shown to increase cell proliferation within the 
scaffold and aid retention of proteoglycans –which are essential for cell signalling, migration and 
uptake of proteins (van Susante et al. 2001; Ferdous & Grande-Allen, 2007).  
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1.5.4. Sources of therapeutic collagen 
 
1.5.4.1. Animal Sources 
 
The global demand for collagen is huge, annually an estimated 50,000 tonnes of collagen (including 
gelatine) are derived from animal sources for use in medical applications (Olsen, 2003). Collagen is 
sourced from bovine skin, intestine and tendons (Patino et al., 2002). While animals may be a cheap 
source of collagenous material, there are many concerns surrounding various unfavourable 
characteristics of animal derived collagen. Disadvantageous qualities include poor biocompatibility, 
homogeneity, characterisation, immunogenicity and the transfer of disease from animal to patient.  
The main point of concern regarding disease and animal derived collagen is bovine spongiform 
encephalopathy (BSE). Although ante-mortem BSE tests are available they are not very reliable, 
therefore the risk of BSE in collagen therapies can only be managed and reduced, it cannot be 
guaranteed (Lasch et al., 2003). This is achieved by: (1) sourcing bovine collagen from certified ‘BSE 
free’ herds (2) using material (usually tendons) which carry a lower risk of infectivity (3) carrying out 
risk reducing procedures in the manufacturing process, such as alkali treatment (4) extracting 
collagen from tissue which has a high collagen content (again tendon) therefore reducing the 
quantity of tissue used (5) limiting the number of collagen treatments to a patient (6) only using 
certain routes of delivery. With these procedures in place the risk of contracting BSE from bovine 
sourced collagen products is reduced to less than one in a million (Friess, 1998). Immunological 
responses to collagen are variable and are dependent on the route of administration and nature of 
the collagen based therapeutic, for example 2.8% patients treated with an injectable collagen filler 
developed inflammation and 6.8% people treated with a collagen bone filler developed allergies 
(Charriere et al., 1989; Lynn et al., 2004). Preparing animal collagen for clinical applications is a 
complicated process. The presence of covalent crosslinks between collagen molecules is the major 
factor which impedes the breakdown of collagen when preparing it for clinical use (Friess, 1998). 
Additionally collagen is insoluble in organic solvents making downstream processing difficult. Once 
non-crosslinked, collagen molecules may be modified to be acylated, methylated or have polymers 
attached to give different properties. Crosslinks are then reintroduced to confer the structure 
required. This is achieved by aldehyde treatment or by physical treatment with UV or heat. Collagen 
is then sterilised by irradiation or ethylene oxide. 
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1.5.4.2. Recombinant sources of human collagen 
 
Recombinant collagen has been produced in a number of organisms (Table 1.3). The major barrier to 
recombinant collagen is the lack of adequate post translational modifications in various recombinant 
expression systems. Without PTMs such as glycosylation and hydroxylation, collagen structure and 
function varies. In some recombinant collagen expression systems collagen genes are co-expressed 
with enzymes for proline hydroxylation. The key enzyme for this process is prolyl-4-hydroxylase 
(P4H). Co-expression of collagen with human P4H has shown to improve proline hydroxylation, 
although not necessarily to the degree observed in native collagens. Alternatively inadequate proline 
hydroxylation can be avoided by expressing collagen in a mammalian cell line which natively 
expresses the enzyme. Plant cells have been also been shown to express low levels of endogenous 
PH4 but it is not high enough to sufficiently hydroxylate proline. Lysyl-hydroxylase-3 (LH3) is 
important for lysine hydroxylation, however it is less commonly coexpressed in cells. Collagen is able 
to trimerise without the mammalian folding chaperone HSP47 (Vuorela et al., 1997). Animal model 
experiments have been carried out using recombinant collagen type VII from CHO cells and show 
promising results, although this collagen is glycosylated in a mammalian way (Hou et al., 2015). 
Another study investigated the effect of prolyl-4-hydroxylase expressing Pichia derived recombinant 
collagen III procollagen, which was matured to collagen III in vitro. When applied to wounds in a pig 
model, healing was enhanced (Nuutila et al., 2015). This demonstrates demand and increased 
acceptability of these treatments.      ……………………………………………………………………………………..
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Table 1.2: Recombinant human collagen production.  
Collagen type, product and titre are listed. Co-expression of enzymes and posttranslational modification are noted, along with the occurrence of 
extracellular secretion. rP4H denotes co expression with recombinant prolyl-4-hydroxylase, rLH3 with recombinant lysyl-hydorxylase-3. Note: Only 
recombinant human protein listed, recombinant C and N collagen telopeptides are not included in this table. 
Cell  Colla
gen 
type 
Collagen product Product titre 
rP
4
H
? 
rL
H
3
? 
Post translational modifications? Extracellul
ar 
secretion? 
Reference 
Insect cell/ 
baculovirus 
III Full length triple helical 
collagen 
40mg/L 
media 
Y N Proline hydroxylation  N Helaakoski, 1996 
Human 
embryonic 
kidney cell 
VI Full length α1(VI) and α2(VI) 
chains (would not form 
collagen trimers) 
50-150µL/ml 
media 
N N 50% successful proline and lysine 
hydroxylation 
Y Tillet et al. 1994 
Pichia pastoris  III Full length triple helixes ~15mg/L Y N 42% successful proline 
hydroxylation 
N Vuorela et al. 
1997 
Pichia pastoris I Full length triple helixes with 
pepsin treatment (no N-
propeptide) 
200-500mg/L  Y N Suggests 100% successful proline 
hydroxylation 
N Nokelainen et al. 
2001 
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Human 
embryonic 
kidney cell 
V Full length triple helix 15µg/ml N N Some lysine hydroxylation, 
glycosylation 
Y Fichard et al. 
1997 
Insect cell/ 
baculovirus 
II Full length triple helix 50mg/L Y Y Lysine hydroxylation, glycosylation 15% 
secreted 
Nokelainen et al. 
1998 
Insect cell/ 
baculovirus 
II Information not available, but 
product formed collagen fibrils 
Not reported Y N Lysine hydroxylation, glycosylation N Notbohm, 1999 
HEK XVI Full length triple helix 80-100µL/L 
media 
N N N-glycosylation, proline and lysine 
hydroxylation 
Y Kassner et al. 
2004 
HEK VII Full length triple helix 2-5mg/L N N  Y Chen et al. 2002 
Saccharomyce
s cerevisiae 
I Full length triple helix 3-4µg/mg 
total protein 
Y N Proline hydroxylation N Toman et al. 2000 
CHO IV Full length α1(IV) and α2(IV) 
chains 
Not reported N N  Y Fukuda et al. 
1997 
Corn I Full length α1(I) chain 120mg/kg 
corn germ 
N N Low level of lysine hydroxylation N Zhang et al. 2009 
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Barley I Full length and 45kDa α1(I) 
chain  
140mg/kg 
seed 
N N Very low level of proline 
hydroxylation 
N Eskelin et al. 2009 
Maize I Full length α1(I) chain 4mg/kg Y N High level of proline hydroxylation N Xu et al. 2011 
Tobacco plant I Full length triple helix 20mg 
procollagen/ 
kg leaves 
Y Y Some proline and lysine 
hydroxylation 
N Stein et al. 2009 
Pichia pastoris III Full length α1(III) chain Not reported Y N Proline hydroxylation Not 
reported 
Xu et al. 2015 
Pichia pastoris I Full length α1(I) chain 89mg from 
30g cells 
N N 33% proline residues hydroxylated Not 
reported 
Setina et al. 2016 
E. coli I Fragment of α1(I) chain (193 
residues = around 23kDa) 
10% total 
cell protein 
Y N ‘High’ Not 
reported 
Buechter et al. 
2003 
E. coli III 38kDa fragment of αI (III) 
chain 
90mg/Litre 
cell culture 
Y Y 26% proline and lysine residues 
hydroxylated 
Not 
reported 
Rutschmann et al. 
2014 
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Heterologous collagen expression has been demonstrated in a range of expression systems, 
however there are common issues. Secreted collagen is rarely observed, therefore cells must 
be lysed or in the case of plant material ground to extract collagen. This is costly and time 
consuming.  
 
1.5.5. Recombinant collagen production in E. coli 
 
Many bacteria express collagen –like proteins which have the same Gly-Xaa-Yaa repeating 
motif of residues. These have been shown to form trimers when expressed in native or 
recombinant (i.e. E. coli) hosts. These could have technological applications themselves (An et 
al., 2016), but also suggests the bacteria have a natural affinity for producing these kinds of 
proteins (Yu et al., 2014). There are no reports of successful expression of recombinant full 
length human collagen in E. coli. Attempts to produce recombinant collagen in E. coli have only 
amounted to the production of human like collagen. This may be synthetically derived repeats 
of the triple motif commonly seen in collagen (Goldberg et al., 1989). Alternatively this may be 
expressed from the cDNA of fragments of human collagen mRNA. This type of collagen forms 
triple helixes similar to human collagen and has been shown to have low immunogenicity and 
is used in some therapeutic technologies (Xu et al. 2012). Expression of this kind of human like 
collagen requires extremely high cell density culture (~OD600 90).  Fragments of human type 1 
and III collagen α chains have also been expressed intracellularly in in E. coli (Buechter et al., 
2003; Rutschmann et al., 2014). 
 
1.5.5.1. Posttranslational modifications 
 
As discussed, post translational modifications, particularly hydroxylation are important in 
collagen biosynthesis. This requires enzymes which are not natively expressed by E. coli. The 
expression of recombinant P4H in E. coli is well reported. E coli derived recombinant P4H has 
been shown to hydroxylate proline residues of collagenous protein in vitro (Pinkas et al., 2011; 
Neubauer et al., 2005). Recombinant LH3 expression was reported to result in hydroxylation of 
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lysine residues of a collagen fragment in E. coli (Rutschmann et al., 2014). O- and N- linked 
glycosylation is also important in collagen biosynthesis.  As explained previously pathways for 
O- and N-linked glycosylation can be recombinantly engineered into E. coli (Wacker et al. 2002; 
Lubas, 2000; Henderson et al. 2011).  
 
1.5.5.2. Proline metabolism 
 
Collagen is a proline rich protein. E. coli are able to produce proline autotrophically , however 
production is limited by a negative feedback loop of proline on glutamate-5-kinase (Adams & 
Frank, 1980). This lack of intracellular proline is likely to limit the yield of recombinant 
collagen. A number of methods have successfully increased the amount of internal proline 
content of E. coli. One method is to remove the feedback inhibition; this has been achieved on 
two occasions by two different point mutations in the proB gene, which encodes glutamate-5-
kinase (Csonka et al., 1988; Rushlow et al., 1985). Alternatively completely removing the 
organism’s ability to produce proline, supplementing the media with proline and giving an 
osmotic shock has been shown to cause cells to uptake proline from the environment, leading 
to high internal proline levels -this has been demonstrated with hydroxyproline (Buechter et 
al., 2003). This demonstrates that the limiting step in proline rich protein production in E. coli 
is the availability of proline and not a lack of tRNA (Jonasson et al., 2002).  While effective this 
method is not suited to scale up, which would be essential for large scale recombinant 
production. Another strategy for improving the amount of intracellular proline is to increase 
the expression of proteins which produce endogenous proline or transport proline from the 
extracellular to intracellular environment and to reduce the expression of proteins which cause 
a reduction in intracellular proline. This may involve knocking out genes which are not 
conducive to proline production or accumulation or changing the promoters of genes which 
aid intracellular proline production or accumulation to confer increased intracellular proline. 
Routes for this strategy can be identified by searching the literature or by modelling the 
proline biosynthesis pathway and are discussed in Chapter 6.  
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Chapter 2. Materials and methods 
2.1. Strains 
 
Table 2.1: E. coli strains used in the study.  
Strains were either purchased commercially, donated by University of Sheffield (UoS) staff or 
generated in the study 
Strain Source 
MC1000: F-  Δ(araA-leu)7697 [araD139]B/r, Δ(codB-lacI)3 galK16 
galE15(GalS) λ- e14 relA1 rpsL150(strR) spoT1 mcrB1 (CGSC) 
Dr Graham Stafford, UoS 
MG1655: F- LAM- rph-1 (CGSC) Dr Graham Stafford, UoS 
MG1655 ΔclpX Professor Jeff Green, UoS 
(DH5α) NEB 5-alpha Competent E. coli: fhuA2 lac(del)U169 phoA 
glnV44 Φ80' lacZ(del)M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17 
New England Biotechnologies 
BL21 (DE3): F–ompT gal dcm lon hsdSB(rB
- mB
-) λ(DE3 [lacI lacUV5-
T7 gene 1 ind1 sam7 nin5]) 
New England Biotechnologies 
MC1000 ΔflhDC::FRT-Km-FRT Dr Graham Stafford, UoS 
MC1000 ΔfliC::FRT-Km-FRT Dr Matthew Hicks, UoS 
MC1000 ΔfliCD::FRT-Km-FRT Dr Matthew Hicks, UoS 
MC1000 ΔfliC ΔflgKL ΔfliCD::FRT-Km-FRT This study 
MC1000 ΔfliC ΔflgKL::FRT-Km-FRT Dr Matthew Hicks, UoS 
MC1000 ΔfliC ΔflgKL Dr Matthew Hicks, UoS 
MC1000 ΔfliC ΔflgKL ΔlrhA::FRT-Km-FRT This study 
MC1000 ΔfliC ΔflgKL ΔdksA::FRT-Km-FRT This study 
MC1000 ΔfliC ΔflgKL ΔclpX::Km This study 
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MC1000 ΔfliC ΔflgKL ΔfliDST::FRT-Km-FRT This study 
MC1000 ΔfliC ΔflgKL ΔflgMN::FRT-Km-FRT This study 
MC1000 ΔfliC ΔflgKL ΔmotAB::FRT-Km-FRT This study 
MC1000 ΔfliC ΔflgKL ΔfliDST::FRT-Cm-FRT ΔflgMN::FRT-Km-FRT This study 
MC1000 ΔfliC ΔflgKL ΔmotAB::FRT-Cm-FRT ΔfliDST::FRT-Km-FRT This study 
MC1000 ΔfliC ΔflgKL ΔmotAB::FRT-Cm-FRT ΔflgMN::FRT-Km-FRT This study 
MC1000 ΔfliC ΔflgKL ΔclpX:: Km ΔfliDST::FRT-Cm-FRT  This study 
MC1000 ΔfliC ΔflgKL ΔclpX:: Km ΔflgMN ::FRT-Cm-FRT This study 
MC1000 ΔfliC ΔflgKL ΔclpX:: Km ΔmotAB::FRT-Cm-FRT   This study 
MC1000 ΔfliC ΔflgKL ΔclpX:: Km ΔmotAB ΔfliDST   This study 
MC1000 ΔfliC ΔflgKL ΔclpX::Km ΔmotAB ΔflgMN   This study 
MC1000 ΔfliC ΔflgKL ΔflgDE::FRT-Km-FRT This study 
MC1000 ΔfliC ΔflgKL ΔproB::FRT-Km-FRT This study 
MC1000 ΔfliC ΔflgKL ΔproB E153A::FRT-Cm-FRT This study 
MC1000 ΔfliC ΔflgKL ΔputA::FRT-Km-FRT This study 
MC1000 ΔfliC ΔflgKL ΔgdhA::FRT-Km-FRT This study 
MC1000 ΔfliC ΔflgKL ΔgdhA ΔputA::FRT-Km-FRT This study 
MC1000 ΔfliC ΔflgKL ΔproB ΔputA::FRT-Km-FRT This study 
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2.2. Plasmids 
 
Table 2. 2: Plasmids used in this study. 
Plasmids were either purchased commercially, kindly gifted, donated by University of Sheffield 
(UoS) staff or generated in the study 
Plasmid Description/function Resistance Source 
pTrc99a-FF pTrc99a with NdeI site in 
multiple cloning region. Empty 
vector for protein expression. 
Referred to as pTrc99a in text. 
Ampicillin Gillian Fraser. 
Oshima et al. 2006 
pTrc99a-E2 fliC Δ191-280 inserted 
between NdeI and BamHI of 
pTrc99a-FF 
Ampicillin Dr. Matthew 
Hicks, UoS 
pJexpress-404-1-47 fliC fliC 5’ UTR- 1-47 secretion 
signal residues- XhoI-TEV- 
EcoR1- PstI- TEV-FLAG tag- 
Step tag- XbaI- HindIII- fliC 3’ 
UTR inserted between NdeI 
and BamHI of pJexpress-404-
1-47 fliC colA1 
Ampicillin Dr. Matthew 
Hicks, UoS 
pJexpress-404-1-47 fliC 
COL1A1 
pJexpress 404 with NdeI- fliC 
5’ UTR- 1-47 secretion signal 
residues- XhoI- TEV- EcoR1- 45 
kDa COL1A1- PstI- TEV- FLAG 
tag- Step tag-XbaI- HindIII- fliC 
3’ UTR- BamHI 
Ampicillin DNA 2.0, USA 
pJexpress-404-1-47 fliC-
Scl2  
Scl2 inserted between EcoRI 
and PstI of pJexpress-404-1-47 
Ampicillin Dr. Matthew 
Hicks, UoS 
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fliC  
pJexpress-404-1-47 fliC-
CH2 
CH2 inserted between EcoRI 
and PstI of pJexpress-404-1-47 
fliC 
Ampicillin Dr. Matthew 
Hicks, UoS, CH2: 
Dr 
Jagroop Pandhal 
pJexpress-404-1-47 fliC-
CH2 (no 5’UTR) 
PCR amplified NdeI- 1-47 
secretion signal residues- 
XhoI- TEV- EcoR1- CH2- PstI- 
TEV- FLAG tag- Step tag-XbaI- 
HindIII- fliC 3’ UTR- BamHI 
inserted between NdeI and 
BamHI of pJexpress-404-1-47 
fliC 
Ampicillin This study 
pJexpress-404-CH2 (no 
5’UTR) 
PCR amplified NdeI-XhoI- TEV- 
EcoR1- CH2- PstI- TEV- FLAG 
tag- Step tag-XbaI- HindIII- fliC 
3’ UTR- BamHI inserted 
between NdeI and BamHI of 
pJexpress-404-1-47 fliC 
Ampicillin This study 
pJexpress-404-1-47 fliC-
cutinase 
cutinase inserted between 
EcoRI and PstI of pJexpress-
404-1-47 fliC 
Ampicillin This study 
pJexpress-404-1-47 fliC-
cutinase (no 3’ UTR) 
PCR amplified NdeI- fliC 5’ UTR 
1-47 secretion signal residues- 
XhoI- TEV- EcoR1- cutinase- 
PstI- TEV- FLAG tag- Step tag-
XbaI- HindIII- BamHI inserted 
between NdeI and BamHI of 
pJexpress-404-1-47 fliC 
Ampicillin This study 
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pJexpress-404-1-47 fliC-
cutinase (no 5’ UTR) 
PCR amplified NdeI- 1-47 
secretion signal residues- 
XhoI- TEV- EcoR1- cutinase- 
PstI- TEV- FLAG tag- Step tag-
XbaI- HindIII- fliC 3’ UTR- 
BamHI inserted between NdeI 
and BamHI of pJexpress-404-
1-47 fliC 
Ampicillin This study 
pJexpress-404-1-47 fliC-
cutinase (no 5’ or 3’ UTR) 
PCR amplified NdeI- 1-47 
secretion signal residues- 
XhoI- TEV- EcoR1- cutinase- 
PstI- TEV- FLAG tag- Step tag-
XbaI- HindIII- BamHI inserted 
between NdeI and BamHI of 
pJexpress-404-1-47 fliC 
Ampicillin This study 
pJexpress-404-26-47 fliC-
cutinase (no 5’ UTR) 
PCR amplified NdeI- 26-47 
secretion signal residues- 
XhoI- TEV- EcoR1- cutinase- 
PstI- TEV- FLAG tag- Step tag-
XbaI- HindIII- fliC 3’ UTR- 
BamHI inserted between NdeI 
and BamHI of pJexpress-404-
1-47 fliC 
Ampicillin This study 
pJexpress-404-26-47 fliC-
cutinase (no 5’ or 3’ UTR) 
PCR amplified NdeI- 26-47 
secretion signal residues- 
XhoI- TEV- EcoR1- cutinase- 
PstI- TEV- FLAG tag- Step tag-
XbaI- HindIII- - BamHI inserted 
between NdeI and BamHI of 
pJexpress-404-1-47 fliC 
Ampicillin This study 
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pJexpress-404-sal 26-47 
fliC-cutinase (no 5’ UTR) 
PCR amplified NdeI- 26-47 
Salmonella secretion signal 
residues- XhoI- TEV- EcoR1- 
cutinase- PstI- TEV- FLAG tag- 
Step tag-XbaI- HindIII- fliC 3’ 
UTR- BamHI inserted between 
NdeI and BamHI of pJexpress-
404-1-47 fliC 
Ampicillin This study 
pJexpress-404-sal 26-47 
fliC-cutinase (no 5’ or 3’ 
UTR) 
PCR amplified NdeI- 26-47 
Salmonella secretion signal 
residues- XhoI- TEV- EcoR1- 
cutinase- PstI- TEV- FLAG tag- 
Step tag-XbaI- HindIII- - BamHI 
inserted between NdeI and 
BamHI of pJexpress-404-1-47 
fliC 
Ampicillin This study 
pJexpress-404-fliC-cutinase 
(no 5’UTR) 
PCR amplified NdeI-  XhoI- 
TEV- EcoR1- cutinase- PstI- 
TEV- FLAG tag- Step tag-XbaI- 
HindIII- fliC 3’ UTR- BamHI 
inserted between NdeI and 
BamHI of pJexpress-404-1-47 
fliC 
Ampicillin This study 
pJexpress-404- fliC-
cutinase (no 5’ or 3’ UTR) 
PCR amplified NdeI-  XhoI- 
TEV- EcoR1- cutinase- PstI- 
TEV- FLAG tag- Step tag-XbaI- 
HindIII- BamHI inserted 
between NdeI and BamHI of 
pJexpress-404-1-47 fliC 
Ampicillin This study 
pKD46 Expression of λ-RED 
recombinase system for 
Ampicillin Barry Wanner, 
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recombineering USA 
pCP20 Expression of FLP recombinase 
for excision of FRT-flanked 
markers 
Ampicillin Barry Wanner, 
USA 
pKD3 Template for overlap PCR and 
cassette construction 
Chloramphenico
l 
Barry Wanner, 
USA 
pKD4 Template for overlap PCR and 
cassette construction 
Kanamycin Barry Wanner, 
USA 
pKD13 Template for overlap PCR and 
cassette construction 
Kanamycin Barry Wanner, 
USA 
pKD32 Template for overlap PCR and 
cassette construction 
Chloramphenico
l 
Barry Wanner, 
USA 
pGPS123-lacZ pGPS123 constructed by XhoI 
and HindIII excision of Km and 
insertion of Gm in pRS551. 
lacZ inserted between EcoRI 
and PstI in pGPS123.  
Ampicillin, 
Gentamycin  
Dr Graham 
Stafford, UoS 
pGPS123-fliA-lacZ fliA-lacZ inserted between 
EcoRI and PstI in pGPS123 
Ampicillin, 
Gentamycin 
Dr Graham 
Stafford, UoS 
pGPS123-fliL-lacZ fliL-lacZ inserted between 
EcoRI and PstI in pGPS123 
Ampicillin, 
Gentamycin 
Dr Graham 
Stafford, UoS 
pGPS123-flhB-lacZ flhB-lacZ inserted between 
EcoRI and PstI in pGPS123 
Ampicillin, 
Gentamycin 
Dr Graham 
Stafford, UoS 
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2.3. Chemicals, reagents and buffers 
 
Unless stated all chemicals and reagents were purchased from Sigma-Aldrich or Fisher 
Scientific. All reagents used were of analytical grade and were purchased from the following 
suppliers (Table 2.3). Buffers were prepared in distilled water and pH adjusted with HCl or 
NaOH. Solutions were sterilised by autoclave or sterile filtration (0.22µm). The manufacturer’s 
instructions were followed during the use of all molecular biology kits. 
Table 2.3: Manufacturers and suppliers of chemicals, reagents, kits and equipment. 
Supplier Location 
BDH Laboratory Supplies Poole, UK 
Beckman Coulter High Wycombe, UK 
Bioline London, UK 
BioRad Laboratories Hertfordshire, UK 
BMG Labtech Ortenberg, Germany  
Calbiochem (Merck Millipore) Watford, UK 
Cell Signalling Technology Danvers, Massachusetts, USA 
Eppendorf  Hamburg, Germany 
Expedeon Swavesey,Cambridgeshire, UK 
Fisher Scientific Loughborough, UK 
FlowGen Biosciences (SLS Life Sciences) Hassle, East Riding of Yorkshire, UK 
GATC Biotech Konstanz, Germany 
GE Healthcare Life Science  Buckinghamshire, UK 
IBA Lifesciences  Goettingen, Germany 
86 
 
Life Technologies Carlsbad, California, USA 
Merck Millipore Watford, UK 
New England Biolabs (NEB) Hitchin, Hertfordshire, UK 
Norgen Thorold, Canada 
Promega Southampton, UK 
Sigma-Aldrich Poole, UK 
Statens Serum Institut Copenhagen, Denmark 
Syngene Cambridge, UK 
Tecan Group Ltd. Männedorf, Switzerland 
Thermo Scientific Leicestershire, UK 
Waring Laboratory Science Torrington, Connecticut, USA 
Xograph Gloucestershire, UK 
 
2.4. Microbiological culture methods 
2.4.1. Bacterial culture 
 
Stocks of bacteria were stored in 12.5% glycerol (v/v) in cryo-vials at -80°C. Luria Broth (LB) 
Agar supplemented with necessary antibiotics (ampicillin: 100µg/mL LB, kanamycin: 50µg/mL 
LB, chloramphenicol: 25µg/mL LB. All filter sterilised) were inoculated with E. coli either from 
cryo-vials or cell pellets following liquid culture. Cells were incubated statically at 37°C 
overnight and inoculated LB agar plates stored at 4°C for up to one month. Single E. coli 
colonies (or around 5 colonies for a secretion assay experiment) were selected from LB agar 
plates and grown in 5mL LB broth in a 20mL universal tube overnight. LB was supplemented 
with relevant antibiotics (aforementioned concentrations). Overnight starter cultures were 
then used to inoculate fresh LB, supplemented with relevant antibiotics. Starter cultures were 
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diluted 1 in 100 in 10mL LB broth in a 50mL Falcon tube. Exceptions to this involved the 
inoculation of 500mL LB broth in a 2.5L conical flask for protein overexpression, 100mL LB 
broth in a 500mL conical flask for secretion or gene expression assay growth curve 
experiments or 200µL LB broth per well for 96 well plate growth curve experiments. If 
necessary, additional supplements were added to initiate promoter induction of plasmids –
these included (isopropyl-β-d-galactopyranoside) IPTG (Calbiochem) and L-arabinose (both 
filter sterilised) Cells were cultured at 37°C unless otherwise stated, with 180rpm agitation 
(140rpm for conical flask cultures). Optical density of cells was measured in a 1mL cuvette at 
OD600 using a spectrophotometer. 
 
2.4.2. Transformation by heat shock  
 
For transformation of plasmids into E. coli heat shock was used. 10mL cultures were grown as 
described in 2.4.1 to OD600 0.4-0.6 and incubated on ice for 20 minutes. Cells were centrifuged 
in a pre-chilled (4°C) centrifuge for 10 minutes, 3500rpm to pellet cells. The pellet was 
resuspended in 10mL chilled 0.1M CaCl2 and incubated on ice for 10 minutes. The 
centrifugation step was repeated and the pellet was resuspended in 1mL 0.1M CaCl2. 3µL 
plasmid DNA was transferred into 200µL cell aliquots in Eppendorfs and incubated on ice for 
30 minutes. Eppendorfs were transferred to a 42°C water bath for 90 seconds and then 
incubated on ice for 2 minutes. 1mL LB was added and cells were left to recover at 37°C for 1 
hour and cells plated onto LB agar plates with the relevant antibiotics. Alternatively at the final 
resuspension step, the cell pellet was resuspended in 1mL 0.1 CaCl2 10% (v/v) glycerol. 200 µL 
cell aliquots were transferred to Eppendorfs and stored at -80°C. Following defrost of these 
aliquots on ice; the protocol could then be resumed.  
 
2.4.3. Transformation by electroporation 
 
Plasmids were also transformed into E. coli by electroporation. 10mL cells were grown as 
described in 2.4.1 to OD600 0.4-0.6 and incubated on ice for 20 minutes. Cells were centrifuged 
in a pre-chilled centrifuge at 7500rpm for 5 minutes, supernatant was resuspended in 10mL ice 
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cold dH2O. This step was repeated three times. Following the final spin cells were resuspended 
in up to 500µL dH2O.  1µL purified PCR product or plasmid DNA was added to 100µL cell 
aliquots, contents were transferred to a pre-chilled electroporation cuvette (Flowgen 
Biosciences). Cells were electroporated in a BIO-RAD MicroPulserTM series 411BR (BioRad 
Laboratories) (EC1 setting, PL5, potential difference: 2.5kV, resistance: 200Ω and capacitance: 
25µF). Cells were recovered in 1mL LB for one hour at 37°C, unless otherwise stated and cells 
plated onto LB agar plates with the relevant antibiotics. For storage at -80°C, at the final 
resuspension step, the cell pellet was instead resuspended in 10% (v/v) glycerol. 100 µL cell 
aliquots were transferred to Eppendorfs and stored at -80°C. Following the defrost of these 
aliquots on ice; the protocol could then be resumed. 
 
2.4.4. Chromosomal mutagenesis by Lambda Red recombination.  
 
Chromosomal mutagenesis was achieved by the method outlined by Datsenko & Wanner 
(2000). Chromosomal disruptions were implemented by Lambda Red recombinase induced 
homologous recombination. Chromosomal disruptions include knockout mutagenesis and 
genomic insertions.  For knockout mutagenesis PCR products were generated which harboured 
FRT (FLP recombinase recognition site) flanked antibiotic resistance cassettes (derived from 
template DNA of pKD3, pKD4 or pKD13) and ~35bp homologous nucleotides to regions 
adjacent to the gene which was inactivated. For genomic insertion, additional DNA (a gene or a 
promoter region) was also incorporated into the PCR product, adjacent to the antibiotic 
resistance cassette. Mutagenesis events occur following electroporation of the PCR product 
into arabinose induced Lambda Red recombinase plasmid pKD46 (a derivative of pINT-ts) 
containing cells. The plasmid harbours γ, ß and exo (λ) (Murphy, 1998). γ inhibits RecBCD 
activity, which digests linear DNA. Exo encodes an exonuclease which digests the 5’-3’ double 
stranded linear DNA. ß is a binding protein capable of annealing complementary single 
stranded DNA.  
Bacterial cultures expressing the Lambda Red recombinase plasmid pKD46 were supplemented 
with 1mM L-arabinose and cultured at 30°C with agitation. Cells underwent transformation by 
electroporation with PCR derived linear FRT flanked DNA. Following incubation for one hour at 
30°C and then overnight at room temperature, cells were spread on to LB agar plates 
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supplemented with relevant antibiotics. Following successful mutagenesis the antibiotic 
resistance site could be removed by a FLP recombinase carrying helper plasmid (pCP20) which 
acts on the FRT sites. The Red and helper plasmids are cured at 43°C. Plasmids were cured so 
that no further recombination events could occur. The antibiotic resistance gene flanked by 
FRT sites was removed from the chromosome of cells expressing the pCP20 plasmid when 
incubated at 43°C. 
 
2.4.5. Chromosomal mutagenesis by P1 phage transduction 
 
P1 phage transduction utilises P1vir phage to move regions of chromosomal DNA from one E. 
coli genome to another. As P1vir is capable of packaging up to 90,000kb DNA, this tool can be 
harnessed to transduce genes linked to selectable genetic markers (e.g. antibiotic resistance 
cassettes). 
 
2.4.5.1. Lysate preparation 
An overnight culture of the donor strain was diluted 1 in 100 in LB broth with 5mM CaCl2 and 
0.2% (w/v) glucose and incubated at 37°C, 150rpm for 1 hour. 100µL P1 phage lysate was 
added to the culture and incubated for 1-3 hours (until the media was clear). Several drops of 
chloroform were added and the culture was vortexed and centrifuged for 2 minutes, 
13000rpm. The supernatant was transferred to a fresh tube and a few drops of chloroform 
were added. The lysate was stored at 4°C. 
 
2.4.5.2. Transduction 
An overnight culture of the recipient strain was centrifuged to pellet the cells. The cell pellet 
was resuspended in half the volume of LB broth with 100mM MgSO4 and 5mM CaCl2. 100µL 
aliquots of culture were transferred into Eppendorf tubes. The Eppendorfs contained (1) Donor 
strain P1 lysate (2) 50µL donor strain P1 lysate. Negative controls contained (3) 100µL recipient 
cells or (4) 100µL donor strain P1 lysate only. Aliquots were incubated at 30°C for 30 minutes 
without agitation. 1mL LB broth was added and cells were incubated at 37°C for 1 hour. Cells 
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were spread on LB agar plates containing relevant antibiotics and 10mM sodium citrate (to 
chelate the calcium and inhibit reinfection). Successful transformants were passaged on LB 
agar with the appropriate antibiotic and sodium citrate three times to ensure the eradication 
of P1. 
 
2.4.6. Strain storage 
Following the conformation of a novel strain or plasmid, cells were stored at -80°C. Single 
colonies were picked from an LB agar plate and grown overnight in LB broth with relevant 
antibiotics. 1mL media was transferred to a cryo-tube with 0.5mL 50% (v/v) glycerol LB media 
and stored at -80°C. 
 
2.4.7. Plate reader growth curve 
For 96 well plate growth curve experiments cells were incubated in the Tecan Infinite 200 Pro 
plate reader (Tecan Group Ltd.) at 37°C, with 6mm orbital agitation –OD600 readings were 
taken every 30 minutes. 
 
2.4.8. Gram Staining 
Cell morphology was visualised by microscopy following Gram staining. Cells were grown in LB 
media and following centrifugation a scoop of the cell pellet was placed on the slide. Cells 
were heat fixed over a Bunsen burner flame. Cells were flooded with crystal violet and 
incubated for one minute. Residual stain was washed off under a running tap; cells were then 
covered in Gram’s iodine and left for one minute. The wash step was repeated and cells were 
decolourised with a few drops of acetone and left for 30 seconds. The slide was rinsed again 
and counter stained with carbol fuchsin for 30 seconds. The slide was rinsed and dried with 
care.  Slides were visualised under a Nikon Eclipse TS100 microscope with a digital camera 
attachment.  
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Crystal Violet 
The stain is a 0.1 % Crystal Violet stain made up of 20 ml Solution A (5 g crystal violet (BDH 
Laboratory supplies) in 95 mL ethanol) and 80 ml Solution B (1% Aqueous Ammonium oxalate 
in H2O).  
 
Gram’s iodine 
1g iodine and 3g potassium iodide were added to 300mL distilled water. 
 
Carbol Fuchsin 
1g carbol fuchsin was added to 100mL 95% ethanol 
 
2.5. Molecular biology methods 
 
2.5.1. DNA methods 
2.5.1.1. Buffers and reagents 
10 x TAE buffer 
DNA agarose gels were prepared with and run in TAE buffer. 48.4g Tris base, 20mL 0.5M EDTA, 
pH 8 and 11.44mL glacial acetic acid were dissolved in up to 1 litre of dH2O. Prior to use a 1 x 
TAE buffer was prepared in dH2O. 
6x DNA loading buffer 
DNA was prepared for gel electrophoresis in 6x DNA loading buffer. 100mL in dH2O with 60mL 
glycerol, 6mL Tris, pH 8, 1.2mL 0.5M EDTA, pH 8 and 60mg bromophenol blue. 
 
2.5.1.2. DNA agarose gel electrophoresis 
Unless specified, DNA analysis was carried out on 1% (w/v) TAE agarose gels. Agarose powder 
was dissolved in 1 x TAE buffer and supplemented with 0.5 µl of ethidium bromide. DNA gels 
were set in casting trays. 6x DNA loading buffer was added to DNA samples which were run 
alongside either GeneRuler 1kb DNA ladder (Thermo Scientific) or PCR Ranger 100bp DNA 
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ladder (Norgen). DNA gels were run at 100V until adequate separation of DNA fragments was 
achieved. DNA was observed under UV light using a G:BOX (Syngene). If DNA bands required 
isolation, bands were cut from the gel with a scalpel. DNA was purified with the ISOLATE II PCR 
and Gel Kit (Bioline). DNA was stored at -20°C. 
 
2.5.1.3. Bacterial plasmid DNA extraction 
Plasmid DNA was isolated from liquid cell culture with the Isolate II Plasmid Mini Kit (Bioline). 
 
2.5.1.4. Bacterial chromosomal DNA extraction 
Chromosomal DNA was isolated from liquid cell culture with Wizard® Genomic DNA 
Purification Kit (Promega). 
 
2.5.1.5. Quantification of DNA concentration 
Following calibration with nuclease free water, the concentration (ng µL-1) 1.5µL isolated DNA 
was measured by a Nanodrop 1000 spectrophotometer (Thermo Scientific). 
 
2.5.1.6. Polymerase chain reaction 
Polymerase chain reaction (PCR) was carried out to amplify existing DNA templates. Primers 
were designed and then synthesised by Sigma-Aldrich. Upon arrival nuclease free water was 
added to the dry oligonucleotides to result in a 10µM solution. Primers were stored at -20°C. 
Prior to use primers were diluted 1 in 10 to form a 100µM solution. Primers with extensions to 
the homologous region at the 5’ end were used to add nucleotides (e.g. restriction enzyme 
sites) to the ends of template DNA. Primers are specified in Appendix 2. 
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2.5.1.6.1. High-fidelity PCR 
Phusion® High-Fidelity DNA Polymerase (New England Biosciences) was used to ensure 
accurate DNA amplification for vector cloning, chromosomal mutagenesis or DNA sequencing. 
PCR reactions for Phusion® reactions were set up as specified in Table 2.4 and  
 
 
 
 
 
 
 
 
Table 2.5.  
Table 2.4: Reagents and quantities for PCR with Phusion® High-Fidelity DNA Polymerase 
50 µL PCR reaction mixes were prepared. For convenience master mixes were also prepared 
when multiple PCR reactions were being carried out with common components.  
Reagent µL 
NF dH20 35.5 
5 x Phusion® High-Fidelity Buffer 10 
DMSO 1 
DNA template (~10µM) 0.5 
Primer 1 (100µM) 0.5 
Primer 2 (100µM) 0.5 
dNTPs (100µM) 0.5 
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Phusion® High-Fidelity DNA Polymerase 0.5 
 
 
 
 
 
 
 
 
 
Table 2.5: Settings for PCR with Phusion® High-Fidelity DNA Polymerase.  
Annealing temperature and duration varied based on the primers. If no product was derived 
following an annealing setting of 55°C for 1 minute (a) the reaction was repeated with an 
annealing setting of 36°C and 2 minutes (b). The extension time varied based on the size of the 
PCR product. There were 30 cycles of the middle three steps. 
Step Temperature (°C) Time (m:s) 
Initial Denaturing 98 3:00 
Denaturing 98 0:30 
Annealing a. 55 or b. 36 a. 1:00 or b. 2:00 
Extension 72 0:30/kb product 
Final Extension 72 7:00 
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2.5.1.6.2. Overlap PCR 
Overlap PCR was used to adjoin DNA templates or implement single point substitutions. As the 
product was then incorporated into genomic DNA for transcription, it was essential that 
replication fidelity was high; therefore Phusion® High-Fidelity DNA Polymerase was used. 
Reactions were set up as described in Table 2.4; however DNA from multiple templates was 
added. The settings for thermocycling were identical to those in those in  
 
 
 
 
 
 
 
 
Table 2.5, with consideration being made for the product length of the adjoined templates 
when calculating extension time. 
 
2.5.1.6.3. Colony PCR 
Colony PCR involves the PCR based confirmation of chromosomal mutagenesis or vector DNA 
ligation in individual E. coli colonies. As fidelity was not essential DreamTaq DNA Polymerase 
(Thermo Scientific) was utilised for PCR reactions which were set up as specified in Table 2.6 
and Table 2.7. 
Table 2.6: Reagents and quantities for PCR with DreamTaq DNA Polymerase. 
20 µL PCR reaction mixes were prepared. The DreamTaq PCR Master Mix comprises of buffer, 
polymerase and dNTPs. For convenience master mixes were also prepared when multiple PCR 
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reactions were being carried out with common components. A small scoop of DNA from a 
single colony was added to the PCR tube instead of isolated template DNA. 
Reagent µL 
NT dH20 9.7 
2 x DreamTaq PCR Master Mix  10 
DMSO 0.1 
DNA template  N/A 
Primer 1 (100µM) 0.1 
Primer 2 (100µM) 0.1 
 
Table 2.7: Settings for PCR with DreamTaq DNA Polymerase.  
Annealing temperature and duration varied based on the primers. If no product was derived 
following an annealing setting of 55°C for 30 seconds (a) the reaction was repeated with an 
annealing setting of 36°C and 1 minute (b). The extension time varied based on the size of the 
PCR product. There were 30 cycles of the middle three steps. In colony PCR the initial 
denaturing time was extended to 5 minutes, to ensure cell lysis occurred. 
Step Temperature (°C) Time (m:s) 
Initial Denaturing 95 5:00 
Denaturing 95 0:30 
Annealing a. 55 or b. 36 a. 0:30 or b. 1:00 
Extension 72 1:00 
Final Extension 72 7:00 
 
 
2.5.1.7. Blunt end cloning 
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Linear DNA (for example, PCR products derived following overlap PCR) was blunt end cloned 
into a storage vector using the CloneJET PCR Cloning Kit (Thermo Scientific). Efficient ligation of 
linear DNA into the vector was ensured through the induction of a suicide gene in re-
circularised vector. Blunt end cloning and use of proofreading enzymes insured that the entire 
DNA fragment including ends was correctly incorporated into the vector. Following 
transformation into cells, this allowed storage of DNA and a simple means of DNA 
amplification, by cell division. Insert DNA was isolated from the vector by either PCR of 
restriction digestion.  
 
2.5.1.8. DNA ligation  
Restriction digestion and ligation were used to clone DNA into vectors. Cloning vectors 
(acceptors) and insert DNA underwent double restriction digest with appropriate restriction 
enzymes and buffers. Insert DNA was derived either from plasmid DNA or PCR reaction. 
Antarctic phosphatase was added to restriction digest reactions of acceptor vector DNA to 
prevent self-ligation of the vector. All restriction enzymes, buffers and Antarctic phosphatase 
were purchased from New England Biosciences. Restriction digest reactions were set up as 
stated in  
 
 
Table 2.8. Reactions were incubated for 2 hours at 37°C. Following incubation, 6µL 10x 
Antarctic Phosphatase Reaction Buffer and 2µL Antarctic Phosphatase enzyme were added to 
acceptor vector DNA digest reactions and the mix was incubated at 37°C for a further hour. 
5µL acceptor vector DNA reaction mix was run on a TAE agarose DNA gel alongside undigested 
donor DNA to confirm successful digestion. Restriction enzymes in acceptor vector DNA 
reaction mixes were heat inactivated by incubating at 65°C for 20 minutes, with the exception 
of BamHI which required inactivation by clean up with the ISOLATE II PCR and Gel Kit (Bioline). 
All of the insert DNA reaction mixture was loaded on to a TAE agarose DNA gel, DNA product 
of the expected size was excised and purified with the ISOLATE II PCR and Gel Kit (Bioline). 
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Table 2.8: Reagents and quantities to restriction enzyme digest. 
The appropriate buffer for the two restriction enzymes was selected using the New England 
Biosciences Double Digest Finder. Reaction mixtures were set up in Eppendorf tubes.  
Reagent µL 
NF dH20 Up to a total of 60 
10 x Buffer 6 
Restriction enzyme 1 2 
Restriction enzyme 2 2 
DNA  1µg total -for example 20µL of 50ng/µL 
 
Following successful digestion, vector and insert DNA were ligated using T4 DNA ligase (New 
England Biosciences). Reaction mixes were set up as listed in Table 2.9 and incubated at room 
temperature overnight.  
 
Table 2.9: Reagents and quantities for DNA ligation. 
Reactions were set up in 0.5mL Eppendorf tubes. A 1:1 ratio of vector to insert sticky ends is 
desirable; as vector DNA is bigger (kbp) than insert DNA, DNA was added to result in a 1:3 
ratio. 
Reagent µL 
NF dH20 Up to 20 
10 x T4 DNA ligase buffer 2 
Vector DNA As required. 1 part 
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Insert DNA As required. 3 parts 
T4 DNA ligase buffer 1 
  
1µL ligation mix was transformed into NEB 5-alpha Competent E. coli (New England 
Biosciences) and screened by plating on LB agar plates supplemented with the relevant 
antibiotic based on the acceptor vector. Sussessful transformants were screened by colony 
PCR. Colonies which yielded positive PCR results were grown for plasmid extraction to undergo 
confirmatory restriction digest and DNA sequening to confirm the correct sequence of DNA.  
 
2.5.1.9. DNA sequencing 
Both chromosomal and plasmid DNA were sequenced using the LIGHTRUN™ Sequencing 
Service (GATC Biotech). The region of chromosomal DNA which required sequencing was first 
amplified using primers which annealed either side of the region and high-fidelity polymerase. 
In an Eppendorf, 5µL of either 80-100ng µL-1 purified plasmid DNA or 20-80ng µL-1 purified PCR 
product DNA was added to 5µL of 5µM primer. Reaction mixes were sent to GATC Biotech. The 
resulting nucleotide sequences were visualised using Finch TV. Multiple reaction mixes were 
prepared for each DNA template, with different primers to yield full coverage of DNA based on 
at least two different primers (which were designed to anneal at either end of the DNA 
template). Sequence coverage was achieved for around 1Kb of DNA; for DNA which exceeded 
this length, primers were also designed to anneal within the DNA template.   
 
2.5.1.10. Gene synthesis 
Synthetic genes were designed and sent for synthesis by GeneArt® Strings DNA Fragments (Life 
Technologies). Upon delivery, dried DNA was resuspended in 50µL nuclease free water and 
blunt end cloned into a storage vector using the CloneJET PCR Cloning Kit (Thermo Scientific). 
The ligation mix was transformed into NEB 5-alpha Competent E. coli (New England 
Biosciences) and screened by plating on an ampicillin supplemented LB agar plate. 
Transformants were confirmed by DNA sequencing.  
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2.5.2. Protein methods 
 
2.5.2.1. Buffers and reagents 
 
SDS-PAGE lower Tris buffer 
For use in SDS-PAGE resolving gel, 6.06g Tris Base and 0.4g Sodium dodecyl sulphate (SDS) 
were dissolved in 100mL dH2O before adjusting the pH to 6.8. 
SDS-PAGE upper Tris buffer 
For use in the SDS-PAGE stacking gel, 18.17g Tris base and 0.4g Sodium dodecyl sulphate (SDS) 
were dissolved in 100mL dH2O before adjusting the pH to 8.8. 
10 x SDS-PAGE running buffer 
SDS-PAGE gels were run in tanks with SDS-PAGE running buffer. 30g Tris base, 144g glycine and 
10g SDS was made up to a volume of 1000mL with dH2O. 1 x SDS-PAGE running buffer was 
prepared in dH2O. 
2x SDS loading buffer 
Protein samples were prepared for SDS-PAGE in 2x SDS loading buffer. This was prepared with 
10mL glycerol, 1g SDS and 0.1g bromophenol blue to a total of 50mL 100mL Tris, pH 6.8. Prior 
to use DTT from a 1M stock was added to a concentration of 200mM. 
Semi dry transfer buffer 
Semi dry transfer buffer was used during protein transfer for Western blot and was made with 
2.9g Tris base, 1.45g glycine, 1.85mL 10% (w/v) SDS and 100mL methanol. The reagents were 
mixed and the total made up to 500mL with H2O.  
10 x TBS buffer 
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TBS was used for incubation of nitrocellulose membranes. 24g Tris base and 88g NaCl was 
dissolved in dH2O and pH adjusted to 7.6 before adding dH2O to a final volume of 1 litre. Prior 
to use a 1 x solution of TBS was prepared in dH2O. 
2.5.2.2. Bacterial protein precipitation  
Protein analysis work was carried out with SDS-PAGE gels and Western blot. Following cell 
culture samples were prepared as follows. Following centrifugation bacterial cell culture cell 
pellets were resuspended in 200µL 2 x SDS loading buffer per OD Unit (1mL cell culture at 
OD600 1.0 is equivalent to 1 OD Unit) of cells and heated at 95°C for 10 minutes. For total 
supernatant protein precipitation as part of the secretion assays, 10% v/v trichloroacetic acid 
(TCA) was added to supernatant fractions and incubated on ice for 30 minutes. The mixture 
was pelleted by centrifugation (4°C) and the supernatant was discarded. The pellet was 
resuspended in the same volume of acetone, vortexed and the mixture was centrifuged before 
supernatant being discarded and the pellet air dried. The pellet was suspended in 50µL 2x SDS 
loading buffer/OD unit and heated at 95°C for 10 minutes. For samples derived from protein 
purification 2x SDS loading buffer was added at a 1:1 ratio and heated for 5 minutes at 95°C. 
 
2.5.2.3. SDS-PAGE  
Protein analysis work was carried out on SDS-PAGE gels. SDS-PAGE gels were prepared using 
equipment from the Mini-PROTEAN® (Bio-Rad) casting kit. Long plates with 1.5mm spacers and 
short plates were cleaned with 70% industrial methylated spirits and assembled on casting 
module. The resolving gel was prepared and poured between the plates. Recipes for SDS-PAGE 
resolving gels are listed in  
 
Table 2.10; an appropriate % crosslinking was selected based on the size of the protein of 
interest.  Isopropanol was layered on top to level the gel and protect it from the air interface. 
Once set, isopropanol was removed, the stacking gel (0.975mL acrylamide, 2.1mL 0.5M Tris pH 
6.8 (upper Tris), 4.725mL H2O, 17µL TEMED, 0.1mL 10% (w/v) ammonium persulphate) poured 
and the comb inserted. Samples were loaded on to SDS-PAGE gels with EZ-Run™ Prestained 
Rec Protein Ladder (Fisher Scientific) and run in a Mini-PROTEAN ® Tetra Vertical 
Electrophoresis Cell in 1 x SDS running buffer. Gels were washed in dH20 three times and 
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strained with either InstantBlue™ (Expedeon) or Silver Stain Plus™ (Bio-Rad) reagents and 
washed three times in dH2O before imaging with a scanner. 
 
Table 2.10: Reagents and quantities for polyacrylamide resolving gels. 
Size of the protein of interest determined the % acrylamide in the resolving gel. 5µL TEMED 
and 0.35mL 10% (w/v) ammonium persulphate were added to the reagents listed below to 
initiate crosslinking.  
% crosslinking  Acrylamide (mL) Lower Tris (1.5M, pH 8.8)(mL) H20 (mL) 
10 2.475 2.5 4.825 
12 3 2.5 4.3 
15 3.75 2.5 3.55 
 
2.5.2.4. Western blot 
An SDS-PAGE gel was stacked with a nitrocellulose membrane (GE Healthcare Life Science) 
sandwiched in 3 layers of chromatography paper (GE Healthcare Life Science). All were 
saturated with 1 x semi-dry transfer buffer. The layers were assembled on a BioRad Trans-Blot 
Semi Dry Transfer Cell (BioRad Laboratories), which was run at 10v for one hour. The 
nitrocellulose membrane was placed in 50mL 3% w/v BSA in 1 x TBS/0.1% TWEEN and left on 
rollers for two hours. The membrane was washed in 1 x TBS/0.1% TWEEN 3 x 10 minutes. 
20mL 1 x TBS/0.1% TWEEN containing the primary antibody was added to the membrane 
which was incubated on rollers for one hour.  Wash steps were repeated. If necessary the 
antibody incubation step and wash steps were repeated with a secondary antibody diluted in 1 
x TBS/0.1% TWEEN. Antibodies are listed in Table 2.11. The membrane was soaked in Pierce® 
ECL Western Blotting Substrates (Thermo Scientific) and placed in cling film and moved into an 
X-Ray cassette folder (Kodak). Sheets of CL-Xposure™ X-ray films (Thermo Scientific) were 
placed in the cassette on the membrane for varying lengths of time. Films were developed 
using a Compact X4 X-ray Film Processor (Xograph). If necessary, nitrocellulose membranes 
were stripped of antibodies to allow probing with alternative antibodies. Membranes were 
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washed in 1 x TBS/0.1% TWEEN 3x 10 minutes and incubated in 10mL Restore™ Western Blot 
Stripping Buffer (Thermo Scientific) for 15 minutes. Wash steps were repeated and the process 
could then be initiated at the blocking stage. 
Table 2.11: Antibodies for probing nitrocellulose membranes for Western blotting. 
The antibody, manufacturer and concentration of antibody in in 1 x TBS/0.1% TWEEN is listed 
Antibody Manufacturer Concentration 
H48 Monospecific H Rabbit 
Antiserum, E. coli  
Statens Serum Institut 1 in 1000 
Anti-rabbit HRP (horse radish 
peroxidase). 
Cell Signalling Technology 1 in 3000 
Monoclonal ANTI-FLAG®M2 
antibody produced in mouse 
Sigma-Aldrich 1 in 1000 
Monoclonal Anti-COL1A1 
antibody produced in mouse 
Sigma-Aldrich 1 in 500 
Anti-mouse HRP (horse radish 
peroxidase) 
Cell Signalling Technology 1 in 3000 
E. coli GroEL Rabbit IgG Sigma-Aldrich 1 in 1000 
 
2.5.2.5. Cell lysis 
Cell lysis was required prior to the purification of intracellular proteins. Cell cultures 
underwent centrifugation, supernatant was discarded and the cell pellet was resuspended in 
the appropriate buffer for subsequent protein purification. Cells which overexpressed 
streptavidin II tagged proteins were lysed by a French pressure cell. Cells underwent three 
repetitions of cell disruption by French press at 1000psi. Cells were incubated on ice for 1 
minute between applications.  
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2.5.2.6. Concentration of protein  
Amicon® Ultra 0.5mL Filters (Merck Millipore) allowed concentration of protein by size 
exclusion either prior to or following protein purification. Up to 500µL protein was applied to 
the column and centrifuged at 13,000rpm, 4°C until the desired volume of sample was 
achieved. Cycles of concentration of protein followed by the addition of an alternative buffer 
and further concentration allowed buffer exchange using this system. For larger volumes of 
protein, Vivaspin 20 Protein Concentrator Spin Columns, MWCO 10000 (GE Healthcare Life 
Science) were utilised, allowing the concentration of volumes up to 20mL. 
 
2.5.2.7. Protein purification 
Protein was purified either for use as a protein standard or to demonstrate TEV cleavage. 
When purifying Streptavidin II tagged protein from the secreted fraction of cell culture protein 
was suspended in 100mM Tris-HCl, 150mM NaCl, 1mM EDTA pH 8 and purified using Strep-
Tactin® Spin Column (IBA Lifesciences) and eluted with 2mM D-biotin in the appropriate buffer 
for subsequent experimental work. Streptavidin II tagged protein from the intracellular 
fraction only was purified on a 1mL StrepTrap™ HP column (GE Healthcare Life Science) 
according to the manufacturer’s instructions. Protein was suspended in 100mM Tris-HCl, 
150nM NaCl, 1mM EDTA, pH8 and applied to the column coupled to a P-1 peristaltic pump (GE 
Healthcare Life Science) according to the manufacturer’s instructions. Protein was eluted with 
2.5mM desthiobiotin and underwent dialysis overnight to yield purified protein in 100mM Tris-
HCl, pH 8. For SDS-PAGE protein standards, protein was immediately prepared in 2x SDS 
loading buffer, aliquoted and stored at -20°C.  
 
2.5.2.8. Quantification of protein concentration  
Purified protein concentration was quantified with the Pierce™ BCA Protein Assay Kit (Thermo 
Scientific) in a clear 96 well plate. Absorbance of solutions was measured by a FLUOstar plate 
reader (BMG Labtech). Results were plotted on a scatter graph and the concentration of 
unknown samples was calculated from the linear equation derived from absorbance of the 
protein standards. 
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2.5.2.9. TEV cleavage 
Purified protein which harboured TEV (Tobacco Etch Virus) sites was cleaved by AcTEV™ 
Protease (Thermo Scientific). The manufacturer’s protocol was followed however on occasions 
protein was initially suspended in 50mM Tris-HCl, 0.5mM EDTA, pH 8 rather than in 100mM 
Tris-HCl, 150mM NaCl, 1mM EDTA, pH 8 as recommended. Around 20µg protein was 
incubated with 1µL AcTEV™ Protease, 7.5µL 10x TEV buffer, 1,5µL 0.1M DTT and nuclease free 
dH2O to a volume of 150µL for 2 hours at room temperature.  
 
2.6. Assays to quantify type III secretion system capacity 
for protein secretion. 
 
2.6.1. Gene expression assay 
 
Gene expression was measured by gene promoter activity using the Miller assay (Miller, 1972). 
The assay measures β galactosidase activity of whole cells which harbour lacZ gene fusion 
plasmids. The assay measures the catalysis of ONPG to ONP. This is dependent on β 
galactosidase activity, which is relative to lacZ activity, which is dependent on fusion gene 
activity. 
LB media was inoculated with overnight cell culture to a starting OD600 of 0.05 along with 
antibiotics. Culture was grown 37°C, 140rpm. A sample of cell culture was transferred to an 
Eppendorf and incubated on ice for 20 minutes. The OD600 was measured. Cells were pelleted 
by centrifugation and resuspended in the same volume of Z buffer. 100µL chloroform, 50µL 
0.1% (w/v) SDS was added and vortexed for 30 seconds. Eppendorfs were equilibrated at 28°C 
for 5 minutes. 200µL ONPG substrate was added, samples were vortexed and the stop clock 
was started. When the solution developed a yellow colour 500µL 0.1M NaCO3 was added, the 
mixture was vortexed and the clock stopped. Samples were centrifuged and OD420 and OD550 
were measured against a Z buffer blank. 
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Miller units were calculated as follows: 1000 x [(OD420 -1.75 x OD550)/(T x V x OD600)] 
Where T = time of ONPG assay in minutes and V = volume of culture in mL 
Z buffer 
0.42g Na2HPO4, 0.28g NaH2PO4.H2O and 0.5mL 1M KCl was added to 40mL dH2O. 135µL 2-
mercaptocethanol was added fresh. The pH was adjusted to 7 and water added to 50mL.  
ONPG 
ONPG (2-nitrophenyl β-D-galactopyranoside) was dissolved in phosphate buffer to a 
concentration of 4mg mL-1 fresh every day. Phosphate buffer was prepared by adding 0.85g 
Na2HPO4 and 1.03g NaH2PO4.2H2O to 90mL dH2O. Adjust pH to 7 and add dH2O to a final 
volume of 100mL. 
 
2.6.2. Protein secretion assay 
 
As described in section 2.4.1. Bacterial culture, LB media was inoculated with overnight cell 
culture along with antibiotics and IPTG if necessary. During incubation OD600 was measured 
and 1 OD unit sample taken either every hour or when OD600 reached 1.0 or 1.5 (for E2 
protein). Samples were prepared for SDS-PAGE and Western blotting as described in 2.5.2.2. 
Bacterial protein precipitation. A protein standard was added to quantify relative 
concentrations of protein loaded onto the SDS-PAGE gel. This was be calculated by 
densitometry of western blot bands using ImageJ (http://rsbweb.nih.gov/ij/). 
 
2.6.3. Flagellin standard to quantify secretion 
 
To quantitatively measure flagellin secretion by strains a flagellin standard (E2) was used. 
pTrc99a harbouring E2 was freshly transformed into MC1000 ΔfliC. 100µL overnight culture 
was plated onto semisoft agar plates (1% w/v tryptone, 0.5% w/v NaCl, 0.8% w/v 
bacteriological agar) and incubated (along with a flask containing water to ensure humidity) at 
37°C for 24 hours. Cells were scraped off motility agar plates with a spreader and transferred 
into 12mL 50mM Tris-HCl, pH 7.8. The solution was agitated in a lab blender (Waring 
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Laboratory Science) for 3 minutes on full power. Contents were transferred into Eppendorfs 
and centrifuged on full speed for 5 minutes at 4°C to remove bacterial cells. The supernatant 
was transferred into Beckman high speed centrifuge tubes (Beckman Coulter) and centrifuged 
at 67500g for 15 minutes at 4°C to collect flagella filaments. The supernatant was discarded 
and the pellet resuspended in the residual supernatant. The centrifugation step was repeated, 
the supernatant removed and the pellet resuspended in 50mM Tris-HCl, pH 7.8.  
To monomerise E2 protein, isolated E2 was sonicated twice for 10 seconds in a sonication 
water bath and then heated at 50°C for 10 minutes. Following centrifugation at 67,500g for 1 
hour supernatant was transferred to a new Eppendorf. E2 concentration is quantified with the 
Pierce™ BCA Protein Assay Kit (Thermo Scientific). 
 
2.6.4. Motility assay 
 
Swimming behaviour of cells was ascertained by measuring the zone of motility which arose on 
a motility agar plate following inoculation with a single colony. A single colony was taken from 
an LB agar plate using a sterile pipette tip and inoculated into a motility assay agar plate (1g LB 
agar in 100mL dH2O for a final concentration of 0.04% agar). Plates were incubated at 30°C in a 
stationary incubator alongside a flask of water to ensure humidity. The radius of the zone of 
motility was measured using a ruler at time points and plates returned to the incubator. 
 
2.6.5. Flagella expression assay 
 
The levels of assembled flagella, was established by shearing flagella from cells by vortexing 
before running on Coomassie gel. The concentration of flagellin was ascertained by 
densitometry of the Coomassie stain or following Western blot and probing with anti-H48 
(FliC) antibody and a suitable secondary antibody. In brief, Cells were incubated in 5mL LB 
media overnight at 30°C, 50rpm. OD600 was measured; cells were centrifuged for 10 minutes, 
3500rpm, 4°C and resuspended in 0.5mL 100mM Tris-HCl, pH 7.8 per OD unit to normalise for 
variation in OD600 in cell cultures. Cells underwent 6 x 10 second rounds of application to the 
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vortex with 30 seconds incubation on ice in between, to shear flagella from cells. The 
suspension was transferred into Beckman high speed centrifuge tubes (Beckman Coulter) and 
centrifuged at 67500g for 1 hour at 4°C. The supernatant was removed and the pellet 
resuspended in the residual supernatant. The centrifugation step was repeated, the 
supernatant removed and the pellet resuspended in 50µL 100mM Tris-HCl, pH 7.8.  
 
2.6.6. MUB assay for cutinase activity 
 
The 4-methylumbelliferyl butyrate (MUB) assay was used to measure the activity of secreted 
cutinase. 10mL cell cultures of cells expressing cutinase were induced with 0.05mM IPTG and 
grown to OD600 1. Supernatant was prepared by centrifugation (15 minutes, 13,000rpm, 4°C) of 
1mL cell culture sample followed by the removal of 900µL supernatant. The use of sterile 
filtration as an alternative was also tested, however it was no more effective at removing cells 
than centrifugation, therefore was abandoned. LB broth was prepared in tandem to facilitate 
the removal of background interference by subtraction. Supernatant samples were normalised 
by OD600 with the addition of LB broth.  
Solutions of MUB were prepared fresh daily. 250mM MUB was dissolved in 
dimethylformamide (DMF) with 1% Triton X-100. This mixture was then diluted in 0.05M 
phosphate citrate (pH5) buffer to a concentration of 500µM MUB. A 500µM solution of 4-
methylumbelliferone (4-MU) was also prepared through the same method, to serve as a 
positive control. 40µL prepared supernatant was added to 96 well plate wells and the reaction 
was initiated with the addition of 160µL 500µM MUB. In addition to wells which contained 
supernatant and MUB substrate –wells were also filled with (1) LB and substrate, (2) substrate 
only, (3) LB and phosphate citrate buffer, (4) phosphate citrate buffer only and (5) 4-MU to aid 
the removal of background interference through subtraction and to serve as a positive control. 
96 well plates were gently rocked for one minute to facilitate mixing of solutions and then 
incubated at 30°C for 30 minutes.  
Following incubation, fluorescence was measured, either by imaging 96 well plates under UV 
light (G:BOX, Syngene) or by quantification using a Tecan Infinite 200 Pro plate reader (Tecan 
Group Ltd.). Based on the manufacturer instructions and corroboration following excitation 
and emission scans, measurements of fluorescence were recorded at an emission setting of 
446nm, following excitation at either 302nm or 365nm. If 365nm excitation was used 50µL 
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reaction mixture was quenched with 100µL 0.1M sodium carbonate buffer, pH 10.5 prior to 
measurement of florescence. Buffering was required as fluorescence measured at this 
excitation wavelength is pH dependent.   
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Chapter 3. Strain improvements for increased 
secretion capacity of native substrates 
through the T3SS 
 
This study aimed to maximise protein secretion through a modified E. coli flagella type III 
secretion system (FT3SS) through a series of gene modifications. High capacity directed 
secretion of protein through the FT3SS could result in a supernatant fraction comprised of 
secreted protein which is both at a concentration which is competitive with that achieved in 
industry and also free of contaminant protein. For example the highest concentration of 
extracellularly secreted recombinant protein in E. coli to date was 12mg L-1 (Majander et al., 
2005), however this was only 50% pure. The highest yield of protein secreted to the periplasm 
is around 1g L-1, however this requires processing to purify protein from the cell and then from 
periplasmic protein (Matos et al., 2012). While the incubation method was optimised to 
ensure protein was expressed to a satisfactory level, the main focus of the study focused was 
on strain based improvements to protein production and secretion. To assess the performance 
of mutant strains, assays were used to measure flagella gene expression and protein secretion. 
The initial focus was to investigate secretion of the native FT3SS substrate, the flagellin (FliC) 
monomer. It is rational to begin investigating the amenability of a modified FT3SS for protein 
secretion with the native substrate, firstly because it is sensible to modify one variable at a 
time to simplify any troubleshooting that may be required and secondly because of the high 
affinity of the FT3SS for FliC protein secretion. As described FliC is the most prevalent FT3SS 
substrate; filaments are comprised of up to 30,000 FliC monomers, equating to a secretion 
capacity of around 1000 subunits per minute (Erhardt et al. 2010). In wild type E. coli FliC 
monomers assemble at the tip under the cap protein FliD, which aids polymerisation. However 
with modifications it is also possible to secrete FliC monomers through the FT3SS into the 
media without polymerisation; these include removing the FliD cap protein or either of the 
hook filament junction proteins (FlgK or FlgL) (Ikeda et al. 1987; Homma et al. 1984). Flagella 
filament length is not regulated, furthermore if flagella are mechanically broken, then 
additional FliC monomers assemble at the tip, resulting in regrowth  (Homma & Lino, 1984). 
These characteristics can be exploited to result in the continual secretion of monomers 
through the FT3SS into the media. 
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3.1. Secretion platform for secretion of native protein 
 
The study first required the construction of a modified FT3SS to allow efficient transport of 
protein monomers through the structure into the media. This also required the production of 
an inducible plasmid based expression system harbouring the flagellin protein tagged for FT3SS 
secretion. 
 
3.1.1. Construct for flagellin secretion 
 
To effectively measure secretion capacity of flagellin in mutant strains, the expression of 
flagellin was decoupled from the native flagella gene expression pathway. Additionally a 
deletion of 89 amino acids was implemented from the central region of the flagellin monomer, 
resulting in the protein known as E2 (Figure 3. 1). E2 is a synthetic test secretion construct 
which describes a flagellin like protein, which is encoded by the E. coli flagellin gene fliC Δ191-
280 that lacks residues 191-280 in the central antigenic region of the construct but assembles 
a fully functional flagella monomer swimming at approximately 80% of wild-type levels 
(personal communication, G Stafford). E2 is similar to full-length native E. coli flagellin; it is 
readily secreted and assembles into filaments and therefore is an excellent model protein for 
testing secretion. While it is referred to as a ‘native’ protein, to distinguish it from entirely 
recombinant protein, it is a native variant protein and therefore also is a good test protein to 
assess the potential to utilise this system to secrete a range of heterologous proteins. 
Furthermore as the E2 protein is 13kDa smaller than native flagellin, the two are 
distinguishable and so any possibility of the strains to revert to wild-type or contamination of 
cultures can be distinguished by a marked size difference in SDS-PAGE and Western blots using 
a FliC specific antibody. The modified flagellin protein was cloned into the pTrc99a plasmid, 
which harbours a gene for ampicillin resistance and allows IPTG induced control of expression 
of the protein, via the trc promoter. The 47 amino acid N-terminal signal peptide of flagellin is 
also present, as this is thought to act as a non-cleavable signal peptide and therefore confers 
targeted FT3SS export protein, but the 5’ UTR is absent (Dobó et al., 2010).  
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Figure 3. 1: Schematic of the native E. coli fliC gene and the E2 variant 
Common features of the two open reading frames include the start and stop codons, the 47 
amino acid FliC secretion signal and the majority of the FliC gene. Transcription and translation 
of the fliC genetic construct (top) will result in the formation of full FliC monomer. Residues 
191-280 are highlighted in the fliC gene. In the E2 secretion construct (bottom) residues 191-
280 are removed and replaced with an EcoRI and SceI site –this will allow further modification 
of the construct to harbour ‘cargo’. Expression of this construct will result in a truncated FliC 
monomer.  
 
3.1.2 Platform strain for flagellin secretion: HAP-less and CAP-less 
flagella 
 
Figure 3.2. The structural differences in wild type flagella type III secretion system and the 
CAPless and HAPless (secretor strain) mutants.  
The wildtype (left), ∆fliCD (middle) and ∆fliC ∆flgKL (right) FT3SS structures are shown. Protein 
components of the wildtype structure are labelled to indicate the mutant strategies.  
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A number of mutants were created for improved secretion by the bacterial FT3SS.  The 
rationale behind mutants was inferred from the literature; while much of this concerns 
Salmonella, the data is relevant to E. coli too, as the two genera are phylogenetically similar 
and the FT3SS highly conserved between the two, although some subtle differences exist. It is 
reported that the removal of FliD, FlgK and FlgL proteins in Salmonella results in secretion of 
FliC into the media in (Homma, 1984; Stafford et al. 2007; Yokoseki et al. 1995) Furthermore 
with the removal of FliC, recombinant proteins can be secreted through the FT3SS without 
competition from the native substrate (Majander et al. 2005; Narayanan et al. 2010; Singer et 
al. 2012). With this in mind two flagella mutant MC1000 strains (ΔfliC ΔflgKL and ΔfliCD) were 
generated (by Dr. Matt Hicks and in this study respectively) to compare secretion. These are 
referred to as the CAPless and HAPless strains respectively (Figure 3.). MC1000 was selected as 
the parent strain for a number of reasons. MC1000 is a K-12 strain, which is similar to MG1655. 
Like MG1655 it is well studied and requires low biosafety measures, however additional 
mutations to the lac and ara operons aid expression of lac and ara inducible plasmids in cells 
(Casadaban & Cohen, 1980). Finally MC1000 is a leucine auxotroph and therefore compliant 
with the requirements of the University of Sheffield Genetic Modification Committee (i.e. 
reducing risk of release given its auxotrophy), furthermore it also adhered to the 
recommendations for ‘regulating synthetic biology’ which were outlined in the Synthetic 
Biology Roadmap for the UK (http://www.rcuk.ac.uk/documents/publications/ 
syntheticbiologyroadmap-pdf/). The CAPless and HAPless strains lack some of the proteins 
which would be present in flagella. Removal of FliC was essential to both strains, as FliC 
expression is competitive to the production and secretion of other proteins. The CAPless strain 
is also deficient of the FliD cap protein, which polymerises flagellin, therefore is not required in 
monomeric secretion. The HAPless stain has no hook junction proteins, upon which 
polymerisation of FliC monomers would occur, even in the absence of FliD (Homma, 1984). 
Rather than flagella, the idea was that the FT3SSs would now function as secretion apparatus, 
which secrete protein monomers from the cytoplasm directly to the extracellular environment.  
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3.1.2.1 PCR product generation for mutagenesis: MC1000 ΔfliCD 
Knockout mutagenesis was implemented by Lambda Red homologous recombination into the 
E. coli chromosome using the method of Datsenko and Wanner (2000) (Figure 3.). The fliCD 
gene knockout was executed in WT MC1000. A PCR reaction was carried out to produce a DNA 
construct for knockout mutagenesis by homologous recombination into the E. coli 
chromosome. The primer set was designed with the following in mind: 50bp gene specific 
flanking sequences to the intended deletion and 20bp sequences that allow amplification of 
the antibiotic resistance gene and FRT cassettes which allow removal of the antibiotic cassette 
from the template DNA plasmid (pKD3). The PCR reaction was considered successful if a 1.1 
kbp band was present when PCR reaction mixtures were run on a DNA gel. A positive result 
was achieved and bands of the correct size were cut out and DNA isolated.  
 
 
Figure 3.3: Lambda Red recombinase knock out mutagenesis.  
Schematic of a cell harbouring plasmid derived Lambda Red recombinase proteins, PCR 
product template (top) and chromosomal DNA (bottom). The isolated PCR product construct 
contains the antibiotic resistance cassette, flanked with FLP recombinase target (FRT) sites, 
and homologous regions (H1 and H2) to chromosomal DNA adjoining the gene which will be 
knocked out.  
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Figure 3.4: DNA gel of fliCD gene knockout construct PCR product.  
PCR reactions were carried out using the templates and primers in Appendix 2 with Phusion® 
High-Fidelity DNA Polymerase. PCR mixtures were analysed on a 1% TAE agarose DNA gel 
supplemented with a trace of ethidium bromide, visualised under UV light and the image 
inverted. Blank lanes were loaded with samples relating to other experiments. Samples were 
run with GeneRuler™ 1kb DNA ladder.  PCR resulted in the formation of a gene knockout 
construct for fliCD harbouring the chloramphenicol antibiotic resistance cassette (fliCD::Cm). 
The PCR product was isolated for transformation cells expressing Lambda Red recombinase. 
 
3.1.2.2. MC1000 ΔfliCD mutant generation via Lambda Red 
recombinase method 
Lambda Red recombinase induces chromosomal disruptions through the insertion of linear 
DNA by homologous recombination. Lambda Red recombinase enzymes are harboured in the 
arabinose inducible plasmid pKD46. When expressed they catalyse the conversion of linear 
DNA to single stranded DNA and the annealing of complementary single stranded DNA. This 
results in the linear DNA template being inserted into chromosomal DNA at homologous 
regions. The pKD46 plasmid is cured at 43°C without selection for ampicillin resistance, so that 
no further recombination events occur and ampicillin plasmids can be used in future studies 
using these strains. Chromosomal disruption is confirmed by the acquisition of antibiotic 
resistance encoded by the linear DNA. Once the chromosomal deletion is confirmed by PCR 
the antibiotic resistance cassette is removed by the activity of FLP recombinase 
Following the isolation of PCR product DNA, cells were prepared for mutagenesis. The Lambda 
Red recombinase and ampicillin resistance harbouring plasmid pKD46 was freshly transformed 
into the parent strain by electroporation. Successful transformants were induced with 1mM 
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arabinose and grown in liquid culture at 30°C for 4 hours and then prepared for 
electroporation. 1µL PCR product (approximately 15ng/µL) was electroporated with 100µL 
fresh electrocompetant cells. Cells were incubated in 1mL LB for 1 hour at 30°C and then left at 
room temperature overnight. Cells were spread on agar plates the following day and 
incubated at 30°C. 
The presence of positive colonies on chloramphenicol supplemented LB plates inoculated with 
cells following electroporation with fliCD::Cm allowed selection of successful transformants. 
This was coupled to the absence of colonies on the negative control chloramphenicol 
supplemented plate following plating of cells which had not been transformed with the 
knockout construct (to detect spontaneous antibiotic resistant colonies or contamination by 
Cm resistant bacteria).  This indicates that antibiotic resistance has been acquired via 
homologous recombination of the PCR construct and indicates that the gene deletion has been 
successful. To ensure no further recombination events occurred in the Lambda Red 
recombinase derived mutants, positive colonies were grown in liquid culture without selection 
for ampicillin resistance at 43°C to cure the Red plasmid (pKD46). This was verified by the loss 
of ampicillin resistance after one further passage at 37°C. 
 
3.1.2.3. MC1000 ΔfliCD mutant conformation by PCR 
To show that successful mutants had the correct chromosomal structure, PCR reactions were 
carried out with chromosomal DNA from the mutant as a template and primers which anneal 
to chromosomal DNA upstream and downstream of the gene deletion (Figure 3.). The size of 
the PCR product determines whether the target gene has been deleted. A positive result 
indicates the presence of the antibiotic resistance cassette and removal of the gene.  
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Figure 3.5: PCR verification of gene knockouts.   
PCR reactions with chromosomal DNA templates from cells following Lambda Red 
recombineering which resulted in  1) an unsuccessful homologous recombination event  2) a 
successful homologous recombination event, which has resulted in gene mutagenesis and 
acquisition of antibiotic resistance. 
 
A PCR product of 1.1kbp was obtained following PCR indicating that MC1000 ΔfliCD was 
successfully generated ( 
Figure 3.). If knockout mutagenesis was unsuccessful then a PCR product of 3.1kbp would have 
been observed.  
 
Figure 3.6: DNA gel to confirm successful gene knockout mutagenesis of the fliCD genes in 
MC1000 through homologous recombination.  
PCR reactions were carried out using the templates and primers in Appendix 2 with Phusion® 
High-Fidelity DNA Polymerase. PCR mixtures were analysed on a 1% TAE agarose DNA gel 
supplemented with a trace of ethidium bromide, visualised under UV light and the image 
inverted. Samples were run with GeneRuler™ 1kb DNA ladder. Image cropped to exclude other 
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experiments to aid ease of viewing. Successful recombination resulted in the formation of a 
1.1kbp PCR product. 
Successful production and conformation of MC1000 ∆fliC ∆flgKL was achieved by M. Hicks in 
previous work in the laboratory but was used in this study- this was reconfirmed in a similar 
manner. Once established, the capacity for protein secretion and growth phenotypes were 
ascertained for both the HAP-less and CAP-less MC1000 based flagella variants, to observe 
which is more suitable for use as the platform strain for protein secretion. This required the 
development of an assay to accurately measure protein secretion. 
 
3.2. Development of a standardised protein secretion 
assay to quantify flagellin secretion 
 
To quantify the secretion profile of strains a secretion assay was designed to measure intra- 
and extracellular concentrations of specific proteins. Initial investigation into the secretion 
capacity via the two secretion platforms was carried out using the ptrc99a E2 plasmid which 
expresses the FliC Δ191-280 construct, described previously. E2 protein was detected either by 
Coomassie stain or a flagellin (H48) antibody and a HRP linked secondary. In conjunction with 
E2 detection, an E2 flagellin monomer protein standard was prepared so that the yield of both 
intracellular and secreted protein could be calculated.  
 
3.2.1. Isolating monomeric flagellin to quantify secretion capacity 
 
To determine quantitative measurements (w/v) of protein expression, a flagellin like (E2) 
protein standard of known concentration was derived. Once a w/v unit measurement was 
quantified this allowed intra- and inter-experimental comparisons of secretion profiles. In 
addition the E2 protein standard serves as a positive control in both Coomassie stain and 
Western blot based experiments. Secreted E2 protein was purified from a flagellin deficient 
(ΔfliC) strain expressing the E2 harbouring plasmid. Following growth of cells on semisoft agar 
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plates, cells were scraped off and subject to agitation in a lab blender to shear flagella from 
cells. Following isolation and monomerisation by sonication and heating to 50°C, E2 protein 
was present in the soluble fraction (Figure 3.). Native E. coli flagellin is a 52 kDa protein (Daniell 
et al., 2003) however as the E2 protein is encoded by a shortened version of the flagellin gene, 
its expected size is 42kDa. The band of E2 protein runs at around 42 kDa on the SDS-PAGE gel.  
 
Figure 3.7: SDS-PAGE protein gel of isolated momomeric E2 
E.coli MC1000 ΔfliC containing the plasmid ptrc99a E2 was grown, cells were harvested and 
monomeric E2 was isolated by shearing, sonication and high speed centrifugation, before SDS-
PAGE. Lanes: (1) EZ-Run™ Prestained Rec Protein Ladder, (2) insoluble protein, (3) soluble 
protein. 
 
A BCA assay was performed to quantify the concentration of E2 in the soluble fraction. The 
concentration of the E2 protein standard was typically in the region of 0.2-0.5µg/mL. 
 
3.2.2. Development of a secretion assay to quantify platform strain 
suitability 
 
An assay to measure both the intracellular and extracellular concentration of E2 protein 
directed for secretion through the modified flagella appendages is detailed here. The pTrc99a 
E2 plasmid was transformed into E. coli strains by heat shock transformation. Following 
transformation and conformation by antibiotic resistance acquisition, E2 expression was 
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induced with 0.05mM IPTG as this concentration had been shown to be effective in the 
production of ptrc99a harboured proteins in the laboratory. Cells were incubated at 37°C, 
180rpm. Once cells reached OD600 1.5 (stationary phase) 1.0 OD unit of cells (i.e. 1ml at OD 1) 
were collected and then prepared for SDS-PAGE of the supernatant and cells to isolate 
secreted proteins. Cells harbouring the empty pTrc99a plasmid were also grown as a negative 
control. The E2 protein standard was also loaded (diluted in 2x SDS loading buffer 2:8 for SDS-
PAGE and 1:9 for Western Blot SDS-PAGE). Western blots were also carried out. Nitrocellular 
membranes were incubated in 1x TBS/0.1% TWEEN with 1 in 1000 anti-FliC antibody (H48) as a 
primary antibody and 1 in 3000 anti-rabbit HRP as a secondary.  The antibody was generated 
against full length flagellin, however adequate antigenic affinity is conferred by the E2 protein. 
Furthermore while the antibody is intended for use as an agglutination agent for screening for 
the presence of clinical E. coli strains, this work established that it can also be used effectively 
in Western blotting experiments.  Densitometry of each band on the Western blots or 
Coomassie stained electrophoresis gels was measured using ImageJ. Densitometry values were 
then calibrated to the E2 protein standard to calculate the concentration of secreted and 
intracellular E2 in the two prototype platform strains for flagella secretion.   
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Figure 3.8: Intracellular and secreted fractions of MC1000 ∆fliC ∆flgKL and ∆fliCD. 
E.coli ΔflgKL ΔfliC (∆CKL) or ΔfliCD containing either the plasmid pTrc empty or pTrc E2 was 
grown in LB supplemented with 0.05mM IPTG. Cells were harvested at OD600 1.5. 1 OD unit of 
cells were prepared for SDS-PAGE and the supernatant from 1 OD unit of cells was precipitated 
with TCA (10% v/v) before SDS-PAGE and Western blot analysis. An E2 protein standard (S) was 
loaded to allow quantification of intracellular and secreted protein concentration. Coomassie 
stained SDS-PAGE of cells harbouring (A) empty pTrc99a plasmid and (B) pTrc99a E2. 
Intracellular: 5µL; secreted: 15µL; standard 5 (left), 10 (right).  (C) Western blot with αH48 and 
appropriate secondary antibody following SDS-PAGE of pTrc99a E2 positive cells. Intracellular: 
2µL; secreted: 15µL; standard 1 (left), 2 (right). Three biological repeats for each strain and 
plasmid combination. 
 
Both strains demonstrated a similar intracellular protein expression pattern (Figure 3.A and 
Figure 3.B), suggesting that both are viable strains. Protein expression of E2 was similar in both 
strains (Figure 3.C). E2 protein is visible in the supernatant of cells expressing the protein 
(Figure 3.C), this suggests that the E2 protein is being successfully targeted for secretion 
through the flagella variants of both platform strains.  In support of this cell lysis was negligible 
in both strains and for both plasmids. This is apparent when observing the lack of protein 
(aside from E2) in the secreted fraction of media (Figure 3.A and Figure 3.B). The results of the 
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Western blot shown here highlight the issues that can arise when using this method, as a high 
background signal is observed in Figure 3.C, which masks the true immunogenic derived signal. 
Densitometry based analysis was carried out on images (where protein bands were not 
obscured) using ImageJ. A worked example is given (Figure 3.). 
 
 
Figure 3.9: Worked example of densitometry analysis of secreted E2 from a Coomassie 
stained SDS-PAGE (Figure 3.B).  
A horizontal box is drawn around the protein of interest, ImageJ then plots the densitometry 
outline for this selection. The lanes are divided up and using the image for reference. Gaps are 
left to show the zones of separation between lanes. Individual lanes are then plotted and 
densitometry values derived for each. 
123 
 
Using the values derived by the route given in Figure 3., and with knowledge of how much E2 
standard was loaded onto the SDS-PAGE, the exact amount of E2 present in each lane can be 
derived. This can then be extrapolated to calculate the amount of protein present in both the 
supernatant (from both Coomassie stained SDS-PAGE and Western blot analysis) and 
intracellular fractions (from Western blot analysis only). When possible, Coomassie stained 
SDS-PAGE gels are preferentially used as there are fewer experimental steps to obtain this, 
therefore the possibility of experimental error is reduced, further to this a linear range of 
detection is insured, whereas this is not always true during Western blotting. Figure 3. shows 
the results derived from the Coomassie stained supernatant samples. Following 3 biological 
replicates per mutant strain, a higher concentration of E2 was observed in the supernatant of 
all ∆CKL cultures, in comparison to ∆fliCD. The highest concentration of E2 in ∆CKL and ∆fliCD 
cultures was 9.19 and 5.57 mg L-1 respectively. When combined, (Figure 3.) the concentration 
of secreted E2 was significantly higher in ∆CKL cultures.  
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Figure 3.10: Results following densitometry analysis of the supernatant samples of the 
Coomassie stained SDS-PAGE seen in Figure 3.. 
E.coli ΔflgKL ΔfliC (∆CKL) or ΔfliCD containing the plasmid pTrc E2 was grown in LB 
supplemented with 0.05mM IPTG. Cells were harvested at OD600 1.5. The supernatant from 1 
OD unit of cells were prepared for SDS-PAGE and Coomassie stain. An E2 protein standard (S) 
was loaded to allow quantification of secreted protein concentration following densitometry 
analysis using Image J. Average from combined concentration of secreted E2 protein per Litre 
of cell culture. 3 biological replicates per mutant strain, grown on the same day. Standard error 
of the mean and result of two way t-test shown (* = p<0.05) 
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Densitometry analysis of the Western blot (Figure 3.C), found that there was a significantly 
higher concentration of E2 in ∆CKL cells. On average almost twice as much E2 was located in 
∆CKL cells (91.36 mg L-1) in comparison to ∆fliCD. Secreted and intracellular concentrations of 
E2 were paired for each biological replicate to calculate the percentage of total E2 which was 
secreted. On average ∆CKL was more efficient at secreting E2 (7.92%) than ∆fliCD (5.88%).   
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Figure 3.11: Results following densitometry analysis of the intracellular samples of Western 
blot seen in Figure 3.. 
E.coli ΔflgKL ΔfliC (∆CKL) or ΔfliCD containing the plasmid pTrc E2 was grown in LB 
supplemented with 0.05mM IPTG. Cells were harvested at OD600 1.5. The cells from 1 OD unit 
of cells were prepared for SDS-PAGE and Western blot analysis using anti-flagellin (H48) 
antibody and an HRP secondary. An E2 protein standard (S) was loaded to allow quantification 
of intracellular E2 protein concentration per Litre of cell culture, following densitometry 
analysis using Image J. 3 biological replicates, grown on the same day. Standard error of the 
mean and result of two way t-test shown (* = p<0.05) 
 
3.2.3. Growth phenotype of secretion platform strains 
 
The deletion of genes often correlates to a change in growth phenotype. This may result in an 
increased rate of growth if genes are removed which previously resulted in the production of a 
protein which was either metabolically costly to produce or resulted in a metabolically costly 
function. Conversely a decreased rate of growth may occur if the mutation is detrimental or if 
metabolic burden is in fact increased by the antibiotic resistance cassette acquired during 
knockout mutagenesis. To ascertain whether this was true of either candidate platform 
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secretion strain, growth was measured over time to visualise this. Cells were grown in 200µL 
LB cultures in a 96 well plate in a TECAN plate reader at 37°C with constant shaking (6mm 
orbital).  
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Figure 3.12: Growth of candidate platform strains for flagella mediated protein secretion 
over time in a 96 well plate. Calibrated to LB media. 
Starter cultures of cells expressing either pTrc empty or pTrc E2 were supplemented with 
ampicillin and 0.05mM IPTG and aliquoted into 96 well plate wells. The 96 well plate was 
incubated in the TECAN plate reader at 37°C with 6mm orbital shaking. OD600 measurements 
were recorded every 30 minutes. From three technical repeats of two biological repeats. ΔCKL 
+ pTrc E2: ▲, ΔCKL + pTrc empty: △, ∆fliCD + pTrc E2: ●, ∆fliCD + pTrc empty: ○.  
 
The optical density of a solution is calculated by spectroscopy and based on the Beer-Lambert  
law. The principle of optical density relies on passing wavelengths of light through a solution 
and measuring the intensity of emitted light. The composition of the solution determines how 
much light is emitted –or scattered in the case of a bacterial suspension (Hall et al., 2014). It is 
therefore dependent on both the composition of the solution (density of culture) and the path 
length of the solution which the light passes through. In a standard cuvette, this is 1cm –
however when measuring the absorbance of a solution in a 96 well plate this will differ, thus 
giving an incorrect measurement of optical density. Using a method for path length correction 
the path length of 200µL bacterial culture was found to be 5.95mm 
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(https://tools.thermofisher.com/content/sfs/brochures/AN-SkanIT-Microplate-Based-
Pathlength-Correction-Technical-Note-EN.pdf). While using the Beer-Lambert equation to 
calculate the precise adjustment multiple would be more accurate this required knowledge of 
the molar absorptivity for a bacterial suspension in LB media. As a reliable value for this could 
not be located in the literature an alternative method was chosen where the OD600 output of 
the same bacterial cultures in both a 1mL cuvette and a 96 well plate well was measured. 
Using a multiplication factor of 2.19 the OD600 acquired from a 96 well plate could be adjusted 
to give an accurate measurement of optical density obtained from a 1mL cuvette. While this 
calculation was not made routinely, when applied to results this adjustment gives OD600 
readings which are more in line with those we are accustomed to, in terms of growth phase -
for example final OD600 is around 2.0. 
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Figure 3.13: Growth of candidate platform strains for flagella mediated protein secretion 
over time in a 96 well plate. Calibrated to LB media and OD600 adjusted for path length. 
Starter cultures of cells expressing either pTrc empty or pTrc E2 were supplemented with 
ampicillin and 0.05mM IPTG and aliquoted into 96 well plate wells. The 96 well plate was 
incubated in the TECAN plate reader at 37°C with 6mm orbital shaking. OD600 measurements 
were recorded every 30 minutes and multiplied by 2.19. ΔCKL + pTrc E2: ▲, ΔCKL + pTrc 
empty: △, ∆fliCD + pTrc E2: ●, ∆fliCD + pTrc empty: ○  
 
The results of growth curve experiments (Figure 3., Figure 3.) show that the initial rate of 
growth is higher in both strains when expressing empty vector (initial (0.5 to 1.5 hours) mean 
generation time from 42 to 70 minutes for ΔCKL and from 49 to 61 in ∆fliCD). However in the 
late log phase ∆fliCD reaches a higher OD at time point 2.5 when expressing E2 protein in 
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comparison to empty vector (statistically significant: p = <0.0001 –paired t-test of average 
OD600 for each time point from 2.5 to 5.5 hours).  Cells expressing E2 reach early stationary 
phase first. When expressing empty vector, ∆CKL consistently displays a higher optical density 
than ∆fliCD in the log stage (p = <0.001 for 0.5 to 5.5 hours). When expressing E2 protein the 
two strains grew at a similar rate, however ∆fliCD has a higher OD600 in late log-early stationary 
phase (also p = <0.0001 for 3.5 to 7.5 hours). Overall neither mutation resulted in cells which 
were not viable or markedly altered in growth characteristics. 
 
3.2.4. Selection of secretion platform strain 
 
Observations show that while the growth of ∆CKL expressing E2 protein is slightly poorer than 
∆fliCD, ∆CKL expresses and secretes (2.16 and 1.77 times more E2 respectively) significantly 
more E2 than ∆fliCD. In addition it is on average 1.35 times more efficient at secreting E2. 
Based on this the HAP-less CKL strain was selected as the platform strain for this work. This 
strain will form the basis of all further secretion work and improvements. This MC1000 ∆flgKL 
∆fliC strain may be referred to as ∆CKL, the (original) secretor strain or (original) secretion 
apparatus strain.  
 
3.3. Optimisation of a standardised protein secretion 
assay to quantify flagellin secretion 
 
While the main focus of this work is to improve protein secretion through the flagella type III 
secretion system through a number of strain based improvements, it was necessary to first 
optimise the protein secretion assay to ensure initial protein secretion is satisfactory, this will 
both ensure protein secretion is measurable and have the added benefit of improving protein 
secretion capacity somewhat prior to the strain based strategy. Further to this is was necessary 
to ensure that cultures were grown for an adequate amount of time prior to harvesting to 
ensure that the amount of E2 detected was representative of the maximum output of cells (i.e. 
secretion has occurred and proteolysis is low). 
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3.3.1. Refining induction of expression vector 
 
As described, ptrc99a harbouring E2 plasmid is IPTG inducible.  E2 protein expression was 
tuned with IPTG concentration to maximise protein secretion in the ∆CKL strain. E2 protein 
expression and secretion were measured as before, however cultures were supplemented 
with 0, 0.05, 0.1, 0.5 or 1mM IPTG.  
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Figure 3.14: Intracellular and secreted fractions of MC1000 ∆fliC ∆flgKL supplemented with 
different concentrations of IPTG.  
E.coli ΔCKL containing the plasmid pTrc E2 was grown in LB supplemented with 0, 0.05, 0.1, 0.5 
or 1mM IPTG. Cells were harvested at OD600 1.5. The cells and supernatant from 1 OD unit of 
cells were prepared for (A) SDS-PAGE and (B) Western blot analysis of supernatant using anti-
flagellin (H48) antibody and an HRP secondary. An E2 protein standard (S) was loaded to allow 
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quantification of intracellular and secreted protein concentration following densitometry 
analysis using Image J. (C) Concentration of intracellular and secreted E2 protein per mL cell 
culture. (D) Secreted protein as a percentage of total protein (both secreted and intracellular). 
 
The absence of proteins in the secreted fraction of protein on the Coomassie stained SDS-
PAGE (Figure 3.A) shows that cell lysis is not evident at any concentration of IPTG. E2 protein is 
visible in the secreted fraction of cells where either 0 or 0.05mM IPTG was added to media, 
however none is visible for increased concentrations of IPTG, suggesting that the 
concentration of E2 secreted was lower than the detection threshold of the Coomassie stain. 
This is confirmed in the corresponding Western blot (Figure 3.B), where it is observed that 
more E2 protein is both expressed and secreted with the addition of 0 or 0.05mM IPTG. 
Densitometry (Figure 3.C) revealed that the addition of 0.05mM IPTG resulted in 236mg L-1 E2 
accumulating intracellularly and 2.48mg L-1 being secreted into the culture media. The next 
most favourable IPTG concentration for protein expression and secretion was to supplement 
cells with 0.00mM IPTG. The addition of 0.1mM IPTG or more resulted in a reduction in E2 
protein expression and secretion; high IPTG can result in cell lysis however this was not evident 
here.  It has previously been reported that induction of pTrc99a with IPTG concentrations in 
excess of 0.1mM resulted in reduced protein production and the formation of inclusion bodies, 
which could be subject to proteolysis (Choi et al., 2006; Jürgen et al., 2010). The results from 
densitometry were also used to assess the secretion capacity of cells (Figure 3.D). While 
variation was seen in the amount of protein expressed and secreted, the amount of protein 
secreted as a percentage of total protein expressed and secreted is consistent with all 
concentrations of IPTG, with around 1% total E2 protein produced by the cell being secreted. 
This suggests that the flagella type III secretion system may have a maximum secretion 
capacity and that while increased expression will result in increased secretion, secretion 
capacity will limit the amount of protein which is secreted. This theory will be investigated 
throughout this project.  
Plasmid protein expression was achieved without IPTG induction- this is because the pTrc99a 
vector is known to exhibit leaky expression of protein (Greer-Phillips et al., 2003). With IPTG 
concentrations above 0.1mM both protein expression and secretion were reduced. The 
amount of E2 both expressed and secreted by cells supplemented with 0.1-1mM IPTG was very 
similar, suggesting that E2 production can become saturated with higher concentrations of 
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IPTG induction. As 0.05mM IPTG resulted in both the highest level of expression and secretion 
of E2 protein, cells were supplemented with this concentration of IPTG throughout protein 
secretion assays concerning the ptrc99a E2 vector.  
It is evident that both the expression and secretion capacity of ∆CKL is variable. In the results 
derived for the data shown in Figure 3. there was almost three times the concentration of E2 in 
the supernatant and just over twice the level of the intracellular E2 compared to Figure 3. 
(0.05mM IPTG only).  Furthermore it was calculated that cells were almost 8 times more 
efficient at secreting E2, than those in Figure 3.. Possible reasons for this will be discussed 
later.  
With the protein secretion assay optimised to ensure that E2 expression and secretion are 
maximised, the focus of the study can now shift to the production of mutant strains with 
increased secretion capacity.  
 
3.4. Improved secretion: master regulator repressor 
mutants 
 
3.4.1. Rationale for mutant generation: lrhA, dksA, clpX 
 
As explained in (Figure 1.6) flagella gene expression is organised into a pyramid like hierarchal 
structure, with all genes either directly or indirectly under the control of the master regulator 
complex, FlhD4C2. As a fulcrum point of control, the master regulator complex serves as an 
excellent point to alter flagella gene expression. It is hypothesised that with increasing FlhD4C2, 
this should in turn increase the number of secretion apparatus expressed and therefore the 
amount of protein secreted through the FT3SS. Many environmental signals cause 
transcriptional repression of flhDC gene expression; furthermore the resulting FlhD4C2 protein 
complex is actively degraded by ClpXP protease. It is hoped that removing transcriptional 
repressors and inhibiting protease targeting of FlhD4C2, may result in increased flagella gene 
expression. The strategies to implement this are explained below.  
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3.4.1.1. lrhA 
The literature reports that lrhA knock out mutants exhibited higher activity of flagella class I 
and II gene promoters (Lehnen et al., 2002) where flhDC promoter activity was 3.5 x higher in 
the lrhA knockout mutant. If lrhA is removed from the secretor strain this may result in more 
secretion apparatus being present, this may result in increased protein secretion into the 
media. 
 
3.4.1.2. dksA 
Previous studies conclude that dksA knock out mutants exhibit higher activity of flagella gene 
promoters for all three classes of flagella proteins (Lemke et al., 2009). lacZ reporter gene 
fusions show that flhDC promoter activity was 2.3 x higher in log phase and 9 x higher in 
stationary phase. Higher gene expression can be extrapolated to more secretion apparatus and 
therefore more secretion, particularly throughout the stationary phase, where both motility 
and flagella gene expression has previously been found to decline (Amsler et al., 1993).  
 
3.4.1.3. clpX 
Along with ClpP, ClpX forms the ClpXP protease complex. While ClpP is the proteolytic 
component of the complex, ClpX is the ATPase which confers substrate specificity –one of 
which is FlhD4C2. ClpX has been shown to actively bind to and denature FlhD4C2, before ClpP 
degrades the protein, resulting in reduced flagella gene expression. ΔclpX mutants were shown 
to accumulate FlhD4C2, the complex had increased half-life and cells were more motile 
(Kitagawa et al., 2011). Removal of clpX has also been shown to result in decreased 
degradation of FlhD4C2, but also increased secretion of the anti-sigma factor FlgM, which 
represses flagella class III transcription (Guo et al. 2014). The removal of clpX resulted in a 
‘greatly increased’ concentration of extracellular FliC and increased flagella gene expression 
(Tomoyasu et al., 2002). Therefore removing ΔclpX from the secretor strain may result in 
increased flagella gene expression and more secretion. The protease ClpP also interacts with 
ClpA, which targets ClpP to different proteins (Gottesman, 1996), therefore ClpP will remain in 
the genome so that these cellular processes are not altered. 
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3.4.2. Mutant generation: lrhA, dksA, clpX  
 
3.4.2.1. Knockout mutagenesis via the Lambda Red recombinase 
method: lrhA and dksA 
lrhA and dksA knockout mutants were derived in using the FLP-recombinase method outlined 
previously. The parent strain was MC1000 ΔfliC ΔflgKL. Primers were designed to amplify 
kanamycin cassettes with homologous ends to those up and downstream of lrhA and dksA. 
The template for the dksA mutant was pKD4 as more genes are located downstream in the 
operon, therefore it is important that translation signals are not disrupted. The scar that arises 
following knock out mutagenesis using the pKD4 template harbours an RBS site and start 
codon, therefore downstream gene expression of other genes in the operon will occur, as in 
the wildtype. The PCR product for lrhA was derived from the pKD13 plasmid, as it is situated at 
the end of the operon, therefore deletion of lrhA should have no downstream deleterious 
effects.  
 
Figure 3.15: Agarose DNA gels showing PCR products to initiate gene knock out mutagenesis 
for (A) dksA and (B) lrhA  
PCR reactions were carried out using chromosomal DNA as template and primers in Appendix 
2 with Phusion® High-Fidelity DNA Polymerase. PCR mixtures were analysed on a 1% TAE 
agarose DNA gel supplemented with a trace of ethidium bromide, visualised under UV light 
and inverted. Samples were run with GeneRuler™ 1kb DNA ladder.   
 
1.6 and 1.4 kbp PCR products were obtained (Figure 3.) and excised from the gel. Using 
electroporation these linear fragments of DNA were then transformed into arabinose induced, 
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pKD46 harbouring parent cells. Following antibiotic resistance screening on kanamycin 
supplemented agar plates, positive colonies were selected for further characterisation by PCR 
screening to ensure that dksA and lrhA had been successfully deleted from the chromosome. 
Once positive colonies were isolated the pKD46 vector was immediately cured from cells as 
previously described to ensure no further recombination events could occur. 
 
3.4.2.2. PCR conformation of knockout mutagenesis: lrhA and dksA 
The acquisition of antibiotic resistance is a good indicator of a successful knockout 
mutagenesis event; however PCR reactions were also carried out to ensure that recombination 
had occurred in the correct location of the chromosome.  PCR reactions using chromosomal 
DNA and a combination of primers designed to anneal either within the kanamycin cassette or 
chromosomal region (up or downstream of the original location of the mutant gene) were 
carried out to further characterise knockout mutagenesis.  
                            
Figure 3.16: Agarose DNA gels showing PCR products to confirm gene knock out mutagenesis 
for (A) dksA and (B) lrhA  
PCR reactions were carried out using chromosomal DNA as template and primers in Appendix 
2 with Phusion® High-Fidelity DNA Polymerase. PCR mixtures were analysed on a 1% TAE 
agarose DNA gel supplemented with a trace of ethidium bromide, visualised under UV light 
and inverted. Samples were run with GeneRuler™ 1kb DNA ladder.  (1) ∆CKL ∆dksA 
chromosomal template. Expected product- lane 1: 548kbp, lane 2: 1109kbp. (2) ∆CKL ∆lrhA 
chromosomal template. Expected product- lane 1: 944kbp 
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Figure 3. indicates that knockout mutagenesis was successful. PCR products were obtained 
using primer sets in which one primer annealed to a region of chromosomal DNA and another 
to the kanamycin cassette. The size of the DNA products indicate that homologous 
recombination occurred in the correct region of chromosomal DNA. 
 
3.4.2.3. Knockout mutagenesis via phage transduction: clpX 
The clpX mutant was derived through an alternative mutagenesis method. As an MG1655 
∆clpX mutant was readily accessible (gifted by J. Green, University of Sheffield), it was not 
necessary to generate the clpX knockout mutant de novo, instead P1 phage transduction could 
be harnessed to transfer the kanamycin linked  ΔclpX  mutation from MG1655 into the 
MC1000 ∆fliC ∆flgKL parent  strain to yield a ΔclpX mutant. In addition to this a MC1000 parent 
strain was also used, resulting in a MC1000 ΔclpX strain with viable flagella to allow motility 
based phenotypic characterisation of a single ΔclpX mutation in an isogenic background.  
Following P1 phage transduction of MG1655 ∆clpX, liquid lysates of the donor strain were 
derived. The recipient strains were inoculated with the lysate, initiating phage transduction of 
donor genetic material to chromosomes of recipient strains.  The presence of colonies 
following inoculation of LB plates supplemented with citrate and kanamycin by recipient cells 
signified successful ΔclpX transduction events. This was coupled to the absence of colonies on 
kanamycin supplemented negative control plates which were inoculated with phage or cells 
only. Transformants were passaged on citrate containing agar plates to eliminate the phage. 
The phage transduction derived mutant cells were passaged on citrate and antibiotic 
containing plates to ensure the phage was eliminated and no further transduction events 
occurred. As the clpX gene is not within 100,000bp of the fliC or flgKL genes, it was not 
necessary to confirm that these genes had been reinstated by the P1 phage during 
transduction, as the phage is not able to package sections of genomic DNA larger than this. 
The phenotype of the ΔclpX mutant was verified to ensure that the mutation is functional in 
the wild-type MC1000 strain. As the secretor strain cells lack filaments they have no motility.  
Therefore the effect of ΔclpX on motility in wild type MC1000 compared to MC1000 ΔclpX on 
motility agar plates was assessed. The latter should display increased motility due to the 
increased concentration of FlhD4C2 which has been reported in E. coli ΔclpX mutants (Kitagawa 
et al., 2011). If this is shown in MC1000 the phenotype may extend to the secretor strain.   
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3.4.3. Mutant characterisation: lrhA 
 
Following verification of mutants, strains were characterised. Secretion was profiled by the E2 
protein secretion assay and flagella gene expression assay. Although the protein standard 
allows the comparison of protein secretion between different experiments, the ∆CKL strain 
was run in tandem to provide a simple visual comparison, so that the standard was not the 
sole point of context. In the flagella gene expression assay the ∆CKL strain experiments must 
be run in parallel to allow comparison between mutant strains against the ∆CKL strain. The 
literature reports that lrhA knock out mutants exhibited higher activity of flagella class I and II 
gene promoters (Lehnen et al., 2002). flhDC promoter activity was 3.5 x higher in the lrhA 
knockout mutant. Therefore it is expected that both gene expression and secretion assays will 
display higher performance in the ΔlrhA mutant strain in comparison to the ∆CKL strain. 
 
3.4.3.1. Effects of deletion of lrhA on FT3SS secretion  
Following verification of the ΔCKL ΔlrhA strain by antibiotic resistance and PCR, the secretion 
assay was performed.  A plasmid harbouring the E2 secretion construct was transformed by 
heat shock into ΔCKL and ΔCKL ΔlrhA cells. The supernatant was analysed by Western blot 
(Figure 3.). Bands were present in all samples with the exception of ΔCKL at hour 4.  
 
Figure 3.17: Secretion of E2 from the secretor strain and ΔlrhA mutant during the growth 
curve.  
E.coli ΔCKL (C) or ΔCKL ΔlrhA (L) containing the plasmid pTrc E2 was grown in LB. Cells were 
harvested at hourly intervals and the OD600 measured. The supernatant from 1 OD unit of cells 
was precipitated with TCA (10% v/v) before SDS-PAGE and Western analysis of supernatant 
using anti-flagellin (H48) antibody and an HRP secondary. An E2 protein standard (S) was 
loaded to allow quantification of secreted protein concentration. 
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Densitometry of each band on the Western blot (Figure 3.) was measured using ImageJ and 
values were calibrated to the E2 protein standard to calculate the concentration of E2 protein 
in samples from both strains at hour time points. Results reflect the amount of E2 secreted per 
OD unit, however if this value is adjusted to account for the volume removed to amount to 1 
OD unit, a mg L-1 culture can be calculated (Figure 3.). Cell densities (OD600) of the two cultures 
were very similar throughout the growth curve, demonstrating that there was no detrimental 
effect of the mutation on strains. In the ∆CKL strain there was no E2 secreted at 4 hours. From 
5 to 24 hours the concentration of E2 in secretor strain culture media increased to a maximum 
of 8.742mg L-1. E2 was present in the media of ΔCKL ΔlrhA after 4 hours. This continued to 
increase up to 7 hours where there was 6.633 mg L-1 E2 in the media. A decrease was observed 
following 24 hours growth. From 4-6 hours protein secretion was higher in ΔCKL ΔlrhA 
however at 7 and 24 hours more extracellular E2 was present in ∆CKL strain media. 
Extracellular E2 concentration continued to increase during the stationary phase for both 
strains, only decreasing after 24 hours in ΔCKL ΔlrhA.  
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Figure 3.18: Secretion of E2 from the secretor strain and ΔlrhA mutant during the growth 
curve 
E.coli ΔCKL and ΔCKL ΔlrhA containing the plasmid pTrc E2 was grown in LB and the OD600 
assayed (ΔCKL: ▲, ΔCKL ΔlrhA: ▼, left hand axis).  In parallel cells were harvested and the 
supernatant from 1 OD unit of cells precipitated with TCA (10% v/v) before SDS-PAGE and 
Western analysis using anti-flagellin (H48) antibody and an HRP secondary.  The amount of 
protein secreted is shown in mg L-1 cell culture as calculated from a standardised amount of E2 
protein using ImageJ based densitometry (ΔCKL: black bar, ΔCKL ΔlrhA: grey bar, right hand 
axis) 
 
The results shown in Figure 3. show the cumulative amount of E2 present in the media, 
however this is not a true representation of secretion over time. By subtracting the total 
protein at a given hour by that calculated for the previous a rate of protein secretion per litre 
of cells per hour can be determined (Figure 3.). For both strains the rate of E2 protein 
secretion into the supernatant increased up until 5 hours, where the rate of protein secretion 
was 2.834 mg L-1  Hour-1  in the ∆CKL strain and 4.260 mg L-1  Hour-1 in the ∆CKL ∆lrhA mutant. 
After 5 hours the rate of protein secretion began to decrease. At 24 hours the rate of protein 
secretion was 0.075mg L-1 Hour-1 in the ∆CKL strain and -0.145 mg L-1  Hour-1  in the lrhA 
mutant. A negative value for the rate of protein secretion is indicative of protein degradation 
exceeding secretion. Overall the rate of protein secretion in the LrhA mutant initially exceeded 
that of the ∆CKL strain from 4 to 5 hours. ∆CKL ∆lrhA also demonstrated the highest rate of 
protein secretion observed at 4.260 mg L-1 Hour-1 , however after 5 hours, while the rate of 
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secretion decreased in both strain, it decreased at a faster rate in ΔCKL ΔlrhA. At 24 hours ΔCKL 
ΔlrhA performed less efficiently to the ∆CKL strain as a negative rate of secretion was 
observed, indicating that secretion was low and degradation high. This information can also be 
used to allude to the impact of protein degradation following secretion –manifesting in a 
negative value for the rate of protein yielded. Protein degradation can be masked by protein 
secretion if secretion exceeds degradation, as the rate of protein secreted will appear as a 
positive number. While it is not possible to conclude how much these impact on the observed 
yield it would seem appropriate to suggest that degradation occurs more in later stages of 
protein secretion, as at 24 hours there a negligible or negative (∆CKL and ∆CKL ∆lrhA 
respectively) rate of protein secretion. Further to this at 6 and 7 hours the rate of protein 
secretion was lower than that seen at the previous hour –however it is not possible to 
conclude whether this is due to a decreased rate of protein secretion or an increased rate of 
protein degradation.  
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Figure 3.19: Secretion of E2 from the secretor strain and ΔlrhA mutant during the growth 
curve per hour 
E.coli ΔCKL and ΔCKL ΔlrhA containing the plasmid pTrc E2 was grown in LB and the OD600 
assayed (ΔCKL: ▲, ΔCKL ΔlrhA: ▼, left hand axis).  In parallel cells were harvested and the 
supernatant from 1 OD unit of cells precipitated with TCA (10% v/v) before SDS-PAGE and 
Western analysis using anti-flagellin (H48) antibody and an HRP secondary.  The amount of 
protein secreted per hour is shown in mg L-1 Hour-1  cell culture as calculated from a 
standardised amount of E2 protein using ImageJ based densitometry (ΔCKL: black bar, ΔCKL 
ΔlrhA: grey bar, right hand axis)  
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These results were inconsistent with the literature – protein secretion was predicted to be 
higher in the ΔlrhA mutant, as it was reported that lrhA knockout mutants exhibited 3.5x 
increased flagella gene expression and were hypermotile (Lehnen et al., 2002). Flagella gene 
expression assays were carried out to assess whether this was a reflection of gene expression 
or whether it was a result of poor secretion capacity.  
 
3.4.3.2. Effect of deletion of lrhA on flagella gene expression 
Increase in flagella gene expression is indicative of an increased number of flagella in the 
phenotype. To measure flagella gene expression, flagella lacZ reporter gene fusions which had 
previously been used by Stafford et al. (2005) were transformed into strains. lacZ encodes the 
β-galactosidase alpha chain which restores enzymatic activity to a defective β-galactosidase 
enzyme. This was implemented by plasmids harbouring the σ70 fliA promoter fragment fused 
to a truncated lacZ gene. Initiation of transcription at the promoter results in the translation of 
the β-galactosidase alpha chain, following complementation and formation of the functional 
enzyme, this cleaves substrates including lactose and o-nitrophenyl-β-d-galactopyranoside 
(ONPG) (Figure 3.).  fliA expression is under the control of two promoters: σ70 and σ28. σ70 is 
directed by the presence of the FlhD4C2 complex, to initiate fliA transcription (Aldridge et al. 
2006.). FliA is also known as σ28, therefore it is also able to self-promote gene transcription. 
However σ28 (FliA) is bound by the anti- σ28 FlgM, therefore only promotes the expression of 
class III genes (fliA included) when FlgM has been exported from the cell, in response to hook 
completion (Figure 1.5). As flagella gene expression is all under a common regulation system 
any flagella gene is a good indicator of overall flagella gene activity. Increase in gene 
expression of fliA by σ70 is indicative of more FlhD4C2 being present and therefore upregulated 
gene expression throughout the flagella gene hierarchy. This should result in the more 
modified flagella being translated, which will allow more product to be secreted.  
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Figure 3.20: Schematic of the gene expression assay.  
Class II promoters are fused to lacZ in the plasmid. Therefore when the master regulator 
FlhD4C2 activates the flagella class II gene promoter, β galactosidase is expressed which 
catalyses the hydrolysis of ONPG into ONP which produces a yellow colour. 
 
A key measurement in the assay is the time taken for a reagent to turn yellow as a result of 
ONPG cleavage and ONP production. This is catalysed by the β galactosidase produced in 
response to promoter activation. As the assay is measuring gene expression over time and in 
multiple strains a range of β galactosidase concentrations will be present, therefore a range 
times and OD results will be observed. It is essential that the assay is accurate through the 
range of concentrations of β galactosidase that may be observed.  The assay was optimised so 
that the time taken for the yellow colour to arise was within a reasonable time and colour 
change was measurable with a spectrophotometer. This was particularly relevant for high OD 
assays as the colour change occurs at a high rate. Preliminary results indicated that performing 
the assay with the same volume of culture to Z buffer was a suitable ratio. 
Flagella gene expression assays were carried out on ΔCKL and ΔCKL ΔlrhA strains to quantify 
flagella gene expression through the growth curve (Figure 3.). Samples of cell culture were 
removed every hour to access gene promoter activity throughout the growth curve. 
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Figure 3.21: Flagella gene expression throughout the growth curve. 
E. coli ΔCKL and ΔCKL ΔlrhA containing the plasmid pGPSfliA was grown in LB and the OD600 
assayed (ΔCKL: ●, ΔCKL ΔlrhA: ∎, left hand axis). In parallel cells were harvested and lysed. A β-
galactosidase assay was carried out with ONPG as the substrate. Miller Units were derived 
from assays (ΔCKL: black bar ΔCKL ΔlrhA: grey bar -right hand axis). One biological replicate of 
each. NOTE: no reading obtained for ΔCKL at 5 hours. 
 
Growth curves of the two strains were very similar for both strains.  The overall trend for both 
strains was an increase in fliA gene expression as OD600 increased. However fliA gene 
expression fluctuated throughout the growth curve in ΔCKL ΔlrhA. ΔCKL promoter activity 
exhibited a constant increase from a negligible amount in the early exponential phase to a high 
amount in the stationary phase. ΔCKL Δlrha fliA promoter activity was consistently higher and 
showed an overall increase during the exponential phase. At 6 hours activity decreased and 
was lower than ΔCKL activity. This was followed by an increase at 7 hours.  ΔCKL Δlrha fliA 
promoter activity levelled off from 7 to 8 hours and was lower than ΔCKL fliA activity.  
lrhA knock out mutants are reported to exhibit higher activity of flagella class I and II gene 
promoters and master regulator promoter activity was 3.5 x higher in the lrhA knockout 
mutant (Lehnen et al., 2002). Therefore it was expected that both gene expression and 
secretion assays would show higher performance of the ΔlrhA mutant strain. This effect was 
not seen in secretion assay results, neither was it observed in gene expression results. Despite 
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this ΔCKL ΔlrhA gene expression results do not reflect the secretion assay results.  Based on the 
secretion assay, gene regulation would be expected to increase up to 7 hours then tail off. 
However gene regulation fluctuated through the growth curve. Consistency between secretion 
and gene expression results was observed in the earlier growth phases (up to 5 hours), as ΔCKL 
ΔlrhA outperformed the ∆CKL strain in both assays. However this was short lived and 
potentially inaccurate, given the poor reliability of results obtained for the remainder of the 
growth curve. 
The regulation phenotype of ΔlrhA was different to that reported in the literature. These 
inconsistencies may be due to the genotype of the strain, which may incur genetic variation 
over time. This can result in the accumulation of suppressor mutations which reverse the 
phenotype. Another possible cause of the unexpected results in that an insertion sequence is 
present in strains. Insertion sequences (IS) are mobile genetic elements which cause genomic 
plasticity (Naas et al., 1994). As some strains of MC1000 have been shown to harbour an IS5 
element in one of two ‘hot spots’ ~300 or ~250 bps upstream of the flhD promoter (Barker et 
al. 2004; Wang & Wood, 2011), Experimental work will turn to investigating whether this is 
true of the strain utilised in this study.  
 
3.4.4. Presence of insertion sequence 5 in the flhDC promoter region 
 
While IS5 has been shown to ‘hop’ upstream of flhD in motile strains, it was found that it 
would not insert in structurally non motile mutants (i.e flgK, motA) therefore if present , the 
IS5 element will have be an inherited from the parent MC1000 strain (Wang & Wood, 2011). 
IS5 elements caused increased motility in these strains, by reducing transcriptional repression. 
IS5 insertion does not alter flhD or the promoter region per se, instead it is thought to alter the 
AT-rich region upstream of flhDC. Through this modification it is assumed that IS5 uncouples 
binding of the LrhA from transcriptional regulation of flhDC (Barker et al., 2004). If the IS5 
element is upstream of flhD in the MC1000 strain used in this thesis, this may account for the 
unexpected results obtained for both secretion and flagella gene expression in the lrhA 
mutant.  
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3.4.4.1. Testing for the presence of insertion sequence 5 in the flhDC 
promoter region  
The presence of the IS5 element upstream of flhD was confirmed when the entire MC1000 
∆CKL strain was sequenced by the MicrobesNG service, University of Birmingham. The 
genomic region is constructed below (Figure 3.). 
  
Figure 3.22: Schematic of the genetic region upstream of the flhD operon with and without 
the IS5 element. 
Construction of the upstream region of flhD in (A) MC1000 without any IS elements, based on 
literature and genomic databases and (B) MC1000 ∆CKL based on sequencing of the whole 
genome. Binding sites for regulatory proteins shown for: H-NS (histone-like nucleoid-
structuring protein), OmpR, LrhA, CRP (cAMP-receptor protein), RscAB and QseB. The flhD 
gene, transcriptional start site of the flhD operon and the -10 and -35 promoter sequences. 
Also shown are the IS5 insertion site and in (2) the IS5 insertion and duplication of the IS5 
insertion site to flank the IS5 element (Yanagihara et al. 1999; Barker et al. 2004). 
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Figure 3.23: Annotated nucleotide sequence of the genetic region upstream of the flhD 
operon with and without the IS5 element. 
Construction of the upstream region of flhD in (A) MC1000 without any IS elements, based on 
literature and genomic databases and (B) MC1000 ∆CKL based on sequencing of the whole 
genome. Binding sites for regulatory proteins shown for: H-NS (histone-like nucleoid-
structuring protein), OmpR, LrhA, CRP (cAMP-receptor protein), RscAB and QseB. The flhD 
gene, transcriptional start site (+1) of the flhD operon and the -10 and -35 promoter sequences 
are also labelled. Also shown are the IS5 insertion site and in (2) the IS5 insertion and 
duplication of the IS5 insertion site to flank the IS5 element (Yanagihara et al. 1999; Barker et 
al. 2004; Clarke & Sperandio, 2005) 
 
As shown in Figure 3. and Figure 3., the IS5 element is present upstream of flhD in the MC1000 
∆CKL strain. This leads to the disruption of the LrhA binding site, one of the H-NS sites and one 
of the QseB sites. It also results in the decoupling of further H-NS sites, one of the OmpR 
binding sites and one of the QseB sites (not shown) from the flhD operon. With regards to LrhA 
and OmpR the IS5 insertion has been shown to result in increased transcriptional activation of 
flhD, presumably due to the inability of transcriptional repressors to bind to sites (Barker et al. 
2004). When osmolality is high, phosphorylated OmpR binds to two sites in the flhD promoter 
region, causing a reduction in flhDC gene expression (Shin & Park, 1995). It is unclear if OmpR 
binding is required at both sites to instigate this effect in E. coli. It was reported that OmpR 
was required at both binding sites to initiate an effect in Yersinia, so this may well be the case 
in E. coli -although it is important to note that in Yersinia OmpR binding causes upregulation of 
flhDC expression therefore conservation between the two species may be low  (Hu et al., 
2009). The H-NS is a positive regulator of the flhD operon, and requires binding at all H-NS sites 
(Soutourina et al., 1999). Throughout the E. coli genome H-NS binds at multiple sites in 
promoter regions, lateral interaction of H-NS proteins causes altered transcriptional control 
(Oshima et al., 2006). Usually H-NS binding exerts negative regulatory control, as it either traps 
or inhibits binding of RNA polymerase; it is suggested that in flagella gene expression H-NS 
binding allows additional transcriptional activators to bind to the promoter region. 
Interestingly HN-S also positively regulates motility, by binding to the FliG motor protein 
promoter region (Donato & Kawula, 1998). The quorum sensing regulator QseB is also a 
positive regulator which binds at two sites in the flhD promoter region -the proximal weak 
affinity site was disrupted and the distal high affinity site (not shown as it is 650+ bp upstream 
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of the flhD transcriptional start site) was decoupled (Clarke & Sperandio, 2005). However as 
the overall effect of IS5 insertion is for a 2.7 fold increase in flhD transcription the negative 
effect of decoupling H-NS and QseB transcriptional control seems to be negated. Some 
transcriptional binding sites are upstream of the IS5 site therefore unaffected by the insertion 
in the MC1000 ∆CKL strain. The binding site for the negative flhDC transcription factor RscAB 
complex remains in situ and can therefore potentially negatively regulate flhD. However the 
CRP binding site is still intact, which is beneficial in terms of flagella gene expression 
upregulation, as in the absence of glucose CRP activity increases flhDC expression (Zhao et al., 
2007). In has been shown in vitro that the presence of CRP can relieve the repression observed 
in an H-NS knockout mutant. This was not shown in vivo but may suggest that a combination of 
transcription factors act to negate the negative effects of HN-S decoupling from flhD by 
positively increasing gene flhD expression beyond their usual capacity (Soutourina et al., 1999).  
Therefore it is possible to conclude that MC1000 is a hypermotile strain and flagella gene 
expression is already upregulated. Therefore the removal of master regulator repressors such 
as LrhA is ineffective in increasing flagella gene expression. While this renders the strategy to 
increase flagella gene expression through the removal of lrhA void, this is not an issue as 
flagella gene expression is already high. Investigation will continue, to observe whether this 
can be improved upon further with the removal of genes which encode transcriptional 
repressors which are not affected by the IS5 insertion or act directly on flhDC/ FlhD4C2 (DksA 
and ClpX respectively).  
 
3.4.5. Mutant characterisation: dksA 
 
Previous studies have shown that flagella gene expression is higher in dksA knock out mutants 
(Lemke et al., 2009). lacZ reporter gene fusions show that flhDC promoter activity was 2.3 x 
higher in log phase and 9 x higher in stationary phase. Here investigation focused on whether 
the ∆CKL ∆lrhA strain exhibited higher flagella gene expression and whether this translates to 
more secretion apparatus and therefore more secretion. This mutant holds promise as it was 
found that protein secretion in the secretor strain decreases in the stationary phase (Figure 3.), 
therefore this mutant has potential to oppose this characteristic and improve protein secretion 
throughout the stationary phase. DksA acts by binding near the active site of RNA polymerase 
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and therefore decreasing the ‘lifespan’ of open RNAP ( Paul et al. 2004). This in turn results in 
reduced RNAP-flhDC promoter DNA complexes and therefore less flhDC gene expression. As 
DksA is indirectly linked to flhDC promoter DNA (through decreased open RNAP), its route of 
action is not altered by the presence of IS5, which only concerns transcriptional control 
upstream of the flhDC promoter.  
 
3.4.5.1. Effects of deletion of dksA on FT3SS secretion  
Once the dksA knockout was confirmed by PCR (Figure 3.) a secretion assay was carried out to 
establish the secretion profile of the strain. As it has been reported that flagella gene 
expression increases in the stationary phase of ΔdksA mutants; the secretion was measured 
through the growth curve, with samples being taken every hour. ΔCKL expressing E2 protein 
were also grown in tandem so that the secretion capacities of the two could be compared. A 
protein standard was also loaded onto the SDS-PAGE gel to allow yields to be quantified. 
Following Western blotting E2 protein could be observed after 5 hours in both strains (Figure 
3.). More protein was seen in the supernatant of ΔCKL cells than  ΔdksA at all time points.  
 
Figure 3.24: Secretion of E2 from the secretor strain and ΔdksA mutant during the growth 
curve.  
E.coli ΔCKL (C) or ΔCKL ΔdksA (D) containing the plasmid pTrc E2 was grown in LB. Cells were 
harvested at hourly intervals and the OD600 measured. The supernatant from 1 OD unit of cells 
was precipitated with TCA (10% v/v) before SDS-PAGE and Western analysis of supernatant 
using anti-flagellin (H48) antibody and an HRP secondary. An E2 protein standard (S) was 
loaded to allow quantification of secreted protein concentration.  
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Densitometry analysis was carried out on the Western blot. While the standard appears only 
faintly on the Western blot, it was detectable in ImageJ software analysis; therefore secreted 
protein yield could be calculated and plotted against OD600 (Figure 3.). The two mutant strains 
grew similarly, suggesting that removing dksA does not confer a change in growth phenotype. 
The concentration of E2 found in culture supernatant was consistently higher in ΔCKL in 
comparison to ΔCKL ΔdksA. The highest concentration of protein observed was 93.117 mg L-1 
in ΔCKL following 6 hours of growth. At every time point following 6 hours the concentration of 
E2 protein decreased -with the exception of ΔCKL after 8 hours, which exhibited a slight 
increase. After 24 hours E2 protein was still detected in the supernatant of both strains at 
concentrations of 48.158 mg L-1 and 15.646 mg L-1 for ΔCKL and ΔCKL ΔdksA respectively.  
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Figure 3.25: Secretion of E2 from the secretor strain and ΔdksA mutant during the growth 
curve 
E.coli ΔCKL and ΔCKL ΔdksA containing the plasmid pTrc E2 was grown in LB and the OD600 
assayed (ΔCKL: ▲, ΔCKL ΔdksA: ▼, left hand axis).  In parallel cells were harvested and the 
supernatant from 1 OD unit of cells precipitated with TCA (10% v/v) before SDS-PAGE and 
Western analysis using anti-flagellin (H48) antibody and an HRP secondary.  The amount of 
protein secreted is shown in mg L-1 cell culture as calculated from a standardised amount of E2 
protein using ImageJ based densitometry (ΔCKL: black bar, ΔCKL ΔdksA: grey bar, right hand 
axis) 
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When visualised as secretion per hour (Figure 3.) it is evident that the majority of E2 protein is 
secreted into the media between hour 4 and 5, where the rate of secretion is 93.117 mg L-1 
Hour-1 and  63.876 mg L-1 Hour-1  for ΔCKL and ΔCKL ΔdksA respectively. Following this (with 
the exception of ΔCKL at hour 7, where a slight positive value for the rate of secretion is 
observed) the values obtained for the rate of protein secretion is always negative, indicating 
protein degradation. The concentration of E2 protein observed here is markedly higher than 
that seen in the previous experiment (Figure 3.). Potential reasons for this will be discussed in 
a later section.  
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Figure 3.26: Secretion of E2 from the secretor strain and ΔdksA mutant during the growth 
curve per hour 
E.coli ΔCKL and ΔCKL ΔdksA containing the plasmid pTrc E2 was grown in LB and the OD600 
assayed (ΔCKL: ▲, ΔCKL ΔdksA: ▼, left hand axis).  In parallel cells were harvested and the 
supernatant from 1 OD unit of cells precipitated with TCA (10% v/v) before SDS-PAGE and 
Western analysis using anti-flagellin (H48) antibody and an HRP secondary.  The amount of 
protein secreted per hour is shown in mg L-1 Hour-1  cell culture as calculated from a 
standardised amount of E2 protein using ImageJ based densitometry (ΔCKL: black bar, ΔCKL 
ΔdksA: grey bar, right hand axis)  
Following the initial positive rate of protein secretion at 5 hours, protein was secreted at an 
increasingly reduced rate; this was opposite to what was expected if ΔCKL ΔdksA had 
performed as anticipated. If the dksA knockout resulted in increased flagella gene expression 
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in the stationary phase as reported in the literature, increased secretion apparatus formation 
and therefore E2 secretion would have been observed. To investigate if flagella gene 
expression was higher in the dksA mutant a gene expression assay was carried out. 
 
3.4.5.2. Effects of deletion of dksA on flagella gene expression  
 
Flagella gene expression was measured throughout the growth curve of both ΔCKL and ΔCKL 
ΔdksA. 
2 3 4 5 6 7
0 .1
1
1 0
0
2 0 0 0 0
4 0 0 0 0
T im e  [H o u rs ]
O
D
6
0
0
M
ille
r
 U
n
its
 
Figure 3.27: Flagella gene expression throughout the growth curve. 
E. coli ΔCKL and ΔCKL ΔdksA containing the plasmid pGPSfliA was grown in LB and the OD600 
assayed (ΔCKL: ●, ΔCKL ΔdksA: ∎, left hand axis). In parallel cells were harvested and lysed. A 
β-galactosidase assay was carried out with ONPG as the substrate. Miller Units were derived 
from assays (ΔCKL: black bar, ΔCKL ΔdksA: grey bar, right hand axis) 
 
Growth curves of the two strains were very similar for both strains.  The overall trend for both 
strains was a decrease in fliA gene expression as OD600 increased. However between hour 3 
and 4 (late log stage) fliA gene expression increased in both ΔCKL dksA and ΔCKL. After 2 hours 
the promoter activity of ΔCKL was higher than ΔCKL dksA, following 3 hours this was still true, 
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however the difference had reduced. From 4 hours the promoter activity of both strains was 
very similar –both exhibiting a steady decrease until the stationary phase where gene 
expression was negligible in both strains.  
It was expected that both gene expression and secretion assays would be higher in ΔdksA 
mutant strain, particularly in the stationary phase. This effect was not seen in either secretion 
assay results or gene expression results, however ΔCKL ΔdksA gene expression results do 
reflect the secretion assay results, both showing a decrease through the growth curve in fliA 
promoter activity and E2 protein secretion respectively. In the early stationary phase both 
strains displayed an increase in gene expression from 3 to 4 hours (Figure 3.); this coincides 
with the high initial rate of E2 secretion seen in both ΔCKL and ΔCKL ΔdksA during the early 
stationary phase in Figure 3..  
 
3.4.6. Mutant characterisation: clpX 
 
As ClpX has been shown to actively degrade the FlhD4C2 complex (Tomoyasu et al., 2002), the 
ClpX knockout mutant is expected to exhibit increased flagella gene expression and therefore 
secretion. This has been shown experimentally as ΔclpX mutants were shown to accumulate 
FlhD4C2, the complex had increased half-life and cells were more motile (Kitagawa et al., 2011). 
Therefore removing ΔclpX from the ∆CKL strain may result in increased flagella gene 
expression and more secretion. Furthermore as this concerns the reduction in proteolysis of 
the FlhD4C2 protein complex, the presence of IS5 is not relevant to this investigation. 
Prior to the investigation of the clpX knockout mutation in the immotile secretor strain, the 
effect of the same mutation was investigated in the wild-type MC1000 strain. As the MC1000 
ΔclpX strain is able to form functional flagella, it enables comparable measurements of motility 
and quantification of the abundance of filament protein in wild type MC1000 and the MC1000 
ΔclpX mutant.  
3.4.6.1. Effects of deletion of clpX on the abundance of filament protein 
Increased flagella gene expression will result in an increase in the amount of filament (FliC) 
protein which is presented on the surface of cells. Relative concentration of filament protein 
associated with the cell surface of MC1000 with and without the ΔclpX mutation was 
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measured to ascertain how the ΔclpX mutation alters flagella assembly and by proxy, type III 
secretion. To achieve this strains were grown with low agitation at 30°C to ensure that flagella 
filaments remained intact. Cells were then carefully collected from the supernatant to ensure 
filaments remained intact and normalised for OD600 to allow direct comparison of the 
concentration of filament proteins obtained from each inoculate. Following vortexing to shear 
the filaments from the cells the filament proteins were isolated via several centrifugation 
steps, ensuring no intracellular filaments contaminated the sample. Isolated filaments were 
then analysed by SDS-PAGE (Figure 3.). 
    
Figure 3.28: Concentration of sheared flagella filaments from WT MC1000 and MC1000 
ΔclpX. 
E.coli MC1000 and MC1000 ΔclpX were grown in LB and the OD600 assayed. Cells were 
harvested and normalised according OD600 of cultures from which they were derived, filaments 
were isolated and loaded onto an SDS-PAGE and stained with Instant Blue. Results from four 
biological replicates. 
 
Densitometry analysis was then carried out on the image of the SDS-PAGE gel, to allow 
quantification of the concentration of filament proteins obtained from the two strains. As a 
protein standard was not loaded onto the SDS-PAGE it is not possible to calculate a numerical 
value for the yield of filament proteins; however a relative value is also informative as to the 
effect of the ΔclpX mutation on the concentration of FliC protein secreted through the flagella 
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type III secretion system. The clpX knockout mutation resulted in an average of 1.95 times 
more filament protein being secreted through the flagella type III secretion system (Figure 3.).  
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Figure 3.29: Relative concentration of sheared flagella filaments from WT MC1000 and 
MC1000 ΔclpX.  
E.coli MC1000 and MC1000 ΔclpX were grown in LB and the OD600 assayed. Cells were 
harvested and normalised according OD600 of cultures from which they were derived, filaments 
were isolated and loaded onto an SDS-PAGE. Using ImageJ based densitometry the abundance 
of filament protein was quantified; results were paired to allow the calculation of relative 
abundance of filament protein to MC1000. Results from four biological replicates, grown on 
the same day. A paired t-test was carried out for the pre-normalised values, to give more 
power to the calculation. Individual data points, mean and standard error of the mean and 
result of two way t-test shown (** = p<0.01) 
 
Significantly more (2 fold) FliC monomers were isolated from the ΔclpX mutant, suggesting 
that more filament proteins assemble in the mutant as opposed to the wild type. As they are 
secreted through the fT3SS, this would suggest higher secretion capacity in ΔclpX mutants. 
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3.4.6.2. Effects of deletion of clpX on motility 
Motility agar plates were inoculated with either WT MC1000 or MC1000 ΔclpX, to allow 
measurements of motility. As flagella are intact in these strains, increased flagella gene 
expression will manifest in increased motility. The swimming motility of ∆CKL mutants was also 
assessed. As these mutant strains do not form functional filaments, it is not expected that they 
will exhibit any motility behaviour. Inoculates from all four strains were stabbed into each 
plate to reduce any variability that may arise from the environment. Following inoculation by 
stabbing individual colonies into the motility agar, plates were incubated at 30°C in humid 
conditions, allowing swimming motility to occur (Figure 3.). The radius of the swimming zone 
from the inoculation point was measured at time intervals and plates were returned to the 
incubator. Over time the swimming zone of motile strains extended and was in some cases 
obscured by the perimeter of the agar plate, therefore a measurement of radius was chosen 
over circumference. Results were used to calculate the rate of swimming. 
 
Figure 3.30: The effect of clpX on the swimming motility of MC1000 and MC1000 ∆flgKL ∆fliC 
strains. 
0.25% LB agar plates were inoculated with (clockwise from the top), MC1000, MC1000 ∆flgKL 
∆fliC, MC1000 ∆clpX and MC1000 ∆flgKL ∆fliC ∆clpX. Swimming motility was measured at time 
intervals during incubation at 30°C. Images were recorded following 1 hour (left) and 24 hours 
(right). 
Results were used to calculate the rate of swimming. Secretion apparatus (∆flgKL ∆fliC) 
mutants always exhibited a lower rate of swimming than strains with intact flagella (Figure 3.). 
After 1 hour a 0.625 and 0.875 mm Hour-1 rate of swimming was observed for the ∆CKL 
mutants, however from 2 hours onwards this rate reduced to around 0 for both strains. This 
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indicated that the ∆CKL mutation resulted in a strain which was entirely immotile, presumably 
due to the absence of flagella. Both the wildtype flagella strains displayed swimming motility 
throughout the experiment –this demonstrates that growth conditions were suitable for 
motility to occur, confirming the immotile phenotype of the secretion apparatus mutants. 
After 1 and 3 hours the rate of swimming in MC1000 strains was slightly higher that MC1000 
∆clpX, however at 2 and 20 hours the rate of motility was significantly higher in MC1000 cells 
with the ∆clpX mutation (p = <0.01. Paired t-test). After 20 hours the average rate of motility 
for MC1000 ∆clpX cells was 1.13 mm Hour-1 -1.33 times that of MC1000. These results 
demonstrate that the removal of clpX from the MC1000 chromosome results in increased 
motility in cells which produce functional flagella.  
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Figure 3.31: The effect of clpX on swimming rate of MC1000 and MC1000 ∆flgKL ∆fliC strains. 
0.25% LB agar plates were inoculated with individual colonies. Swimming motility was 
measured at time intervals during incubation at 30°C and recorded, allowing the rate of 
swimming to be calculated. MC1000: ∎, MC1000 ∆fliC ∆flgKL: □, MC1000 ∆clpX: ● and 
MC1000 ∆fliC ∆flgKL ∆clpX: ○. Four biological replicates for each strain. 
The secretion capacity of the ∆CKL ∆clpX mutant was then investigated to see if the phenotypic 
effects observed in Figure 3. extend to the modified FT3SS secretion platform. 
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3.4.6.3. Effects of deletion of clpX on FT3SS secretion 
As discussed, the literature suggests that the removal of clpX from the chromosome will result 
in an increase in FlhD4C2 complex, therefore increased flagella gene expression. The secretion 
capacity of ∆CKL ∆clpX in comparison to the ∆CKL strain was investigated throughout the 
growth curve. A plasmid harbouring the E2 secretion construct was electroporated into ΔCKL 
and ΔCKL ΔclpX cells. Following inoculation and induction with 0.05mM IPTG measurements of 
OD600 were taken every hour and the supernatant and cells were prepared for SDS-PAGE and 
Western blot (Figure 3.), to ascertain the concentration of E2 protein. Previously only the 
supernatant of cells has been analysed by Western blot in secretion experiments through the 
growth curve, however more information can be obtained by observing the concentration of 
E2 located intracellularly. Bands were present in all samples at each time point. A higher 
concentration of E2 protein was seen both intracellularly and in the secreted fraction of ΔCKL 
ΔclpX mutants in comparison to ΔCKL at all times.  
 
Figure 3.32: Intracellular and secreted E2 from the secretor strain and ΔclpX mutant during 
the growth curve.  
E.coli ΔCKL (C) or ΔCKL ΔclpX (C) containing the plasmid pTrc E2 was grown in LB. Cells were 
harvested at hourly intervals and the OD600 measured. 1 OD unit of cells were prepared with 2x 
SDS-PAGE loading buffer. The supernatant from 1 OD unit of cells was precipitated with TCA 
(10% v/v) and prepared with 2x SDS-loading buffer. Samples underwent SDS-PAGE and 
Western blot analysis of cells and supernatant using anti-flagellin (H48) antibody and an HRP 
secondary. An E2 protein standard (S) was loaded to allow quantification of intracellular and 
secreted protein concentration. 
Densitometry of each band on the Western blot (Figure 3.) was measured using ImageJ and 
values were calibrated to the E2 protein standard to calculate the concentration of E2 protein 
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in samples from both strains at hour time points. In addition to the results obtained by the 
Western blot shown in Figure 3., a further biological repeat was analysed and is included in the 
following results. Results reflect the amount of E2 secreted per OD unit, however if this value 
is adjusted to account for the volume removed to amount to 1 OD unit, a mg L-1 culture can be 
calculated (Figure 3.) for both intracellular and secreted E2 protein. Cell densities (OD600) of the 
two cultures were very similar throughout the growth curve, demonstrating that there was no 
detrimental effect of the mutation on strains. The concentration of E2 in the supernatant of 
ΔCKL ΔclpX was always greater than that in ΔCKL (Figure 3.: left). The highest concentration of 
secreted E2 in the ΔCKL strain was observed in the mid log phase at 5 hours (1.237 mg L-1); 
after which slight fluctuations in E2 concentration were observed, however the concentration 
was always lower in the hours following this initial measurement. From 5 to 6 hours the 
concentration of E2 in the secreted fraction of ΔCKL ΔclpX cells increased from 3.029 to 4.220 
mg L-1 and then began to decrease to 2.324 mg L-1 secreted E2 following 24 hours growth. As 
observed in the secreted fraction (Figure 3.: right), the highest intracellular concentration of E2 
(1.748 g L-1) was observed at 5 hours in ΔCKL. After 24 hours there was 0.440 g L-1 E2 protein 
present in cells. There was always more E2 present in ΔCKL ΔclpX cells than ΔCKL. The highest 
concentration of intracellular protein in ΔCKL ΔclpX was observed after 5 hours (2.633 g L-1) 
and decreased every hour following this, with the exception of 7 hours where there was a 
slight increase. After 24 hours 1.439 g L-1 E2 was visible in cells.  
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Figure 3.33: Intracellular and secreted E2 from the secretor strain and ΔclpX mutant during 
the growth curve 
E.coli ΔCKL and ΔCKL ΔclpX containing the plasmid pTrc E2 was grown in LB and the OD600 
assayed (ΔCKL: ▲, ΔCKL ΔdksA: ▼, left hand axis). In parallel 1 OD unit of cells were prepared 
with 2x SDS-PAGE loading buffer. The supernatant from 1 OD unit of cells precipitated with 
TCA (10% v/v) and prepared with 2x SDS-PAGE loading buffer. Samples underwent SDS-PAGE 
and Western blot analysis using anti-flagellin (H48) antibody and an HRP secondary.  The 
amount of protein secreted (A) or located intracellularly (B) is shown in mg L-1 cell culture as 
calculated from a standardised amount of E2 protein using ImageJ based densitometry (ΔCKL: 
black bar, ΔCKL ΔdksA: grey bar, right hand axis). Results from two biological replicates. 
 
By subtracting the concentration of E2 present in the supernatant at the previous hour from 
each value it is possible to observe the rate of protein secretion at each time point in mg L-1 
Hour-1, rather than a cumulative view. A positive value shows that protein secretion exceeds 
degradation, while a negative value suggests the opposite. The highest rate of E2 secreted by 
ΔCKL was 1.971 mg L-1 Hour-1 and 3.745 mg L-1 Hour-1 for ΔCKL ΔclpX. For both strains this high 
rate of E2 secretion was observed from 4 to 5 hours (the mid log phase). As the concentration 
of E2 was not measured at 4 hours, it is not possible to ascertain whether the rate observed at 
5 hours is accurate or whether protein was also secreted prior to 4 hours. After 5 hours the 
rate of E2 secreted by ΔCKL was either negative or negligible, suggesting that secretion was 
low and degradation high. After 6 hours cells reached early stationary phase the rate of 
secretion observed in the clpX knockout mutant was reduced, but positive –suggesting that 
either (or both) secretion was slightly lower or degradation slightly higher than at 5 hours. 
After 6 hours ΔCKL ΔclpX demonstrated a negative rate of protein secretion, suggesting protein 
degradation was higher than secretion of E2. The rate of secretion observed between 9 and 24 
hours for both strain was around 0 –suggesting that both E2 protein secretion and degradation 
were matched. 
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Figure 3.34: Secretion of E2 from the secretor strain and ΔclpX mutant during the growth 
curve per hour 
E.coli ΔCKL and ΔCKL ΔclpX containing the plasmid pTrc E2 was grown in LB and the OD600 
assayed (ΔCKL: ▲, ΔCKL ΔclpX: ▼, left hand axis).  In parallel cells were harvested and the 
supernatant from 1 OD unit of cells precipitated with TCA (10% v/v) before SDS-PAGE and 
Western blot analysis using anti-flagellin (H48) antibody and an HRP secondary.  The amount 
of protein secreted per hour is shown in mg L-1 Hour-1  cell culture as calculated from a 
standardised amount of E2 protein using ImageJ based densitometry (ΔCKL: black bar, ΔCKL 
ΔclpX: grey bar, right hand axis)  Results from two biological replicates. 
 
One of the advantages of measuring both secreted and intracellular protein is that a broader 
picture of strain effects can be inferred, to include translational and secretion capacity of 
strains. By calculating the total concentration of protein in cell cultures (both secreted and 
intracellular), it is then possible to calculate the proportion of total protein which is secreted 
(expressed as a percentage of total protein). This provided information as to which strain is the 
most efficient secretor. This is informative as it is probable that the tuning of protein 
production to secretion capacity may be beneficial to improving the rate of protein secretion. 
For example if the cell invests metabolic energy in producing recombinant protein, less energy 
is available to produce secretion machinery.  
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Figure 3. shows the secretion efficiencies of both ΔCKL and ΔCKL ΔclpX over the growth curve. 
The ΔclpX mutant is more efficient at protein secretion than the ΔCKL strain throughout the 
growth curve. At 6 hours (late log phase) it is over 5 times more efficient at secreting E2 
protein than ΔCKL. Although it is reasonably consistent, the overall trend is for the efficiency of 
E2 protein secretion to increase through the growth curve. The highest proportion of secreted 
protein observed was 0.217%. This indicates very low efficiency of protein secretion. With 
additional strain improvements and alterations to the fermentation method, it may be 
possible to improve this.  
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Figure 3.35: The proportion of E2 secreted from the secretor strain and ΔclpX mutant during 
the growth curve 
E.coli ΔCKL and ΔCKL ΔclpX containing the plasmid pTrc E2 was grown in LB and the OD600 
assayed (ΔCKL: ▲, ΔCKL ΔclpX: ▼, left hand axis). In parallel 1 OD unit of cells were prepared 
with 2x SDS-PAGE loading buffer. The supernatant from 1 OD unit of cells precipitated with 
TCA (10% v/v) and prepared with 2x SDS-PAGE loading buffer. Samples underwent SDS-PAGE 
and Western blot analysis using anti-flagellin (H48) antibody and an HRP secondary.  Following 
the calculation of the amount of protein secreted or located intracellularly (mg L-1 cell culture), 
the percentage of secreted protein as a proportion of total protein was ascertained (ΔCKL: 
black bar, ΔCKL ΔdksA: grey bar, right hand axis). Results from two biological replicates.  
As the measure of secretion efficiency of the FT3SS is devised by comparing secreted and 
intracellular protein, it cannot distinguish the route by which protein appears in the 
supernatant. A high value for secretion efficiency may suggest that cell lysis is occurring. This 
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was investigated by stripping the nitrocellulose membrane used for Western blotting of 
antibodies and reprobing this with an anti-GroEL and suitable secondary-HRP conjugated 
antibody (Figure 3.). As GroEL is a cytoplasmic contaminant, the presence of it in the secreted 
fraction suggests some level cell of lysis has occurred- although this cannot be related to cell 
numbers or concentrations of GroEL. As a degree of cell lysis is expected in cell culture, a low 
level of GroEL is always expected to be present in samples (visible band at all time points, in 
both strains in Figure 3.) and is never observed at a high enough level to suggest it accounts for 
the differences in secretion levels observed. The exception to this is seen following 24 hours 
growth, as a higher concentration of GroEL is detected in the secreted fraction (more so with 
the clpX knockout mutation), suggesting an increased rate of cell lysis. This means that E2 
found in the extracellular fraction following 24 hours growth, may in part be due to cells lysis, 
rather than directed FT3SS secretion.  
 
  
Figure 3.36: Abundance of GroEL in the supernatant of ΔCKL and the ΔclpX mutant through 
the growth curve 
E.coli ΔCKL (C) or ΔCKL ΔclpX (C) containing the plasmid pTrc E2 was grown in LB. Cells were 
harvested at hourly intervals and the OD600 measured. 1 OD unit of cells were prepared with 2x 
SDS-PAGE loading buffer. The supernatant from 1 OD unit of cells was precipitated with TCA 
(10% v/v) and prepared with 2x SDS-loading buffer. An E2 protein standard (S) serves as a 
negative control. Samples underwent SDS-PAGE and Western blot analysis of cells and 
supernatant using anti-GroEL  antibody and a HRP secondary.  
 
The effect of the ΔclpX  mutation appears to have a positive effect of both the amount of E2 
protein produced intracellularly, the concentration secreted protein, the rate at which this 
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protein is secreted and finally the proportion of total protein that is secreted. This is very 
promising in terms of the aim of improving protein secretion through the fT3SS.  
It was hypothesised that an increase in FT3SS secretion would be observed in ΔclpX mutants 
due to decreased FlhD4C2 complex degradation and therefore increased FlhD4C2 half-life, which 
will amount to increased flagella gene expression. In order to investigate whether this increase 
in protein secretion is due to increased flagella gene expression, gene expression assays were 
carried out. As described previously, the use plasmids which harbour a flagella gene promoter 
fragment, fused to a truncated lacZ gene (which encodes β galactosidase) allowed gene 
expression to be measured based on the rate of ONPG cleavage. Despite several rounds of 
optimisation and the use of plasmids harbouring either the lacZ-fliA promoter fusion used 
previously, or a lacZ-flhB promoter fusion it was not possible to obtain results for gene 
expression in the ΔclpX mutant. As assays of β galactosidase activity through lacZ fusions in 
∆clpX mutants is reported in the literature, it is unlikely due to incompatibility. In fact one 
example investigates β galactosidase activity through a fliA-lacZ fusion in ∆clpXP mutant 
strains, and concludes that fliA gene expression is increased almost 4 fold with the ∆clpXP 
mutation (Kitagawa et al., 2011). While this investigation was carried out in 
enterohaemorrhagic E. coli, the experimental procedure was otherwise very similar, although 
this was in a ∆clpXP not ∆clpX background, so potentially free ClpP could be affecting β 
galactosidase, although this has never been reported. Another possibility is that flagella gene 
expression has not been increased, instead the increase in E2 expression may be due to the 
absence of ClpX directed degradation of FliC (E2), RNA polymerase or ribosome degradation 
for example (although there is no experimental evidence for this in the literature). As it is 
evident from the literature that the removal of clpX from the chromosome of E. coli resulted in 
increased flagella gene expression (Tomoyasu et al., 2003; Kitagawa et al., 2011), it is 
postulated that this is the route by which E2 protein secretion was increased in the ΔCKL ΔclpX 
strain. 
While ΔclpX had a positive effect of the concentration of E2 protein secreted through the 
FT3SS into the media, the literature also highlights that ClpX protease acts on many proteins in 
addition to FlhD4C2 and alters many gene regulatory pathways in addition to flagella. ClpX 
protease confers protein quality control, control of stress response and DNA damage, 
stationary phase gene expression and cell division (Flynn et al. 2003; Baker & Sauer, 2012) It 
has been previously shown that as ClpX modulates the balance of cell division proteins, the 
163 
 
absence of ClpX protein leads to elongated filamentous E. coli (MC784 strain) and that cell 
division is delayed (Camberg et al., 2011). The phenotype of ΔCKL ΔclpX was investigated to 
observe whether it is phenotypically altered in any way –both by observing the growth and 
visual phenotype of the strain in comparison to ΔCKL.   
 
3.4.6.4. Effects of deletion of clpX on growth phenotype 
A number of factors can alter the growth phenotype of cells (chromosomal mutations, the 
production of plasmid derived protein, growth conditions). The effect of this can vary from 
marginally increasing or decreasing the growth rate, altering the time at which stages of the 
growth curve are reached or entirely compromising cell growth, should the strain be non-
viable. The clpX knockout mutant proved beneficial in increasing the concentration of E2 
protein both produced and secreted -this modification may also alter the growth phenotype of 
the mutant in comparison to the ∆CKL strain. In addition to this the expression of plasmid DNA 
and production of protein can also change the growth phenotype of cells. This effect is usually 
detrimental to cell growth, as metabolic energy is diverted to non-chromosomal protein 
production and away from growth processed. Both the effect of ∆clpX and the production of 
plasmid derived E2 was investigated with regard to cell growth. 
Figure 3. shows that the induction of gene expression in cells harbouring pTrc E2 resulted in a 
decrease in growth rate. Cells exhibited a prolonged lag phase (until 1.5 or 2.5 hours, as 
opposed to 1 hour) and the rate of growth (mean generation time increased 1.36 and 1.49 fold 
for ∆CKL and ∆clpX respectively) in the log phase was reduced. However in late stationary 
phase similar final OD600 values for the cultures were achieved. This effect was more 
pronounced in ∆clpX cells, which were shown to exhibit significantly lower optical densities 
throughout the growth curve when expressing pTrc E2 in comparison to empty vector (p = 
<0.0001. Paired t-test of average OD600 values at each time point). The introduction of ∆clpX to 
cells resulted in a lower rate of growth in cells expressing either empty pTrc or pTrc E2. In cells 
expressing empty vector, this effect was not significant –while the addition of ∆clpX did 
compromise growth rate it was not sufficient enough to suggest the mutation is very 
detrimental to cell growth. Optical densities at all times were significantly lower for ∆clpX + 
pTrc E2 than all other strain and plasmid combinations vector (p = <0.0001. Paired t-test of 
average OD600 values at each time point). The lag phase was 1.5 hours longer, growth rate in 
164 
 
log phase slower and the time taken to reach stationary phase longer. This is likely to be an 
additive effect of the reduced growth rate of both cells expressing pTrc E2 and the ∆clpX 
mutation, although it would appear that the production of E2 protein contributes more to this 
effect. Growth of ∆clpX +pTrc E2 was still satisfactory, however it reveals that while the ∆clpX 
strain may be preferable for secretion of E2 protein, it may require a longer incubation time, as 
the growth lags. 
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Figure 3.37: Growth of the secretor strain and the ∆clpX mutant with pTrc or pTrc E2 plasmid 
in LB media over time in a 96 well plate. Calibrated to LB media.  
E.coli ΔCKL and ΔCKL ΔclpX containing either empty pTrc vector or the pTrc E2 were grown in 
96 well plate wells in LB and the OD600 assayed. Cells were supplemented with 0.05mM IPTG to 
induce plasmid expression. Results were calibrated to values for LB only values. Averages were 
calculated to account for technical repeats and then biological repeats. The standard error of 
the mean is shown for biological repeats (N=3). ΔCKL + pTrc E2: ●, ΔCKL + pTrc empty: ○, ΔCKL 
ΔclpX +pTrc E2: ∎ , ΔCKL ΔclpX +pTrc empty: □ 
 
3.4.6.5. Effects of deletion of clpX on cell morphology 
Previous studies have shown that the absence of ClpX protein leads to elongated filamentous 
E. coli (Camberg et al., 2011). This observation was made in a MG1655 background strain with 
a ∆minC deletion, this knockout mutation resulted in elongated cell phenotype, presumably 
because MinC inhibits the cell division protein FtsZ. The removal of ClpX in the ∆minC strain 
resulted in increased cell elongation. Therefore the overall conclusion was that removal of ClpX 
165 
 
resulted in a higher abundance of proteins which delay cell division and lead to cell elongation. 
This was investigated by measuring the length of ∆CKL cells -with and without the ∆clpX 
mutation- following growth in liquid culture, prior to fixing cells onto microscope slides and 
Gram staining cells. Images were captured at 100x magnification and a scale was added to the 
images (Figure 3.). Cell length was measured using ImageJ from these images. A range of 
lengths are visible by eye and care was taken not to preferentially select cells of a certain 
length, instead a small area was selected and 33 cells lengths were measured for each 
biological sample. Cell morphology looks similar by eye, although it is evident that there are 
some very elongated cells present in the ∆CKL ∆clpX images (i.e. Figure 3.: ∆CKL ∆clpX 3). 
 
  
Figure 3.38: Microscope images of Gram stained ∆CKL and ∆CKL ∆clpX cells. 
Following liquid culture cells were fixed onto microscope slides and Gram stained before 
imaging under 100x magnification. Three biological replicates of each strain: top: ∆CKL, 
bottom: ∆CKL ∆clpX. A 20µm scale was added to images. Cell length was measured using 
ImageJ and adjusted by calibration to the scale to calculate the length of cells. 
 
The results following measurement of cell length show that ∆clpX results in elongation of cells 
from an average of 0.611µm for ∆CKL to 0.782µm for ∆CKL ∆clpX, this represents a 1.28 fold 
increase which was found to be statistically significant (Figure 3.: left). Sorting this data into 
bins with 0.1µM increments for the centre of each bin, revealed that the distribution of sizes 
differs for the two strains (Figure 3.: right). ∆CKL ∆clpX were more commonly larger in length 
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that ∆CKL. The modal length of ∆CKL cells was centred at 0.5µM, whereas for ∆CKL ∆clpX it was 
0.9µM. The distribution of ∆CKL ∆clpX cell length extended beyond the highest length seen for 
∆CKL (1.0µM), to 1.5 µM. 
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Figure 3.39: Length of Gram stained ∆CKL and ∆CKL ∆clpX cells and histogram following bin 
sorting for length. 
Following liquid culture cells were fixed onto microscope slides and Gram stained before 
imaging under 100x magnification and length under analysis with ImageJ. Cell length was 
adjusted by calibration to the scale to calculate the length of cells. N = 99 (33 measurements 
from each biological replicate; three biological replicates of each strain). Left: Average length 
of cells. Standard error of the mean shown. **** = p <0.0001. Unpaired t-test. Right: Results 
sorted into bins for length (0.1µM centres). Black: ∆CKL. Grey: ∆CKL ∆clpX 
 
3.5. Negative control of FT3SS secretion 
 
Altering the secretion capacity of the FT3SS by altered flhDC expression was not feasible in the 
case of lrhA or dksA, however some progress was made with ∆clpX. Prior to implementing 
additional strategies to improve FT3SS secretion, negative control of FT3SS secretion was 
investigated, to ensure the presence of E2 in the supernatant is indicative of FT3SS directed 
secretion and no other route.  
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3.5.1. Rationale for mutagenesis: negative control of protein secretion 
through the FT3SS 
 
As the E2 protein harbours the secretion signal for FT3SS, it is expected that this is the route 
for protein secretion into the supernatant. Currently the low and consistent concentration of 
GroEL detected in the supernatant of cells, suggests that cell lysis is not prevalent enough to 
be responsible for the presence of the majority of E2 visible in the supernatant of cells. To 
confirm this with more confidence, strains were developed which do not form fully functional 
secretion apparatus to observe whether E2 protein would be found in the supernatant of 
these cultures. 
 
3.5.1.1. flhDC 
As described the class I operon flhDC sits at the top of the flagella gene transcriptional 
hierarchy (Figure 1.6) and initiates all flagella gene expression (whether directly or indirectly). 
The removal of flhDC in the ∆CKL strain will result in the total absence of flagella gene 
expression and thus lack flagella structures (i.e. secretion apparatus). The basis of the 
secretion platform is the directed secretion of proteins which harbour the 47 amino acid FliC 
secretion signal though the FT3SS, therefore secretion of FliC secretion signal tagged proteins 
will not be achieved in strains void of secretion apparatus. Any protein observed in the 
supernatant will be a result of undirected extracellular transit i.e. cell lysis, cytoplasmic 
leakage. 
 
3.5.1.2. flgDE 
The rationale behind the ∆flgDE mutant concerns the early and late substrates of flagella gene 
expression. As flagella synthesis is a metabolically expensive process, it is under tight 
regulatory control, with checkpoints throughout. A key point of control of flagella gene 
expression is the inhibition of class III gene transcription until the hook structure is in situ 
(Figure 1.5). Prior to the formation of the hook structure FlgM is retained by the cell and 
inhibits class III gene expression by binding to the transcriptional initiator of class III gene 
expression: FliA (σ28 factor). Upon completion FlgM is secreted through the hook structure and 
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class III gene transcription is initiated by free σ 28 (Claret & Hughes, 2002; Karlinsey et al. 2000).  
The ∆flgDE strain should not secrete FliC, although this is not just due to inhibition of class III 
gene expression, the strain will also be ‘early locked’ in terms of substrates and late substrates 
(FliC included) will not be secreted. Previous work has demonstrated that FliC secretion signal 
tagged proteins are not secreted through hook deficient strains. As stated, FliC would not 
usually be present in a ∆flgDE strain (Stafford et al., 2007). However as the design of the 
secretion construct allows induction of plasmid expression via the IPTG inducible trc promoter 
of the pTrc vector, it will be possible to express the FliC variant E2 in this strain, regardless of 
the incomplete hook-basal body structure.  
 
3.5.2. Mutant generation: flhDC and flgDE 
 
3.5.2.1. Knockout mutagenesis via phage transduction: flhDC 
Attempts to use P1 phage transduction to transfer a kanamycin linked ∆flhDC mutation from 
an MC1000 ∆flhDC parent stain into MC1000 ∆CKL consistently resulted in strains with poor 
growth in liquid culture –this could possibly be attributed to the retention of phage, however 
the sodium citrate procedure was carried out multiple times to eliminate phage. Therefore the 
MC1000 ∆flhDC parent strain was utilised as a negative control. While the absence of flgKL and 
fliC from the chromosome would have represented a true negative control, the fact that the 
absence of flhDC will in turn ensure that these genes (along with all flagella genes) are not 
expressed –will effectively result in the same phenotype. 
 
3.5.2.2. Knockout mutagenesis via the Lambda Red recombinase 
method: flgDE 
As a strain with the flgDE knockout mutation was not readily available, it was necessary to 
derive ∆CKL ∆flgDE de novo using the Lambda Red recombineering method. Primers were 
designed to amplify the FRT flanked resistance gene from the appropriate template plasmid 
(pKD4). Successful PCR reactions were confirmed by the presence of product DNA which 
corresponded to the anticipated PCR product size of 1.6 kbp.   A positive result was achieved 
(Figure 3.), the band was excised and DNA isolated. Product DNA comprises of FRT flanked 
169 
 
kanamycin resistance cassette, with homologous ends to the up- and downstream regions of 
flgDE. 
 
Figure 3.40: DNA gel of gene knockout construct PCR products.  
PCR reactions were carried out using the pKD4 template and primers in Appendix 2 with 
Phusion® High-Fidelity DNA Polymerase. PCR mixtures were analysed on a 1% TAE agarose 
DNA gel supplemented with a trace of ethidium bromide, visualised under UV light and 
inverted. Samples were run with GeneRuler™ 1kb DNA ladder. PCR resulted in the formation of 
the flgDE gene knockout construct harbouring the kanamycin resistance cassette  
 
Once isolated, the linear PCR derived DNA was electroporated into parent strains expressing 
Lambda Red recombinase enzymes. This resulted in the linear DNA template being inserted 
into chromosomal DNA at homologous regions. Successful recombination events were 
screened by plating on agar plates supplemented with kanamycin. Positive colonies were 
observed for all and following the curing of the Red recombinase plasmid so that no further 
recombination events occur, the deletion of flgDE was confirmed with PCR. 
 
3.5.2.3. PCR conformation of knockout mutagenesis: flgDE 
To confirm that the acquisition of antibiotic resistance was indicative of the removal of the 
gene targeted PCR reactions using combinations of primers which anneal either in the 
antibiotic resistance cassette or the region of chromosomal DNA upstream of flgDE were 
carried out. The presence of a 1333kbp PCR product confirmed flgDE::Km knockout 
mutagenesis (Figure 3.).   
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Figure 3.41: Agarose DNA gel of PCR product to confirm successful knockout mutagenesis of 
flgDE.  
PCR reactions were carried out using the templates and primers in Appendix 2 with Phusion® 
High-Fidelity DNA Polymerase. PCR mixtures were analysed on a 1% TAE agarose DNA gel 
supplemented with a trace of ethidium bromide, visualised under UV light and inverted. 
Samples were run with GeneRuler™ 1kb DNA ladder. PCR resulted in the formation of a 1333 
kbp PCR product.  
 
3.5.3. Mutant characterisation: Further optimisation of the secretion 
assay 
 
Prior to the assessment of the secretion capacity of the negative control strains, the secretion 
assay was optimised to improve throughput. While informative, this secretion assay was time 
consuming, as samples and measurements must be taken every hour during growth. In 
addition, as sample must be removed from the cultures every hour, cultures must be a large 
volume –this limits the number of experiments which can be carried out in tandem, due to 
limited incubator space. These two factors limit the throughput of the secretion assay, 
therefore the assay was modified so that secretion was assessed based on a single time point, 
allowing smaller culture volumes to be grown.  
As the secretor strain was grown alongside all of the growth curve secretion assays for the 
strains which were designed to increase flagella master regulator expression (∆lrhA, ∆dksA, 
∆clpX),  a wealth of information about the secretion capacity of the original secretor strain 
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through the growth curve has been gathered in this thesis (Figure 3., Figure 3. and Figure 3.). 
Overall, so far in this thesis, the highest concentration of E2 in the supernatant of ∆CKL and 
fastest secretion rate was observed between OD600 1 and 2. Therefore OD600 1.5 was selected 
as the optimal time point to measure secretion capacity of strains expressing E2 protein 
herein. The volume of cells grown was scaled down from 100mL to 10mL cultures, allowing 
many experimental variables and repeats to be tested in one experiment.  
 
3.5.4. Negative control mutant characterisation: Effects of deletion of 
flhDC and flgDE on FT3SS secretion 
 
While the secretion capacity for E2 protein by the original secretor strain and mutants has 
been investigated it cannot be confirmed that cell lysis, a leaky cell membrane or undirected 
protein secretion through other secretion systems are not the cause of this. Routine 
Coomassie stain SDS-PAGE gels of the supernatant of cell cultures provides evidence cell lysis is 
not prevalent, as supernatant fractions are clear of contaminating proteins. Further to this 
Western blotting of supernatant fractions and probing with an antibody for the cytoplasmic 
chaperone protein GroEL does not reveal major cytoplasmic contamination of the supernatant 
prior to the late stationary phase (Figure 3.). Despite this information, the utilisation of a 
negative control for FT3SS secretion would add more power to this assumption. Protein 
expression and secretion of E2 was measured in the original secretion strain MC1000 ∆CKL, the 
most promising mutant strain MC1000 ∆CKL ∆clpX and the two negative controls MC1000 
∆flhDC and MC1000 ∆CKL ∆flgDE (Figure 3.).  
Aside from the 42kDa E2 protein in the supernatant fractions no other protein is visible in the 
Coomassie stained SDS-PAGE, showing that the supernatant is free of protein contaminants. It 
is apparent that E2 is overexpressed in the cell fraction of all strains; however it is only visible 
in the supernatant of ∆CKL and ∆CKL ∆clpX. In this experiment the concentration of secreted 
E2 is higher in the ∆clpX mutant. The same pattern of expression and secretion is observed in 
the H48 antibody probed Western Blot of the same protein samples. This shows that the two 
methods give an accurate representation of the concentration of E2 protein present both in 
the cell and secreted fractions of all strains.  Despite the E2 seen in the Coomassie strained 
SDS-PAGE being more linear, the Western blot underwent densitometry analysis, as the cell 
172 
 
fractions of the Coomassie stain are not suitable for analysis by this method, due to the 
abundance of other protein. However it is evident from the Coomassie stained SDS-PAGE 
(Figure 3.: top), that E2 is visible in the intracellular fractions of all strains at a similar 
concentration, with the exception of ∆CKL ∆flgDE where the concentration is lower. While no 
E2 is seen in the secreted fractions of ∆flhDC and ∆flgDE mutants, around four times more is 
seen in the supernatant of ∆CKL ∆clpX cells in comparison to ∆CKL. Densitometry analysis of 
Coomassie stained SDS-PAGE shown confirmed this to be 3.8 times more E2.  
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Figure 3.42: Intracellular and secreted E2 from the secretor strain, ΔflhDC, ΔflgDE and ΔclpX 
mutants. 
E.coli ΔCKL (C), ΔflhDC (DC), ΔCKL ΔflgDE (DE) or ΔCKL ΔclpX (X) containing the plasmid pTrc E2 
was grown in LB. Cells were harvested at OD600 1.5. 1 OD unit of cells were prepared with 2x 
SDS-PAGE loading buffer. The supernatant from 1 OD unit of cells was precipitated with TCA 
(10% v/v) and prepared with 2x SDS-loading buffer. Samples underwent SDS-PAGE and either 
Coomassie staining with Instant Blue or Western blot analysis of cells and supernatant using 
anti-flagellin (H48) antibody and an HRP secondary. An E2 protein standard (S) was loaded to 
allow quantification of intracellular and secreted protein concentration. Intracellular: 5µL; 
secreted: 15µL; standard: 5µL. 
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Densitometry analysis by ImageJ was carried out on two biological repeats of the experiment. 
The use of the E2 protein standard allowed the protein concentration to be quantified for both 
intracellular and secreted protein, this enabled values from the two replicates to be combined 
(Figure 3.).  A higher concentration of E2 was found in the intracellular fractions of mutant 
strains in comparison to the ∆CKL. ∆clpX displayed both the highest intracellular (1350 mg L-1 
cell culture) and extracellular (23.457 mg L-1) E2 concentration. No E2 protein was found in the 
secreted fraction of either MC1000 ∆flhDC or MC1000 ∆CKL ∆flgDE. 
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Figure 3.43: Intracellular and secreted E2 from the secretor strain, ΔflhDC, ΔflgDE and ΔclpX 
mutants. 
E.coli ΔCKL, ΔflhDC, ΔCKL ΔflgDE or ΔCKL ΔclpX containing the plasmid pTrc E2 were grown in 
LB to OD600 1.5. An E2 protein standard was loaded to allow quantification of intracellular and 
secreted protein concentration. Following Western blot analysis of cells and supernatant using 
anti-flagellin (H48) antibody and an HRP secondary, densitometry analysis was carried out 
using ImageJ. The amount of protein located intracellularly (cells) or secreted (SN) is shown in 
mg L-1 cell culture as calculated from a standardised amount of E2 protein. Data from two 
biological replicates. Individual data points, mean and standard error of the mean are given.  
 
In addition to this the same protein samples were also examined for the presence of GroEL by 
stripping the Western blot probed with αH48 antibody and reprobing with αGroEL antibody. 
As a cytoplasmic chaperone protein GroEL is expected to be present in similar concentrations 
in intracellular protein fractions across strain. The presence of GroEL in the secreted fraction 
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indicated some leakage of protein from the cytoplasm into the supernatant. It is apparent that 
the abundance of GroEL in the intracellular fractions of the strains is very similar –while this is 
expected it is also a useful indicator that protein loading onto the SDS-PAGE is accurate (Figure 
3.). Less GroEL is present in the supernatant in comparison to cells; there is more GroEL 
present in the supernatant of MC1000 ∆flhDC than the other three strains.  
 
Figure 3.44: Abundance of GroEL in the intracellular and supernatant fractions of ΔCKL and 
the ΔflhDC, ΔflgDE and ΔclpX mutants, following expression and secretion of E2 protein 
through the FT3SS. 
E.coli ΔCKL (C), ΔflhDC (DC), ΔCKL ΔflgDE (DE) or ΔCKL ΔclpX (X) containing the plasmid pTrc E2 
was grown in LB. Cells were harvested at OD600 1.5. Samples underwent SDS-PAGE and 
Western blot analysis of cells and supernatant using anti-groEL antibody and an HRP 
secondary. Intracellular: 5µL; secreted: 15µL. 
 
Densitometry allowed comparison of the abundance of GroEL in both the cell and secreted 
fractions of all strains in both biological replicates. As a GroEL protein standard was not used it 
was not possible to absolutely quantify the concentration of GroEL, therefore to enable the 
comparison of results across biological replicates densitometry results were normalised to the 
value calculated for either secreted or intracellular ∆CKL (Figure 3.). As seen in Figure 3., the 
abundance of intracellular GroEL of all strains was very similar and demonstrated low 
variability –suggesting accurate loading of cell protein onto the SDS-PAGE. This is interesting as 
it has been reported that GroEL levels are elevated in clpX knockout mutants (Weichart et al., 
2003). In secreted fractions of protein very low levels of GroEL were detected in both ΔflgDE 
and ΔclpX mutants, suggesting that cell lysis and cytoplasmic leakage were low. The 
concentration of GroEL in ΔflhDC was slightly higher overall than in the secretion apparatus 
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mutant. Despite the presence of cytoplasmic protein in the supernatant of ΔflhDC, E2 protein 
was not detected (Figure 3.). This suggests E2 detected in the supernatant of other strains 
(∆CKL and ∆CKL ∆clpX) has been secreted through the modified FT3SS. 
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Figure 3.45: Densitometry analysis of the abundance of GroEL in the intracellular and 
supernatant fractions of ΔCKL and the ΔflhDC, ΔflgDE and ΔclpX mutants, following 
expression and secretion of E2 protein through the FT3SS. 
E.coli ΔCKL, ΔflhDC, ΔCKL ΔflgDE, or ΔCKL ΔclpX containing the plasmid pTrc E2 was grown in 
LB. Cells were harvested at OD600 1.5. Samples underwent SDS-PAGE and Western blot analysis 
of cells and supernatant (SN) using anti-GroEL antibody and an HRP secondary. Densitometry 
analysis was then carried out, and results normalised to the value derived for ΔCKL to allow 
comparison across biological replicates (N=2). 
 
The complete absence of E2 protein observed in the supernatants of both ΔflhDC and ΔCKL 
ΔflgDE confirm that they are both suitable strains to demonstrate negative control of FliC 
secretion signal directed E2 protein secretion through the FT3SS. Complementary to this 
finding is the evidence that cell lysis or cytoplasmic leakage are not prevalent in the positive 
secretion strains; contaminating protein is not observed in the Coomassie strains of the 
supernatant fractions and the concentration of GroEL is not higher in positive strains in 
comparison to negative strains.  
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Now that negative control of E2 protein secretion has been established, it can be concluded 
with confidence that E2 found in the supernatant fraction is present due to directed FT3SS 
secretion.  
 
3.6. Improved FT3SS secretion: reduced metabolic 
burden and negative feedback 
 
3.6.1. Rationale for mutants: reduced metabolic burden and feedback 
mutants 
 
An alternative strategy is to improve flagella gene expression by reducing internal negative 
feedback which occurs within the FT3SS gene expression hierarchy. An additional strategy 
would be to remove FT3SS genes which are obsolete in the modified FT3SS mutant. This may 
include genes linked to motility or precursors or chaperones to deleted genes. It is presumed 
that the removal of any gene will result in decreased metabolic cell burden and therefore 
increased energy for other processes (such cell growth, the production of secretion apparatus 
or plasmid protein). The rationale for the mutants (∆CKL) ∆motAB, ∆fliDST and ∆flgMN 
comprise of a combination of these strategies. 
 
3.6.1.1. motAB 
The MotAB complex attaches to the cell wall via the MotB protein forming the flagella motor 
stator. In addition the complex forms the channel which allows proton and sodium transport 
down their electrochemical potential gradient through the cell membrane. This process 
provides energy (known as proton or sodium motive force) which drives the flagella motor 
(Hosking et al. 2006; Minamino et al. 2016). MotB blocks this channel prior to the other FT3SS 
elements being in place, only unlocking it when it comes into contact with the basal body 
motor. Overexpression of MotAB increases the proton permeability of cells and causes a 
reduction in proton motive force, which results in growth impairment (Blair & Berg, 1990; 
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Zhou et al. 1998). Whereas, increased proton motive force has been shown to increase 
secretion of FT3SS substrates through the existing structure (Minamino et al. 2016). MotAB 
has been shown to be essential in flagella rotation but not assembly, and therefore by proxy 
one can infer secretion (Blair, 1995). This suggests that deleting MotAB in the ∆CKL strain 
should have no effect on the secretion properties of the secretion apparatus. The ∆CKL 
∆motAB strain may have a reduced metabolic burden, therefore direct more resources to cell 
growth and potentially flagella and secretion protein production. In addition to this the 
knockout mutation may result in reduced proton permeability of cells, therefore an increase in 
proton motive force and an increase in growth rate and improved secretion due to more 
secretion apparatus being in situ 
 
3.6.1.2. flgMN  
FlgN is a chaperone to FlgK and FlgL therefore unnecessary in the secretor strain. It is also a 
translational regulator of class II anti-sigma 28 factor FlgM (Figure 3.) (Aldridge et al., 2003). 
Loss of FlgN leads to reduced FlgM (FlgM is still present as it is still translated from the class II 
promoter), resulting in higher levels of sigma 28 gene expression (Karlinsey et al. 2000). 
Conversely it is reported that reduced levels of sigma 28 are observed in FlgM mutants, this is 
because FlgM tightly binds sigma 28 and while this inhibits function, it also protects it from 
proteolysis (Barembruch & Hengge, 2007). Sigma 28 is transcribed from fliA, which also has 
two promoters – one class II and one class III. When uninhibited by FlgM, sigma 28 activates 
class III gene expression. While the majority of class III genes are involved in rotation or hook 
and filament proteins and are therefore not conducive in the secretor strain; sigma 28 has 
been shown to activate transcription of the master regulator flhDC, increasing flagella numbers 
(Clarke & Sperandio, 2005). Deletion of FlgM and FlgN in the secretor strain should have no 
effect on the existing secretion apparatus structure. It should result in the metabolic burden 
being reduced and if fliA activity is increased, an increase in class III and flhDC gene expression, 
the latter of which may result in an increased number of secretion apparatus. 
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Figure 3.46: Schematic of the gene regulatory network of the FlgMN proteins 
 
3.6.1.3. fliDST 
Another operon which if removed has potential to both reduce metabolic burden and have an 
effect on regulation of the master regulator, is fliDST (Figure 3.). As discussed previously FliD is 
the cap protein which aids the assembly of FliC proteins to form the filament. Therefore in a 
FliC deficient mutant, FliD and the corresponding chaperone FliT, are not necessary (Fraser et 
al., 1999). Furthermore FliT has been shown to be an anti FlhD4C2 factor, preventing the 
protein binding to class II promoters (Yamamoto and Kutsukake, 2006).  FliS is the chaperone 
of FliC, therefore unnecessary in the ∆fliC secretor strain (Yokoseki et al., 1995). FliS has also 
been shown to bind and stabilise flgM in the cytoplasm prior to fliA expression (FliA displaces 
FliS) and supress secretion of FlgM upon hook-basal body completion (Galeva et al., 2014). The 
removal of all genes in the fliD operon have been shown to result in an increase in secreted 
FlgM (Yokoseki et al., 1996), which as discussed leads to an increase in class III flagella gene 
transcription. ΔfliDST mutants are non-motile, however as motility is not required this is not 
problematic. The main advantage of this strategy is that FliT will not inhibit FlhD4C2 and FliS will 
not bind FlgM, therefore class II and III gene expression will be increased respectively, this may 
result in the presence of more secretion apparatus (Aldridge et al., 2010).  
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Figure 3.47: Schematic of the gene regulatory network of fliDST  
 
3.6.2. Mutant generation: fliDST, motAB, flgMN  
 
3.6.2.1. Knockout mutagenesis via the Lambda Red recombinase 
method: fliDST, motAB, flgMN 
 
Primers were designed to amplify the FRT flanked resistance genes from the appropriate 
template plasmid. Successful PCR reactions were confirmed by the presence of product DNA 
which corresponded to the anticipated PCR product size (Table 6.).   
 
Table 6.1: PCR products for gene knockouts 
Gene knockout Antibiotic resistance Template plasmid Size of product (kbp) 
motAB Cm pKD3 1.1 
motAB Km pKD4 1.6 
fliDST Km pKD13 1.4 
flgMN Cm pKD3 1.1 
flgMN Km pKD4 1.6 
181 
 
Positive results for all PCR experiments were achieved (Figure 3.) -bands of the correct size 
were cut out and DNA isolated. Product DNA comprises of FRT flanked antibiotic resistance 
cassettes, with homologous ends to the up- and downstream regions of chromosomal DNA of 
the gene selected for knockout mutagenesis. 
 
Figure 3.48: DNA gels of gene knockout construct PCR products.  
PCR reactions were carried out using the templates and primers in Appendix 2 with Phusion® 
High-Fidelity DNA Polymerase. PCR mixtures were analysed on a 1% TAE agarose DNA gel 
supplemented with a trace of ethidium bromide, visualised under UV light and inverted. 
Samples were run with GeneRuler™ 1kb DNA ladder. PCR resulted in the formation of the gene 
knockout constructs harbouring antibiotic resistance cassettes (as listed in Table 6.). A. 
motAB::Cm, motAB::Km, fliDST::Km. B. flgMN::Cm , flgMN::Km.  
 
Once isolated, the linear PCR derived DNA was electroporated into parent strains expressing 
Lambda Red recombinase enzymes. This resulted in the linear DNA template being inserted 
into chromosomal DNA at homologous regions. Successful recombination events were 
screened by plating on agar plates supplemented with the relevant antibiotic (chloramphenicol 
or kanamycin). Positive colonies were observed for all recombination strains and following the 
curing of the Red recombinase plasmid so that no further recombination events occur, the 
deletion of chromosomal genes was confirmed with PCR. 
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3.6.2.2. PCR conformation of knockout mutagenesis: fliDST, motAB, 
flgMN 
To confirm that the acquisition of antibiotic resistance was indicative of the removal of the 
gene targeted PCR reactions using combinations of primers which anneal either in the 
antibiotic resistance cassette or the region of chromosomal DNA either side of the target 
knockout gene. Either the size or the presence of the resulting PCR products allowed further 
confirmation of knockout mutagenesis.  
 
Table 6.2: PCR products for confirmation of knockout mutagenesis in the secretor strain. 
Positive results were obtained for the following knockout mutagenesis conformations. The size 
of PCR products which denote positive results is given along with the size of the PCR product (if 
relevant) expected if knockout mutagenesis was not successful. 
Gene knockout Antibiotic Resistance Size of product if 
positive (kbp) 
Size of product if 
negative (kbp) 
motAB Cm 492 N/A 
motAB Km 777 N/A 
fliDST Km 993 N/A 
flgMN Km 1698 813 
 
Ideally the primer pair used to confirm mutagenesis is comprised of one primer which anneals 
in the antibiotic resistance cassette and one in the chromosomal region flanking the target 
knockout gene. When knockout mutagenesis by homologous recombination of the antibiotic 
resistance cassette into the chromosome is successful a positive result will arise. The size of 
the PCR product can be predicted. If knockout mutagenesis is not achieved this will result in a 
null PCR result as the primer designed to anneal to the ABC will not. This is denoted by ‘N/A’ in 
Table 6.. In the case of ∆flgMN::Km PCR conformation by this method was not successful , 
instead a primer pair which annealed in chromosomal DNA either side of the target gene was 
utilised. In this instance a positive PCR result will arise whether mutagenesis is achieved or not. 
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Here knockout mutagenesis can be confirmed by the size of the resulting product, as the 
expected size differs depending on whether the primers anneal to chromosomal DNA flanking 
either the flagella gene or the antibiotic resistance gene.  
Positive PCR results were achieved for all flagella gene knockout mutants with the exception of 
flgMN::Cm.  
 
Figure 3.49: Agarose DNA gels of PCR products to confirm successful knockout mutagenesis.  
PCR reactions were carried out using the templates and primers in Appendix 2 with Phusion® 
High-Fidelity DNA Polymerase. PCR mixtures were analysed on a 1% TAE agarose DNA gel 
supplemented with a trace of ethidium bromide, visualised under UV light and inverted. 
Samples were run with GeneRuler™ 1kb DNA ladder. PCR resulted in the formation of products 
of the sizes listed in Table 6.. A. motAB::Cm, B. motAB::Km, C. fliDST::Km, D. flgMN::Km  
 
The secretion capacity of these strains was then assessed, to observe whether they resulted in 
improved rates of protein secretion via the FT3SS. 
 
3.6.3. Reduced metabolic burden and feedback mutants: Effects of 
deletion of motAB, flgMN and fliDST on FT3SS secretion 
 
Once derived, the expression and secretion capacity of E2 protein was measured in these 
strains to ascertain the suitability of these mutants. The expression of pTrc E2 in ΔmotAB and 
ΔflgMN resulted in secretion of E2 into the media of cells (Figure 3.). E2 was also secreted in 
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the original secretor strain and the ∆CKL ∆clpX mutant, allowing comparison of secretion 
capacity to be made in relation to strains already investigated (Figure 3.). Densitometry 
analysis was carried out on the secreted fractions of protein shown in Figure 3.. As an E2 
protein standard was not included on this SDS-PAGE, the concentration of E2 protein secreted 
cannot be quantified per se, however relative improvement in comparison to ∆CKL can be 
ascertained. This confirmed that ∆flgMN secreted a very similar amount (0.94) of E2 protein to 
∆CKL. Secretion of E2 was 1.52 times higher in the ∆motAB mutant in comparison to ∆CKL, 
however the ∆clpX mutant secreted the highest concentration of protein (1.82 times ∆CKL), 
which is similar to the fold improvement seen in Figure 3.. The lack of protein (aside from E2) 
in the supernatant of all strains, suggests that lysis is not prevalent in any of the mutant stains. 
Due to experimental failure a reliable result could not be obtained for a αH48 (flagellin) 
antibody probed Western blot, it is not possible to measure the concentration of intracellular 
E2 protein in strains. The concentration of E2 in the cells of strains appears to be similar, as 
there is no clear overexpression in any of the strains. 
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Figure 3.50: Intracellular and secreted E2 from the ∆CKL strain, ΔmotAB, ΔflgMN and ΔclpX 
mutants. 
E.coli ΔCKL (C), ΔCKL ΔmotAB (M), ΔCKL ΔflgMN(MN) or ΔCKL ΔclpX (X) containing the plasmid 
pTrc E2 was grown in LB. Cells were harvested at OD600 1.5. 1 OD unit of cells were prepared 
with 2x SDS-PAGE loading buffer. The supernatant from 1 OD unit of cells was precipitated 
with TCA (10% v/v) and prepared with 2x SDS-loading buffer. Samples underwent SDS-PAGE 
and Coomassie staining with Instant Blue. 
 
E2 secretion was then quantified in the most promising novel strain: ΔCKL ΔmotAB (Figure 3.) 
and the as yet untested ΔCKL ΔfliDST strain. While the concentration of E2 located in the 
media of ΔmotAB cells in comparison to the secretor strain looked lower in the Coomassie 
stained SDS-PAGE, it appeared much higher in the Western blot (Figure 3.). This is an example 
of the lack of linearity of Western blots. Intracellularly, less E2 was observed in the ΔmotAB 
mutant, suggesting that it is also more efficient at secreting E2. In contrast the ΔfliDST mutant 
expressed less E2 than the secretor strain and secreted a small amount (some observed in the 
Coomassie stain, none detected in the Western blot.) This is presumably due to the similarity 
of E2 to the FliS chaperoned FliC, this will be discussed later.  
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Figure 3.51: Intracellular and secreted E2 from the secretor strain, ΔfliDST and ΔmotAB 
mutants. 
E.coli ΔCKL (C), ΔCKL ΔfliDST (DST) or ΔCKL ΔmotAB (M) containing the plasmid pTrc E2 was 
grown in LB. Cells were harvested at OD600 1.5. 1 OD unit of cells were prepared with 2x SDS-
PAGE loading buffer. The supernatant from 1 OD unit of cells was precipitated with TCA (10% 
v/v) and prepared with 2x SDS-loading buffer. Samples underwent SDS-PAGE and either 
Coomassie staining with Instant Blue or Western blot analysis of cells and supernatant using 
anti-flagellin (H48) antibody and an HRP secondary. The BLUeye Prestained Protein Ladder was 
loaded, as was an E2 protein standard (S) to allow quantification of intracellular and secreted 
protein concentration.  
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These observations were confirmed with densitometry analysis of the Western blot (Figure 3.). 
Very little E2 protein was detected in the supernatant of ΔfliDST cells, whereas E2 secretion 
was improved over two fold, from 0.612 µg mL-1 in the secretor strain to 1.534 µg mL-1 in 
ΔmotAB. When secreted E2 is calculated as a proportion of total E2 protein it is evident that 
ΔmotAB is not only the strain with the highest secretion capacity, but also the most efficient 
protein secretor –secreting over 17% of the total E2 protein expressed (Figure 3.).  
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Figure 3.52: Intracellular and secreted E2 from the secretor strain, ΔfliDST and ΔmotAB 
mutants. 
E.coli ΔCKL, ΔCKL ΔfliDST or ΔCKL ΔmotAB containing the plasmid pTrc E2 were grown in LB to 
OD600 1.5. An E2 protein standard (S) was loaded to allow quantification of intracellular and 
secreted protein concentration. Following Western blot analysis of cells and supernatant using 
anti-flagellin (H48) antibody and an HRP secondary, densitometry analysis was carried out 
using ImageJ. The amount of protein located intracellularly (cells) or secreted (SN) is shown in 
µg L-1 cell culture as calculated from a standardised amount of E2 protein. ΔflgMN and ΔclpX 
mutants, following expression and secretion of E2 protein through the FT3SS. .  
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Figure 3.53: The proportion of secreted E2 as a percentage of total E2 expressed and 
secreted  by the secretor strain, ΔfliDST and ΔmotAB mutants, following expression and 
secretion of E2 protein through the FT3SS. 
E.coli ΔCKL, ΔCKL ΔfliDST or ΔCKL ΔmotAB, containing the plasmid pTrc E2 was grown in LB. 
Cells were harvested at OD600 1.5. Samples underwent SDS-PAGE. Densitometry analysis was 
then carried out using ImageJ and the proportion of secreted protein calculated as the 
concentration of secreted protein in comparison to the concentration of total E2 protein (both 
secreted and intracellular). 
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3.7. Discussion: a prototype secretion platform for 
secretion of native protein  
 
The focus of this chapter has been to produce a prototype platform E. coli strain for secretion 
from a base chassis strain. MC1000 was chosen on the basis of its broad similarity to a 
‘standard’ K12 strain but also since it is well characterised and contains a leucine and thiamine 
auxotrophy for safety. Secretion of protein from the cytoplasm to the extracellular media was 
achieved in the chassis strain by modifying the flagella type III secretion system (FT3SS) to form 
a pipe like secretion apparatus. Strain improvements were then employed to this strain with 
the aim of increasing the amount of secretion apparatus expressed or by removing 
unnecessary flagella genes to reduce the metabolic burden. It was hypothesised that this 
would result in more protein being secreted into the media. 
Development of assays that quantified secretion and flagella gene expression in strains was 
central to all of the work in this study. Without an accurate assay method, suitable for 
application to all strains it would not be possible to assess if strain modification resulted in 
improved secretion.  Protein secretion via the modified FT3SS has been measured in a number 
of mutant strains -including strains which were designed to exhibit total absence of FT3SS 
secretion, which serve as negative controls. This could be paired with information on flagella 
gene expression to give an extensive view of flagella protein secretion in strains.  These results 
are used to assess whether strain improvements have been effective. 
 
3.7.1. Protein secretion assay development 
 
Through knockout mutagenesis it was possible to develop a novel platform strain capable of 
secreting a variant (E2) of the native flagella filament protein FliC through truncated FT3SS and 
into the media of cells –this forms the basis of the protein secretion assay, which allowed 
accurate quantification of protein expression and secretion in mutant strains. The secretion 
assay provides a method of quantifying protein secretion in strains either as a concentration 
per volume of media or as a secretion rate or efficiency. The secretion assay was optimised to 
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report protein secretion in strains throughout the growth curve. Utilisation of a protein 
standard allowed the calculation of a weight per OD unit or weight per volume of cell culture 
concentration of protein to be derived from Coomassie stained SDS-PAGE or Western blots. 
Quantifications of secretion rates are powerful as they provide information on the change in 
secretion capacity of cells over time or with the implementation of mutations. The w/v 
measurement is advantageous because it allows direct comparison of secretion efficiency 
between experiments and is a common industry standard used by contract manufacturing 
organisations to compare protein yields from fermentations -which is ultimately the aim of this 
work. A variation of the protein secretion assay involved growing cell cultures in smaller 
volumes and measuring secretion at one time point; this improved the throughput of the 
assay, allowing protein secretion to be measured in more mutant strains in parallel 
experiments. These points combined mean that a wealth of information can be gained from 
the secretion assay, to aid secretor strain improvement.  
 
3.7.2. A modified FT3SS platform secretion strain 
 
Strain improvements were made to E. coli to implement protein secretion through the FT3SS. 
It was established that E2 protein secretion occurred in both ΔfliC ΔflgKL (HAPless) and the 
ΔfliCD (CAPless) mutant E. coli (Figure 3.). As both the volume of protein produced and 
secreted was around double that observed in the HAPless strain this formed the basis of 
further strain optimisation in this study (Figure 3.). This effect may be due to the shorter 
distance that secreted protein has to pass through to reach the extracellular environment, 
although it has been demonstrated that length of the existing flagella structure does not alter 
the rate of secretion (Evans et al., 2013). Additionally it may be due to the effect of FliT on the 
master regulator. FliT is the chaperone to FliD, therefore in the absence of FliD, more FliT is 
available to negatively regulate flhDC, which in turn will result in downregulation of all flagella 
genes (Yamamoto and Kutsukake, 2006). Less flagella gene expression will lead to less 
secretion apparatus and therefore a reduction in secretion. In the HAPless mutant FliD is 
expressed, therefore FliT is less readily available for interaction with flhDC.  FlgK and FlgL are 
secretion competitors to FliC (and any other protein directed for secretion through the FT3SS, 
furthermore it has been shown that they are preferentially secreted, as their chaperone FlgN 
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has a higher affinity for the secretion apparatus  (Evans et al. 2006); therefore this may 
account for the reduced concentration of E2 secreted through the CAPless strain, as flgKL is 
still present. Finally as FlgN is the chaperone to FlgK and FlgL, there is more free FlgN when 
these proteins are absent. As FlgN is a translational regulator of FlgM, this will lead to 
increased FliA inhibition (but with increased protection), which has been shown to result in 
increased flagella gene expression (Aldridge et al., 2003). 
 
3.7.3. Negative control of FT3SS secretion 
 
Negative control of E2 secretion through the modified FT3SS was established, confirming that 
the presence of E2 in the supernatant of strains was due to directed secretion through 
secretion apparatus and not through cell lysis or cytoplasmic leakage. This was characterised 
by an absence of E2 protein in the supernatant of cultures of ∆flhDC and ∆CKL ∆flgDE, paired 
with the presence of E2 in the intracellular fraction (Figure 3.). To ensure the absence of 
secreted E2 was not due to experimental failure, samples from strains with functional 
secretion apparatus were run in tandem. Following Western blotting the nitrocellulose 
membranes were then stripped and reprobed with α-GroEL, to demonstrate that cytoplasmic 
contaminants (i.e. GroEL) were not present at a high concentration in the supernatant of 
strains with or without functional secretion apparatus (Figure 3.), confirming that directed 
FT3SS secretion and not cell lysis or membrane leakage is the route of E2 transport into the 
supernatant. Although some lysis was GroEL was detected, this antibody is known to be very 
sensitive; therefore it is unlikely to represent a lot of cytoplasmic derived protein –this is 
supported by the lack of cellular contaminants seen in the secreted fraction of Coomassie 
stained SDS-PAGE gels. It would be beneficial to carry out a complete cell lysis to see how this 
compared to the concentration of GroEL observed in these blots, this is true for GroEL 
detection throughout this thesis.  
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3.7.4. Strain improvements: reduced negative regulation of the master 
regulator  
 
Based on the literature, additional strain improvements (∆lrhA, ∆dksA, ∆clpX) were made to 
∆CKL to decrease negative transcriptional control of flhDC or degradation of the FlhD4C2 
complex. This should result in an increased number of secretion apparatus and therefore an 
increase in the amount of protein secreted. With the exception of ΔclpX which was derived by 
phage transduction, all gene knock outs in this chapter were implemented with lambda Red 
recombinase (Datsenko & Wanner, 2000). P1 phage was successfully eradicated from ΔCKL 
ΔclpX. The ‘gene-doctoring’ variation on this method (where linear DNA is incorporated into a 
plasmid until cleavage by SceI is induced in vivo prior to homologous recombination) was 
considered and there are now versions of this method which do not result in FRT scars in the 
chromosome (Kim et al. 2014; Lee et al. 2009), however as the method used was selected as it 
was well established in the laboratory. All mutant strains have been verified and assay based 
secretion characterisation was carried out the strains.  
 
3.7.4.1. Effects of deletion of lrhA on FT3SS secretion  
ΔCKL ΔlrhA secretion (Figure 3.) and flagella gene expression (Figure 3.) results showed 
disparity with one another and were inconsistent with those reported in the literature (Lehnen 
et al., 2002). This is due the presence of an IS5 element upstream of flhD (Figure 3.), therefore 
reduced transcriptional repression of the master regulator is already active as the IS5 site 
decouples negative transcriptional regulation sites from the promoter. Consequentially 
removing master regulator transcription repressors had limited effect. The presence of the IS5 
element is not a drawback as is beneficial to improved secretion. Evolution has already 
resulted in an improved strain by IS5 insertion. With this evidence in mind it seemed more 
beneficial to focus on other routes to improving flagella gene expression, because while there 
is still scope for some increased transcription, this will be incremental. This strain can be 
improved further by other strategies such as reducing metabolic burden which is still valid as 
the effect of IS5 is not concerned here.  
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3.7.4.2. Effects of deletion of dksA on FT3SS secretion  
Although gene expression (Figure 3.) and secretion (Figure 3.) results complement each other 
in the ΔCKL ΔdksA mutant, the observations are not concordant with expectations based on 
the literature. E2 secretion was much lower in ΔCKL ΔdksA in comparison to the ∆CKL strain 
and showed a negative correlation in the amount secreted over the growth curve (i.e. in the 
stationary phase).  However Lemke et al., 2009 reported that flagella gene expression for all 
three classes of flagella genes were increased with the removal of ΔdksA from strains. 
Furthermore the literature states that flagella gene activity increased during the stationary 
phase (from 2 times to 9 times wild type gene expression), therefore an increase in secretion 
should be expected in the stationary phase, not the decrease observed in this thesis. As DksA 
inserts into RNA polymerase (RNAP) to cause a structural change, which in turn acts on the 
flhDC promoter. The presence of the IS5 element is not responsible for these differing 
observations as it concerns genetic elements upstream of the promoter, whereas DksA 
induced disruptions in RNAP-promoter binding occurs in the -6 to +6 positions (relative to the 
+1 transcriptional start site) (Rutherford et al. 2009). 
This unexpected effect may be due to the nature of the assay. DksA inhibits ribosomal RNA 
promoter activity and also binds to RNAP, reducing the lifespan of open RNAP. DksA also 
amplifies the activity of the alarmone ppGpp, which also binds to RNAP. Lemke et al. (2009) 
found that this effect was much more pronounced when genes which encode the alarmone 
ppGpp was also deleted from the genome, however it is assumed that ppGpp was intact in this 
work. Another reason may be linked to the fact that experiments in this thesis were carried 
out in rich media. While DksA is produced at a relatively constant rate ppGpp is linked to the 
stringent response and produced in response to low nutrient concentration (Lemke et al. 2009; 
Magnusson et al. 2007; Paul et al. 2004). ppGpp causes the redirection of a cells resources 
away from costly biosynthetic processes. Therefore rather than producing more flagella to 
move to an area where nutrients are more abundant, ppGpp initiates an alternative strategy 
where the cell represses non-essential functions (such as motility) in a bid to conserve 
nutrients. Lemke et al. (2009) performed experiments in minimal media where nutrients were 
low.  Therefore the effect of ΔdksA in this study may be not as expected because experiments 
were carried out in rich media, therefore the stringent response would not be in effect and 
therefore ppGpp would be present at a low abundance. Further searching of the literature has 
uncovered results which suggest that DksA activity may differ to that reported in the Lemke et 
al. (2009) paper. One study concluded that ΔdksA mutants were immotile and that DksA 
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positively regulated flagella expression (Magnusson et al., 2007). Reports on the effect of DksA 
on flagella expression are very conflicting, suggesting that DksA may not be a very suitable 
target. It should be considered that in this work or any of the other studies that the mutant 
may have reverted to be +dksA and this may be the reason for conflicting results. Finally, the 
unexpected secretion and gene expression results may have come about due to the fact that, 
as DksA alters gene expression throughout the genome via RNAP it is likely that there are other 
phenotypic alterations to the strain beyond flagella gene expression. Many promoters are 
directly affected by DksA conformational change of RNAP, these include promoters involved in 
ribosome synthesis, membrane stress response and transport and amino acid biosynthesis and 
transcription may either be activated or inhibited (Lemke et al., 2009; Rutherford et al., 2009). 
While the growth of the ΔCKL ΔdksA strain was not hindered in comparison to ΔCKL, the remit 
for additional strain effects to cause unexpected observations linked to any of the 
aforementioned DksA regulated genes is likely. Due to the poor secretion performance of the 
strain and the inconclusiveness of the literature, focus will concern other strategies to increase 
flagella expression.  
 
3.7.4.3. Effects of deletion of clpX on FT3SS secretion  
The effect of the removal of clpX on the FT3SS was tested in both strains which produced 
wildtype flagella and in the modified FT3SS secretion apparatus strain (∆CKL). Both the 
increased concentration of sheared filament protein (Figure 3.) and swimming motility (Figure 
3.) in clpX knockout mutants in the MC1000 strain background and the increased E2 secretion 
capacity of ∆CKL strains with the clpX knockout mutation, suggest that the removal of clpX 
from the chromosome results in increased flagella gene expression. This is likely due to 
reduction in negative regulation of flagella gene expression, which is usually downregulated 
due to ClpX directed proteolysis of the FlhD4C2 complex by ClpP (Tomoyasu et al., 2002; Takaya 
et al., 2012). This is independent of the presence of the IS5 element, as it concerns the FlhD4C2 
complex. More FlhD4C2 is present in ∆clpX mutants, which demonstrate upregulated flagella 
gene expression, and increased flagella type III secretion (Kitagawa et al. 2011; Tomoyasu et al. 
2003). However as reliable results were not obtained for flagella gene expression assays in 
strains with the ∆clpX mutation, this cannot be confirmed experimentally in this study. In 
further work it would be desirable to assess flagella gene expression using RT-qPCR. This 
technique involves first converting cell mRNA to cDNA using reverse transcription, then using 
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primers to amplify cDNA. The incorporation of fluorophores results in fluorescently labelled 
DNA and allows the concentration of product to me measured at each cycle. With each cycle 
DNA and therefore fluorescence increase –as this is proportional to the initial concentration of 
mRNA in the sample, this can be used gene expression. This would allow quantification of the 
concentration of flagella gene mRNA in cells -allowing direct comparison of strains for flagella 
gene expression. Furthermore as primers can be designed to amplify any cDNA, the gene 
expression of a number of flagella genes could be assessed, providing a more detailed picture 
of gene expression throughout the hierarchy. As ClpX proteolysis is evident throughout the 
cell, there is a possibility that flagella gene expression is not increased due reduced FlhD4C2 
degradation, but instead due to an indirect effect –for example ClpX has been previously been 
shown to degrade a subunit of the RpoS RNA polymerase  (Pesavento & Hengge, 2012), 
therefore it would be interesting to carry out proteomic analysis on clpX knockout mutants to 
investigate changes at a proteomic level also, so see if flagella protein is effected in a different 
manner to that expected with information on genomics. 
While an increase FT3SS secretion was observed in ∆clpX mutants, the fact that ClpX acts as a 
cell wide protease means that the mutation may have other effects on cell phenotype. ClpX 
targets SsrA- and non-SsrA tagged proteins for degradation, these include RpoS, a sigma factor 
that induces cell stress resistance (Schweder et al., 1996). RpoS has also been shown to 
negatively regulate flagella biosynthesis, however if this was the case in this mutant, this effect 
if presumably compensated elsewhere (Patten et al., 2004). ClpX recognises FlhD4C2 directly, 
however degradation is accelerated with the YdiV adapter protein, as it directs ClpXP to 
proteins to undergo degradation (Takaya et al., 2012) and no SsrA site is present in the protein 
sequence of FlhD or FlhC. Reduced ClpX mediated proteolysis could also be beneficial i.e. less 
degradation of other flagella proteins (although there is no experimental evidence for this). 
SsrA is added post translationally to incompletely translated protein at the ribosome. This 
occurs in 0.5% proteins, of which >90% are degraded by ClpXP (Lies & Maurizi, 2008). 
Therefore ClpX is capable of degrading a wide range of protein, although whether these 
incompletely translated proteins would become released from ribosomes and complete 
enough to be functional is not certain. A notable reported phenotype of clpX mutant is a 
reduced optical density in the stationary phase and decreased survival of cells if stationary 
phase is prolonged; this was linked to an increase in growth-phase regulated proteins 
(Weichart et al., 2003). This was alluded to in the experimental work carried out in this thesis 
as it was observed that the ∆clpX mutant had a detrimental effect of growth in comparison to 
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strains which did not carry this mutation, however it was not a large difference. An additional 
phenotypic observation is the elongation of cells with clpX knockout mutations, due to the role 
of ClpX in the regulation of protein associated with cell division (Camberg et al., 2011). While in 
the experiments for this thesis, cells looked similar in microscope images, analysis of length 
found that cells with the ∆clpX mutation were 1.28 times longer than those without (Figure 3. 
and Figure 3.), thus confirming this report and highlighting that the removal of clpX does result 
in wide phenotypic effects. As the Camberg et al. (2011) study was carried out on cells with a 
∆minC background (which is therefore already susceptible to altered phenotype related to cell 
division), this is the first time this effect has been reported in WT cells. Interestingly ClpXP has 
been shown to degrade DksA (Flynn et al., 2003), however as results for the effect of the 
removal of dksA on flagella gene expression were inconclusive, it is not possible to comment 
on this based on this study. 
 
3.7.4.4. Promoter replacement or promoter region modification for 
increased transcription of the master regulator 
As discussed improvements to FT3SS secretion through increased flhDC expression are 
hampered slightly by the presence of IS5, however improvement can still be made. The 
promoter region could be modified to remove the negative regulators (RscAB) still present and 
restore IS5 disrupted or decoupled positive regulatory binding sites (i.e. H-NS, QseB, OmpR). In 
isolation -or in combination this may result in improved flhDC expression.   A promoter 
replacement strategy may provide a route of greater change. Replacement of native flhD 
promoter with a strong promoter may result in increased flagella gene expression in excess of 
that reached through the presence of the IS5 element. In another study an arabinose inducible 
extra copy of the flhD promoter was inserted into the chromosome, this resulted in a 60 fold 
mRNA increase, however only 5 fold change was seen in class II flagella gene expression 
(Erhardt & Hughes, 2010), suggesting that there may be limits to how much increased flhDC 
expression can increase gene expression throughout the hierarchy –due to feedback regulation 
for example. Promoters of varying strengths are characterised and available as BioBricks on 
The Registry of Standard Parts and would be ideal to carry out this work. A clear choice for this 
would be to place a strong sigma 70 promoter upstream of flhDC to overexpress the FlhD4C2 
complex and in turn upregulate all flagella genes. This may result in more flagella and 
therefore more secretion. Additionally there are benefits in using inducible promoters so that 
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there is an element of control of gene and therefore protein expression with regards to 
strength and timing of induction (Dubendorf & Studier, 1991; Dragosits et al. 2012). It must be 
noted that increasing promoter strength may have detrimental effects on the cell with regard 
to homologous protein production and therefore cell growth and viability (Dong et al., 1995). If 
this occurs, the promoter could be exchanged for a weaker promoter, which would still 
upregulate gene activity in comparison to wild type levels. 
 
3.7.5. Strain improvements: reduced metabolic burden and negative 
feedback  
 
Alternative strategies to increase flagella gene expression independent of the master regulator 
included reducing metabolic burden by removing unnecessary genes. It was hoped this would 
result in either the redistribution of energy to processes concerning growth, secretion 
apparatus and plasmid protein production or a reduction in negative feedback on flagella gene 
expression. 
 
3.7.5.1. Effects of deletion of motAB on FT3SS secretion  
It was predicted that the removal of motAB from cells would result in an increase in protein 
secretion due to reduced metabolic burden and increased proton motive force. The removal of 
motAB from ∆CKL resulted in just over double the concentration of secreted E2 protein, 
despite the concentration of intracellular E2 being 0.75 fold that seen in ∆CKL (Figure 3. and 
Figure 3.), this demonstrates that the removal of motAB from cells increased the efficiency of 
E2 secretion through the secretion apparatus. This is possibly due to the reduction in 
metabolic burden due to the absence of MotAB allowing more metabolic expenditure on other 
cellular activities, including cell growth, and expression of E2 and the modified FT3SS 
apparatus. It is also anticipated that as the MotAB complex acts as a proton conductive 
pathway, the absence of MotAB will result in reduced drain on proton motive force. Cells have 
a more robust growth phenotype, which may aid protein production as cells will be more 
productive, furthermore as PMF is required for secretion of substrates, this may facilitate 
increased protein secretion (Minamino et al. 2016; Zhou et al. 1998; Blair & Berg, 1990; 
Hosking et al. 2006; Minamino & Namba, 2008). As supernatant fractions were free of cellular 
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contaminants (Figure 3. and Figure 3.), it was not evident that the absence of MotAB caused 
membrane breakage or permeability, although it would be beneficial to confirm this with a 
more sensitive method, such as Western blot analysis of supernatant fractions with an α-GroEL 
antibody. It would also be preferential to have growth curve data for this strain, to observe 
whether growth rate is increased when motAB is removed from the genome. These factors will 
be investigated in Chapter Four. 
 
3.7.5.2. Effects of deletion of flgMN on FT3SS secretion  
The main focus of this strategy was the removal of the anti-sigma 28 factor (FliA) FlgM. Prior to 
hook completion FlgM binds FliA and inhibits both flagella class III gene and flhDC 
transcription. While FlgM inhibits FliA, it also protects it from proteolysis and the literature 
reports either increased or decreased flhDC expression following the removal of FlgM 
(Karlinsey et al. 2000; Barembruch & Hengge, 2007). The removal of FlgN was also 
implemented as it is a chaperone to FlgK and FlgL and a transcriptional regulator of FlgM 
(Aldridge et al., 2003), therefore unnecessary in the ∆CKL ∆flgM mutant. While only one 
biological repeat was carried out and it was not possible to measure the concentration of 
intracellular E2 in the mutant, it would appear that it did not result in an increase in secretion, 
as less E2 (0.94 fold) was seen in the ∆CKL ∆flgMN strain compared to ∆CKL(Figure 3.). This is 
likely due to the role of FlgM in protecting FliA from degradation –in the absence of FlgM, the 
concentration of FliA should be reduced and therefore flhDC gene expression was reduced. 
Investigation into the gene activity of this strain with the lacZ fusion assay used in this thesis, 
would give insight into whether this was true here, however since the aim of this project is to 
investigate strains which result in increased secretion, this was not a priority  
 
3.7.5.3. Effects of deletion of fliDST on FT3SS secretion  
Many strategies interplayed to support the removal of fliDST from ∆CKL. At the most basic this 
involved the removal of chaperone and cap proteins to deleted proteins to reduce metabolic 
burden. Other intricacies included the removal of flhDC inhibitor FliT and FlgM binding FliS 
with the inclination that this would cause class II and III gene expression will be increased 
respectively, which may result in the presence of more secretion apparatus (Aldridge et al. 
2010; Yamamoto & Kutsukake 2006; Yokoseki et al. 1996). 
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The failure of the fliDST knockout mutation to result in improved secretion of E2 protein 
centres on the inability of the cell to accumulate intracellular E2 (Figure 3.). It is beyond the 
scope of the experiments conducted to ascertain whether E2 gene expression was reduced in 
the ∆fliDST strain, therefore the focus of my discussion on this will be at a protein level. 
Knowledge from the mechanism of flagella protein expression in the literature, would suggest 
that the absence of the flagellin chaperone protein FliS is the route of this phenomenon. As E2 
is a variant of the native FliC subunit, and the chaperone binding region is conserved, it is likely 
that it benefits from the chaperone effects of FliS. While the removal of fliD or fliT does not 
inhibit the production of viable flagella in certain environments, the removal of fliS was shown 
to greatly reduce the length to flagella (Yokoseki et al., 1995). FliS prevents premature 
polymerisation of FliC in the cytoplasm (Auvray et al., 2001), this should also be true of E2. If 
E2 was present in the intracellular fraction and not the secreted (as found with FliC in the 
Yokoseki et al. (1995) study), this could be because of secretion inhibition of E2 due to 
polymerisation in the absence of FliS. However as it is also displays reduced concentration 
intracellularly it is likely that E2 is degraded more readily in the FliS mutant. However while the 
disordered C-terminal region of FliC (present in E2 also) is degraded in the absence of FliS, this 
is not true of the whole FliC protein and resulted in a 5kDa smaller product (Ozin et al., 2003). 
This discrepancy in size was not observed with E2 protein. In addition to this the negative 
secretion strains ∆flhDC and ∆flgDE should also be FliS deficient, as class III gene transcription 
will not occur in either. Slightly less E2 was seen in the cells of ∆flgDE, however the 
concentration in ∆flhDC was similar (Figure 3.). A low rate of secretion can also be attributed 
to the absence of FliS, as FliC secretion is initiated by FliS. In a FliS-FliC complex, FliS binds to 
docking platform FlhA, anchoring FliC to the export gate, where FliC is unfolded for efficient 
export (Furukawa et al., 2016). It was recently found that a major rate limiting factor in 
reduced FliC secretion was lack of FliS, resulting in inadequate unfolding of FliC (Furukawa et 
al., 2016). In summary, as with FliC, both E2 intracellular accumulation and export may be 
hindered in the FliS mutant. In later chapters the chaperone binding site is absent in secretion 
constructs, therefore chaperone-decoupled expression and secretion in this strain can be 
investigated. 
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3.7.6. Limitations of the E2 protein secretion assay  
3.7.6.1. Variation in results 
Inter-experimental variation of yields of both intracellular and secreted E2 was observed; while 
variation is common in biological systems (Endy, 2005), discussion will focus on experimental 
sources of variation. In the growth curve E2 protein secretion assays variation was common, 
for ease only the highest recorded secreted E2 yield is discussed. Figure 3. (below) shows that 
there was large variation between experiments –as the results for ∆CKL yield are biological 
replicates. While great care was taken to ensure that experimental procedure was consistent, 
the yields vary dramatically. Steps taken to ensure consistency across experiments included, 
thoroughly rinsing glassware of detergent or residual salts before use and using the same 
brand of LB media and agar throughout; these steps were of particular importance because it 
is reported that increased concentrations of NaCl results in elongated hooks and reduced 
flagellin secretion –this was in a flgE pseudo-revertant background, however still applicable 
(Saito et al., 1998). Frozen aliquots of IPTG and antibiotics were used to ensure concentration 
remained consistent. And as temperature alters flagella assembly (Gerber et al., 1973), cells 
were incubated in the same incubator every time, as temperature (and agitation) was found to 
vary between incubators, despite the settings reporting the same setup. pH has also been 
shown to result in differential flagella gene expression (Maurer et al., 2005), therefore in the 
future less variable results may be obtained following buffering of LB broth. 
A source of error relates to the lack of linearity exhibited by Western blot analysis of protein 
concentration. This refers to the disparity in concentration of protein and chemiluminescent 
output. It is known that results derived by Western blot show limited linearity, this leads to 
inaccuracies in the estimation of concentration (Taylor et al., 2013). This could be investigated 
further by measuring chemiluminescent output related to protein concentration, by producing 
a standard curve of dilutions of E2 and relating to densitometry results. Alternatively Western 
blot technology which relies on infrared signal, rather than chemiluminescence could be 
utilised instead, however it was not possible to access one for this work. This would allow 
confidence that the protein levels detected are within the linear dynamic range of the Western 
blot. Even if this was implemented the nature of Western blots lends itself to inaccuracy due to 
the number of steps associated with the experiments, there are multiple opportunities for 
variation to occur. Use of Coomassie stain eliminates inaccuracy which may occur due to lack 
of linearity of Western blots and also has less experimental steps, therefore less sources of 
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potential error; however in low concentrations of secreted E2 it is unsuitable as it is not 
detectable. Additionally, Western blots provide information on the concentration of 
intracellular E2, this is not possible with Coomassie stained SDS-PAGE gels. It should also be 
noted that use of densitometry based analysis serves as a source of error, while care is taken 
to remove background saturation and define the boundaries of protein bands, this is 
subjective. These facts do not make the method void, but it is important to be aware that 
there are sources of error associated.  
 Another source of inconstistency is likely to have arisen from the E2 protein standard. Protein 
was not initially stored in aliquots therefore was subject to successive freeze thawing, which 
can degrade protein (Cao et al., 2003). This would affect the quantitative yield values derived, 
meaning that absolute protein secretion values cannot accurately be derived; however 
quantitative comparisons between experiments are reliable. While the concentration of the 
protein standard may be variable between experiments, intra-experimental results are 
proportional; therefore this will not affect the relationships observed. Following growth curve 
secretion experiments, protein standards were aliquoted to eliminate any freeze-thaw effects. 
While preventing E2 standard degradation would reduce variation in quantification of yield, 
the use of a protein standard itself is another source of inaccuracy as it contributes another 
variable in measurement of E2 concentration. This is evident in Figure 3.; where the pattern of 
results for strains in comparison to ∆CKL vary depending on whether secreted E2 yield was 
measured in mg L-1 or as a relative concentration (Figure 3.), For this reason ∆CKL is always 
grown, prepared and analysed in tandem so that relative concentrations can also be derived, 
so that the concentration of E2 can be assessed based on two points of reference and very 
variable results (i.e. very low quantitative yields of ∆motAB and ∆flgMN in Figure 3.A) can be 
excluded.  
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Figure 3.54: Combined results from E2 secretion assays in this chapter.  
Both absolute quantifications (A and B) and relative yields in comparison to the one achieved 
for ∆CKL in that experiment (C and D) are given for each strain. Results are comprised of 
secreted (A and C) and intracellular (B and D). Note: only results for cultures grown in 10mL LB 
broth, supplemented with the 0.05mM IPTG are included. Standard error of the mean is 
shown. Unpaired t-test of ∆CKL to each strain: **, *** and **** denote p = <0.01, 0.001 and 
0.0001 respectively. 
 
3.7.6.2. E2 as a substrate 
The use of E2 as a substrate allowed quantification of intracellular and secreted protein to be 
measured in a number of strains, however as a variant of the native FliC protein it is subject to 
biological factors associated with the cell environment (as seen in with the removal of FliS in 
Figure 3.). Production of a non-native protein would be desirable as it may reduce the effect of 
native biological control on protein expression, therefore reducing variables from strain to 
strain. Furthermore, the ability of the modified FT3SS to secrete recombinant proteins, would 
be beneficial both in terms of showcasing the capability of the modified FT3SS structure and 
also in opening up the strain for further applications concerning the production and secretion 
of industrially relevant proteins. 
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3.7.7. Outcomes of strain improvements to the FT3SS platform 
secretion strain 
 
Despite the limitations described the addition of knockout mutations to the ∆CKL strain did 
lead to improvements in E2 concentration. Overall the implementation of ∆clpX resulted in 
great improvements to the concentration of E2 both expressed and secreted whether 
measured by quantification or relative E2 (Figure 3.). The addition of ∆motAB resulted in the 
highest average yield of secreted E2 relative to that achieved for ∆CKL grown in the same 
technical replicate. This shows that it is possible to implement additional gene knockouts in 
the secretor strain to further improve the directed secretion of E2 through the secretion 
apparatus. Based on the difference in E2 concentrations in intracellular and secreted protein 
fractions, it is clear that it is not the production, but the secretion capacity of E2 which limits 
the yield of secreted E2 protein. Through the addition of knockout mutations (∆motAB), it is 
possible to improve the secretion capacity of the secretion apparatus (more secreted in 
comparison to intracellular). This may be indicative of improved capacity of the secretion 
apparatus itself or that show that tuning of E2 expression to secretion capacity is important so 
as not to overload cells with high concentrations of intracellular E2. This will be investigated in 
the next two chapters. 
In 10mL cultures (with a non-freeze thawed E2 protein standard) the highest yield of secreted 
E2 protein achieved was just under 35 mg L-1 following 6 hours of culture of ∆CKL ∆clpX cells. 
This is an improvement to the concentrations reported in studies which have previously 
modified the FT3SS for protein secretion (12 mg L-1 following at least 16 hours growth in 
Majander et al. 2005 and 1.8 mg L-1 Hour-1 in Widmaier et al. 2009, which would equate to 10.8 
mg L-1  in this system, assuming cultures are grown for six hours). This shows great promise of 
this protein secretion platform in relation to secretion capacities previously reported. 
In this chapter a modified FT3SS secretion platform for the secretion of protein into the 
extracellular media was established. A protein secretion assay was developed and it was found 
that the addition of knockout mutations to the ∆CKL strain resulted in variation in the 
secretion capacity of the secretion apparatus. While some of these mutations appear to 
increase the secretion capacity of the modified FT3SS, further improvement is required for this 
secretion system to be competitive with industry  and competitors in different research 
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groups–for example the 60mg L-1 yield of periplasmic secreted GFP in a small batch 
fermentation (Matos et al., 2012). The work in this chapter laid a good foundation for both 
measuring and improving secretion in strains.  However as it was found that the use of E2 to 
measure secretion is not compatible with all strains, the next chapter will investigate the 
development of a secretion assay for a non-native industrially relevant protein -which is of 
course main aim of the thesis. This should allow quantification of expression and secretion in 
all strains and also show scope for secretion of a range of proteins through the secretion 
apparatus. 
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Chapter 4. Further development and testing of 
the engineered FT3SS system: non-native 
protein secretion and assay development 
 
Following the successful development of a platform strain for the secretion of native protein 
through a modified flagella type III secretion system (FT3SS), it was desirable to make further 
improvements to extend the secretion capacity of the platform technology to non-native 
recombinant proteins. This was for a multitude of reasons; firstly, it was found that production 
and secretion of the native E2 protein was not compatible with all strains and therefore 
constituted a limitation of the suitability of the protein secretion assay which was developed to 
assess secretion capacity of strains. Second, it will showcase that the secretion platform design 
permits secretion of a range of proteins. Finally, secretion of recombinant proteins through the 
FT3SS is central to the suitability of this platform technology for bio-manufacturing.  
 
4.1. Design of a synthetic modular secretion construct for 
FT3SS secretion 
 
Previously, secretion of a near-native flagellin termed E2 was achieved by expressing E2 
protein fused to a 47 amino acid FliC secretion signal peptide. The signal peptide could be 
fused to a recombinant protein and the same principle could be applied, however while this 
strategy was successful, there are some limitations. Protein detection by Western blot with 
H48 (flagellin) antibody was protein specific; therefore it would be necessary to use a novel 
antibody for each recombinant protein. This would be costly, time consuming (as each 
antibody would require optimisation) and limit the range of recombinant proteins to those 
with corresponding antibodies. Another limitation concerns downstream processing of protein 
following secretion. Currently secreted E2 is not readily isolated from the media; furthermore 
if E2 protein was isolated it is not able to be cleaved from the FT3SS signal peptide to yield a 
purified product and is prone to polymerisation due to it being similar to native FliC, flagellin. 
Therefore to facilitate directed secretion of recombinant proteins, followed by purification 
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then isolation, a synthetic modular secretion construct was generated. This was achieved 
previously in the laboratory by a process of in silico design and synthesis (by DNA 2.0) and was 
the basis for studies here.  
 
Figure 4.1: Schematic of (A) the prototype synthetic modular secretion construct inserted 
into an IPTG inducible plasmid and (B) the resulting peptide.  
(A) The genomic prototype modular secretion construct is comprised of the transcribed 
elements of the secretion construct along with the fliC 5’ and 3’ untranslated regions (UTRs) 
and the start and stop codons. Restriction enzyme sites are incorporated throughout to allow 
modification of the secretion construct in a modular fashion. The prototype secretion 
construct is under transcriptional control of the IPTG inducible T5 promoter and the sigma 
factor-28 (FliA) inducible fliC promoter which is harboured in the 5’ UTR. The secretion 
construct shown harbours CH2 cargo (B) The resulting peptide comprises of the FliC 47 amino 
acid secretion signal, tobacco etch virus protease (TEV) sites, a FLAG tag, a streptavidin II tag 
and the protein for secretion –here shown with CH2 cargo. Note: it is also possible to express 
an ‘empty’ secretion construct, with no protein cargo between the EcoRI and PstI sites. 
 
The genetic prototype secretion construct consists of the 5’ UTR region of FliC, the 47 amino 
acid N-terminal secretion signal peptide of FliC, restriction sites to incorporate interchangeable 
protein for secretion, TEV protease recognition sites, a FLAG antigen epitope tag (FLAG tag) 
and Streptavidin-II purification tag (Strep tag) and the 3’ UTR of the fliC gene (Figure 4.). A TEV 
protease site was selected as the incorporation of just seven amino acid residues, allows highly 
site specific enzyme cleavage, furthermore its use is very well characterised and although 
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other protease are available which are much more efficient at cleaving protein, TEV protease 
activity is adequate (Frey & Görlich, 2014; Waugh, 2011). Both the Strep II and FLAG tags are 
also small and readily expressed in E. coli and are compatible a large range of laboratory based 
systems for purification and antibody detection, additionally although in principle they may be 
a bit costly, they are acceptable in industry (Saraswat et al., 2013). Strep II does not interfere 
with folding or activity of fusion proteins or induce protein aggregation and facilitates one-step 
purification of high yields of protein. The hydrophilic nature of FLAG means that it is presented 
on the outside of protein, so easily assessable to antibodies (Zhao et al., 2013). The construct 
has restriction enzyme sites to insert the whole construct into a vector (the IPTG inducible 
pJexpress in this study) and to interchange the protein for secretion via central PstI and EcoR1 
sites. The FliC UTR regions were incorporated into the secretion construct as they have been 
shown to be critical in the implementation of FT3SS secretion of native or non-native proteins, 
possibly due to the presence of a secretion signal (Majander et al., 2005) –this will be 
examined more thoroughly in the next chapter. Furthermore the 5’ UTR harbours the fliC 
promoter; therefore it was incorporated to allow natural induction of the secretion construct 
by the cell –as it seemed sensible to make use of native flagella gene regulation as well as 
being able to induce higher expression using the IPTG-responsive T5 promoter on this plasmid 
backbone (pJexpress404). Translation results in a multifunctional protein suitable for secretion 
by the FT3SS. The N-terminal 47 amino acids of FliC are thought to act as a non-cleavable signal 
peptide which confer targeted FT3SS export of the construct (Dobó et al., 2010). The FLAG tag 
provides a means of detection of secreted protein by FLAG specific antibody. The Strep tag 
allows purification of the secretion construct following secretion into the media by affinity 
chromatography. Finally the tobacco etch virus (TEV) protease recognition site allows the 
cleavage of the purification tags and signal peptide following purification, so that the final 
product is comprised of the protein of interest only.  
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4.2. Antibody fragment within the synthetic modular 
secretion construct  
 
Once the synthetic modular secretion construct (secretion construct) was developed a number 
of proteins (including enzymes and antibody fragments) were inserted by DNA ligation 
between the PstI and EcoRI sites. This included the antibody fragment ‘CH2’, which was 
generously donated by Dr Jagroop Pandhal, University of Sheffield. Following preliminary 
protein secretion tests, the antibody fragment CH2 (CH2), which had been codon optimised for 
E. coli, was found to express and secrete reliably and for this reason forms the basis for the 
investigation of the secretion of non-native protein in through the modified FT3SS. CH2 refers 
to the second (of three) constant heavy (CH) domain of an immunoglobulin antibody. CH2 is of 
particular interest because unlike other antibody domains it is able to form a stable monomer. 
CH2 is amenable to modification for target binding and also for use as a scaffold, examples of 
which include HIV binding therapeutic molecules therefore has many uses in biotechnology 
(Gehlsen et al., 2012; Ying et al., 2014). 
 
 4.3. Investigation of the performance of the synthetic 
modular secretion construct 
 
Prior to the investigation of the secretion capacity of CH2 through the modified FT3SS of 
mutants, initial research focused on the robustness of the secretion construct. This involved 
testing the suitability of the FLAG tag for antibody based detection of protein, the performance 
of the Step tag during protein purification and the effectiveness of the TEV sites in isolating 
protein product from the secretion construct.  
 
4.3.1. Protein purification of the CH2 harbouring secretion construct  
 
To confirm functionality of the Strep tag located in the secretion construct, CH2 was 
overexpressed in BL21 (DE3). Cells were harvested and lysed by French press, before 
undergoing Strep tag purification on a Strep-trap column. The insoluble and insoluble fractions 
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of cell lysate, along with samples collected from the flow through, wash and elution steps of 
the Strep-trap column protocol underwent SDS-PAGE and Coomassie staining. 
 
 
Figure 4.2: Protein fractions following overexpression and purification of Strep tagged CH2 
protein. 
E.coli BL21 (DE3) containing the plasmid pJexpress-FliC-CH2-FLAG-Strep was grown in LB to 
OD600 0.6-0.8 before induction with 1mM IPTG. Cells were harvested 3 hours after induction 
and resuspended in 100mM Tris-HCl, 150mM NaCl, 1mM EDTA pH 8, prior to cell lysis by 
French pressure cell. The resulting lysate was centrifuged for 10 minutes, 13,000g, 4°C to 
remove cell debris. The resulting supernatant was then centrifuged for a further 30 minutes 
and to yield insoluble (pellet) and soluble (supernatant) cell lysate protein fractions. Soluble 
Strep tagged CH2 protein was purified using a Strep-trap column. Protein was applied to the 
column; residual protein was washed off with 10 column volumes of 100mM Tris-HCl, 150mM 
NaCl, 1mM EDTA, pH 8 buffer and eluted with 2mM D-biotin. The flow through, wash and 
elution fractions were collected. 2 x SDS loading buffer was added to protein samples at a 1:1 
ratio. Samples were run on 15% SDS-PAGE gels. Protein samples were loaded as follows. Lane: 
(1) EZ-Run™ Prestained Rec Protein Ladder, (2) insoluble cell lysate, (2) soluble cell lysate, (3) 
Strep column flow through, (4) elution following wash step, (5-15) elution fractions 1-10. 5µL 
sample was loaded in lanes 2-4 and 15µL in lanes 5-15. SDS-PAGE gels were then stained with 
InstantBlue™ Coomassie stain. 
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The expected size of the CH2 protein is 12.6kDa however within the secretion construct it is 
predicted to be 22.4 kDa. An overexpressed protein can be seen clearly in the insoluble protein 
and in elution fractions 1-3. As the protein ran just below the 26 kDa marker, it can be 
assumed that this is the CH2 protein. Despite around 50% of CH2 protein being insoluble in 
this strain when expressed at these high levels, adequate soluble protein allowed protein 
purification on the Strep-trap column. The wash fraction is free of CH2 protein, suggesting that 
CH2 remains bound once associated with the Strep-trap column. Elution of CH2 was achieved 
within the application of the first 1mL elution buffer. The highest concentration of CH2 was 
eluted in the third elution fraction; following this no CH2 was detected in elution fractions. 
There are some additional protein contaminants in the elution fractions which contain CH2, 
which are seen at 72kDa, around 55 and 36kDa and in the third elution fraction only, around 
20kDa. The concentration of these contaminants seems to increase, with increased 
concentration of CH2. Despite efforts to remove these contaminants it was not possible. This 
included altering the Strep column protocol, by using different buffers for binding, different 
concentrations of D-biotin in the elution buffer and also by applying additional downstream 
steps. These additional steps included dialysis, with the best results achieved following 
overnight dialysis (40000 MWCO) in 100mM Tris-HCl, pH 8 (Figure 4.); the 72 and 36kDa 
protein contaminants are no longer visible and the 20kDa protein contaminant can be seen 
faintly in elution fractions 2 and 3. The major remaining protein contaminant is seen around 
55kDa and is present at a similar concentration to the CH2 protein, which runs at 26kDa here.  
It is possible that this could be a dimeric version of the 26kDa protein, although dimers should 
be absent following preparation with DTT and SDS it is around double the size. There was less 
total protein in elution fraction 1 prior to dialysis; following dialysis very little protein is visible. 
Elution fractions 2 and 3 both contain adequate protein for detection by Coomassie stain. 
There is a higher concentration of both CH2 and the 55kDa protein contaminant in elution 
fraction 3.  
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Figure 4.3: CH2 containing protein fractions following purification and dialysis. 
Soluble Strep tagged CH2 protein was purified using a Strep-trap column. Fractions which 
contained CH2 protein were dialysed overnight in 100mM Tris, pH 8. 2 x SDS loading buffer 
was added to protein samples at a 1:1 ratio. Samples were run on 15% SDS-PAGE gels, with 
empty lanes between each. Protein samples were loaded as follows. Lane: (1) elution fraction 
1, (2) empty lane, (3) elution fraction 2, (4) empty lane, (5) elution fraction 3, (6) EZ-Run™ 
Prestained Rec Protein Ladder. 30µL sample was loaded. SDS-PAGE gels were then stained 
with InstantBlue™ Coomassie stain. CH2 protein indicated by arrow. 
 
4.3.2. Antibody detection of CH2 protein in the secretion construct 
 
While dialysis aided the removal of some of the protein contaminants in purified CH2, it was 
not possible to remove them all (Figure 4.). Protein fractions were analysed by Western blot to 
investigate whether the FLAG-tag was functional in CH2 and to see if protein contaminants 
harboured a FLAG-tag (Figure 4.).  
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Figure 4.4: Detection of the FLAG-tag in CH2 containing protein fractions following 
purification and dialysis. 
Soluble Strep tagged CH2 protein was purified using a Strep-trap column. Fractions which 
contained CH2 protein were dialysed overnight in 100mM Tris, pH 8. 2 x SDS loading buffer 
was added to protein samples at a 1:1 ratio. Samples were run on 15% SDS-PAGE gels. Protein 
samples were loaded as follows. Lane: (1) elution fraction 1, (2) elution fraction 2, (3) elution 
fraction 3. 5µL sample was loaded. SDS-PAGE gels then underwent Western blotting with an 
anti-FLAG antibody. 
 
The FLAG-tag was detected at around the 26kDa marker as before, supporting the observation 
from the Coomassie stain. This was the only FLAG-tag signal detected, demonstrating that the 
contaminant proteins, including the 55kDa protein did not harbour FLAG-tags. In keeping with 
observations from the Coomassie stained SDS-PAGE gel, there was an increasing concentration 
of CH2 from elution fraction 1 to 3. In elution fraction 1 is can be assumed that the 
concentration of FLAG-tagged protein was below that of the detection threshold of the anti-
FLAG antibody. As CH2 was visible in elution fraction 1 on the Coomassie stained SDS-PAGE, 
this would suggest poor transfer efficiency of protein on to the nitrocellulose membrane.  
 
4.3.3. CH2 protein isolation from the secretion construct 
 
TEV sites were incorporated into the secretion construct to facilitate cleavage of accessory 
peptides in final produced proteins (i.e. the FT3SS signal peptide, FLAG and Strep tags). The 
effectiveness of this strategy was assessed by incubating purified CH2 protein from elution 
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fractions with TEV enzyme. Following a repeat of the purification protocol (protein eluted in 
fractions 2 and 3 again, as seen in Figure 4.), protein was then incubated in buffer with AcTEV™ 
Protease and DTT for 2 hours at room temperature. As a negative control, tandem reactions 
were set up without TEV protease. The resulting mixtures were prepared for SDS-PAGE 
followed by Coomassie stain or Western blot to ascertain whether cleavage at the TEV sites 
had occurred in the presence of TEV protease (Figure 4.). In the elution fractions following 
dialysis there is more total protein in elution fraction 3, both in terms of CH2 and also 
additional protein contaminants. The TEV protease is visible on the Coomassie stained SDS-
PAGE gel and runs at 27kDa. When fused to the secretion construct CH2 runs just below the 
26kDa marker but following successful TEV cleavage it should run at 13kDa. TEV protease is 
visible in lanes 9, 11 and 13. CH2 protein fused to the secretion construct is visible following 
incubation without TEV protease (lanes 10 and 12), but not in fractions where TEV protease 
was present. A protein with a small molecular weight (around 13kDa) is seen in elution fraction 
2, following TEV cleavage. This same protein is seen in all fractions which contain elution 
fraction 3 (whether TEV treated or not), suggesting some non TEV directed cleavage of CH2 
protein. This could also be a contaminant protein, however as a higher concentration of this 
band is present following incubation with TEV as opposed to without (Figure 4.: last four lanes 
in Coomassie), this is more likely to be the TEV cleavable CH2 protein. Furthermore if protein 
dilution during incubation with (or without) TEV protease is considered, a higher concentration 
of the small band is seen following TEV cleavage in comparison to that seen in the elution 
fraction 3 only. In the Western blot when a high concentration of protein was loaded (pre-TEV 
treated samples) a HRP fluorescent signal was detected for multiple bands, suggesting that the 
anti-FLAG antibody bound non-specifically to protein. In samples with CH2 protein and no TEV 
protease, an antibody signal is detected. This is not as strong as the signal seen in elution 
fraction prior to incubation with TEV protease, due to dilution of protein and perhaps protein 
degradation during incubation. No FLAG-tag is detected at any other molecular weights 
following incubation with or without TEV protease. When CH2 protein is incubated with TEV 
protease, no anti-FLAG-HRP signal is detected, this shows that FLAG-tag fused CH2 is no longer 
present in the protein fraction, demonstrating successful TEV protease cleavage of CH2 from 
the FLAG tag. This combined with the appearance of a higher concentration of protein which is 
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around 13kDa, suggests TEV cleavage is successful at both TEV sites in the secretion construct.  
 
Figure 4.5: Protein fractions following overexpression and purification and TEV cleavage of 
CH2. 
CH2 protein was overexpressed in BL21 (DE3) and soluble protein was purified using a Strep-
trap column. Fractions which contained CH2 protein were dialysed overnight in 100mM Tris-
HCl, 150mM NaCl, 1mM EDTA, pH 8 and then incubated for two hours either with or without 
TEV protease. 2x SDS loading buffer was added to protein samples at a 1:1 ratio. Samples were 
run on 15% SDS-PAGE gels. Protein samples were loaded as follows. Lane: (1) EZ-Run™ 
Prestained Rec Protein Ladder, (2) elution fraction 2 following dialysis, (3 and 4) empty, (5) 
elution fraction 3 following dialysis, (6-8) empty, (9) TEV protease only, (10) elution fraction 2 
only, (11) elution fraction 2 and TEV protease, (11) elution fraction 3 only, (12) elution fraction 
3 and TEV protease. 20µL sample was loaded. SDS-PAGE gels were then stained with 
InstantBlue™ Coomassie stain (top) or underwent Western blotting with anti-FLAG antibody 
(bottom). 
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4.3.4. CH2 protein structural properties 
 
CH2 can also dimerise, due to the weak carbohydrate-mediated interchain protein–protein 
interactions that occur between two CH2 domains at residue 297 in addition one intra- and 
one inter- chain disulphide bonds form (Chintalacharuvu et al., 2002) -the interchain bond 
forms between the hinge regions associated with CH2 (Prabakaran et al., 2008). As E. coli are 
not capable of glycosylation or disulphide bond formation (without the aid of strains such as 
CyDisCo, which produces catalysts for disulphide bond formation and isomerisation or 
expression of the N-linked glycosylation system in Campylobacter jejuni (Wacker et al., 2002; 
Matos et al., 2014)), it was not known if intracellular expression of CH2 would result in 
disulphide bond formation. Formation of disulphide bridge requires a non-reducing 
environment; however as CH2 protein is routinely prepared for SDS-PAGE in 2x SDS loading 
buffer with the reducing agent DTT, only the monomer has been detected. To investigate 
whether recombinant CH2 harboured in the secretion construct was capable of forming 
dimeric structures, purified CH2 was prepared for SDS-PAGE in 2x SDS loading buffer with and 
without the DTT component and run on SDS-PAGE gels. On the Coomassie stained SDS-PAGE 
gel it is evident that this round of protein purification resulted in an elution fraction with less 
contaminant protein. -with DTT a band is seen at 26kDa, however the band at 55kDa is not 
present. Without DTT the 26kDa band is not present, instead a band is seen at around 15 and 
20kDa (both too small to be the predicted 22.6kDa CH2-secretion construct protein).  When 
probed with anti-FLAG antibody on a Western blot (Figure 4.), the 26kDa band is detected and 
a very faint signal just below 55kDa is detected with DTT. In the absence of DTT the band 
which is present at around 26kDa is not present, whereas a band is visible at around 50kDa, 
which could suggest a dimeric form of the 26kDa CH2 protein. 
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Figure 4.6: CH2 protein following overexpression and purification prepared for SDS-PAGE 
followed by Coomassie stain or Western blotting in both the presence and absence of DTT. 
Soluble Strep tagged CH2 protein was overexpressed in BL21 (DE3) and purified using a Strep 
column. Fractions which contained CH2 protein were dialysed overnight in 100mM Tris-HCl, pH 
8. 2x SDS loading buffer either with or without DTT was added to protein samples at a 1:1 
ratio. Samples were run on 15% SDS-PAGE gels and underwent (A) Coomassie staining or (B) 
Western blotting with anti-FLAG antibody. The resulting Western blot was cropped to remove 
irrelevant lanes. Lanes shown are (left) CH2 with DTT, (right) CH2 without DTT. 20µL sample 
was loaded.  
 
Experimental work has shown that CH2 protein expressed within the secretion construct is 
amenable to overexpression, Strep-tag mediated purification, antibody detection by FLAG-tag 
and TEV protease cleavage of accessory peptides. In addition to these secretion construct 
facilitated characteristics, the CH2 protein was also shown to be functional in forming dimeric 
structures, presumably by disulphide formation. While successful, these findings all concern 
intracellular derived protein, focus will now move to secreting this protein through the FT3SS 
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into the extracellular media but they at least show the feasibility of the use of this construct 
and some element of native function in terms of dimerisation. 
 
4.4. Investigation of secretion of the synthetic modular 
secretion construct through the FT3SS. 
 
4.4.1. Secretion of the CH2 harbouring synthetic modular secretion 
construct through the modified FT3SS 
 
In the previous section, CH2 was overexpressed in BL21 (DE3). It was confirmed that the 
secretion construct plasmid expressed protein upon induction and also established that 
purification (Strep II) and antigen tags (FLAG) were faithfully presented. TEV cleavage 
capability was also verified.   However, investigation of the potential of the modified FT3SS to 
secrete a heterologous protein within this prototype secretion construct required expression 
of the pJexpress-FliC-CH2-FLAG-Strep plasmid in FT3SS secretion strains. Initial investigation of 
CH2 expression and secretion was carried out in the original ∆CKL secretor strain as a starting 
point for studies. Following cell culture of the secretor strain, with induction of the plasmid 
harbouring the FliC secretion signal peptide-linked CH2 in the secretion construct; FLAG-tagged 
protein was visible by Western blot in both the intracellular and supernatant (secreted) 
fractions (Figure 4.). Less CH2 protein was seen in the secreted fraction and no FLAG signal was 
detected in the cells or supernatant of cells expressing the empty vector.  
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Figure 4.7: CH2 protein in the secreted and intracellular fractions of ∆CKL secretor strain cell 
culture. 
E.coli ∆CKL containing either the plasmid pJexpress-FliC-CH2-FLAG-Strep or pJexpress-empty 
vector were induced with 0.05mM IPTG and grown in LB at 37°C with 180rpm agitation. Cells 
were harvested when cell culture reached OD600 1.5. 1 OD unit of cells were prepared for SDS-
PAGE and the supernatant (SN) from 1 OD unit of cells was precipitated with TCA (10% v/v) 
before SDS-PAGE and Western blot analysis with anti-FLAG antibody. Protein samples were 
loaded as follows. Lane: (1) CH2 –SN, (2) empty vector –SN, (3) CH2 –cells, (4) empty vector –
cells.  
 
4.4.2. Optimisation of a standardised protein secretion assay to 
quantify secretion of CH2 through the modified FT3SS: induction  
 
The data presented above showed that the secretor strain was effective in both expressing and 
secreting CH2 protein, however the expression protocol carried out was based on that derived 
from the optimisation of secretion of the E2 monomer following expression of pTrc E2. As CH2 
secretion involves the expression of an entirely different protein and more importantly from a 
different plasmid backbone (pJexpress), a range of expression protocols was tested to ensure 
that CH2 expression and secretion are robust before the effect of strain improvements is 
assessed. As described, there are two means of expression of genes within pJexpress-FliC-CH2-
FLAG-Strep plasmid: with IPTG via the T5 promoter and through native expression of the FliC 
promoter which is still incorporated in the FliC 5’UTR. While induction through the FliC 
promoter is regulated by the flagella genetic regulon via flhDC and fliA, CH2 protein expression 
was tuned with IPTG to maximise protein secretion in the ∆CKL strain. CH2 protein expression 
and secretion were measured as before, however cultures were supplemented with 0, 0.01, 
0.05, 0.1 or 1mM IPTG.  
219 
 
  
Figure 4.8: Intracellular and secreted fractions of MC1000 ∆fliC ∆flgKL supplemented with 
different concentrations of IPTG. 
E.coli ΔCKL containing the plasmid pJexpress-FliC-CH2-FLAG-Strep was grown in LB 
supplemented with 0, 0.01, 0.05, 0.1 or 1mM IPTG. Cells were harvested at OD600 1.5. The cells 
and supernatant from 1 OD unit of cells were prepared for (top) SDS-PAGE and (bottom) 
Western blot analysis of supernatant using anti-FLAG-HRP antibody. 15µL supernatant derived 
protein was loaded onto SDS-PAGE gels and 5µL and 2µL cell derived protein was loaded on to 
SDS-PAGE gels for Coomassie staining and Western-blotting respectively.  
 
The Coomassie stained SDS-PAGE gel shows that the addition of different concentrations of 
IPTG did not alter levels of total intracellular protein expression and that overexpressed CH2 
protein was not visible, suggesting expression may not be as strong as in BL21(DE3) (Figure 4.: 
top). Secreted fractions are clear of protein, demonstrating that cell lysis did not occur at a 
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detectable level with the induction of recombinant protein expression with any concentration 
of IPTG. The absence of any visible protein in secreted fractions also suggests that the 
concentration of secreted CH2 was below the detection threshold of Coomassie stain. The 
results of the Western blot show that CH2 was both produced intracellularly and secreted 
without and with IPTG induction (Figure 4.: bottom). CH2 expression was lowest with the 
addition of 0 or 0.01mM IPTG and was optimal at 0.1mM but surprisingly dropped off at 1mM 
IPTG. This was mirrored with secreted CH2, where CH2 was detected in the supernatant 
increased from 0 to 0.05mM IPTG where after the concentration of secreted CH2 decreased 
with the addition of more IPTG. This was confirmed following analysis with densitometry 
(Figure 4.). Secretion efficiency was calculated by adding the values derived for secreted and 
intracellular CH2 (total CH2) in a strain and then dividing this by the value for secreted CH2. 
This showed that the most efficient secretion occurred with the addition of 0.01mM IPTG 
(Figure 4.C). There was little difference in the secretion efficiency of cultures supplemented 
with 0.05 to 1mM IPTG, however 0.05mM resulted in the next most efficient secretion 
capacity of CH2. 
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Figure 4.9: Expression and secretion capacities of MC1000 ∆fliC ∆flgKL supplemented with 
different concentrations of IPTG.  
E.coli ΔCKL containing the plasmid pJexpress-FliC-CH2-FLAG-Strep was grown in LB 
supplemented with 0, 0.01, 0.05, 0.1 or 1mM IPTG. Cells and supernatant were harvested and 
prepared for SDS-PAGE and Western blotting with an anti-FLAG-HRP antibody, Densitometry 
analysis was carried out on the resulting Western blot using Image J. Results are shown for (A) 
densitometry value of secreted protein as a percentage of total secreted CH2 protein for all 
IPTG induction concentrations, (B) as stated, but for intracellular CH2, (C) as a proportion of 
CH2 detected in the supernatant in comparison to the intracellular fraction. 
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In subsequent CH2 secretion assay experiments, media was supplemented with 0.05mM IPTG. 
Although secretion wasn’t most efficient at this level of induction, it did result in the second 
highest intracellular and highest secreted concentration of CH2. During the investigation of E2 
secretion samples were taken once cultures reached OD600 1.5, here samples will be taken at 
OD600 1.0 due to the time constraints associated. 
 
4.4.3. Isolating monomeric CH2 to quantify secretion capacity 
 
As with the E2 secretion assay, it was beneficial to derive a CH2 protein standard to allow 
quantitative measurements of CH2 expression and secretion. This will give an indication of w/v 
yields of CH2 protein and also allow inter-experimental comparison of expression and 
secretion capacity. CH2 protein was overexpressed in BL21 (DE3) and purified and dialysed as 
described in previous sections. The concentration of CH2 was measured by BCA assay, 
however as multiple protein bands were seen in purified protein the total concentration of 
protein calculated by BCA assay cannot all be attributed to CH2. To account for this 
densitometry analysis was carried out on the Coomassie stained SDS-PAGE gel of CH2 protein 
standards (Figure 4.), this then allowed the proportion of CH2 in total protein to be 
determined and therefore the concentration of CH2 to be calculated. 
 The total concentration of protein found in elution franction 3 of the protein loaded onto 
Figure 4. was 41.4µg mL-1. Densitometry calcualted that the band present at around 26kDa 
(CH2) comprised 33.708% total protein seen on the Coomassie stained SDS-PAGE gel. 
Therefore the concentration of CH2 protein in the protein standard is 14µg mL-1. Therefore 
following Western blotting with the anti-FLAG-HRP antibody it can be concluded the intensity 
of the band seen at around 26kDa for the protein standard is due to a 14µg mL-1 concentration 
of CH2. This allows calculation of the concentration of CH2 in other samples due to 
proportional densitometry.  
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4.5. Improved secretion of recombinant protein through 
the FT3SS 
 
With the protein secretion assay optimised to ensure that CH2 expression and secretion 
through the modified FT3SS are maximised and measurable in a quantitative manner, the 
focus of the study could now shift to testing the secretion capacity of CH2 in the secretor strain 
mutants, with the aim of improving CH2 protein secretion. 
 
4.5.1. Establishing that secretion in engineered strains is truly FT3SS 
dependent 
 
Prior to the investigation of improved secretion of CH2 through the modified FT3SS of strains 
with additional knock out mutations, it was important to ensure that CH2 secretion was 
facilitated by the FT3SS and not through cell lysis or other routes of non-directed protein 
secretion. This was investigated by measuring protein secretion in the negative secretion 
strains MC1000 ∆flhDC and MC1000 ∆flgKL ∆fliC ∆flgDE.  
As seen in Figure 4., CH2 was detectable by anti-FLAG-HRP in the intracellular fraction of all 
strains, however in strains designed to act as negative controls for secretion of CH2 through 
the FT3SS (ΔflhDC and ΔflgDE) less CH2 was produced. In terms of strains which should 
demonstrate CH2 secretion, the ΔflgMN mutation resulted in slightly reduced CH2 expression 
in comparison to ∆CKL. These observations were confirmed with densitometry analysis of 
Western blots (two biological replicates) and quantification of CH2 protein concentration by 
calibration with the protein standard. In terms of intracellular protein, 54.8 mg L-1 and 33.9 mg 
L-1 CH2 was produced. While the ΔflgMN mutation did not result in more intracellular CH2 it 
did result in more secreted CH2: on average ∆CKL secreted 69.31 µg L-1 CH2 and ∆CKL ΔflgMN 
128.21 µg L-1, suggesting it is also more efficient at secreting protein than ∆CKL. Although a 
maximum of 0.51% total protein was secreted into the supernatant.  
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Figure 4.10: Intracellular and secreted CH2 from the ∆CKL, ΔflhDC and ∆CKL ΔflgMN and 
∆CKL ΔflgDE mutants. 
E.coli ΔCKL (C), ΔflhDC (DC), ΔCKL ΔflgMN (MN) or ΔCKL ΔflgDE (DE) containing the plasmid 
pJexpress-FliC-CH2-FLAG-Strep was grown in LB supplemented with 0.05mM IPTG. Cells were 
harvested at OD600 1.0. 1 OD unit of cells were prepared with 2x SDS-PAGE loading buffer. The 
supernatant from 1 OD unit of cells was precipitated with TCA (10% v/v) and prepared with 2x 
SDS-loading buffer. Samples underwent SDS-PAGE and Western blot analysis of cells and 
supernatant using an anti-FLAG-HRP antibody. A CH2 protein standard (S) was loaded to allow 
quantification of intracellular and secreted protein concentration. Samples were loaded as 
follows: Supernatant: 20µL, cells: 2µL, standard: 5µL. Note supernatant and cell fractions were 
run on separate SDS-PAGE gels. 
 
To measure cell lysis, Western blots were stripped of anti-FLAG-HRP and reprobed with anti-
GroEL to observe the presence of the cytoplasmic GroEL protein. Roughly similar 
concentrations were seen in the intracellular fractions of the different strains, however in the 
secreted fractions more GroEL was present with the addition of the ΔflgMN and ΔflgDE (where 
no secretion of CH2 was seen) mutations. As in Chapter 3, in the absence of a total cell lysis 
sample, it is not possible to calculate how much lysis this represents, however on account of 
the lack of protein in the supernatant fractions, this is unlikely to be very high at all. 
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Figure 4.11: Abundance of GroEL in the intracellular and supernatant fractions of the 
secretor strain, ΔflhDC, ΔflgMN and ΔflgDE mutants, following expression and secretion of 
CH2 protein through the FT3SS. 
E.coli ΔCKL (C), ΔflhDC (DC), ΔCKL ΔflgMN (MN) or ΔCKL ΔflgDE (DE) containing the plasmid 
pJexpress-FliC-CH2-FLAG-Strep were grown in LB. Cells were harvested at OD600 1.0. Samples 
underwent SDS-PAGE and Western blot analysis of cells and supernatant using anti-GroEL 
antibody and an HRP secondary. Samples were loaded as follows: Supernatant: 20µL, cells: 
2µL. 
 
While CH2 is seen in the supernatant of positive secretion strains and is negligible in negative 
secretion strains, it is not possible to conclude that this is due to the FT3SS secretion alone 
because negative secretion strains express much less CH2 protein (Figure 4.). Therefore at this 
stage it is not possible to confirm that CH2 protein seen in the media is due to FT3SS directed 
secretion. The reduced level of CH2 expression in negative secretion strains is due to the 
presence of the fliC promoter in the secretion construct. The fliC promoter is subject to native 
transcriptional control of the cell, therefore as the ΔflhDC and ΔflgDE mutations result in 
reduced class III gene transcription due to trapping of FlgM inside the cell, less plasmid derived 
protein is expressed. To counteract this, the media of negative secretion strains was 
supplemented with additional IPTG, with the aim of compensating for reduced fliC promoter 
induction via increased T5 promoter induction. An alternative to this would be to produce a 
∆flgDE ∆flgM mutant, resulting in free 28 and therefore decoupling hook completion and the 
initiation of class III gene transcription. Despite several attempts to produce this mutant 
through Lambda-Red recombineering and phage transduction it was not achieved. It is not 
thought that this mutation combination would be lethal; therefore no explanation for this can 
be given, other than the common synthetic biology concept of the unpredictability of biology.  
225 
 
To investigate whether increased induction of the T5 promoter in the CH2 secretion construct 
harbouring plasmid, would result in increased CH2 expression in the negative control strains 
(ΔflhDC and ΔflgDE) the media was supplemented with additional IPTG. Following SDS-PAGE 
and Coomassie staining no visible differences in total intracellular protein were observed. CH2 
was not visibly overexpressed with the addition of increasing concentrations of IPTG (Figure 
4.B), neither was it observable in the supernatant fractions of cell culture (Figure 4.A). There is 
evidence of some intracellular protein contamination of the supernatant of ΔflhDC in all 
induction conditions. This is also true of ΔflgDE but is less pronounced. The result of the 
Western blot (Figure 4.C) showed that increasing concentrations of IPTG correlated with an 
increase in intracellular CH2 concentration. While ΔflhDC and ΔflgDE expressed less CH2 than 
the secretor strain with the addition of 0.05mM IPTG, this could be compensated with the 
addition of 1mM IPTG. This was confirmed by densitometry analysis (Figure 4.). CH2 was found 
in the supernatant of the secretor strain (837.36 µg L-1) and in low quantities in ΔflhDC (108.36 
µg L-1) when supplemented with 1mM IPTG -in what was almost certainly a phenomenon 
caused by cell lysis in these cells (as illustrated by anti-GroEL Western below -Figure 4.). This 
amounted to 4.59% CH2 protein being secreted in the secretor strain, as opposed to 0.64% in 
ΔflhDC or 0% in ΔflgDE with the addition of 1mM IPTG. 
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Figure 4.12: Intracellular and secreted CH2 from the secretor strain and the ΔflhDC and 
ΔflgDE mutants when supplemented with increasing concentrations of IPTG 
E.coli ΔCKL (C), ΔflhDC (DC) or ΔCKL ΔflgDE (DE) containing the plasmid pJexpress-FliC-CH2-
FLAG-Strep was grown in LB supplemented various concentrations of IPTG (see annotation).  
Cells were harvested at OD600 1.0. 1 OD unit of cells were prepared with 2x SDS-PAGE loading 
buffer. The supernatant from 1 OD unit of cells was precipitated with TCA (10% v/v) and 
prepared with 2x SDS-loading buffer. Samples underwent SDS-PAGE and either staining with 
Instant Blue Coomassie stain (A and B) or Western blot (C) analysis of cells and supernatant 
using an anti-FLAG-HRP antibody. A CH2 protein standard (S) was loaded to allow 
quantification of intracellular and secreted protein concentration during Western blot analysis. 
Note supernatant and cell fractions were run on separate SDS-PAGE gels. Samples were loaded 
to as follows: Supernatant: 20µL, standard 10µL.  Cells: 2µL (Western blot), 5µL (Coomassie 
stain), standard: 5µL.  
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Figure 4.13: Quantitative measurement of intracellular CH2 from the secretor strain, ΔflhDC 
and ΔflgDE mutants following the addition of various concentrations of IPTG. 
E.coli ΔCKL (C), ΔflhDC (DC), ΔCKL) or ΔCKL ΔflgDE (DE) containing the plasmid pJexpress-FliC-
CH2-FLAG-Strep were grown in LB supplemented with various concentrations of IPTG to OD600 
1.0. A CH2 protein standard (S) was loaded to allow quantification of intracellular protein 
concentration. Following Western blot analysis of cells using anti-FLAG-HRP, densitometry 
analysis was carried out using ImageJ to calculate the concentration of CH2 in cells per litre of 
cell culture. 
 
Cell lysis was measured by measuring supernatant fractions for the presence of the 
cytoplasmic chaperone protein GroEL (Figure 4.). The secretor strain and ΔflgDE mutant had 
similar concentrations of GroEL in the supernatant of cell culture, whereas ΔflhDC mutants had 
higher concentrations suggesting that cell lysis was higher in this strain. This complemented 
results seen in the Coomassie stain (Figure 4.). The addition of increasing concentrations of 
IPTG did not result in increased GroEL. Cell lysis suggests that cells are not healthy, however it 
is not documented that the flhDC mutant should have poor fitness, in fact it is a more 
competitive in animal and plant models (Gauger et al., 2007; Tans-Kersten et al., 2004). It is 
possible that some deleterious mutations have occurred in the strain; therefore it may be 
favourable to generate a fresh version of this mutant knockout. However for the purpose of 
this investigation lysis was still relatively low and presence of E2 protein in the supernatant 
was only visible following 1mM IPTG induction, suggesting that cytoplasmic leakage was very 
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low. For these reasons it was concluded that the strain is still suitable for use as a negative 
control. Most importantly little GroEL was detected in the supernatant of ΔCKL cells, 
suggesting that any protein seen in the supernatant of this sample is due to directed secretion 
and not lysis. 
 
Figure 4.14: GroEL in the supernatant fraction of the CH2 expressing secretor strain and the 
ΔflhDC and ΔflgDE mutants with the addition of IPTG.  
E.coli ΔCKL (C), ΔflhDC (DC) or ΔCKL ΔflgDE (DE) containing the plasmid pJexpress-FliC-CH2-
FLAG-Strep was grown in LB supplemented various concentrations of IPTG (see annotation).  
Cells were harvested at OD600 1.0. Samples underwent SDS-PAGE and Western blot analysis 
using anti-groEL antibody and an HRP secondary. 
 
Addition of higher concentrations of IPTG is an effective means of counteracting reduced fliC 
promoter activity in negative secretion strains. This allowed conformation that FT3SS secretion 
signal peptide tagged protein is not present in the supernatant of strains which lack fully 
functional secretion apparatus. With negative control established it can be confidently stated 
that the presence of these proteins in the supernatant of strains with functional secretion 
apparatus is due to directed FT3SS secretion alone. 
 
4.5.2. Secretion construct modification for negative control of FT3SS 
secretion  
 
While negative control of FT3SS secretion has been demonstrated by the absence of FliC 
secretion signal peptide tagged protein in the supernatant of strains with either non-functional 
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or incomplete secretion apparatus, the specificity of the secretion signal peptide has not been 
investigated. The creation of a secretion construct without the secretion signal peptide will 
serve as a negative control for protein secretion through the FT3SS. In addition to this the 
removal of the 5’ UTR may alleviate the issue of cell mediated negative regulation on plasmid 
expression through the fliC promoter, as the promoter is situated in this 5’ UTR region.  
 
4.5.2.1. Production of the modified secretion construct 
The region of the prototype secretion construct upstream of the protein cargo is currently 
comprised of the 5’ UTR region of fliC followed by the 47 amino acid FliC secretion peptide. 
Primers were designed to amplify DNA from the plasmid pJexpress-FliC-CH2-FLAG-Strep 
without the 5’ UTR or without the 5’ UTR and the 47 amino acid FliC secretion signal peptide. 
As the secretion construct ribosome binding site and start codon were incorporated into the 5’ 
UTR and signal peptide respectively, it was required to integrate them into the forward 
primers so that PCR products would harbour extensions of the original template with these 
motifs. The forward primer is capped with an NdeI restriction enzyme site and the reverse a 
BamHI restriction enzyme site, this will allow the PCR product to be cloned into pJexpress with 
NdeI and BamHI sticky ends.  
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Figure 4.15: Schematic of the existing prototype secretion construct harbouring CH2 and the 
alternative secretion constructs (SCA and SCB) following the removal of the 5’ UTR or 47 
amino acid secretion peptide.  
The genetic construct (left) and resulting protein based secretion construct (right) are given for 
three variations of CH2 harbouring constructs. The original prototype CH2 secretion construct 
which contains the 5’ UTR and 47 amino acid secretion signal (A) was used as a template for 
PCR using one of two forward and one reverse primers with elongated ends. Restriction 
enzyme sites featured in the elongated ends of all primers and ribosome binding site (RBS) and 
start codon featured in the two forward primers. This resulted in the generation of donor DNA, 
which following restriction digest with NdeI and BamHI was ligated into a NdeI/BamHI cut 
plasmid harbouring the empty secretion construct. This resulted in the generation of two novel 
plasmids which novel genetic constructs (B and C), known as SCA and SCB. Expression of these 
resulted in the peptide products denoted on the right for each.   
 
PCR products for both primer sets were derived by high-fidelity PCR. The size of PCR products 
when run on a DNA agarose gel confirmed the successful amplification of template DNA with 
the aforementioned primer mediated DNA extensions. PCR products were excised from the gel 
and isolated. 
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Figure 4.16: Agarose DNA gels showing SCA and SCB PCR products for ligation into NdeI and 
BamHI cut pJexpress-FliC-empty-FLAG-Strep 
PCR reactions were carried out using pJexpress-FliC-CH2-FLAG-Strep as template and primers 
in Appendix 2 with Phusion® High-Fidelity DNA Polymerase. PCR mixtures were analysed on a 
1% TAE agarose DNA gel supplemented with a trace of ethidium bromide, visualised under UV 
light and inverted. Samples were run with GeneRuler™ 1kb DNA ladder.  Left: 50µL NdeI-RBS-
ATG-47aa-CH2-Strep-FLAG-3’ UTR-BamHI (964bp). Right: (1) Ladder, (2 and 3) not relevant to 
this experiment, (4) 10µL NdeI-RBS-ATG-CH2-Strep-FLAG-3’ UTR-BamHI (823bp) 
 
Isolated PCR products and pJexpress-FliC-empty-FLAG-Strep underwent restriction digest with 
NdeI and BamHI in CutSmart buffer. Following this incubation step the acceptor vector was 
treated with Antarctic phosphatase to discourage re-circularisation and then run on a DNA 
agarose gel to confirm successful restriction digest. As a control, acceptor vector which had 
been incubated without restriction digest enzymes was also loaded on to the gel. As opposed 
to the smaller supercoiled circular DNA seen in lane 1, two DNA products are visible in the 
second lane, showing the cut acceptor vector (3967kbp) and the 772kbp section of DNA 
comprising of the empty secretion construct. 
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Figure 4.17: Agarose DNA gel showing uncut and NdeI and BamHI cut pJexpress-FliC-empty-
FLAG-Strep 
Restriction digest reactions were carried out both with and without the addition of restriction 
enzymes. 5µL restriction digest mixture was prepared for DNA electrophoresis and loaded on a 
1% TAE agarose DNA gel supplemented with a trace of ethidium bromide and visualised under 
UV light and inverted. Lanes: (1) GeneRuler™ 1kb DNA ladder, (2) uncut vector, (3) NdeI and 
BamHI cut vector 
 
 As the product resulting from restriction digest of PCR products was only 18bp shorter than 
the original product, these restriction digest mixtures were not visualised by DNA 
electrophoresis. All restriction digest reactions underwent PCR clean up to inactivate 
restriction enzymes, as BamHI is not amenable to heat inactivation. DNA concentration of both 
acceptor vector and PCR products following restriction digest and clean up was measured and 
DNA ligation reactions were set up to contain the cut acceptor vector and either SCA or SCB 
DNA. Following incubation overnight, ligation reactions were transformed into NEB 5-alpha 
Competent E. coli and screened by plating on LB agar plates supplemented with ampicillin. 
Positive colonies were screened by colony PCR to confirm successful ligation of DNA. 
Plamid DNA was isolated from colonies which yeilded positive colony PCR results and were 
sent for sequencing with primers which annealed to DNA regions flanking the insertion site of  
donor DNA following ligation. Sequences from both plasmids alligned to the expected 
sequence exactly. Protein expression and secretion can now be assessed for these newly 
derived plasmids. 
233 
 
4.5.2.2. Testing the modified secretion construct 
Following the successful cloning of two versions of the CH2 harbouring secretion construct; 
one without the FliC 5’ UTR (SCA) and one lacking both the FliC 5’ UTR and the 47 amino acid 
secretion signal peptide (SCB) the expression and secretion of these plasmids was investigated 
in both the secretor strain and the negative secretion strain ∆flgDE.  
As seen in the Coomassie stained SDS-PAGE gel, CH2 was not distinguishable in either the cell 
or secreted protein fractions (Figure 4.). The secreted protein fraction was clear of other 
protein contaminants aside from a large protein seen at around 72kDa. Despite this, as the 
remainder of the fraction as clear, it can be assumed that cell lysis did not occur in cell culture 
for any combination of plasmid or strain. Western blot analysis showed that CH2 harboured in 
the original secretion construct was produced intracellularly and secreted in ∆CKL cells (Figure 
4.: bottom), whereas (as seen previously in Figure 4.) a very low concentration was produced 
in the ∆flgDE mutant. In the absence of the FliC 5’ UTR the same concentration of CH2 was 
produced in ∆CKL cells as was when it was present. In the ∆flgDE mutant the absence of the 5’ 
UTR resulted in an increase in CH2 expression as opposed to when it was present –in fact the 
concentration of CH2 was in line with that seen in ∆CKL cells. Without the 5’ UTR CH2 was 
absent in the supernatant of both strains. In the absence of the FliC 5’ UTR and the 47 amino 
acid secretion signal peptide, it was predicted that the size of the CH2 product would reduce to 
13.5kDa; this was seen in the Western blot. ∆flgDE expressed slightly more than ∆CKL; 
however both strains had much more intracellular CH2 in the absence of the secretion signal, 
this was not expected. As expected in the absence of the secretion signal the supernatant of 
cells cultures of both ∆CKL and ∆flgDE was void of CH2 protein. This pattern was seen in two 
biological replicates.  
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Figure 4.18: Intracellular and secreted CH2 from the secretor strain and ∆CKL ΔflgDE mutant 
with variable FliC 5’ UTR and FliC secretion signal peptide sequences 
E.coli ΔCKL (C) or ΔCKL ΔflgDE (DE) containing the either the plasmid pJexpress-FliC-CH2-FLAG-
Strep or the SCA or SCB variant plasmid was grown in LB supplemented with 0.05mM IPTG.  
Cells were harvested at OD600 1.0. 1 OD unit of cells were prepared with 2x SDS-PAGE loading 
buffer. The supernatant from 1 OD unit of cells was precipitated with TCA (10% v/v) and 
prepared with 2x SDS-loading buffer. Samples underwent SDS-PAGE and either staining with 
Instant Blue Coomassie stain (top) or Western blot (bottom) analysis of cells and supernatant 
using an anti-FLAG-HRP antibody. Samples were loaded to as follows: Supernatant: 20µL. Cells: 
2µL (Western blot), 5µL (Coomassie stain).  
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4.5.3. Reduced metabolic burden and negative regulation mutants: 
Effects of deletion of motAB, flgMN, fliDST and clpX on FT3SS secretion 
of CH2 
 
With the development of a protein secretion assay for the non-native protein CH2 and the 
confirmation of control of directed FT3SS secretion with the negative secretion strains ∆flhDC 
and ∆CKL ∆flgDE, the investigation into the secretion capacity of CH2 in the suite of promising 
secretion strains which have been generated could begin. CH2 protein secretion assays were 
carried out to investigate the expression and secretion capacity of the ∆CKL strain with the 
addition of ∆motAB, ∆fliDST, ∆flgMN and ∆clpX mutations. ∆CKL was assessed in tandem for 
reference and the CH2 protein standard often utilised to calculate both expression and 
secretion yields.  
Figure 4. serves as an example of one of a number of biological replicates of CH2 protein 
secretion assay experiments, which were carried out. As seen in the Coomassie stained SDS-
PAGE gel, while CH2 was not visible, the supernatant protein fraction was routinely clear of 
additional protein contaminants, suggesting that cell lysis was not commonplace. Western blot 
analysis demonstrated that intracellular CH2 concentration is variable between strains, 
however reasonable amounts are expressed in all, suggesting that CH2 expression is 
compatible in all mutant strains tested. This is also true of secreted protein; all mutant strains 
are capable of secreting CH2 through the modified FT3SS and into the media. As a CH2 protein 
standard was not loaded onto this Western blot it is not possible to quantify the concentration 
of CH2 protein loaded onto the gel to give a yield, however it is possible to use densitometry 
analysis to calculate intracellular or secreted CH2 in strains relative to that in the secretor 
strain. Samples for each strain on an SDS-PAGE gel were derived in tandem -from cell culture 
to sample preparation and finally Western blot analysis, therefore it is valid to normalise 
results for each strain to ∆CKL. As ∆CKL is common to every experiment, normalised results can 
be compared across experiments. 
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Figure 4.19: Intracellular and secreted CH2 from the secretor strain and ΔmotAB, ΔflgMN, 
ΔfliDST and ΔclpX and mutants. 
E.coli ΔCKL (C), ΔCKL ΔmotAB (M), ΔCKL ΔflgMN (MN), ΔCKL ΔfliDST(DST) or ΔCKL ΔclpX (X) 
containing the plasmid pJexpress-FliC-CH2-FLAG-Strep were grown in LB supplemented with 
0.05mM IPTG.  Cells were harvested at OD600 1.0. 1 OD unit of cells were prepared with 2x SDS-
PAGE loading buffer. The supernatant from 1 OD unit of cells was precipitated with TCA (10% 
v/v) and prepared with 2x SDS-loading buffer. Samples underwent SDS-PAGE and either 
staining with Instant Blue Coomassie stain (top) or Western blot (bottom) analysis of cells and 
supernatant using an anti-FLAG-HRP antibody. Samples were loaded to as follows: 
Supernatant: 15µL. Cells: 2µL (Western blot), 5µL (Coomassie stain).  
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Following densitometry analysis of the Western blot shown in Figure 4. along with additional 
biological replicates, relative levels of CH2 expression and secretion in comparison to the 
secretor strain were derived (Figure 4.). Aside from secreted CH2 in the ΔmotAB mutant, there 
is quite a lot of variation observed in the relative CH2 concentrations in comparison to ∆CKL. 
The trend observed is that all additional knockout mutations result in on average, less 
intracellular CH2 and more secreted CH2 in comparison to the ∆CKL. ΔCKL ΔflgMN produced 
0.71 CH2 protein in comparison to the ∆CKL, this was significantly less. In terms of secreted 
CH2, the ΔfliDST mutation resulted in an average of 1.64 CH2 relative to ∆CKL, however this 
was not found to be significant. The three other knockout mutations all resulted in significantly 
more secreted CH2 relative to ΔCKL (ΔCKL ΔmotAB = 1.53, ΔCKL ΔflgMN =1.46, ΔCKL ΔclpX = 
1.55). These findings suggest that all four strategies to improve CH2 are effective, as more CH2 
is secreted and furthermore as less CH2 is found intracellularly, these strains are more efficient 
at secreting CH2 than the original secretor strain. 
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Figure 4.20: Western blot densitometry analysis of intracellular and secreted protein 
fractions of CH2 expressing secretor strain and ΔmotAB, ΔflgMN, ΔfliDST and ΔclpX and 
mutants.  
E.coli ΔCKL, ΔCKL ΔmotAB, ΔCKL ΔflgMN, ΔCKL ΔfliDST, or CKL ΔclpX containing the plasmid 
pJexpress-FliC-CH2-FLAG-Strep were grown in LB supplemented with 0.05mM IPTG.  Cells were 
harvested at OD600 1.0. Following Western blot analysis of cells and supernatant using anti-
FLAG-HRP, densitometry analysis was carried out using ImageJ. Results were then normalised 
to the value obtained for either secreted or intracellular CH2 in the ΔCKL strain (1). Individual 
data points, average and standard error of the mean are given for secreted (left) and 
intracellular (right) relative concentration of CH2. Unpaired t-test was carried out (* = p<0.05, 
*** = p<0.0005). Biological replicates (secreted, intracellular): ΔCKL (6, 7), ΔCKL ΔmotAB (4, 4), 
ΔCKL ΔflgMN (9, 8), ΔCKL ΔfliDST (5, 4), CKL ΔclpX (6, 4) 
 
While relative concentrations of intracellular and secreted CH2 are informative, it is desirable 
to obtain quantitative yields so that productivity can be compared to industry standards. CH2 
protein standard was loaded alongside many biological samples; however the high incidence of 
high background and weak fluorescent signal resulted in many being unsuitable for analysis by 
densitometry. From the results obtained, the overall trend was the same as that observed in 
Figure 4.: the addition of all mutations resulted in the average yield of secreted protein being 
higher in the secreted fraction and lower in the intracellular fraction (Figure 4.: A and B). In 
addition, all mutations resulted in more efficient secretion of CH2 into the media of cell 
cultures (Figure 4.C), the highest being ΔCKL ΔclpX which secreted 1.39% total CH2 protein into 
the media. ΔCKL ΔflgMN achieved both the highest yield and average yield of secreted protein 
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(219.66 and 128.64 µg L-1). ΔCKL demonstrated the highest level of CH2 protein expression 
(maximum: 75.66 mg L-1, average: 41.83 mg L-1). 
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Figure 4.21: CH2 yield in the intracellular and secreted protein fractions of the secretor strain 
and ΔmotAB, ΔflgMN, ΔfliDST and ΔclpX mutants.  
E.coli ΔCKL, ΔCKL ΔmotAB, ΔCKL ΔflgMN, ΔCKL ΔfliDST, or CKL ΔclpX containing the plasmid 
pJexpress-FliC-CH2-FLAG-Strep were grown in LB supplemented with 0.05mM IPTG.  Cells were 
harvested at OD600 1.0. A CH2 protein standard was loaded onto SDS-PAGE gels along with 
biological samples. Following Western blot analysis of cells and supernatant using anti-FLAG-
HRP, densitometry analysis was carried out using ImageJ and CH2 protein yields were 
calculated per Litre of cell culture for secreted (left) and intracellular (middle) protein 
fractions. The proportion of secreted protein was also calculated as a % of total CH2 protein 
both secreted and retained intracellularly. Biological replicates (secreted, intracellular): ΔCKL 
(3), ΔCKL ΔmotAB (1), ΔCKL ΔflgMN (5), ΔCKL ΔfliDST (1), CKL ΔclpX (1). No significant results 
were found. 
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4.5.4. Reduced metabolic burden: Effects of deletion of motAB, flgMN, 
fliDST and clpX on growth phenotype 
 
Gene deletions may lead to reduced metabolic burden as protein production is a metabolically 
costly process. It was hypothesised that the mutant strains would result in reduced metabolite 
expenditure and the reallocation of metabolites to essential processes such as cell growth but 
also to producing the remaining flagella proteins. Conversely the production of recombinant 
protein (i.e. CH2) will add to metabolic burden and may lead to a reduction in growth rate. 
Finally gene deletion may lead to strains which are not viable or less healthy if essential genes 
or processes are affected. To evaluate the effect of gene deletion and CH2 expression on 
growth phenotype, growth curves were obtained for ΔCKL and ΔCKL ΔmotAB, ΔCKL ΔflgMN, 
ΔCKL ΔfliDST, or CKL ΔclpX expressing either CH2 or empty vector.  
When expressing empty secretion construct ΔCKL had highest OD600 at all times (Figure 4.). The 
next was ΔfliDST, followed by ΔflgMN and ΔmotAB. A lower OD600 for ΔclpX was consistently 
recorded, both in the log phase and stationary (statistically significant for both parts of the 
growth phase- Paired t-test of average OD600 values for each strain. p = <0.005). While all other 
strains reached a similar final stationary phase OD600, ΔclpX was significantly lower.  When 
expressing CH2 the growth phenotype of all strains was very similar. In the late log phase 
ΔfliDST (Paired t-test of average OD600 values for each strain from 5 to 10 hours. p = <0.0001) 
had a slightly higher OD600 and ΔmotAB slightly lower OD600 than the other strains (Paired t-test 
of average OD600 values for each strain from 6 to 11 hours. All at least p = <0.01). The mean 
generation time for ΔCKL is 1.15 fold higher when expressing CH2, suggesting that overall 
expressing recombinant CH2 does lower growth slightly -this was investigated further in Figure 
4.. 
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Figure 4.22: Growth of the ΔCKL strain and (ΔCKL) ΔmotAB, ΔflgMN, ΔfliDST and ΔclpX 
mutant strains expressing empty or CH2 harbouring secretion construct over time in a 96 
well plate. Calibrated to LB media. 
Starter cultures of cells expressing either pJexpress-FliC-empty-FLAG-Strep (left) or pJexpress-
FliC-CH2-FLAG-Strep (right) were grown in LB supplemented with ampicillin and 0.05mM IPTG 
and aliquoted into 96 well plate wells. The 96 well plate was incubated in the TECAN plate 
reader at 37°C with 6mm orbital shaking. OD600 measurements were recorded every 30 
minutes. ΔCKL: □, ΔmotAB: ▽ , ΔflgMN: ○, ΔfliDST: ▲, ΔclpX: ♦. Results represent the 
combination of three technical repeats, of six biological repeats. 
 
When visualised by strain it is possible to evaluate the effect of CH2 expression on cell growth 
phenotype (Figure 4.). Both ΔCKL and ΔfliDST have similar early log and stationary phase OD600, 
however in the late log phase optical density was significantly reduced in cells expressing CH2 
(Paired t-test of average OD600 values for strain expressing empty or CH2 vector from 4 to 12 
and 5.5 to 10.5 hours respectively. Both p = <0.0001). ΔmotAB and ΔflgMN had similar early 
log optical densities whether expressing CH2 or not, however in the late log and stationary 
phase (7 hours onwards) cells expressing CH2 exhibited significantly lower cell density (Paired 
t-test of average OD600 values for strain expressing empty or CH2 vector. Both p = <0.0001). 
The growth rate of ΔclpX cells in the log phase was comparable whether expressing CH2 or 
empty vector (mean generation time 1.03 fold higher for empty secretion construct), however 
in the very late log and stationary phase cells expressing CH2 had a higher OD600 (Paired t-test 
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of average OD600 values for strain expressing empty or CH2 vector from 8 hours onwards. Both 
p = <0.0001). The main finding of this data is that CH2 is not toxic to cells and that cells from all 
strains are healthy for the duration of the growth curve. When expressing empty secretion 
construct ΔclpX does not grow very well, however this observation is off set when expressing 
CH2 protein as ΔclpX has a higher rate of growth when expressing CH2. This shows that not 
only were knockout mutations non-deleterious to strains, but that cell death (and therefore 
lysis) is not prevalent, therefore FT3SS secretion is true. 
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Figure 4.23: Growth of ΔCKL and ΔmotAB, ΔflgMN, ΔfliDST and ΔclpX mutant strains 
expressing empty or CH2 harbouring secretion construct over time in a 96 well plate. 
Calibrated to LB media. 
Starter cultures of cells expressing either pJexpress-FliC-empty-FLAG-Strep (white fill) or 
pJexpress-FliC-CH2-FLAG-Strep (black fill) were grown in LB supplemented with ampicillin and 
0.05mM IPTG and aliquoted into 96 well plate wells. The 96 well plate was incubated in the 
TECAN plate reader at 37°C with 6mm orbital shaking. OD600 measurements were recorded 
every 30 minutes. Results represent the combination of three technical repeats, of six 
biological repeats. 
  
245 
 
4.6. Discussion: Secretion of a non-native antibody 
fragment through the FT3SS 
 
4.6.1. Performance of the synthetic modular secretion construct 
 
The prototype secretion construct was designed to mediate secretion of recombinant protein 
through the modified FT3SS. Design features were included to allow protein purification, 
antibody detection and finally isolation of the protein product from the remainder of the 
secretion construct. Initial experimental work set out to assess the effectiveness of these 
features. While a number of recombinant proteins could have been selected, preliminary tests 
found that expression of the antibody fragment, CH2 was both efficient and consistent in ΔCKL 
cells, therefore the focus of this work was the expression and secretion of the prototype 
secretion construct with CH2 cargo (shortened to ‘CH2’ for the purpose of this discussion). 
Prior to investigation of recombinant CH2 secretion through the modified FT3SS, the features 
of the secretion construct were tested to ensure they were effective, as they would enable all 
characterisation and downstream processing of CH2 following secretion. Design features 
included a Strep-tag for protein purification, FLAG-tag for antibody detection and TEV protease 
sites to yield pure CH2 product, free of the secretion construct. Protein purification of 
intracellularly expressed CH2 was achieved using a StrepTrap™ HP column. This resulted in 
purification of CH2 protein (Figure 4.). The CH2 protein was predicted to be 22.4kDa by 
ExPASy, however the prominent band seen following purification ran slightly larger than this. 
Despite this discrepancy in size it can be assumed that this was the full CH2 protein as it is 
common for proteins to run at slightly different sizes to those predicted on SDS-PAGE gel, this 
may be due to a number of factors, for example the amount of SDS which binds to the protein 
may vary to that predicted, giving the protein a different negative charge, resulting in a 
different movement through the SDS-PAGE gel matrix. Other proteins consistently co-eluted 
with CH2, they had no affinity for anti-FLAG-HRP therefore they are not aggregated or 
degraded CH2 protein. While steps were explored to reduce contaminants in the elution 
fractions or to remove them with dialysis or chromatography, they were not effective. This 
showed that it is possible to express CH2 in the secretion construct at high levels and at least 
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partially purify protein- although more work is needed to understand how to improve this. 
Since the ultimate goal is secretion, purification from the cytoplasm is relevant, but not the 
ultimate goal so it was not pursued further. It does highlight issues with cytoplasmic protein 
purification and demonstrates one of the reasons why industrial biotechnology companies are 
so interested in true secretion. In the future more methods could be explored, for example 
purifying CH2 from a different expression strain to BL21 (DE3). However it still allowed the 
derivation of a CH2 protein standard to quantify yield of secreted CH2, therefore these 
observations were not limitations to the study.  
CH2 detection was facilitated by the FLAG-tag. Anti-FLAG-HRP proved effective in Western blot 
analysis of CH2 protein (Figure 4.). Again the corresponding band was larger than predicted, 
however as it corroborates with the size of the protein seen in Coomassie stained SDS-PAGE 
gels following protein purification (Figure 4. and Figure 4.), this further confirmed that this 
protein was CH2. When high concentrations of CH2 protein were loaded onto the SDS-PAGE 
gel some additional HRP signal was detected for different sized proteins (Figure 4.), one of 
which ran at around 55kDa and may be the dimeric form or CH2. The other bands were small 
and therefore likely to be degradation products of CH2. As CH2 is the most abundant protein 
which anti-FLAG-HRP detects, this is not an issue experimentally. 
Isolation of CH2 from the rest of the secretion construct with TEV protease was effective. The 
results of Western blot analysis clearly show the loss of the full size CH2 protein following 
incubation with TEV protease (Figure 4.). The Coomassie stain was less conclusive, but 
suggested that some non TEV directed cleavage of CH2 protein occurred, however a higher 
concentration was always present following incubation with TEV as opposed to without. 
Analysis of TEV cleavage of CH2 by Coomassie stain was hindered for a number of reasons; 
firstly the initial concentration of CH2 was low, therefore not clearly visible. Additionally, the 
sizes of the CH2 and TEV protease were similar, meaning it was difficult to distinguish them. In 
the future loading a higher concentration of CH2 onto SDS-PAGE gels would be preferential in 
terms of visibility. In would also be desirable to remove the TEV protease from the reaction 
mixture, so that it does not obscure the visualisation of CH2 –this would also allow pure CH2 to 
be isolated from the resulting solution by centrifugation. This could easily be achieved as a His-
tag is incorporated into AcTEV™ Protease to facilitate its removal from solution.  
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Overall the secretion construct was effective in facilitating CH2 overexpression, protein 
purification, antibody detection and finally isolation of CH2 from the secretion construct. 
Furthermore the CH2 protein is able to form dimeric structures as seen in Figure 4.. 
 
4.6.2. Secretion of CH2 through the modified FT3SS 
 
Expression and secretion of CH2 was achieved in all strains with functional secretion apparatus 
(i.e. not negative controls). The anti-FLAG-HRP antibody was effective at detecting CH2 both in 
the intracellular and secreted cell culture protein fractions (Figure 4.). It was found that the 
addition of 0.05mM IPTG to cell cultures resulted in the highest concentration of secreted CH2 
(Figure 4.) therefore all further work was carried out with this induction protocol as increased 
secreted protein is the ultimate goal of this project. For ease of experimental work it was 
decided to grow cells to OD600 1.0, so that time constraints were limited and therefore 
experimental output could be high. A CH2 protein standard was derived and although the 
issues of co-elution were also a factor here, the combination of densitometry analysis and 
protein concentration assay allowed the calculation of the concentration of CH2 protein. This 
could be correlated to the HRP signal which resulted from detection of CH2 to accurately 
measure the concentration of CH2 in biological samples. These considerations resulted in a 
protein secretion assay which is suitable to measure variable CH2 expression and secretion in 
modified FT3SS secretion strains, furthermore as the cargo protein can be substituted, this 
secretion assay is suitable for detection of a multitude of recombinant proteins, should they be 
inserted into the secretion construct.  
 
4.6.3. Secretion of CH2 through the modified FT3SS: strain mediated 
negative control 
 
It was imperative to ensure that CH2 detected in the media of cell culture resulted from 
directed FT3SS secretion and not through other routes. While other research groups have 
demonstrated secretion of recombinant protein through the FT3SS, they rarely take adequate 
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steps to ensure negative control of protein secretion, which effectively exclude cell lysis as a 
route for extracellular protein.  
Negative control strains were derived (∆flhDC and ∆CKL ∆flgDE) and following 
supplementation with additional IPTG -to compensate for flagella gene expression being 
negatively regulated via the fliC promoter in the negative secretion strains- absence of CH2 
protein in the supernatant of negative secretion strains was confirmed (Figure 4.). The 
comparable intracellular CH2 expression in intracellular protein fractions of all strains and the 
absence of cell lysis in ∆CKL cells (Figure 4.), gave added weight to this conclusion, as it 
confirms that protein seen in the supernatant of these cells was directed by secretion and not 
cell lysis.  Some GroEL was detected in the supernatant of ∆flhDC  cells cultures suggesting that 
cell lysis had occurred, however as GroEL was detected at a low concentration for ∆flhDC and 
high for ∆flgDE cells in Figure 4., this suggests that strains do not inherently lyse and therefore 
it can be concluded with confidence that any increase in CH2 in the supernatant is due to 
increased capacity of the FT3SS.  
The second control strategy involved the removal of the FliC 5’ UTR from the secretion 
construct (SCA). In addition to this a secretion construct which also lacked the 47 amino acid 
FliC secretion signal peptide (SCB) was also constructed to confirm that secretion was under 
the control of the signal peptide. The modified secretion constructs were successfully 
produced and expressed in both the ∆CKL and the negative secretion strain ∆CKL ∆flgDE 
(Figure 4.). Removal of the 5’ UTR did alleviate the reduction in CH2 expression previously 
observed in negative secretion strains (Figure 4.), as a similar concentration of CH2 was 
expressed in ∆flgDE cells as in ∆CKL when this SCA was expressed. Interestingly the removal of 
the fliC promoter did not cause reduced CH2 expression in ∆CKL cells, whereas it might be 
hypothesised that the removal of one of the two promoter sites for plasmid gene expression 
would result in less gene expression.  
As CH2 was visible in the secreted fraction of secreted ∆CKL cells when expressed in the 
prototype secretion construct, but not SCA or SCB, this suggests that the 5’ UTR is essential for 
secretion through the FT3SS, this is in line with the findings of (Majander et al., 2005; 
Narayanan et al., 2010). As both the 5’ UTR and 47 amino acid secretion signal were absent in 
SCB, it is not possible to conclude whether the 47 amino acid secretion signal is essential for 
secretion. In the future it would be beneficial to produce a secretion construct which harbours 
the 5’ UTR without the 47 amino acid secretion signal, to enable this investigation. This effect 
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of the presence and absence of the UTRs and the 47 amino acid secretion signal will be 
investigated further in the next chapter.  
 
4.6.4. Effects of reduced metabolic burden and negative regulation 
mutants on FT3SS secretion of CH2 
 
Once the non-native FT3SS protein secretion assay had been optimised and control of 
secretion established with negative secretion strains, it was possible to begin to test the 
secretion capacity of modified FT3SS secretion strains with confidence that CH2 present in the 
supernatant was due to directed secretion through the modified FT3SS. Unlike the E2 protein 
(Figure 3. and Figure 3.) CH2 was effectively expressed and secreted in all secretor strain 
mutants (Figure 4.). This was expected due to the decoupling of CH2 from any native 
chaperones. This also demonstrates that a substantial concentration of CH2 was maintained 
intracellularly without the requirement of a chaperone. On average all mutations resulted in 
strains that secreted a higher concentration of CH2 through secretion apparatus into the 
media (Figure 4.). Therefore the strain improvement mutagenesis strategies which were 
theorised to result in increased secretion capacity, were effective. Mutant strains were 
reasonably similar in their secretion output, ranging from 1.46 to 1.64 times the output of 
∆CKL. While ∆CKL ∆fliDST produced the highest single and average relative CH2 secretion 
value, it was not significant, whereas the other mutant strains were significantly more effective 
at secreting CH2 than ∆CKL. Conversely all mutant strains produced less intracellular CH2 in 
comparison to ∆CKL, however aside from ∆flgMN (which produced 0.71 fold intracellular CH2 
in comparison to ∆CKL) these were not statistically significant observations. As the percentage 
of secreted protein through the FT3SS is consistently very low, it is unlikely that this reduction 
in intracellular CH2 is wholly an artefact of high secretion through the secretion apparatus. 
That aside –combined, decreased intracellular and increased secreted concentrations of CH2 
does mean that mutant strains were more efficient at secreting CH2 than ∆CKL, as a higher 
percentage of total CH2 was located in the supernatant (Figure 4.C).  
In terms of yields, while it would be desirable to obtain some more measurements it can be 
concluded that the concentration of intracellular CH2 ranges from an average of 41.83 mg L-1 
in ∆CKL to 6.72 mg L-1 in ∆fliDST (Figure 4.). The highest single concentration of secreted CH2 
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observed was 219 µg L-1 in ∆flgMN, this strain also demonstrated the highest average at 
128.64 µg L-1. This compared to 71.08 µg L-1 in ∆CKL (meaning either a three or two fold 
increase in yield of secreted protein with the ∆flgMN mutation depending on whether you use 
highest or average yield figures). This demonstrates that secretion capacity of strains may be 
substrate dependent as in the previous chapter both ∆motAB and ∆clpX secreted higher 
concentrations of E2 into the media (Figure 3.).  
In comparison to the yields achieved for E2, CH2 was much lower by all measurements. For 
example ∆CKL cells produced an average of 443.92 mg L-1 E2, in comparison to 41.83 mg L-1 –
around 10 times less. This was expected as CH2 is a non-native protein; therefore the cell is 
unlikely to be as effective at producing it. More striking is the inefficiency of the modified 
FT3SS to secrete CH2 in comparison to E2. While an average of 3.06% total E2 protein was 
secreted into the media of ∆CKL cells, only 0.24% CH2 was. Reduced expression and secretion 
manifested in a reduced yield of secreted CH2 (71.08 µg L-1) by around 100 times, in 
comparison to E2 (7.75 mg L-1). Considering that E2 is essentially the native substrate of the 
FT3SS, whereas the only commonality of CH2 is the UTR regions and secretion signal 
harboured in the secretion construct, this was logical. This demonstrates the limitations of 
using recombinant expression systems and also highlights that while the FT3SS has affinity for 
non-native proteins, it is not as efficient as secreting them as it is native substrates. In 
comparison to other reports of FT3SS secretion of recombinant protein (12mg L-1 and 10.8mg 
L-1 for Majander et al. (2005) and Widmaier et al. (2009) respectively), the yield achieved here 
was around 150 times lower. In comparison to the 2mg L-1 yields reported for T1SS secretion of 
recombinant protein into the extracellular space this was around 30 times less (Fernández, 
2004; Fernandez & de Lorenzo, 2001). However aside from the T1SS data, the yields reported 
in the literature were calculated based on a period of growth around three times longer than 
observed here, therefore yields could be improved upon if cell culture was prolonged. The 
concentration of CH2 reported for T2SS secretion is higher again; however as it is not 
extracellular secretion this was not strictly comparable. 
The yields achieved for the production and secretion of CH2 were also low in comparison to 
industrial standards for other extracellular protein secretion expression strains –for example 
1.5g insulin or 2.5g amylase secreted per Litre in Pichia or Saccharomyces respectively, 
although again this was over a period of 80 or 96 hours  and at high cell density as opposed to 
around 6 hours  and an optical density of 1.0 in these experiments (Gurramkonda et al., 2010; 
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Rodríguez-Limas et al., 2015).  In terms of intracellular production of CH2 protein, this was in 
line with yields reported for antibody fragment production in the literature, for example a 
yield of 79mg L-1 for a Fab antibody fragment was achieved in E. coli (49mg L-1 was secreted 
into the periplasm by an unknown route) which was comparable to the 75.66 mg L-1 yield 
attained here (Jalalirad, 2013).  
As stated the highest single intracellular and secreted CH2 yields were 75.66 mg L-1 (∆CKL) and 
219 µg L-1 (∆flgMN) respectively. This yield relates to the weight of CH2 per Litre of cell culture 
at OD600 1.0. However to make the production of low yield, low value products economically 
feasible, industry routinely grow their cell cultures to optical densities in excess of OD600 100 to 
reduce production costs (Soini et al. 2008; Shiloach & Fass, 2005), therefore a litre of cell 
culture, will contain exponentially more cells that in the cultures grown in this study. Therefore 
the weight per litre yield is misleading. For example a crude calculation estimates that 1mL of 
culture at OD600 1.0 will contain 8.0 x 10
8 E. coli, compared to 8.0 x 1010 at OD600 100. If the 
same yield was reported per litre of cell culture for cells at both OD600 1.0 and 100, the cells in 
the OD600 100 culture would be 100 times less efficient. Culture of E. coli to a high optical 
density, requires adequate aeration and nutrient supply (often supplemented with glucose for 
example) and requires a longer period of cell culture (e.g. 24 hours minimum to reach OD600 
100), compared to cell cultures in this thesis (Soini et al., 2008). This is unlikely to be a linear 
effect as other factors such as limited oxygen and nutrient supply, along with build-up of 
growth limiting chemicals such as acetate, will interplay at different optical densities; however 
this is an important conceptual point. The main finding here is that a modification of the FT3SS 
followed by strain improvements and the construction of a modular secretion construct 
resulted in an intracellular concentration of the antibody fragment CH2 which could rival other 
yields reported in the literature, however the next chapter will focus on the implementation 
and combination of more strategies to increase FT3SS secretion, with the aim of improving this 
yield.  
It is evident that these experiments produce variable results. Nevertheless, statistically 
significant differences were obtained for some strains with regards to secreted and 
intracellular protein. Efforts to reduce variability have been put in place both experimentally 
and through data analysis. Experimentally secretion assays for different strains are run in 
tandem. A stock solution of LB media with antibiotics and IPTG is aliquoted into individual cell 
culture vessels prior to inoculation to ensure concentrations of supplements are uniform. 
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Cultures are incubated in the same incubator, so that heat and agitation are the same. Protein 
samples are also prepared in tandem, in an effort to ensure treatment is the same. In terms of 
analysis while quantification of yield is more informative, relative concentrations in 
comparison to ∆CKL secretor strain are beneficial in terms of reducing variability between 
experiments, as day to day overall fluxes in productivity are reduced. These steps aim to 
reduce intra-experimental variation, however despite meticulous repetition of this protocol 
inter-experimental variation does occur. This resonates with the synthetic biology concept of 
unpredictability in biological systems (Endy, 2005).  In addition to this the use of Western blots 
is likely to be a big source of variation, as discussed in the previous chapter, lack of linearity 
and the sheer number of experimental steps account for error. With this in mind it would be 
preferential to develop a non-Western blot based secretion assay. This will be in the form of an 
enzyme based secretion assay and will have the added benefit of allowing larger scale testing 
of constructs because throughput should be reduced; this will be investigated in the next 
chapter. 
While it was hypothesised that the deletion of flagella linked genes may lead to reduced 
metabolic burden in cells and therefore more metabolic energy available for growth processes, 
the growth phenotypes of mutant strains were for optical density to be slightly lower than 
∆CKL when expressing empty secretion construct (Figure 4.), suggesting that the knockout 
mutations slightly compromised the fitness of cells through pleiotropic effects. Despite this, 
this effect was very slight it was concluded that none of the strains were compromised enough 
to consider them unsuitable. In Figure 4. it is evident that expressing CH2 results in a slightly 
lower optical density of cells at some point in the growth curve of strains, this is expected as 
the expression of CH2 requires metabolic energy, therefore energy is diverted from cell 
growth. Interestingly the opposite is true of ∆clpX. The optical densities of ∆clpX cultures 
expressing empty vector were consistently lower than other strains, particularly in the 
stationary phase. However this was not the case when ∆clpX was expressing CH2. Optical 
densities of ∆clpX were higher when expressing CH2 (especially in the late-log and stationary 
phase) as opposed to empty vector (Figure 4.), suggesting that the production of CH2 may 
stabilise the growth phenotype of ∆clpX. This effect may be because in the absence of ClpX, 
there is an increase in free ClpP. In a wild type strain ClpP would be directed to specific protein 
degradation targets by ClpX (Kitagawa et al. 2011; Gottesman, 1996). It is possible that in the 
absence of ClpX, non-specific (or ClpA directed) ClpP proteolysis is more common, leading to a 
reduction in growth rate in cells (as seen in empty secretion construct expressing cells). 
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However, when CH2 is expressed, it is possible that this recombinant protein is targeted by 
ClpP instead of native protein, therefore growth is restored. The only caveat to this is that 
intracellular CH2 concentration is similar in ∆clpX strains in comparison to +clpX strains. 
The mutations implemented in the strains tested in this chapter (aside from the negative 
secretor strains) were designed to improve the secretion of CH2 by increasing the number of 
secretion apparatus. The rationale behind mutants either involved the reduction of metabolic 
burden by the removal of genes which encode proteins which are now redundant in the ∆CKL 
mutant so that more metabolic energy was available to expend of secretion apparatus 
production (and to recombinant protein production) or the removal of genes which should 
result in the upregulation of flagella gene expression and therefore result in more secretion 
apparatus. These strategies were effective, as CH2 secretion was increased in all mutant 
strains, however it is beyond the scope of this study to determine which of the two strategies 
is more effective at increasing FT3SS secretion, however further investigation of improved 
secretion following the implementation of these strategies and also combinations of these 
strategies in the next chapter should reveal more information on this. 
The implementation of negative control means that it can be confidently stated that the 
presence of CH2 in the media is a result of FT3SS, however is not possible to confirm whether 
increased secreted CH2 is due to the incidence of more secretion apparatus or whether 
individual apparatus are capable of secreting a greater number of CH2 protein subunits. To 
ascertain this it would be beneficial to image the FT3SS hook basal bodies of strains, this would 
be possible with a number of microscopy techniques, for example electron microscopy or 
fluorescence microscopy using fluorescent antibodies which have affinity for the hook protein 
or primary anti-hook anitbodies. This could also be investigated by cell membrane preparation 
and purification of hook subunits, which could be visualised by Coomassie or Western blot 
analysis with an anti-FlgE antibody (many commercially available). Finally at a genetic level 
qPRC could be utilised to investigate whether flgE expression was increased in mutant strains 
in comparison to ∆CKL. 
The implementation of the CH2 protein secretion assay utilising the modular synthetic 
secretion construct has allowed accurate and quantifiable measurements of intracellular and 
secreted CH2 in all mutant strains, along with the calculation of secretion efficiencies. This 
reassuringly mirrors the overall effect of secretion observed with the E2 substrate. Each 
strategy for improved protein secretion through the modified FT3SS resulted in increased 
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protein secretion capacity and increased protein secretion efficiency; however the yields 
obtained are still low in comparison to those reported by industry. While the combination of 
these knockout mutations will be investigated in the next chapter, to see if the increases in 
secretion capacity will be additive. This will involve the construction and characterisation of 
many mutant secretor strains. Furthermore alteration will be made to the secretion construct 
to see if secretion can be improved through this route. While the assay was effective, it does 
show variability and is throughput limited as the assay is lengthy. Therefore work in the next 
chapter aimed to harness the modularity of the secretion construct to substitute the cargo 
protein from CH2 to an enzyme, with the view of developing an enzyme based protein 
secretion assay. It is hypothesised that this will be more accurate, less variable and more high 
throughput for the testing of a wider range of strains and constructs.  
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Chapter 5: Development of a high-throughput 
assay for FT3SS secretion to screen a 
multitude of secretion strains and plasmids 
 
5.1. An enzyme based FT3SS secretion assay 
 
The successful development of protein secretion assays in Chapters Three and Four and 
subsequent preliminary development of secretion competent strains allowed measurement of 
secretion capacity of a modified FT3SS secretion apparatus. It was shown that the 
implementation of strain improvements increased secretion capacity of native flagellin variant 
(E2) protein through the modified FT3SS (∆CKL), with additional (∆CKL) ∆clpX (∆CKL) ∆motAB 
and (∆CKL) ∆flgMN mutants showing promise as high level secretion strains. Following this it 
was shown that recombinant protein could also be secreted and that strain improvements 
resulted in around double the secreted yield of CH2 antibody fragment protein.  These data 
were largely based on use of Western blotting and Coomassie staining to assess protein 
secretion, both of which have limitations in terms of throughput.  They also do not assess the 
folding-state of the proteins since no attached function or enzymatic activity can be measured. 
This chapter therefore focuses on the development of an enzyme based secretion assay to 
achieve this higher throughput nature of an assay, in order to assess both a large array of 
strains and constructs but also to build a robust system for future studies in this area. Hence 
the aim was to express and secrete a recombinant enzyme through the FT3SS and then analyse 
enzyme activity of the culture supernatant as a proxy for protein secretion and visualisation by 
other means.   A subsequent outcome of such a goal would also be the broadening of 
substrate range for the FT3SS system and also indicate the ability of proteins to refold in a 
functional state post-secretion. As functionality of protein is important in biotechnology (i.e. 
medicines), this folding is required should this secretion system be utilised in the 
biotechnology industry. It should also enable quick and accurate screening of secretion, 
allowing a number of strains and plasmids to be tested, with the aim of identifying 
combinations which allow high levels of FT3SS secretion. The design of the synthetic modular 
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secretion construct allows simple substitution of the protein cargo –this will be exploited to 
incorporate an enzyme into the secretion construct -as shown below. 
Measurement of enzyme activity in biological systems is ubiquitous in biological research, 
investigation may concern an organism’s natural capacity to produce an enzyme (for example 
the production of digestive enzymes in filamentous fungi (Beneyton et al., 2016)) or involve 
production of non-native enzymes to aid experimentation. Examples of this have already been 
utilised in this work, for example the production of enzymes to confer antibiotic resistance 
markers (i.e. β-lactamase conferring ampicillin resistance) or as a reporter (i.e. expression of β-
galactosidase linked to promoter fragments.). Use of enzyme activity to measure secretion is 
established in a range of organisms including Bacillus, Pichia and E. coli (Eom et al. 2005; 
Degering et al. 2010; Lee et al. 2001; Weis et al. 2004). In some studies the enzyme secreted is 
of industrial importance, in others it is used solely as a reporter for protein secretion; in this 
study both are relevant for the enzyme. Other screening assays for secretion capacity have 
focused on secretion of intrinsically fluorescent protein (i.e. GFP) or protein which is suitable 
for fluorescent labelling (such as tetracysteine) (Haitjema et al., 2014; DeLisa et al., 2002). 
 
5.2. Choice of enzyme for production within the synthetic 
modular secretion construct 
 
For this part of the project, an enzyme with robust properties in terms of environmental 
stability, biochemical characterisation and useful facile enzyme assay was required.  One such 
enzyme was the cutinase from Fusarium solani, which was chosen for recombinant production 
and secretion in the synthetic modular secretion construct because it is well studied, useful in 
industry, suitable for ester based assays (Liu et al. 2009) and previously expressed in E. coli. 
Cutinase describes a group of hydrolases which occur in plants, fungi and yeast, while their 
primary role is to degrade plant cutin (a polyester), they are in the hydrolase family and are 
multifunctional polyesterases, which have also been shown to behave like lipases and 
therefore catalyse hydrolysis reactions in a range of substrates including triglycerides, water 
soluble esters and plastics (Ahmed Al-Tammar et al., 2016; Carvalho et al., 1998; Fojan et al., 
2000). Cutinase is used in a wide range of industries, including food, agriculture, chemical, 
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textiles and detergent.  Cutinase activity can be measured through biocatalysis reactions of a 
range of substrates, such as p-nitrophenyl butyrate and 4-methylumbelliferyl butyrate or 
acetate which result in reaction products that can be assayed by production of a fluorescent 
coloured end-product (Griswold et al., 2003; Yang et al., 2013). The cutinase used in this work 
is derived from the filamentous fungi Fusarium solani pisi which has been well characterised 
since its discovery in the 1960s and become a model system for the study of cutinases. F. 
solani cutinase is a stable, 197 residue, 22kDa –it is active as a monomer and the active site is 
at the site of a triad of residues (Ser 120, Asp 175, His 188). The formation of two 
intramolecular disulphide bridges is important for maintaining catalytic activity (Carvalho et al., 
1998). This cutinase was previously utilised in the cotton and synthetic textile industry (Chen et 
al., 2013). Cutinase has been expressed recombinantly in a range of fungi, yeast and bacteria 
(Carvalho et al., 1998; Griswold et al., 2003).  
 
5.2.1. Cloning cutinase into the synthetic modular secretion construct 
 
5.2.1.1. Design of synthetic cutinase gene  
The F. solani cutinase in this study has previously been expressed in E. coli, however it was 
reported that codon optimisation for E. coli was essential to initiate secretion of signal peptide 
tagged-recombinant cutinase into the periplasm, so a similar approach was utilised in this 
work (Griswold et al., 2003). Furthermore this is a commonly implemented strategy to improve 
protein expression of recombinant protein (Gustafsson et al., 2004). –therefore codon 
optimisation was implemented in this work.   
The sequence for F. solani cutinase was obtained from the NCBI database (accession no. 
K02640), codon optimised for E.coli using the GeneOptimizer® sliding window algorithm and 
sent for synthesis by GeneArt® Strings. In the design, EcoRI and PstI restriction enzyme sites 
flanked the cutinase gene and consideration was taken to exclude any other restriction 
enzyme sites that are present in the secretion vector or constructs (NdeI, XhoI, EcoRI, PstI, 
XbaI, HindIII, BamHI). Upon arrival DNA was immediately cloned into a blunt end cloning 
storage vector and stored in NEB 5-alpha. Following colony PCR with primers which annealed 
to either side of the cloning site, it was confirmed that the cutinase gene was harboured in the 
storage vector (Figure 5.) and cells were stored at -80°C. 
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Figure 5.1: Agarose DNA gel showing a PCR product following colony PCR of cells to confirm 
blunt end cloning of the synthesised cutinase gene into the storage vector.  
PCR reactions were carried out using plasmid harbouring E. coli colonies as template and 
primers in Appendix 2 with DreamTaq DNA Polymerase. PCR mixtures were analysed on a 1% 
TAE agarose DNA gel supplemented with a trace of ethidium bromide, visualised under UV 
light and inverted. Samples were run with GeneRuler™ 1kb DNA ladder. Lane 1: successful PCR 
resulted in a 736bp DNA product. 
 
5.2.1.2. Production of the cutinase harbouring secretion construct 
 
Figure 5.2: Genetic and protein schematic of the secretion construct harbouring cutinase  
Following ligation into pJexpress-FliC-empty-FLAG-Strep the cutinase harbouring secretion 
construct was derived (A), which resulted in the expression of a FT3SS signal peptide cutinase 
flanked by FLAG and Strep tags and TEV protease sites (B) 
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Ligation of donor DNA (from pJET 1.2 cutinase) into the pJexpress-FliC-empty-FLAG-Strep 
acceptor should result in the product seen in Figure 5.. Both donor and acceptor DNA 
underwent restriction digest with EcoRI and PstI, and ligation overnight. Following 
transformation and antibiotic resistance screening, positive colonies were screened by 
restriction digest. Successful ligation of cutinase into the acceptor vector, will result in the 
presence of a 617 bp DNA product following restriction digest with EcoRI and PstI. Positive 
results were obtained for colony 2 and 6 (Figure 5.), which were then sequenced using primers 
which anneal to secretion construct DNA flanking the cutinase cargo. The resulting sequences 
both aligned exactly with the predicted DNA sequence, therefore ligation was successful.  
 
Figure 5.3: Agarose DNA gel showing plasmid from colonies DNA digested with EcoRI and 
PstI.  
Plasmid DNA was isolated from positive colonies following ligation and antibiotic screening. 
Restriction digest reactions were carried out with EcoRI and PstI. 5µL restriction digest mixture 
was prepared for DNA electrophoresis and loaded along with GeneRuler™ 1kb DNA ladder on a 
1% TAE agarose DNA gel supplemented with a trace of ethidium bromide and visualised under 
UV light and inverted.  
 
Once cloned into the secretion construct the expression and secretion of cutinase through the 
modified FT3SS was investigated. While secreted cutinase is intended to be utilised for an 
enzyme based protein secretion assay, as cutinase is harboured in the secretion construct, 
investigation of cutinase expression and secretion is also enabled by the FLAG-tag. The 
concentration of both intracellular and secreted cutinase will be measured using Western 
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blotting and antibody detection with αFLAG-HRP; in addition an assay will be developed to 
measure the amount of secreted cutinase by enzyme activity.  
 
5.2.2. Secretion of the cutinase harbouring synthetic modular secretion 
construct through the modified FT3SS 
 
Initial investigation of cutinase expression and secretion was carried out in the original ∆CKL 
secretor strain. Following cell culture and IPTG induction of ∆CKL freshly transformed with 
either empty or cutinase harbouring secretion construct; FLAG-tagged protein was visible in 
both the intracellular and supernatant (secreted) fractions of cells expressing cutinase (Figure 
5.). The size of the cutinase-secretion construct protein was predicted to be 30.6 kDa, this 
corresponds to the size of the protein identified by the αFLAG-HRP antibody. A lower 
concentration of cutinase protein was observed in the secreted fraction and there was no non-
specific binding of the FLAG antibody to protein in cells expressing cutinase or empty secretion 
construct. In the accompanying Coomassie stained SDS-PAGE gel (not shown), the secreted 
fraction was clear of all protein, demonstrating that lysis was not prevalent in cell culture, but 
also that secreted cutinase is present at a concentration below that detectable by Coomassie 
stain.  
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Figure 5.4: Cutinase protein in the secreted and intracellular fractions of ∆CKL secretor strain 
cell culture. 
E.coli ∆CKL containing either the plasmid pJexpress-FliC-cutinase-FLAG-Strep or pJexpress-
empty vector were induced with 0.05mM IPTG and grown in LB at 37°C with 180rpm agitation. 
Cells were harvested when cell culture reached OD600 1.0. 1 OD unit of cells (intracellular) were 
prepared for SDS-PAGE and the supernatant (secreted) from 1 OD unit of cells was precipitated 
with TCA (10% v/v) before SDS-PAGE and Western blot analysis with αFLAG-HRP antibody. 
Protein samples were loaded as follows. Lane: Secreted -(1) cutinase, (2) empty vector. 
Intracellular -(3) cutinase, (4) empty vector.  
 
5.3. Development of a standardised protein secretion 
assay to quantify cutinase secretion 
 
Following the confirmation that cutinase was adequately expressed and secreted in the ∆CKL 
strain, efforts were made to develop an enzyme based secretion assay.  
 
5.3.1. Trail development of a tributyrin and pNPB protein secretion 
assay 
 
It was reported that cutinase activity could be measured by the breakdown of tributyrin 
substrates. Methods describe that organisms secreting cutinase can be plated onto agar plates 
supplemented with tributyrin and that zones of clearing will develop around colonies which 
secrete cutinase (Kwon et al., 2009). Despite efforts to optimise this assay no zones of clearing 
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were evident.   However, F. solani cutinase (either from F. solani or recombinantly expressed in 
bacteria) hydrolytic activity has been reported for p-nitrophenyl (pNP)-esters, where cutinase 
cleaves the substrate to yield a 4-nitrophenol molecule, which presents as a yellow colour 
detectable by absorbance at 405nm (Liu et al. 2009; Chen et al. 2008). Attempts to develop a 
pNP-butyrate assay resulted in positive results in terms of change in absorbance (405nm) in 
the presence of the supernatant of cell culture secreting cutinase, however results were 
inconsistent and optimisation proved difficult, therefore this assay was abandoned and an 
alternative substrate chosen based on an analogous ability to cleave ester type bonds between 
a reporter substrate and a 4-carbon butyrate chain- in this case, 4-methylumbelliferyl butyrate 
(MUB). 
 
5.3.2. Development of a MUB based cutinase protein secretion assay 
 
Cutinase catalyses the cleavage of MUB to yield a fluorescent 4-methylumbelliferone (4-MU) 
molecule (Yang et al., 2013). Fluorescence is visible under UV light excitation visually and 
qualitatively and detectable in a quantitative manner using a plate reader. The principle of this 
assay relies on the fact that the amount of MUB cleaved and therefore 4-methylumbelliferone 
released can be measured using fluorescence and detected. An assay was developed to 
measure the abundance of cutinase in the secreted fraction of cell culture, as a factor of 
fluorescence. This involved the preparation of cell culture supernatant, addition of substrate, 
incubation and finally measurement of fluorescent output.  It was hoped that this assay would 
provide a means of increasing the throughput and accuracy of the assessment of relative 
protein secretion through the modified FT3SS. Assay development was important, as it is 
imperative that the assay was both reliable and accurate and also able to detect a wide range 
of concentrations of cutinase protein. Consideration was also made to the ease of 
experimental set up and robustness, as this will aid the high-throughput nature of the assay 
and therefore enable screening the secretion capacity of many strains for future workers. To 
ensure that results from fluorescent cutinase protein secretion assays were representative of 
the concentration of cutinase located in the supernatant of cell cultures, Western blot analysis 
was also carried out in tandem.  The assay was developed with reference to the Sigma-Aldrich 
product guidelines for the substrate and by following literature and laboratory expertise with 
methylumbelliferyl-sialic acids.  
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5.3.3. Preliminary MUB assay: active secreted cutinase  
 
Prior to assay optimisation it was first established that the recombinant cutinase could 
effectively cleave MUB and that this was detectable by fluorescence. First LB and supernatant 
from cells expressing either empty or cutinase harbouring secretion construct was added to 
MUB dissolved in Tris Buffer, pH 8. Reaction mixes were loaded into wells of a black walled, 
clear bottom 96 well plate to allow UV excitation through the clear bottom, without cross 
excitation or emission from adjacent wells. Samples were collected from the same cell culture 
analysed by Western blot in Figure 5., therefore the presence (and absence) of cutinase in 
culture supernatant was confirmed. Following incubation at room temperature and 
visualisation by image capture under UV light (approximately 302nm), it was evident that the 
addition of supernatant which contained cutinase resulted in the cleavage of MUB and 
therefore production of a fluorescent emission when excited with UV light (Figure 5.). 
Conversely this was not seen following the addition of LB media or the supernatant of cells 
which expressed empty secretion construct. This demonstrates that the assay is effective in 
reporting the presence of FT3SS secreted cutinase in the crude supernatant of cells. It also 
shows that it was possible to secrete a recombinant protein through the FT3SS and that it was 
able to fold correctly in the supernatant to result in an active enzyme. 
 
Figure 5.5: Fluorescence emission of reaction mixtures containing MUB and either LB media 
or cell culture supernatant.  
E.coli ∆CKL containing either the plasmid pJexpress-FliC-cutinase-FLAG-Strep or pJexpress-
empty vector were induced with 0.05mM IPTG and grown in LB at 37°C with 180rpm agitation. 
Cells were harvested when cell culture reached OD600 1.0. The supernatant was obtained by 
centrifugation. Either LB media or cell supernatant was added to 500mM MUB in Tris, pH 8 and 
added to a 96 well plate. Following incubation the black walled clear bottom, 96 well plate was 
imaged with a G:BOX during excitation with UV light. Well: (1) LB + MUB, (2), supernatant 
(cutinase) + MUB, (3) supernatant (empty) + MUB 
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5.3.4. Development of the MUB assay: early considerations 
 
Once the assay had been shown to be effective in this preliminary context, some early 
considerations to experimental procedure were made. Initial thought was given to the 
preparation of supernatant, the ratio of substrate to enzyme and the adequate buffering of 
solutions. Substrate comprised of buffered MUB and ‘enzyme’ (secreted protein in LB media 
and buffer). In all optimisation experiments enzyme containing supernatant was freshly 
derived from cultures of ∆CKL cells expressing either cutinase harbouring or empty secretion 
construct; supernatant was obtained by centrifugation. This was as a proxy for pure enzyme, 
as it was important experiments were optimised in the context of cell supernatants. Dissolving 
MUB in buffer solution proved difficult, but was facilitated by the addition of Triton X-100 and 
(dimethylformamide) DMF (Vaneechoutte et al., 1988). It was desirable for substrate to be in 
excess so that the reaction was not rate limited by its availability. Additionally as it was 
observed that LB emitted background fluorescence following excitation at 365 nm, preliminary 
investigation found that results were more satisfactory when the concentration of LB 
(supernatant) in reaction mixtures was low. With these considerations and preliminary 
evidence, a ratio of 20:80 supernatant (equivalent to enzyme): buffered substrate solution was 
used throughout –it was also confirmed experimentally that this was sufficient to effectively 
buffer reaction mixes, to the given pH. Finally following some investigation it was established 
that adequate separation of cells from supernatant was possible with centrifugation at 
13,000rpm for 15 minutes and that steps such as sterile filtration of supernatant was not 
necessary. With a basic assay framework in place steps were taken to optimise the assay for 
accurate measurement of fluorescent output as a factor of cutinase cleavage of MUB. All work 
was carried out in black 96 well plates to avoid cross- excitation and emission from adjoining 
plates. 
 
5.3.5. Development of the MUB assay: buffer pH 
 
The recommended pH-dependent excitation wavelength reported by Sigma-Aldrich for both 
MUB and 4-MU is 365nm. Therefore this was used during assay development. The pH of the 
enzyme-substrate reaction mix required some optimisation, as the optimum pH for cutinase 
and MUB, do not necessarily concord. According to the literature, F. solani cutinase is active 
265 
 
from pH 2-12, however maximal enzymatic activity occurs at pH 8.5 for a range of substrates 
(Petersen et al., 2001; Ni & Chen, 2009). Sigma report excitation and emission data for MUB 
for Tris pH 8, however the literature reports fluorescence of negative controls is high when 
MUB is buffered at pH 8, presumably due to non-enzymatic cleavage of MUB, whereas at pH 5 
less background fluorescence is observed (Vaneechoutte et al., 1988). High fluorescence of 
negative controls (i.e. LB + MUB or supernatant of cells secreting empty vector) when 
incubated in pH 8 buffer was also observed in preliminary investigation during this work, 
therefore the remainder of experiments were carried out in pH 5 buffered solution. The 
optimal temperature for native cutinase directed substrate cleavage is dependent on the 
substrate but ranges from 30 to 60°C; however the literature does not report an optimum 
temperature for F. solani activity with MUB substrate (Chen et al., 2008). Experiments were 
carried out at 30°C, as at this temperature the reaction proceeded fast enough to measure but 
not too fast to overflow the plate reader detector during the experiments.  Quenching the 
reaction with the addition of a high pH buffer is a standard procedure for MU-based substrates 
as the fluorescence output of the product 4-MU under certain excitation emissions (365nm 
included), is pH dependent and maximal in the range of pH 10 upwards (Fink & Koehler, 1970; 
Zhi et al. 2013).  
 
5.3.6. Development of the MUB assay: substrate concentration 
 
Another factor of importance is that the concentration of substrate remains high enough 
throughout the course of the experiment to not limit the rate of reaction either in terms of 
affinity of binding to the enzyme but also that it does not become exhausted in solution 
resulting in false reduction in activity if measured over longer time periods. Equally as the plate 
reader is only sensitive within a range of fluorescent intensities it is important that the output 
of experiments does not exceed these limits –this is particularly relevant to the upper limits of 
detection, as it is hoped that this assay will be utilised to measure increased cutinase secretion 
and therefore increased AU readings. A range of substrate concentrations were investigated 
(500, 100, 50, 10, 5 µM) and LB or supernatant from cell culture of cutinase or empty secretion 
construct harbouring ∆CKL cells was added. A MUB only control was also included. Mixtures 
were left overnight to allow more time for cutinase to catalyse 4-MU production and to 
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investigate whether MUB self cleaves over a prolonged period of time, note that this exceeds 
the time of later experiments. Excitation was carried out at 365nm, and emission was scanned 
so that the peak emission could be established for future work. This was essential as it is 
reported that the emission wavelength of 4-MU varies in different solutions (e.g. LB v water), 
therefore the manufacturer’s guidelines could not be relied on  (Fior et al., 2009). 500µM MUB 
resulted in emission intensities higher than the detection limit of the plate reader. At 5 and 
10µM low substrate concentration appeared to be rate limiting on the reaction as low 
fluorescence output was measured. At 50µM and 100µM fluorescence readings for samples 
incubated with cutinase were much higher than without and while LB and empty secretion 
construct resulted in higher fluorescence than MUB alone, it was very low (Figure 5.). 446nm 
resulted in the highest output and was selected as the emission wavelength for future 
measurements of fluorescence. Readings at 446nm are situated at the peak of the emission 
spectra curve and therefore result in larger differences between results for different reaction 
mixes; this will enable investigation into the differences between 4-MU concentrations (and 
therefore cutinase concentration) in experiments. The difference between MUB incubated 
with or without cutinase is larger for 100µM MUB than 50 µM (60833 compared to 41481 at 
446nm), therefore it was concluded that this concentration was the most advisable to use as 
differences between reaction mixtures were larger, but all within the range of detection by the 
plate reader. 
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Figure 5.6: Emission spectra for pH 5 buffered 50µM and 100µM MUB with LB media or cell 
culture supernatant from cells expressing cutinase or empty FT3SS signal peptide tagged 
secretion constructs.  
E.coli ∆CKL containing either the plasmid pJexpress-FliC-cutinase-FLAG-Strep or pJexpress-
empty vector were induced with 0.05mM IPTG and harvested as in Figure 5.. Either LB media 
or cell supernatant (40µL) was added to 160µL pH 5 buffered, 50µM or 100 µM MUB solution 
and added to a 96 well plate. A MUB only and MUB + LB reaction were also run to observe 
fluorescence of all components. Following incubation at 30°C overnight, the reaction mix was 
added to quenching buffer (1:2 ratio) fluorescence was measured from 420 to 480nm 
following excitation at 365nm. Results from one biological replicate, with three technical 
repeats. Standard error of the mean displayed. 
 
5.3.7. Development of the MUB assay: time and sensitivity to a range of 
concentrations of cutinase 
 
Length of an enzyme catalysed reaction is an important consideration. Reactions undergo a 
period of linear rate of reaction followed by a plateau where the rate of reaction slows as 
substrate runs out. This plateau can be linked a reduction in either substrate (due to product 
formation) or enzyme (due to degradation). Fluorescence output is more accurately linked to 
4-MU and therefore cutinase concentration, when the rate of reaction is linear- i.e. the initial 
phase; therefore it is important to calculate when this occurs in a given enzyme-substrate 
reaction. This was investigated by measuring the fluorescence output of reactions over time. In 
addition to investigation of the appropriate reaction length, the effect of different 
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concentrations of enzyme containing supernatant was also investigated to establish if this 
linearly reduced the amount of product produced. This is of particular relevance of the aim of 
this assay is to measure varying concentrations of cutinase supernatant. To mimic this, the 
cutinase containing supernatant was diluted 2 fold with empty secretion construct 
supernatant.  
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Figure 5.7: Fluorescence output (AU) of reaction mixtures over time. 
E.coli ∆CKL containing either the plasmid pJexpress-FliC-cutinase-FLAG-Strep or pJexpress-
empty vector were induced with 0.05mM IPTG and grown and prepared as in Figure 5.. Either 
LB media or cell supernatant (40µL) was added to 160µL 100µM MUB solution (0.05M 
phosphate citrate buffer, pH 5) and added to a 96 well plate. A MUB only reaction was also run 
to observe fluorescence of all components. Measurements were taken every 5 minutes for the 
first 60 minutes and then at 120 and 240 minutes during incubation at 30°C. Fluorescence was 
measured at 446nm following excitation at 365nm.  
 
Fluorescence output of reaction mixtures was measured every 5 minutes from 5 to 50 minutes 
and then at 60, 120 and 240 minutes (Figure 5.). LB and supernatant do contribute to 
fluorescence, however it is evident that in the absence of cutinase the emission from reaction 
mixtures remains consistent throughout the experiment (Figure 5.: MUB, MUB + LB, MUB + 
empty). This is indicative that MUB is not subject to breakdown to form 4-MU in the absence 
of cutinase. Furthermore LB and the supernatant of cells void of cutinase does not facilitate 
the production of 4-MU during two hours of incubation, instead the emission observed is 
intrinsic to the solution. This observation gives confidence to the finding that cutinase is 
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actively cleaving MUB to yield fluorescent 4-MU, as increased fluorescence output of reaction 
mixtures over time is only evident in the presence of cutinase. Therefore cutinase catalysed 
MUB cleavage is the route for 4-MU derivation and therefore fluorescence. Furthermore the 
assay is sensitive to different concentrations of cutinase in reaction mixtures, as incubation of 
MUB with diluted cutinase supernatant resulted in linearly roughly 2-fold lower fluorescence 
readings, this shows that the assay is sensitive enough to detect different concentrations of 
secreted cutinase. The rate of fluorescence output for mixtures containing cutinase was linear 
from 5 to 40 minutes with the higher concentration of cutinase and 5 to 50 minutes when 
twice diluted. Following this the rate of reaction reduced, although fluorescence continued to 
increase up to 240 minutes. 30 minutes would be the optimum time to take fluorescence 
readings, as it is evident that the rate of reaction is linear for a range of enzyme 
concentrations, with substrate concentration not rate limiting at this stage. However in reality 
this was rarely effective -an example is given below.  
A small scale investigation was carried out to confirm negative regulation of cutinase secretion 
and also measure cutinase secretion in two of the strains which exhibited increased 
concentration of secreted E2 and CH2 proteins, to see if the MUB protein secretion assay could 
detect these differences. ∆CKL, ∆CKL ∆flgMN and ∆CKL ∆clpX and the negative secretion 
strains ∆flhDC and ∆CKL ∆flgDE were transformed with either empty or cutinase harbouring 
secretion construct, supplemented with the appropriate concentration of IPTG to induce 
plasmid expression and incubated at 37°C, with agitation. When cultures reached OD600 1.0 
samples were then taken and prepared the for the MUB protein secretion assay. Following 
centrifugation and the addition of LB to account normalise for the variation in OD600 measured 
in different cell cultures, supernatant was mixed with 100µM MUB and incubated for 30 
minutes at 30°C, the reaction was then quenched with sodium carbonate pH 10.5 and 
fluorescence was measured at 365nm excitation, 446nm (Figure 5.). Following 30 minutes of 
incubation fluorescence readings for reaction mixtures containing potential cutinase 
containing supernatants were often only marginally higher that the results obtained for those 
without (for example ∆CKL + empty secretion construct or either value for the negative 
secretion strain ∆flhDC). In addition the differences in fluorescence reading for reaction mixes 
which presumably had variable cutinase concentrations were both small, as the aim is to 
screen a large number of strains and secretion constructs by this method it would be 
preferential for more variation to be seen between strains. If reaction mixtures were 
incubated for a longer period of time the differences would be more pronounced (as seen in 
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Figure 5.), however the rate of reaction would not be linear, and therefore results would not 
be as accurate. Instead the MUB assay was modified slightly, so that the excitation wavelength 
was in the UV range –this was based on the observed fluorescence following UV excitation in 
preliminary MUB-cutinase investigation (Figure 5.). Fluorescence was high in the well 
containing supernatant with cutinase and absent in the wells without. 
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Figure 5.8: Fluorescence output (AU) of reaction mixtures following incubation of MUB with 
the secreted fraction of ΔCKL, ΔflhDC, ΔCKL ΔflgDE, ΔCKL ΔflgMN or ΔCKL ΔclpX cells 
secreting empty or cutinase harbouring secretion construct. Excitation 365nm, Emission 
446nm. 
E.coli ∆CKL, ΔflhDC, ΔCKL ΔflgDE, ΔCKL ΔflgMN or ΔCKL ΔclpX containing either the plasmid 
pJexpress-FliC-cutinase-FLAG-Strep (cutinase) or pJexpress-FliC-empty-FLAG-Strep (empty) 
were induced with 0.05mM IPTG (or 1mM for ΔflhDC and ΔflgDE) and grown in LB at 37°C with 
180rpm agitation. Cells were harvested when cell culture reached OD600 1.0. The supernatant 
was obtained by centrifugation. Either LB media or cell supernatant (40µL) was added to 160µL 
100µM MUB solution (0.05M phosphate citrate buffer, pH 5) and added to a 96 well plate. 
Citrate buffer, buffer + LB, 100µM MUB and MUB + LB reaction mixes were also included to 
provide information on the AU of all components of the reaction. Following incubation at 30°C 
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for 30 minutes, the reaction mix was added to quenching buffer (1:2 ratio) and fluorescence 
was measured at 446nm following excitation at 365nm. Results from one biological replicate, 
with three technical repeats. Standard error of the mean displayed. Two-way ANOVA 
(variables: strain and plasmid) p= <0.0001. 
 
5.3.8. Development of the MUB assay: excitation in the UV region of the 
spectrum 
 
One final consideration concerned the fact that the image in Figure 5. was taken by a camera 
attached to a standard UV-transilluminator-digital camera (UV-filter attached) (G:Box). 
Therefore the possibility of using both a transilluminator based assay and potentially a plate 
reader assay using UV excitation wavelengths was explored as this may have given better 
results than the traditional 365nm excitation. The UV-transilluminator (Syngene) used has an 
excitation wavelength of 302nm. Therefore fluorescence was measured following excitation at 
302nm – UV excitation occurs from the bottom up in the plate reader, therefore this required 
the use of black walled, clear bottom 96 well plates, to allow measurement of fluorescence for 
each well following UV excitation, without interference from adjoining wells. Excitation at 
302nm is also pH dependent, however at excitations below 320nm 4-MU fluorophore emission 
is highest at pH 5-6, quenching is not required, as reaction mixtures are already buffered to pH 
5. The only consideration that was checked was the appropriate emission wavelength, again 
because there is evidence that MU has differing emission properties in different solutions (Fior 
et al., 2009). Supernatant of ∆CKL cells from the cultures expressing cutinase or empty 
secretion construct were incubated with 100µM MUB for 30 minutes at 30°C prior to an 
emission scan following excitation at 302nm (Error! Reference source not found. 5.9). At all 
emission wavelengths fluorescence was highest for MUB incubated with cutinase containing 
supernatant. This resulted in maximal emission at 446nm, as before -this was also a 
wavelength at which the contribution of LB to the fluorescence output was reduced (i.e. MUB 
+ LB has a negative linear distribution, however at 446nm it is relatively low, in comparison to 
420nm for example). Finally, the MUB only sample emitted very little fluorescence at any 
emission wavelength. This suggests that LB not MUB contributes to background fluorescence. 
At 302nm excitation and 446nm emission the difference between MUB + cutinase and MUB + 
empty (the next highest) was 3648 units. This is larger than the difference seen between these 
two reaction mixes when excited at 365nm in Figure 5., which amounted to 3236.  
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Figure 5.8: Emission spectra for pH 5 buffered MUB with LB media or cell culture supernatant 
from cells expressing cutinase or empty FT3SS signal peptide tagged secretion constructs- 
excitation at 302nm.  
E.coli ∆CKL containing either the plasmid pJexpress-FliC-cutinase-FLAG-Strep or pJexpress-
empty vector were induced with 0.05mM IPTG and grown and prepared for the MUB protein 
secretion assay as in Figure 5.. A MUB only and MUB + LB reaction was also run to observe 
fluorescence of all components. Following incubation at 30°C for 30 minutes, fluorescence was 
measured from 420 to 480nm following excitation at 302nm. Results from one biological 
replicate, with two technical repeats. Standard error of the mean displayed.  
 
Efforts were then made to assess whether an image based MUB protein secretion assay could 
be utilised, where MUB and cell culture was incubated and then a photo taken as it Figure 5.. It 
was hoped that densitometry could be used to quantify fluorescence, however shadowing in 
wells was an issue and the sensitivity was not high enough to distinguish between different 
fluorescent outputs of different mutant strains -though the difference between control and 
experimental samples for secretion was always clear- as in Figure 5.. This method would be a 
useful for screening mutants (from a mutant library for example), to ascertain whether 
mutants exhibited secretion of cutinase occurred or not. The results from one of these 
experiments is shown in Appendix 5. 
Carrying out the MUB assay in a plate reader with fluorescence excitation at 302nm, should 
result in more pronounced differences between readings for reaction mixtures when cutinase 
is present or absent. Additionally as quenching is not required, the assay is simplified, thus 
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improving the high throughput nature further. Investigation into the performance of this plate 
reader MUB protein secretion assay was then tested using the same biological samples used in 
Figure 5.. In addition intracellular fractions and secreted fraction of cell cultures were prepared 
for Western blot analysis, to provide information on the concentration of intracellular protein 
and also to give confidence that the relative changes in fluorescence reported by MUB assay 
did relate to secreted cutinase concentration. 
The results of Western blot analysis show that cutinase was expressed in all strains, although it 
was quite low in the ∆flgDE mutant, despite the addition of extra IPTG (Figure 5.). Secreted 
cutinase was visible in the supernatant of ∆CKL, around twice as much was visible in the 
secreted fractions of ∆flgMN and ∆clpX, whereas cutinase was absent from the supernatant of 
∆flhDC and ∆flgDE cells. This confirms that excitation at 365nm produced unreliable results as 
Figure 5. suggest that ∆flgMN cells secreted less cutinase than ∆CKL and that ∆clpX secreted 
marginally more. 
 
Figure 5.10: Intracellular and secreted cutinase from the secretor strain and ΔflhDC, ΔflgDE, 
ΔflgMN and ΔclpX and mutants. 
E.coli ΔCKL (C), ΔflhDC (DC), ΔCKL ΔflgDE (DE), ΔCKL ΔflgMN (MN) or ΔCKL ΔclpX (X) containing 
the plasmid pJexpress-FliC-CH2-FLAG-Strep were grown in LB supplemented with 0.05mM 
IPTG (or 1mM for DC and DE).  Cells were prepared for Western blot analysis with anti-FLAG-
HRP antibody as in Figure 5.. Samples were loaded to as follows: Supernatant: 20µL. Cells: 2µL  
 
 
Following centrifugation and the addition of LB to normalise for the variation in OD600 
measured in different cell cultures, supernatant was mixed with 100µM MUB and incubated. 
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When reaction mixes are excited at 302nm again the highest fluorescence readings are derived 
for reaction mixes containing the supernatant of cutinase expressing ∆CKL, ΔflgMN and ΔclpX 
cells (Figure 5.). It is evident that the fluorescence readings for all other reaction mixes 
containing cell culture supernatant or LB are uniformly lower (and not statistically different 
from each other (Two-way ANOVA: Tukey’s multiple comparison test). It is also evident that 
background fluorescence is due to LB alone (MUB only low, buffer + LB and MUB + LB equally 
high). This is not a limitation as the concentration of LB (or supernatant) is constant in reaction 
mixes. In terms of results for MUB incubated with supernatant containing cutinase the highest 
was for ΔclpX (6788), followed by ΔflgMN (5748) and 4712 for ΔCKL. This assay was sensitive 
enough to differentiate differences between different concentrations of secreted cutinase; all 
cutinase containing supernatant reactions resulted in fluorescence values which were 
statistically different to each other (p = <0.0001. Two way ANOVA: Tukey’s multiple 
comparison test). Finally fluorescence output of negative control strains expressing cutinase, 
was statistically lower than those measured for ΔCKL –demonstrating that negative control is 
established and that cutinase in the supernatant arises by directed secretion through the 
FT3SS alone.   
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Figure 5.11: Fluorescence output (AU) of reaction mixtures following incubation of MUB with 
the secreted fraction of ΔCKL, ΔflhDC, ΔCKL ΔflgDE, ΔCKL ΔflgMN or ΔCKL ΔclpX cells 
secreting empty or cutinase harbouring secretion construct. Excitation 302nm, Emission 
446nm. 
E.coli ∆CKL, ΔflhDC, ΔCKL ΔflgDE, ΔCKL ΔflgMN or ΔCKL ΔclpX containing either the plasmid 
pJexpress-FliC-cutinase-FLAG-Strep (cutinase) or pJexpress-FliC-empty-FLAG-Strep (empty) 
were induced with 0.05mM IPTG (or 1mM for ΔflhDC and ΔflgDE) and grown and prepared for 
the MUB protein secretion assay as in Figure 5.. Citrate buffer, buffer + LB, 100µM MUB and 
MUB + LB reaction mixes were also included to provide information on the AU of all 
components of the reaction. Following incubation at 30°C for 30 minutes, fluorescence was 
measured at 446nm following excitation at 302nm. Results from one biological replicate, with 
three technical repeats. Standard error of the mean displayed. Two-way ANOVA (variables: 
strain and plasmid) and Tukey’s multiple comparison test: **** = p <0.0001. 
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These results reflected the results of the Western blot, ΔCKL was found to have the lowest 
concentration of secreted cutinase for both experiments. ΔflgMN and ΔclpX should display 
twice the cutinase activity of ΔCKL as around twice as much cutinase was visible in the 
Western blot. For this purpose the average MUB + LB background was removed to give a 
clearer representation of the effect of cutinase on fluorescence output; this showed a 2.06 fold 
increase in AU for ΔclpX and a 1.53 fold increase for ΔflgMN. For ΔclpX this is concordant with 
the Western blot, it is a little lower for ΔflgMN, however still representative of the fact that 
removing flgMN from ΔCKL resulted in improved cutinase secretion. 
The establishment of a reliable, high-throughput MUB assay to measure cutinase secretion 
through the modified FT3SS allowed investigation of the secretion output of a number of 
strains in one quick and accurate experiment. This can now be utilised to screen a multitude of 
potential strain and plasmid based improvements. Throughout all of the results chapters, 
either Western blot analysis or the MUB protein secretion assay have demonstrated that gene 
knockout mutation based strain improvements can result in increased secretion of FT3SS 
secretion signal peptide tagged protein through the FT3SS. It was hoped that the combination 
of these knock out mutations which had previously been found to improve secretion, would 
result in an additive effect on secretion capacity.  
 
5.4. Combination of strain improvement strategies for 
increased FT3SS capacity 
 
The existing gene knockouts which had been found to result in increased secretion output 
through Western blot analysis of secreted E2, CH2 or cutinase or by MUB based cutinase 
secretion assay, were combined in the hope that these effects would be incremental. These 
were fliDST, motAB, flgMN and clpX. As strains with antibiotic linked gene knockouts or DNA 
templates of FRT flanked antibiotic resistance cassettes (ABCs) for gene knockout 
implementation are already established, it was possible to generate combination mutants with 
reasonable ease. The aim was to generate strains which incorporated multiple gene knockouts, 
to assess the effect of the consolidation of two or three strategies at once.  
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5.4.1. Mutant generation: multiple gene knockout strain improvements 
 
5.4.1.1. Knockout mutagenesis via the Lambda Red recombinase 
method 
The strains (∆CKL) ∆clpX ∆motAB, ∆clpX ∆flgMN, ∆clpX ∆fliDST, ∆motAB ∆flgMN and ∆motAB 
∆fliDST were all generated using this method. In Chapter 3 linear DNA was derived by PCR 
which comprised of FRT flanked antibiotic resistance genes -with homologous ends to the 
chromosomal region either side of the target gene for knockout mutagenesis. These linear 
DNA fragments were electroporated into the appropriate parent strain expressing Lambda Red 
recombinase enzymes (Table 5.). Successful recombination events resulted in linear DNA 
template being inserted into chromosomal DNA at homologous regions. Successful 
recombination was screened for by plating on agar plates supplemented with the relevant 
antibiotic (chloramphenicol or kanamycin). Positive colonies were observed for all 
recombination strains and following the curing of the Red recombinase plasmid so that no 
further recombination events occur; the deletion of chromosomal genes was confirmed with 
PCR (Figure 5.).  
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Table 5.1: Parent strain and the additional gene knockout targets, with PCR products for 
confirmation of knockout mutagenesis in the various parent strains. 
Parent strains already harboured antibiotic resistance, due to prior gene knockout 
mutagenesis by FRT flanked ABC cassette homologous recombination. Additional gene 
knockouts were successfully implemented with different ABCs in the following strains. 
Following mutagenesis colony PCR was carried out on successful transformants. The size of 
PCR products which denote a positive result for each new mutant is given, along with the size 
of the PCR product (if relevant) expected if knockout mutagenesis was not successful. 
Parent Strain: 
MC1000 ∆CKL 
∆flgKL 
Resista
nce 
Additional 
knockout 
mutation 
Resistance 
and 
template 
plasmid 
PCR 
conformation 
primers (forward, 
reverse) 
Size of PCR product if 
knockout: 
Successful Unsuccessful 
∆clpX Km ∆motAB Cm, pKD3 motAB F, motAB 
R 
1198 1913 
∆clpX Km ∆flgMN Cm, pKD3 flgMN F and 
flgMN R 
1198 813 
∆clpX Km ∆fliDST Cm, 
pKD32 
fliDST F, C1 264 N/A 
∆motAB Cm ∆flgMN Km, pKD4 flgMN confo, kt 1338 N/A 
∆motAB Cm ∆fliDST Km, 
pKD13 
fliDST confo and 
k2 
993 N/A 
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Figure 5.12: Agarose DNA gels of PCR products to confirm successful knockout mutagenesis.  
PCR reactions were carried out using the templates and primers in Appendix 2 with DreamTaq 
DNA Polymerase. PCR mixtures were analysed on a 1% TAE agarose DNA gel supplemented 
with a trace of ethidium bromide, visualised under UV light and inverted. Samples were run 
with GeneRuler™ 1kb DNA ladder. PCR resulted in the formation of products of the sizes listed 
in Table 5.. This confirmed the successful knockout mutagenesis and therefore the generation 
of the following strains: A. clpX::Km motAB::Cm, B. clpX::Km flgMN::Cm, C. clpX::Km fliDST::Cm, 
D. motAB::Cm flgMN::Km, E. motAB::Cm fliDST::Km 
 
5.4.1.2. Knockout mutagenesis via the P1 phage transduction method: 
While Lambda-Red recombineering is the preferred method for knockout mutagenesis (due to 
the absence of phage), the efficiency is poor and therefore it can take multiple attempts of the 
protocol to generate mutants- when necessary P1 phage transduction was carried out to 
achieve knockout mutants in a short space of time. This resulted in the successful generation 
of (∆CKL) ∆flgMN ∆fliDST, ∆clpX ∆motAB ∆flgMN and ∆clpX ∆motAB ∆fliDST from the parent 
strains and P1 phage lysates listed in Table 5.. As the number of ABCs which could be linked to 
gene knockout DNA constructs was limited to kanamycin or chloramphenicol, FRT linked 
antibiotic resistance was sometimes removed from the chromosome using the Flp 
recombinase gene harbouring pCP20 plasmid. This resulted in the excision of the ABC leaving 
an 82 or 85 bp FRT scar site for chloramphenicol or kanamycin cassettes respectively. This 
method was implemented in all three of the parent strains listed in 5.Table 5.. 
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Table 5.2: Parent strain and associated knockout mutations implemented by P1 phage 
transduction with chromosomal DNA packaged from donor strains.  
Parent strain. ∆fliC ∆flgKL: P1 transduced mutation Donor strain. ∆fliC ∆flgKL: 
∆flgMN ∆fliDST:: Km ∆fliDST:: Km 
∆motAB ∆flgMN ∆clpX::Km ∆clpX::Km 
∆motAB ∆fliDST ∆clpX::Km ∆clpX::Km 
 
Once successful transformatants were obtained cells were passaged on sodium citrate plates, 
to eradicate phage. Growth was always normal in these strains, suggesting that phage was 
eliminated from these strains. Care was taken to ensure that there was no possibility of 
existing genes knockouts in the parent strain being reinstated by chromosomal DNA packaged 
by the P1 phage during homologous recombination. The chromosomal location of genes 
targeted for knockout mutagenesis are listed in Table 5.. P1 phage is capable of packaging and 
initiating the homologous recombination of up to 100,000bp of donor chromosomal DNA into 
a parent strain. Therefore if the gene selected for knockout mutagenesis by P1 phage was 
within 100,000bp of the site of any existing gene knockouts in the donor strain, PCR 
conformation would be required to ensure this gene was not restored by P1 phage 
transduction in the newly derived strain. The site of ∆clpX (and therefore ∆clpX::Km) is distant 
from all other target genes. fliDST (and ∆fliDST::Km) is within 100,000bp of fliC therefore there 
would be potential for restoration of the ∆fliC mutation, however as donor DNA was derived 
from a ∆fliC strain, this is not possible. Therefore PCR conformation of retention of knockout 
mutagenesis genotype was not required. 
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Table 5.3: Chromosomal location (bp) of genes which underwent knockout mutagenesis and 
existing gene knockouts. 
Gene Chromosomal location 
Start End 
∆fliC 2053401 2054069 
∆flgKL 1140598 1140943 
∆motAB 2024187 2025997 
∆flgMN 1131700 1132404 
∆fliDST 2054069 2056275 
∆clpX 412775 414049 
 
It was hoped that either Lambda-Red recombination or P1 phage transduction could be 
utilised to also produce ∆fliC ∆flgKL ∆motAB ∆flgMN ∆fliDST and ∆fliC ∆flgKL ∆motAB ∆flgMN 
∆fliDST ∆clpX however attempts were unsuccessful. Following either mutagenesis protocol 
positive colonies were not detected following antibiotic screening. It is not through that these 
combinations of mutations should result in lethality; therefore it is believed that with more 
time these strains could be generated. Despite absence of the full complement of 
combinations of knockout mutant strategies, a plethora of combinations were derived. These 
were characterised by growth phenotype and FT3SS secretion capacity using the MUB plate 
reader cutinase protein secretion assay. For ease abbreviated versions of these strains will be 
used in figures and in text throughout this section (Table 5.).  
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Table 5.4: Strains tested for expression and secretion of cutinase through the modified 
FT3SS. 
All strains are in the MC1000 background. Abbreviations are often shorted in figure labels to 
exclude the ‘Δ’ from the notation. e.g.  ΔfliC ΔflgKL ΔfliDST ΔflgMN or ΔDST ΔMN or DST MN 
Strain (MC1000) Abbreviation 
ΔfliC ΔflgKL ΔCKL 
ΔfliC ΔflgKL ΔclpX  ΔX 
ΔfliC ΔflgKL ΔfliDST ΔDST 
ΔfliC ΔflgKL ΔflgMN ΔMN 
ΔfliC ΔflgKL ΔmotAB ΔM 
ΔfliC ΔflgKL ΔflgMN ΔfliDST ΔMN ΔDST  
ΔfliC ΔflgKL ΔmotAB ΔfliDST ΔM ΔDST 
ΔfliC ΔflgKL ΔmotAB ΔflgMN ΔM ΔMN 
ΔfliC ΔflgKL ΔclpX ΔfliDST  ΔX ΔDST 
ΔfliC ΔflgKL ΔclpX ΔflgMN ΔX ΔMN 
ΔfliC ΔflgKL ΔclpX ΔmotAB   ΔX ΔM 
ΔfliC ΔflgKL ΔclpX ΔmotAB ΔfliDST   ΔX ΔM ΔDST 
ΔfliC ΔflgKL ΔclpX ΔmotAB ΔflgMN   ΔX ΔM ΔDST 
ΔflhDC ΔDC 
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5.4.2. Combined strategies for improved FT3SS secretion: Effects of 
multiple gene deletions on growth phenotype 
 
As previously described, gene deletions may lead to reduced metabolic burden and therefore 
increased cell growth. Equally gene deletion may lead to strains which are not viable or less 
healthy if essential genes or processes are affected. In addition the production of recombinant 
protein (i.e. cutinase) will add to metabolic burden and may lead to a reduction in growth rate, 
for example it was found that the growth phenotypes of mutant strains expressing empty or 
CH2 harbouring secretion construct grew slightly slower or to a lower final optical density than 
∆CKL in the majority of strains (Figure 4.). Additionally when expressing recombinant protein, 
optical densities of all strains (with the exception of ∆clpX) were slightly lower at some point in 
the growth curve in comparison to when the same strains were expressing empty secretion 
construct (Figure 4.). As the gene knockouts investigated here were combined, it was 
important to observe whether they have an additive effect on growth phenotype or whether 
extensive mutagenesis had resulted in strains which were non-viable. To evaluate the effect of 
gene deletion and cutinase expression on growth phenotype, growth curves were obtained for 
ΔCKL and the newly derived mutant strains expressing either empty or cutinase harbouring 
secretion construct.  
Figure 5. shows that the growth phenotype of all strains was fairly similar and all strains were 
viable. In the log phase lower optical density readings were found for all strains in comparison 
to ∆CKL whether cells were expressing empty or cutinase containing secretion construct. With 
the exception of ∆X ∆M when expressing cutinase harbouring secretion construct (Figure 5.B), 
∆M ∆DST had lower optical densities than all other strains when expressing either plasmid 
(Figure 5.A and B). 
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Figure 5.13: Growth of ∆CKL and (∆CKL) ∆MN ∆DST, ∆M ∆MN, ∆M ∆DST, ∆X ∆M, ∆X ∆MN, ∆X 
∆DST, ∆X ∆M ∆MN and ∆X ∆M ∆DST mutant strains expressing either empty or cutinase 
harbouring secretion construct over time in a 96 well plate. Calibrated to LB media. 
Starter cultures of cells expressing either pJexpress-FliC-empty-FLAG-Strep or pJexpress-FliC-
cutinase-FLAG-Strep were grown in LB supplemented with ampicillin and 0.05mM IPTG and 
aliquoted into 96 well plate wells. The 96 well plate was incubated in the TECAN plate reader 
at 37°C with 6mm orbital shaking. OD600 measurements were recorded every 30 minutes. 
Results split into four graphs for ease of viewing - ∆CKL with relevant plasmid on all graphs to 
allow comparison.  A and C: ∆CKL: ○, ∆flgMN ∆fliDST: ●, ∆motAB ∆flgMN: ■, ∆motAB ∆fliDST: 
□, ∆clpX ∆motAB: ▲. B and D: ∆CKL: ○,  ∆clpX ∆flgMN: △, ∆clpX ∆fliDST: ▼, ∆clpX ∆motAB 
∆flgMN: ▽ and ∆clpX ∆motAB ∆fliDST: X. Results represent the combination of two biological 
repeats, with three technical replicates of each biological.  
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Viewing that data for the growth curve of each strain individually allows observations to be 
made on the effect of recombinant protein expression on cell growth (Figure 5.). The 
differences in OD600 for ∆MN ∆DST expressing either plasmid were alike. ∆X ∆M grew to 
slightly higher and ∆X ∆MN slightly lower optical densities in the late log phase when 
expressing empty secretion construct. ∆X ∆DST, ∆X ∆M ∆MN and ∆X ∆M ∆DST all displayed 
higher OD600 readings throughout the log and early stationary phase when not expressing 
cutinase, whereas ∆M ∆MN and ∆M ∆DST had slightly higher optical densities in the log phase 
when expressing cutinase. In summary the differences between strain growth phenotype 
when expressing empty or cutinase containing secretion construct was small and all strains 
were shown to be viable. 
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Figure 5.14: Growth of ∆CKL and (∆CKL) ∆MN ∆DST, ∆M ∆MN, ∆M ∆DST, ∆X ∆M, ∆X ∆MN, ∆X 
∆DST, ∆X ∆M ∆MN and ∆X ∆M ∆DST mutant strains expressing either empty (no fill) or 
cutinase (black) harbouring secretion construct over time in a 96 well plate. Calibrated to LB 
media. 
Starter cultures of cells expressing either pJexpress-FliC-empty-FLAG-Strep (white fill) or 
pJexpress-FliC-cutinase-FLAG-Strep (black fill) were grown in LB supplemented with ampicillin 
and 0.05mM IPTG and aliquoted into 96 well plate wells. The 96 well plate was incubated in 
the TECAN plate reader at 37°C with 6mm orbital shaking. OD600 measurements were recorded 
every 30 minutes. Results represent the combination of two biological repeats, with three 
technical replicates of each biological. 
 
No combination of mutant knockouts resulted in strains which grew poorly, therefore all 
strains had potential to be viable secretion platform strains. The FT3SS secretion phenotype 
was investigated in all strains to investigate whether secretion capacity was improved.  
 
5.4.3. Combining strategies for improved FT3SS secretion: Effects of 
multiple gene deletions on FT3SS secretion of cutinase 
 
With a high-throughput assay established for the measurement of directed secretion through 
the modified FT3SS, the suite of mutant strains which had been generated could be quickly 
characterised in terms of secretion capacity. While the cutinase secretion assay is effective at 
measuring secreted cutinase, it is not able to determine the concentration of intracellular 
cutinase. Previously information on intracellular and secreted protein have been combined to 
calculate the secretion efficiency of strains, therefore to give an idea of this, the cell pellets 
from cultures were prepared for Western blot analysis. While this did limit the throughput 
somewhat, it was worthwhile, furthermore it was the preparation of the supernatant fraction 
for SDS-PAGE, which was most time consuming and therefore throughput limiting. All 13 ∆CKL 
background mutant strains which had been generated were tested, along with ∆flhDC to 
ensure negative control of secretion was established. Cells cultures were grown in tandem and 
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following harvesting, samples were prepared for either SDS-PAGE or Coomassie staining or 
Western blotting (cell pellets) or MUB protein secretion assay (supernatant). 
The intracellular protein fractions of cell cultures were run on SDS-PAGE gels. Following 
Coomassie staining (Figure 5. top) it was evident that all fractions look similar in terms of the 
pattern and relative concentration of bands. The exception to this was a band between 17 and 
26kDa which was overexpressed in ΔX ΔM, ΔX ΔDST and ΔM ΔDST. This is too small to be full 
length cutinase in the secretion construct as this is expected (and has been shown by Western 
blot) to be 30.6kDa, furthermore Western blot analysis does not detect this protein (not 
shown as image cropped for ease of viewing). Western blot analysis shows that the 
concentration of intracellular cutinase is fairly uniform in all strains (Figure 5. bottom), 
including those which displayed overexpression of the smaller protein. 
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Figure 5.15: Intracellular cutinase from ∆CKL and all additional mutant strains.  
The E.coli strains listed in Table 5. containing the plasmid pJexpress-FliC-cutinase-FLAG-Strep 
were grown in LB supplemented 0.05mM IPTG (or 1mM for ΔflhDC).  Cells were harvested at 
OD600 1.0. 1 OD unit of cells were prepared with 2x SDS-PAGE loading buffer. Samples 
underwent SDS-PAGE and either staining with Instant Blue Coomassie stain (top) or Western 
blot (bottom) analysis of cells and supernatant using an anti-FLAG-HRP antibody. Samples were 
loaded as follows: 2µL (Western blot), 5µL (Coomassie stain). One biological replicate of each 
strain shown. 
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Densitometry analysis was carried out following three biological replicates of each strain to 
quantify the concentration of intracellular cutinase in each strain relative to ΔCKL from 
Western blot (Figure 5.).  Although no statistically significant differences in intracellular levels 
were noted, the results suggest that the trend is for the removal of genes (in addition to ΔCKL) 
to result in expression of a higher concentration of intracellular cutinase in comparison to ΔCKL 
alone –the only exception to this was ΔX ΔM ΔDST. The highest individual intracellular cutinase 
concentration was observed in a ΔM ΔDST strain and was 5.88 fold higher than that measured 
for ΔCKL in that experiment. The second highest was a 5.68 fold increase on ΔCKL for a 
ΔmotAB strain. ΔmotAB also exhibited the highest average fold increase (3.42 higher than that 
seen in ΔCKL).  
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Figure 5.16: Western blot densitometry analysis of intracellular protein fractions of cutinase 
expressing ΔCKL, ΔflhDC and ΔCKL strains with additional mutations  
The E.coli strains listed in Table 5. containing the plasmid pJexpress-FliC-cutinase-FLAG-Strep 
were grown in LB supplemented 0.05mM IPTG (or 1mM for ΔflhDC). Cells were harvested at 
OD600 1.0. Following Western blot analysis of cells and supernatant using anti-FLAG-HRP, 
densitometry analysis was carried out using ImageJ. Results were then normalised to the value 
obtained for intracellular cutinase in the ΔCKL strain. Individual data points, average and 
standard error of the mean are given. Three biological replicates were carried out for each 
strain. 
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To measure the concentration of secreted cutinase, the supernatant from these cell cultures 
(Figure 5.) and cell cultures of all strains secreting empty-secretion construct was prepared for 
the cutinase protein secretion MUB assay. Following incubation of culture supernatant with 
MUB, the fluorescent output measured following excitation at 302nm can be related to the 
presence of 4-MU, therefore the amount of cutinase cleaved MUB and therefore the amount 
of cutinase present. Data was handled in a number of ways to allow normalisation and 
therefore combination of results from different experiments and also to remove background 
fluorescence. This involved calculating AU relative to that measured for MUB + LB in each 
replicate (Figure 5.9A) or for cutinase expressing cell cultures, following adjustment for MUB + 
LB, the relative AU value of strains compared to that seen for ∆CKL expressing cutinase (Figure 
5.9B).  
Figure 5.9A shows that once normalised to MUB + LB the AU values derived for MUB incubated 
with either the supernatant of strains expressing empty-secretion construct or ∆flhDC 
expressing cutinase were all similar to both each other and MUB + LB itself. This demonstrates 
that once background fluorescence had been accounted for, fluorescence emission was low in 
the absence of cutinase. On average ∆MN, ∆DST, ∆MN ∆DST, ∆M ∆MN, ∆X ∆M ∆MN and ∆X 
∆M ∆DST all had lower emission readings than ∆CKL (2.90 fold higher than MUB + LB), 
suggesting less cutinase was present in the supernatant of these cells. The AU of ∆X ∆MN was 
very similar to ∆CKL, ∆X ∆DST was the next highest, followed by ∆M. The three highest 
emission readings were measured in ∆X, ∆X ∆M and ∆M ∆DST –with the latter being found to 
be significantly higher (5.24 fold higher) than that measured for ∆CKL expressing cutinase 
(Tukey’s multiple comparison test). A slightly different pattern of results was seen when these 
results were then normalised relative to the value derived for ∆CKL + cutinase in each set of 
experiments (Figure 5.9B). Variation was reduced and the results on a one-way ANOVA were 
found to be significant. ∆flhDC resulted in a significantly lower fluorescent output than ∆CKL. 
∆MN, ∆DST, ∆MN ∆DST, ∆M ∆MN and ∆X ∆M ∆DST again had lower average fluorescent values 
that ∆CKL. However as opposed to in Figure 5.9A, with this calculation, ∆X ∆M ∆MN 
fluorescence was higher than ∆CKL. This demonstrates the effect data handling can have on 
the interpretation of results. All other strains had higher emission outputs than ∆CKL, the 
highest two averages were derived from ∆M ∆DST (1.64 fold higher) and ∆X ∆M (1.67 fold 
higher), which were found to be significant.  
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Figure 5.9: Fluorescence output (AU) of reaction mixtures following incubation of MUB with 
the secreted fraction of ∆CKL and all ∆CKL background mutant strains secreting empty (-) or 
cutinase (+) harbouring secretion construct.  
The E. coli strains listed in Table 5.  containing either the plasmid pJexpress-FliC-cutinase-FLAG-
Strep (+) or pJexpress-FliC-empty- FLAG -Strep (-) were induced with 0.05mM IPTG (or 1mM for 
ΔflhDC) and grown and prepared for the MUB protein secretion assay as in Figure 5.. MUB + LB 
reaction mixes were also included to provide information on the AU of components which 
provide background fluorescence. Following incubation at 30°C for 30 minutes fluorescence 
was measured at 446nm following excitation at 302nm. Results from three biological 
replicates, with three technical repeats for each. Individual data points, average and standard 
error of the mean are given. To allow comparison of results between experiments, results 
were either (A) normalised to the average value for MUB + LB in each experiment, (B) values 
calculated in ‘A’ normalised to the average value for ∆CKL cells secreting cutinase. Standard 
error of the mean displayed. Two-way ANOVA of A: not significant. One-way ANOVA of B: p = 
<0.0001. Tukey’s multiple comparison test of cutinase expressing strain compared to cutinase 
expressing ∆CKL (*: p = <0.05, **: p = < 0.01) 
 
As ∆motAB ∆fliDST and ∆clpX ∆motAB were found to result in consistently high statistically 
significant fluorescent outputs whichever way the data was handled these two strains became 
candidate high secretion platform strains. Fresh transformed cells from these strains were 
grown in tandem with ∆CKL and prepared for Western blot analysis of supernatant, to confirm 
that the high fluorescence output observed was related to increased secreted cutinase 
concentration. From the Coomassie stain it is again evident that the protein at around 23kDa is 
overexpressed in the ∆clpX ∆motAB strain, however it is not evident in ∆motAB ∆fliDST as it 
was in Figure 5.. The supernatant is free of cellular contaminants suggesting that cell lysis is 
not prevalent in any of the strains. Western blot analysis of cell culture fractions with an 
antibody for the cytoplasmic chaperone protein GroEL did reveal that cell lysis or cytoplasmic 
membrane leakage was increased in ∆motAB ∆fliDST and ∆clpX ∆motAB (Figure 5.11), however 
as this antibody is very sensitive and the Coomassie stained SDS PAGE gel does not suggest cell 
lysis occurred at a high rate, it can be assumed that the majority of cutinase found in the 
supernatant of cell culture has been secreted through the FT3SS. In terms of secreted cutinase, 
achieving a satisfactory result was difficult; in one biological replicate (not shown) cutinase was 
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only seen in the secreted fraction of ∆clpX ∆motAB cells. In the other biological replicate it was 
necessary to overexpose the X-ray film for a prolonged period of time to achieve a result 
where cutinase could be seen in the secreted fraction of all strains (Figure 5.10 top). By eye it 
appears that ∆CKL secretes the least, ∆motAB ∆fliDST secreted slightly more and ∆clpX 
∆motAB secreted around four times as much cutinase. The Western blot shows that the 
concentration of cutinase in the intracellular fractions is very similar for all strains. Although 
the background exposure is high, densitometry analysis was carried out and found there to be 
1.02 and 0.84 fold more cutinase in the cells of ∆clpX ∆motAB and ∆motAB ∆fliDST 
respectively. Whereas ∆clpX ∆motAB was shown to have secreted 3.58 times the amount of 
cutinase that ∆CKL did, which looks accurate, however densitometry analysis calculated that 
∆motAB ∆fliDST secreted 2.2 times the concentration ∆CKL did, which does seem higher than 
what the image suggests. 
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Figure 5.10: Intracellular and secreted cutinase from ∆CKL and the ΔclpX ΔmotAB and 
ΔmotAB ΔfliDST mutants 
E.coli ΔCKL (C), ΔCKL ΔclpX ΔmotAB (X M) or ΔCKL ΔmotAB ΔfliDST (M DST) containing the 
plasmid pJexpress-FliC-cutinase-FLAG-Strep was grown in LB supplemented with 0.05 IPTG. 
Cells were prepared for SDS-PAGE as in Figure 5. and were either stained with Instant Blue 
Coomassie stain or Western blot analysis of cells and supernatant using an anti-FLAG-HRP 
antibody. Samples were loaded to as follows: Supernatant: 20µL.  Cells: 2µL (Western blot), 
5µL (Coomassie stain).  
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Figure 5.11: Abundance of GroEL in the intracellular and supernatant fractions of ∆CKL and 
the ΔclpX ΔmotAB and ΔmotAB ΔfliDST mutants, following expression and secretion of 
cutinase protein through the FT3SS. 
E.coli ΔCKL (C), ΔCKL ΔclpX ΔmotAB (X M) or ΔCKL ΔmotAB ΔfliDST (M DST) containing the 
plasmid pJexpress-FliC-cutinase-FLAG-Strep was grown in LB. Cells were harvested at OD600 1.0. 
Samples underwent SDS-PAGE and Western blot analysis of cells and supernatant using anti-
GroEL antibody and an HRP secondary. Samples were loaded as follows: Supernatant: 20µL, 
cells: 2µL.  
 
In addition to analysis by Western blot (Figure 5.10) supernatant was also used in a MUB assay, 
along with the supernatant from the strains expressing empty secretion construct. If results 
are concordant this will validate the results of the Western and MUB assay. Normalisation to 
MUB + LB eliminated any background fluorescence in the assay. Overall the fluorescent output 
of cells expressing empty secretion construct was lower than that observed in MUB + LB for all 
strains (Figure 5.). ΔCKL exhibited cutinase activity, however the fluorescent output measured 
for the reaction mixtures incubated with ΔclpX ΔmotAB and ΔmotAB ΔfliDST was significantly 
higher than ΔCKL. This amounted to a 5.35 or 4.74 fold increase in fluorescent output when 
normalised to ΔCKL.  
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Figure 5.20: Relative fluorescence output (AU) of reaction mixtures following incubation of 
MUB with the secreted fraction of ∆CKL, ∆flhDC, ΔclpX ΔmotAB or ΔCKL ΔmotAB ΔfliDST 
secreting empty (-) or cutinase (+) harbouring secretion construct.  
E. coli ∆CKL, ∆flhDC, ΔclpX ΔmotAB or ΔCKL ΔmotAB ΔfliDST containing either the plasmid 
pJexpress-FliC-cutinase-FLAG-Strep (+) or pJexpress-FliC-empty-FLAG-Strep (-) were induced 
with 0.05mM IPTG (or 1mM for ∆flhDC) and grown and prepared for the MUB protein 
secretion assay as in Figure 5.9. Fluorescence was measured at 446nm following excitation at 
302nm. Results from one biological replicate, with three technical repeats for each. Standard 
error of the mean is displayed. To allow comparison of results between experiments, results 
were either normalised to the average value for MUB + LB in each experiment. A two-way 
ANOVA found the variance of data to be statistically significant both between strains and 
secretion construct cargo. (p = <0.0001). Tukey’s multiple comparison test of cutinase 
expressing strains compared to cutinase expressing ∆CKL (****: p = <0.0001) 
 
The MUB protein secretion assay enabled secretion capacity in 13 strains to be assessed in a 
time effective manner. Both the MUB and antibody detection protein secretion assay showed 
that more cutinase was secreted in the ΔclpX ΔmotAB and ΔmotAB ΔfliDST strains, with ΔclpX 
ΔmotAB consistently secreting the highest concentration of cutinase. Currently ΔclpX ΔmotAB 
is the best secretion strain, based on the large improvements to secretion capacity. However 
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this may be cutinase substrate specific, therefore secretion capacity of both ΔclpX ΔmotAB and 
ΔmotAB ΔfliDST was investigated for E2 and CH2 protein. 
 
5.4.4. Candidate high capacity secretion strains: E2 and CH2 secretion 
To investigate whether ΔclpX ΔmotAB and ΔmotAB ΔfliDST had a high capacity to secrete 
either E2 or CH2 through the modified FT3SS, the relevant plasmids were transformed into 
these strains and intracellular and secreted concentrations of protein were measured by 
Western blot analysis. 
 
5.4.4.1. Secretion of E2 through the modified FT3SS of the best 
candidate secretion strains 
E2 protein (pTrc E2) and empty vector was expressed in ΔCKL and the two most promising 
secretion strains. E2 was visible in the supernatant of all strains expressing E2 (Figure 5. top); 
however it was not as distinguishable as it has been in past experiments shown in Chapter 3. 
This was in part due to the low concentration of E2 in general (low concentration observed in 
ΔCKL too) and in part due to the incidence of some cell lysis, especially in ΔclpX ΔmotAB. This 
level of cell lysis was seen in all biological replicates. The highest concentration of E2 was 
visible in the supernatant of ΔclpX ΔmotAB, followed by ΔCKL, then ΔmotAB ΔfliDST No E2 
protein or evidence of cell lysis was observed when strains expressed empty vector. 
Intracellularly, as seen in Figure 5. and Figure 5.10 a protein of around 22kDa was visible in the 
intracellular fractions of ΔclpX ΔmotAB when expressing E2 protein or empty vector –
suggesting it is not a result of recombinant protein expression (whether cutinase or E2) the 
potential origin of this will be discussed later. The Western blot (Figure 5. bottom) confirmed 
that there was more E2 in the supernatant of ΔclpX ΔmotAB cells, similar concentrations were 
seen in ΔCKL and ΔmotAB ΔfliDST. Intracellularly very similar concentrations of E2 were seen in 
all strains. 
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Figure 5.21: Intracellular and secreted E2 from ΔCKL, ΔclpX ΔmotAB and ΔmotAB ΔfliDST. 
E.coli ΔCKL (C), ΔclpX ΔmotAB (X M) and ΔmotAB ΔfliDST (M DST)containing the plasmid pTrc 
E2 or pTrc empty was grown in LB. Cells were harvested at OD600 1.5 and prepared for SDS-
PAGE as in Figure 5.. Samples underwent SDS-PAGE and either Coomassie staining with Instant 
Blue (constrast adjusted) or Western blot analysis of cells and supernatant using anti-flagellin 
(H48) antibody and an HRP secondary. EZ-Run™ Prestained Rec Protein Ladder was loaded, as 
was an E2 protein standard (S) to allow quantification of intracellular and secreted protein 
concentration. Sample loaded (supernatant, cells, standard): for Coomassie: 15, 5, 5. Western: 
10, 1, 1.  
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Densitometry analysis was carried out the Western blot shown here and three other biological 
replicates. The results show that ΔmotAB ΔfliDST secretes the least E2 protein, this is expected 
as discussed previously (Figure 3.) the absence of FliS reduced E2 expression and secretion. 
ΔCKL secreted an average of 1.06µg E2 per Litre of culture supernatant as opposed to 3.98µg 
for ΔclpX ΔmotAB. This represented a significant 3.75 fold increase, however it is evident that 
cell lysis did occur, therefore how much of this can be attributed to FT3SS secretion is unclear. 
Intracellular E2 was lowest in ΔCKL 54.36mg L-1. The other strains expressed around twice this 
with averages of 126.63 and 109.00 mg L-1 being observed for ΔclpX ΔmotAB and ΔmotAB 
ΔfliDST respectively. In terms of the proportion of secreted E2 ΔclpX ΔmotAB was the most 
efficient secretor, secreting 5.73% total E2 protein.  
 
Figure 5.22: Western blot densitometry analysis of intracellular and secreted protein 
fractions of E2 expressing ΔCKL, ΔclpX ΔmotAB and ΔmotAB ΔfliDST.  
E.coli ΔCKL, ΔclpX ΔmotAB or ΔmotAB ΔfliDST containing the plasmid pTrc E2 were grown in LB 
supplemented with 0.05mM IPTG.  Cells were harvested at OD600 1.5. Following Western blot 
analysis of cells and supernatant using an anti-flagellin (H48) antibody and an HRP secondary, 
densitometry analysis was carried out using ImageJ. An E2 protein standard allowed exact 
quantification of E2 in cell culture. Individual data points, average and standard error of the 
mean are given for (A) secreted and (B) intracellular E2. (C) Proportion of secreted E2 as a 
proportion of total E2 both secreted and retained in cells. Four biological replicates for each 
strain. One-way ANOVA and Tukey’s multiple comparison test carried out (*: p = <0.05) 
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5.4.4.2. Secretion of CH2 through the modified FT3SS of the best 
candidate secretion strains 
CH2 protein was also secreted in the two best candidate secretion strains. Cells expressing 
empty secretion construct were also grown, to assess the effect of CH2 expression on total 
protein expression and cell lysis in strains. Figure 5. (top) shows that the supernatant was free 
of intracellular contaminants, suggesting cell lysis was not prevalent. In the intracellular 
fractions of ΔclpX ΔmotAB the 22kDa protein was again overexpressed, whether cells were 
expressing CH2 or empty secretion construct. From the Western blot (Figure 5.-bottom) it is 
apparent that less CH2 was expressed in ΔmotAB ΔfliDST compared to the other strains which 
are quite similar. ΔclpX ΔmotAB secretes much more CH2 than the other two strains. 
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Figure 5.23: Intracellular and secreted CH2 from ΔCKL, ΔclpX ΔmotAB and ΔmotAB ΔfliDST 
E.coli ΔCKL (C), ΔclpX ΔmotAB (X M) and ΔmotAB ΔfliDST (M DST) containing the plasmid 
pJexpress-FliC-CH2-FLAG-Strep or pJexpress-FliC-empty-FLAG-Strep were grown in LB 
supplemented with 0.05mM IPTG.  Cells were grown and prepared as in Figure 5.. Samples 
underwent SDS-PAGE and either staining with Instant Blue Coomassie stain (top) or Western 
blot (bottom) analysis of cells and supernatant using an anti-FLAG-HRP antibody. Samples were 
loaded to as follows: Supernatant: 20µL. Cells: 2µL (Western blot), 5µL (Coomassie stain). 
Standard: 5µL 
 
Two biological replicates were carried out however secreted CH2 was only detected in the blot 
shown in Figure 5.. Densitometry analysis was carried out when CH2 protein was visible. It was 
established that 86.76µg CH2 was secreted into a Litre of media of ΔclpX ΔmotAB cells, this 
was 2.56 fold higher than ΔCKL which secreted 33.94µg L-1 and much higher than the 4.85 µg L-
1 measured in ΔmotAB ΔfliDST. Intracellularly ΔclpX ΔmotAB expressed the most CH2 (4.64mg 
L-1 on average), despite this it still demonstrated the highest proportion for secreted protein as 
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a proportion of total CH2 in cell culture, secreting 0.024% CH2 -this was very low in 
comparison to values derived in the previous chapter.  
 
Figure 5.24: Western blot densitometry analysis of intracellular and secreted protein 
fractions of CH2 expressing ΔCKL, ΔclpX ΔmotAB and ΔmotAB ΔfliDST.  
E.coli ΔCKL, ΔclpX ΔmotAB and ΔmotAB ΔfliDST containing the plasmid pJexpress-FliC-CH2-
FLAG-Strep were grown in LB supplemented with 0.05mM IPTG.  Cells were harvested at OD600 
1.0. Following Western blot analysis of cells and supernatant using anti-FLAG-HRP, 
densitometry analysis was carried out using ImageJ. A CH2 protein standard allowed exact 
quantification of CH2 in cell culture. Individual data points, average and standard error of the 
mean are given when possible for (A) secreted and (B) intracellular CH2. (C) Proportion of 
secreted CH2 as a proportion of total CH2 both secreted and retained in cells. One biological 
replicate for A and C, two biological replicates for B. 
 
Despite the promise of ΔmotAB ΔfliDST with respect to increased secretion capacity for 
cutinase protein, it is evident that this secretion capacity ability did not extend to all proteins. 
However the discovery of the high capacity cutinase secretor ΔclpX ΔmotAB also proved to be 
a good platform strain for the secretion of E2 and CH2 protein. Therefore from the 13 modified 
FT3SS tested, ΔCKL ΔclpX ΔmotAB was the most promising, due to its high capacity to secrete a 
range of protein substrates. 
To date investigation has focused on strain improvement to increase secretion capacity of the 
FT3SS. This has been successful and the combination of strategies has been shown to 
culminate in an additive effect of secretion improvement, leading to the identification of two 
high secretion strains. Focus will now shift to investigate whether the secretion capacity can be 
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improved by modifying the secretion construct. In Chapter 4 is was shown that the secretion 
construct could be modified to inhibit FT3SS secretion, in this Chapter modifications will be 
implemented with the aim of improving FT3SS secretion 
 
5.5. Modification of the synthetic modular secretion 
construct for increased secretion through the FT3SS 
 
The term ‘secretion construct’ has been commonly used to refer to the transcribed and 
translated protein secretion construct. For the purpose of this section this will also refer to the 
untranslated (UTR) regions of the genetic secretion construct too. The current secretion 
construct harbours the 5’ and 3’ UTR region and a 47 amino acid secretion signal and was 
designed as a prototype. In the previous chapter it was found that altering these regions 
resulted in differential expression and secretion. The 5’ UTR region of FliC contains the fliC 
promoter and ribosome binding site (RBS). It is reported that is also harbours a signal for 
secretion (in Salmonella) and that secretion can be directed with the 5’ UTR alone (Majander 
et al., 2005; Anton et al., 2010).  However, necessity of the 5’ UTR was unsupported for both 
Salmonella and E. coli in the Végh et al. 2006 study. In the previous Chapter it was found that 
the removal of the 5’ UTR resulted in increased intracellular expression of protein, as it 
alleviated cell mediated negative regulation on plasmid expression through the fliC promoter, 
as the promoter is situated in this 5’ UTR region (Figure 4.). However absence of the 5’ UTR did 
seem to inhibit secretion. While the 5’ UTR may permit some secretion, the 47amino acid 
secretion signal is attributed as the primary facilitator of FT3SS secretion (Dobó et al., 2010). 
Removal of the signal peptide has been shown (here (Figure 4.) and in the literature) to result 
in inhibition of secretion, however the literature suggests that the entire signal peptide is not 
required to mediate FT3SS secretion. Instead, secretion can be achieved with just the 26-47 
amino acid region of the signal peptide in both Salmonella and E. coli (Végh et al., 2006). The 3’ 
UTR does not appear to be essential for secretion through the FT3SS (Anton et al., 2010; Végh 
et al., 2006).  
Despite the sometimes conflicting evidence, it is apparent that the presence or absence of UTR 
region and secretion signal peptide can incur variation in secretion, therefore a number of 
variant secretion constructs were generated. The aim was to assess whether secretion could 
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be improved with (a combination of) the removal of either UTR or the 1-25 N terminal amino 
acid sequence of the secretion signal peptide. Since much of the investigation into FT3SS 
secretion concerned Salmonella, a secretion construct was also designed to harbour the 26-47 
Salmonella FliC secretion signal peptide. It was hoped that one (or more) of these variant 
secretion constructs would surpass the secretion capacity facilitated by the prototype 
secretion construct and therefore serve as an improved secretion construct.   
 
5.5.1. Production of variants of the modified secretion construct 
 
Nine variations of the secretion construct were produced (Table 5.). Cutinase cargo was used 
so that the high-throughput MUB protein secretion assay could be implemented, to efficiently 
screen secretion construct mediated variation in FT3SS secretion. Primers were designed to 
amplify the relevant section of the secretion construct with restriction enzyme sites flanking 
the product, to allow cloning into a restriction enzyme digested pJexpress-FliC-empty vector. If 
necessary an RBS site and a start codon or stop codon was incorporated into the primers –this 
was essential if the 5’ or 3’ UTR were removed respectively, as they harbour these important 
genetic features. The 26-47 amino acid signal of E. coli and Salmonella typhimurium is 
conserved from 29-47, however while 26-28 encode SSS in E. coli it is GTA in S. typhimurium. A 
primer was designed which was homologous to the secretion signal from the 28th residue, 
however the 5’ UTR region included the nucleotides to transcribe GTA. Nucleotides were 
codon optimised for E. coli to aid translation. A graphical interpretation of primers and 
homologous sites is shown in Figure 5.. 
 
 
 
 
 
 
307 
 
Table 5.5: Guide to the production of variations of the pJexpress-FliC-cutinase-FLAG-Strep 
plasmid.  
Nine variations of the original pJexpress harbouring secretion construct were produced by PCR 
product amplification, restriction digest and ligation. PCR reactions (primers and size of 
product) are listed for each product and were carried out with the pJexpress-FliC-cutinase-
FLAG-Strep plasmid as a template. 
Reaction/secreti
on construct 
number 
Product (in pJexpress)/secretion 
construct (SC) 
F R Size 
(bp) 
1 NdeI- 5’ UTR-47aa-cutinase-Strep-
FLAG-BamHI 
5’ UTR 
47aa F 
no 3’ R 1158 
2 NdeI-RBS-ATG-47aa-cutinase-
Strep-FLAG-3’ UTR-BamHI 
47aa F 3’ UTR R 1226 
3 NdeI-RBS-ATG-47aa-cutinase-
Strep-FLAG-BamHI 
47aa F no 3’ R 897 
4 NdeI-RBS-ATG-E. coli 26-47-
cutinase-Strep-FLAG-3’ UTR-
BamHI 
coli 26-47 
F 
3’ UTR R 1148 
5 NdeI-RBS-ATG-E. coli 26-47-
cutinase-Strep-FLAG-BamHI 
coli 26-47 
F 
no 3’ R 825 
6 NdeI-RBS-ATG-Salmonella 26-47-
cutinase-Strep-FLAG-3’ UTR-
BamHI 
sal 26-47 
F 
3’ UTR R 1148 
7 NdeI-RBS-ATG-Salmonella 26-47-
cutinase-Strep-FLAG-BamHI 
sal 26-47 
F 
no 3’ R 825 
8 NdeI-RBS-ATG-cutinase-Strep-
FLAG-3’ UTR-BamHI 
No 5’ or 
47aa 
3’ UTR R 1084 
9 NdeI-RBS-ATG-cutinase-Strep-
FLAG-BamHI 
No 5’ or 
47aa 
no 3’ R 761 
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Figure 5.25: Schematic of the existing secretion construct harbouring cutinase and the 
primers used to generate alternative secretion constructs following the removal or 
modification of the 5’ or 3’ UTR regions or the 47 amino acid secretion peptide.  
The genetic version of the cutinase harbouring secretion construct is shown. This contains the 
5’ and 3’ UTR and 47 amino acid secretion signal was used as a template for PCR using a 
combination of the forward and reverse primers with elongated ends shown here. Restriction 
enzyme sites featured in the elongated ends of all primers. RBS site, start or stop codons or 
codon optimised regions featured in primers if necessary. This resulted in the generation of 
donor DNA, which following restriction digest with NdeI and BamHI was ligated into an 
NdeI/BamHI digested plasmid harbouring the empty secretion construct. This resulted in the 
generation of novel plasmids which harbour novel genetic secretion constructs (Table 5.).  
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Following high-fidelity PCR, DNA products of the anticipated size (Table 5.) were derived for all 
primer combinations. This was confirmed by running PCR products on a DNA agarose gel 
(Figure 5.). PCR products were excised from the gel and isolated, for restriction digestion. 
 
 
Figure 5.26: Agarose DNA gels showing PCR products for ligation into NdeI and BamHI 
digested pJexpress-FliC-empty-FLAG-Strep 
PCR reactions were carried out using pJexpress-FliC-cutinase-FLAG-Strep as template and 
primers in Appendix 2 with Phusion® High-Fidelity DNA Polymerase. PCR mixtures were 
analysed on a 1% TAE agarose DNA gel supplemented with a trace of ethidium bromide, 
visualised under UV light and inverted. Samples were run with GeneRuler™ 1kb DNA ladder. 
The lane annotations refer to the product number listed in Table 5.; the sizes of products are 
also given in this table.   
 
Isolated PCR products and pJexpress-FliC-empty-FLAG-Strep underwent restriction digest with 
NdeI and BamHI in CutSmart buffer. Following this incubation step the acceptor vector was 
treated with Antarctic phosphatase to discourage re-circularisation and then run on a DNA 
agarose gel to confirm successful restriction digest. As a control, acceptor vector which had 
been incubated without restriction digest enzymes was also loaded on to the gel. As opposed 
to the smaller supercoiled circular DNA seen in lane 1, two DNA products are visible in the 
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second lane, showing the cut acceptor vector and the faint 772kbp section of DNA comprising 
of the empty secretion construct (Figure 5.). Although the digested acceptor vector appears to 
run bigger than the 3967kbp expected, the increase in size compared to the undigested and 
presence of the excised secretion construct give confidence that it is the correct product. As 
the product resulting from restriction digest of the PCR products was only 18bp shorter than 
the original product, these restriction digest mixtures were not visualised by DNA 
electrophoresis. As BamHI cannot be heat inactivated all digested DNA underwent PCR clean 
up prior to ligation.  
 
Figure 5.27: Agarose DNA gel showing uncut and NdeI and BamHI cut pJexpress-FliC-empty-
FLAG-Strep 
Restriction digest reactions were carried out both with and without the addition of restriction 
enzymes. 5µL restriction digest mixture was prepared for DNA electrophoresis and loaded on a 
1% TAE agarose DNA gel supplemented with a trace of ethidium bromide and visualised under 
UV light and inverted. Lanes: (1) GeneRuler™ 1kb DNA ladder, (2) uncut vector, (3) NdeI and 
BamHI cut vector 
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Following overnight ligation of all PCR products into pJexpress-FliC-empty-FLAG-Strep, ligation 
reactions were transformed into NEB 5-alpha Competent E. coli and screened by plating on LB 
agar plates supplemented with ampicillin. Positive colonies were screened by colony PCR with 
DreamTaq DNA polymerase and relevant primers to confirm successful ligation of DNA. 
Positive colonies were then sequenced and full sequence alligment was confirmed for at least 
one plasmid for each product.  
 
5.5.2. Production of variants of the modified secretion construct 
 
Once the full set of secretion construct variants had been established expression and secretion 
of cutinase was investigated to see if any of the newly derived constructs resulted in improved 
FT3SS secretion. Plasmids harbouring all nine of the variant secretion constructs –along with 
the original prototype secretion construct were freshly transformed in to ∆CKL. The ∆CKL strain 
was chosen so that secretion of variant secretion constructs could be related to the best 
characterised secretion strain. ∆flhDC secreting cutinase and ∆CKL secreting empty secretion 
construct were included as negative controls; ∆clpX secreting cutinase was also included as a 
positive reference, so that ∆CKL secreting the original secretion construct was not the sole 
point of context to previous experiments. The MUB protein secretion assay was utilised to 
investigate secreted cutinase and Western blot analysis was used to investigate expression. 
The Coomassie stain (Figure 5. top) reveals that intracellular protein expression was uniform in 
all strains when expressing all plasmids. Expression of cutinase SC8 did result in a visible 
protein band at around 26kDa. Following Western blot analysis it was evident that when 
expressed from the prototype secretion construct cutinise was present in all strains. 
Modification of the secretion construct resulted in variable intracellular expression of cutinase, 
the highest being when SC8 was expressed. In some strains very little cutinase was observable 
in cells. In comparison to the 30.6kDa full length prototype secretion construct, candidate 
secretion constructs 4-7 were all slightly smaller (predicted size 27.8kDa), owing to the fact 
residues 1-25 were not present and SC8 and SC9 smaller again because of the absence of all 47 
residues of the secretion signal peptide (predicted size 25.8kDa). As expected removal of UTRs 
did not alter protein size. 
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Figure 5.28: Intracellular cutinase in original prototype cutinase-secretion construct 
expressing ΔflhDC and ΔCKL ΔclpX and ΔCKL expressing the prototype secretion construct 
and nine candidate secretion constructs 
Both E.coli strains ΔflhDC, ΔCKL ΔclpX and ΔCKL expressing pJexpress-FliC-cutinase-FLAG-Strep 
and ΔCKL expressing pSC1-9 were grown in LB supplemented 0.05mM IPTG (or 1mM for 
ΔflhDC).  See Table 5. for numerical labelling of secretion constructs. Cells were harvested at 
OD600 1.0. 1 OD unit of cells were prepared with 2x SDS-PAGE loading buffer. Samples 
underwent SDS-PAGE and either staining with Instant Blue Coomassie stain (top) or Western 
blot (bottom) analysis of cells and supernatant using an anti-FLAG-HRP antibody. Samples were 
loaded to as follows: 2µL (Western blot), 5µL (Coomassie stain). One biological replicate of 
each strain shown. 
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Results in Figure 5. were analysed by densitometry and combined with another biological 
replicate by normalising all values to that measured for ΔCKL expressing the original cutinase 
harbouring secretion construct (Figure 5.). This confirmed that significantly less cutinase was 
present in the intracellular fractions of cells expressing secretion construct variants which do 
not have the 3’ UTR (SC1, 3, 5, 7). In contrast expressing SC8 resulted in significantly higher 
intracellular cutinase expression (2.19 fold). 
 
Figure 5.29: Western blot densitometry analysis of intracellular protein fractions of 
prototype cutinase-secretion construct expressing ΔflhDC and ΔCKL ΔclpX and ΔCKL 
expressing the prototype secretion construct and nine candidate variant secretion 
constructs. 
The Western blot derived image from Figure 5. and one other biological replicate following the 
same protocol underwent densitometry analysis with ImageJ. Results were then normalised to 
the value obtained for intracellular cutinase in the ΔCKL strain expressing the original 
prototype cutinase harbouring secretion construct. Individual data points, average and 
standard error of the mean are given. Two biological replicates were carried out for each 
strain. One-way ANOVA carried out on data derived from ΔCKL cells expressing cutinase (i.e. 
variable is secretion construct) p = < 0.0001. Tukey’s multiple comparison test in comparison to 
ΔCKL secreting original prototype secretion construct. *: p = <0.05, **: p = <0.01. 
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Next a MUB protein secretion assay was performed on the supernatant fraction of cells 
expressing the candidate secretion constructs. Following incubation of the supernatant 
fractions of the cell cultures described in Figure 5. and Figure 5. with MUB, reaction mixes 
were excited at 302nm and emission at 446nm was read. Results were normalised to the 
average AU for MUB + LB in each experiment and then normalised to the AU for ΔCKL cells 
expressing cutinase in the original secretion construct to allow the combination of biological 
replicates and ease of data interpretation. Florescent output values were low for all negative 
controls. The AU for ΔclpX expressing cutinase was on average 1.61 fold higher than that seen 
in ΔCKL, this is in line with previous observations, suggesting that the fluorescent output 
recorded for ΔCKL is dependable on for comparison of cutinase secretion of secretion 
construct variants. Secretion constructs 2-9 all had emission values which were higher than the 
values measured for ΔCKL secreting empty secretion construct, however they were 
significantly lower than the emission value for ΔCKL with the prototype secretion construct, 
suggesting that secretion was hindered in these secretion constructs in comparison to the 
prototype secretion construct. The only variant to result in higher AU readings than the 
prototype was SC1, which was on average 1.78 times higher –this was found to be significant. 
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Figure 5.30: Relative fluorescence output (AU) of reaction mixtures following incubation of 
MUB with the secreted fraction of prototype secretion construct expressing ∆flhDC and ΔCKL 
ΔclpX  and ∆CKL expressing the prototype secretion construct and nine candidate variant 
secretion constructs.  
Both E.coli strains ΔflhDC, ΔCKL ΔclpX and ΔCKL expressing pJexpress-FliC-cutinase-FLAG-Strep 
or pJexpress-FliC-empty-FLAG-Strep and ΔCKL expressing pSC1-9 were grown in LB 
supplemented 0.05mM IPTG (or 1mM for ΔflhDC). See Table 5. for numerical labelling of 
secretion constructs. Cells were grown and prepared for the MUB protein secretion assay as in 
Figure 5.9. Fluorescence was measured at 446nm following excitation at 302nm. Results from 
three biological replicates, with three technical repeats for each. Individual data points, the 
mean and standard error of the mean is displayed. To allow comparison of results between 
experiments, results were normalised to the average value for ΔCKL secreting the original 
secretion construct once adjusted for MUB + LB background AU in each experiment. One-way 
ANOVA carried out on data derived from ΔCKL cells expressing cutinase (i.e. variable is 
secretion construct) p = < 0.0001. Tukey’s multiple comparison test in comparison to ΔCKL 
secreting original prototype secretion construct. All at least p = < 0.001 (***). 
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Investigations found that SC8 expressed significantly more cutinase than any other secretion 
construct, however it secreted little. In contrast SC1 secreted a high concentration of cutinase, 
however little was found intracellularly. Interestingly the second highest intracellular and 
secreted concentration of cutinase were both recorded in the original secretion construct in  
SC8 refers to the secretion construct without the 5’ or 3’ UTR regions or 47 amino acid signal 
and SC1 the secretion construct without the 3’ UTR region. Reasons for these observations will 
be discussed later.  
 
5.6. Investigation of secretion through the FT3SS 
following both strain and secretion construct 
improvements 
 
While ΔclpX ΔmotAB was found to have the highest secretion capacity, ΔmotAB ΔfliDST was 
also effective at secreting cutinase (if not the other two substrates), therefore was also 
included in this section of investigation. Expression and secretion were investigated with 
combinations of the two strains with the highest secretion capacity (ΔmotAB ΔfliDST and ΔclpX 
ΔmotAB) and the secretion construct which resulted in the highest secretion capacity (SC1). In 
the absence of a protein standard to quantify absolute yield, both the prototype secretion 
strain (ΔCKL) and prototype secretion construct were used in conjunction to allow comparison 
of secretion improvements. Cells were cultured and prepared for MUB secretion assay and 
Western blot analysis as before. The secreted fraction of cell cultures was also prepared for 
SDS-PAGE to visualise secreted cutinase by another means, but mainly to assess whether cell 
lysis occurred with any combination of strain or secretion construct.   
The absence of intracellular protein in the Coomassie stained SDS-PAGE gel of secreted protein 
fractions show that cell lysis was not prevalent in any of the strain or plasmid combinations 
(Figure 5.A). A band is present at around 72kDa, however as this was also present in lanes with 
no sample loaded, this is likely to be an artefact of buffers used to make and run the SDS-PAGE 
gels. The intracellular fractions look similar, aside from the commonly overexpressed protein in 
ΔclpX ΔmotAB cells expressing any plasmid (Figure 5.C). Western blot analysis shows that 
cutinase was secreted in all strain combinations aside from ΔmotAB ΔfliDST with SC1 (Figure 
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5.B). A very small amount of cutinase was present in the supernatant of ΔCKL cells, ΔclpX 
ΔmotAB and ΔmotAB ΔfliDST secreted a reasonable amount of cutinase, however the highest 
concentrations were seen when ΔCKL or ΔclpX ΔmotAB expressed SC1 - ΔclpX ΔmotAB 
resulting in the highest concentration. Intracellularly cutinase was not visible in the cells of 
ΔmotAB ΔfliDST expressing SC1, which explains why none was secreted in this strain. ΔclpX 
ΔmotAB expressed more cutinase that ΔCKL with both secretion constructs and strains 
expressed more cutinase with the prototype secretion construct (Figure 5.D). 
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Figure 5.31: Intracellular and secreted cutinase from ∆CKL and the ΔclpX ΔmotAB and 
ΔmotAB ΔfliDST mutants expressing either cutinase harboured in either the prototype (P) 
secretion construct or SC1 (1). 
E.coli ΔCKL (C), ΔCKL ΔclpX ΔmotAB (X M) or ΔCKL ΔmotAB ΔfliDST (M DST) expressing either 
pJexpress-FliC-cutinase-FLAG-Strep (P), pSC1 (1) or pJexpress-FliC-empty-FLAG-Strep (-) was 
grown in LB supplemented with 0.05 IPTG.  Cells were grown and prepared as in Figure 5.. 
Samples underwent SDS-PAGE and either staining with Instant Blue Coomassie stain or 
Western blot analysis of cells and supernatant using an anti-FLAG-HRP antibody. (A) Samples 
from all cultures were loaded onto the Coomassie stained SDS-PAGE ((A).Supernatant: 20µL. 
(C) cells: 5µL), samples from cultures expressing cutinase (P or 1) were loaded on to the SDS-
PAGE gel for Western blotting: (B) Supernatant: 20µL.  (D) Cells: 2µL.  
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Densitometry allowed the results from two biological replicates of the data shown in Figure 5. 
to be combined. This was achieved by normalising results to ΔCKL expressing the prototype 
secretion construct. The relative abundance of secreted protein was variable (Figure 5.). The 
highest observed concentration of secreted cutinase was derived from ΔclpX ΔmotAB when 
expressing pSC1 – 4.36 times more on average in comparison to the 2.81 fold increase seen 
when ΔCKL expressing pSC1 compared to the prototype. Cutinase was not observed in the 
intracellular or secreted fractions of ΔmotAB ΔfliDST cells when expressing pSC1 for either 
biological replicate. Intracellularly the concentration of cutinase in the other two strains was 
similar whether expressing cutinase in the prototype or pSC1 secretion construct –the 
concentration was always higher in ΔclpX ΔmotAB. 
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Figure 5.32: Western blot densitometry analysis of intracellular and secreted protein 
fractions of ∆CKL and the ΔclpX ΔmotAB and ΔmotAB ΔfliDST mutants expressing cutinase 
harboured in either the prototype secretion construct or SC1. 
E.coli ΔCKL, ΔCKL ΔclpX ΔmotAB or ΔCKL ΔmotAB ΔfliDST containing the plasmid pJexpress-FliC-
cutinase-FLAG-Strep or pSC1 was grown in LB supplemented with 0.05 IPTG.  Cells were 
harvested at OD600 1.0. Following Western blot analysis of cells and supernatant using anti-
FLAG-HRP, densitometry analysis was carried out using ImageJ and results were normalised to 
ΔCKL expressing cutinase in the prototype secretion construct in each experiment. Individual 
data points, average and standard error of the mean are given when possible for (A) secreted 
and (B) intracellular cutinase. Two biological replicates of for each. Two-way ANOVA found 
that variance was significant between strains for both secreted and intracellular cutinase (p = 
<0.05) 
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The results of Western blot following probing with the cytoplasmic protein antibody anti-GroEL 
demonstrate that there was little cell lysis or membrane leakage in the ΔclpX ΔmotAB cells 
when expressing either secretion construct (slightly higher with the prototype, but still 
negligible) (Figure 5.). Both ΔCKL and ΔmotAB ΔfliDST have slight cytoplasmic contamination 
when expressing all both secretion constructs, a slightly higher level of cytoplasmic 
contamination was seen in the supernatant of ΔmotAB ΔfliDST when expressing SC1. However 
given the sensitivity of this antibody, it can be concluded that cell lysis or membrane leakage is 
not high in any of the cell cultures shown here. 
 
Figure 5.33: Abundance of GroEL in the intracellular and supernatant fractions of ∆CKL and 
the ΔclpX ΔmotAB and ΔmotAB ΔfliDST mutants, following expression and secretion of 
cutinase protein either in the prototype secretion construct or SC1 through the FT3SS. 
E.coli ΔCKL (C), ΔCKL ΔclpX ΔmotAB (X M) or ΔCKL ΔmotAB ΔfliDST (M DST) containing the 
plasmid pJexpress-FliC-cutinase-FLAG-Strep or pSC1 was grown in LB. Cells were harvested at 
OD600 1.0. Samples underwent SDS-PAGE and Western blot analysis of cells and supernatant 
using anti-GroEL antibody and an HRP secondary. Samples were loaded as follows: 
Supernatant: 20µL, cells: 2µL. 
 
Following incubation of the supernatant of the cell cultures analysed in Figure 5.-Figure 5. with 
MUB, emission values were derived. To combine biological replicates, results were subtracted 
by the average fluorescence reading for MUB + LB to reduce the effect of background 
fluorescence, finally results were normalised to that calculated for ΔCKL expressing the 
prototype secretion construct in each experiment, to aid interpretation. Both strain and 
secretion construct resulted in significant variation in results (Two-way ANOVA. p = <0.0001) 
(Figure 5.).  Empty secretion construct resulted in low fluorescent outputs as did ΔmotAB 
ΔfliDST when expressing either of the cutinase containing secretion constructs. However 
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compelling results were observed for ΔclpX ΔmotAB and SC1. In terms of the prototype 
secretion construct ΔclpX ΔmotAB had 7.67 times more fluorescent output than ΔCKL. When 
expressing SC1 this resulted in a 15.70 and 23.78 fold increase in fluorescent output for the 
ΔCKL and ΔclpX ΔmotAB strains respectively. All of these increments were shown to be 
significantly higher than ΔCKL with the prototype secretor strain. Additionally the difference 
between ΔclpX ΔmotAB secreting the two secretion constructs was significant, as was the 
difference or ΔCKL and ΔclpX ΔmotAB secreting SC1. These amounted to a 3.10 and 1.51 fold 
change for each of the aforementioned significant increases in emission output. Therefore not 
only were great improvements made in terms of secretion strain and construct, they are also 
additive. 
 
 
 
 
 
 
 
322 
 

C
K
L
 +
 e
m
p
ty
 

C
K
L
 +
 p
ro
to
ty
p
e

C
K
L
 +
 S
C
1
'

X
 
M
 +
 e
m
p
ty

X
 
M
 +
 p
ro
to
ty
p
e

X
 
M
 +
 S
C
1

M
 
D
S
T
 +
 e
m
p
ty

M
 
D
S
T
 +
 p
ro
to
ty
p
e

M
 
D
S
T
 +
 S
C
1
0
1 0
2 0
3 0
A
U
 r
e
la
ti
v
e
 t
o
 C
K
L
 +
 c
u
ti
n
a
s
e
****
****
****
  
Figure 5.34: Relative fluorescence output (AU) of reaction mixtures following incubation of 
MUB with the secreted fraction of ∆CKL and the ΔclpX ΔmotAB and ΔmotAB ΔfliDST mutants, 
following expression and secretion of either the empty secretion construct or cutinase 
protein either in the prototype secretion construct or SC1.  
E. coli ∆CKL, ∆flhDC, ΔclpX ΔmotAB or ΔCKL ΔmotAB ΔfliDST containing either the plasmid 
pJexpress-FliC-cutinase-FLAG-Strep,  pSC1 or pJexpress-FliC-empty-FLAG-Strep were induced 
with 0.05mM IPTG and grown and prepared for the MUB protein secretion assay as in Figure 
5.9. Fluorescence was measured at 446nm following excitation at 302nm. Results from two 
biological replicates, with three technical repeats for each. Individual data points, mean and 
standard error of the mean is displayed. To allow comparison of results between experiments, 
results were normalised to the average value for MUB + LB in each experiment and then 
normalised to the results for ∆CKL expressing the prototype cutinase construct in each 
experiment. A two-way ANOVA found the variance of data to be statistically significant both 
between strains and secretion construct cargo. (p = <0.0001). Tukey’s multiple comparison test 
of cutinase expressing strains compared to the prototype cutinase secretion construct 
expressing ∆CKL (****: p = <0.0001) 
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5.7. Discussion: Development of a high-throughput assay 
for FT3SS secretion to screen a multitude of secretion 
strains and plasmids 
 
5.7.1. Secretion of active cutinase through the modified FT3SS 
 
This Chapter aimed to incorporate the esterase cutinase into the secretion construct to 
continue to characterise secretion of recombinant protein through the modified FT3SS. While 
cutinase is an industrially relevant enzyme, the major motivation to investigate the secretion 
of this enzyme was to develop a high-throughput assay. The assay should efficiently and 
accurately measure secretion capacity with the aim of screening a large number of potential 
strains and variants of the secretion construct to establish the most promising combination for 
achieving a high concentration of secreted protein. It also allowed demonstration that a 
recombinant secreted protein could fold correctly once secreted into the media, as enzyme 
activity is dependent on structure. 
The recombinant F. solani cutinase protein cargo was designed and synthesised de novo and 
successfully cloned into the secretion construct. While Western blot analysis had been 
successfully utilised in Chapters 3 and 4 to ascertain the concentration of secreted protein and 
therefore secretion capacity of strain, there were some limitations –namely related to the time 
consumed and inaccuracies which arise due to inherent properties of the procedure, for 
example lack of linearity of chemiluminescent signal.  Development of an enzyme based 
secretion assay was key to improving the throughput of secretion capacity characterisation; 
the specifications were that it should be time efficient and provide accurate results. A 
multitude of assays have been reported for the cutinase enzyme –although fewer have been 
reported suitable for the F. solani cutinase specifically (Kwon et al. 2009; Liu et al. 2009; Chen 
et al. 2008). The use of tributyrin, Rhodamin B and pNPB were all tested in preliminary 
experiments, however MUB proved to yield the best results in preliminary testing (Figure 5.), 
therefore was chosen as the substrate for the development of the cutinase protein secretion 
assay. This result was impressive as it indicated that the modified FT3SS had the capacity to 
secrete a protein, which was able to fold correctly in the extracellular space to exhibit 
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functionality. SDS-PAGE based analysis of cell cultures was still of importance in this work to 
ensure that cell lysis wasn’t commonplace and to visualise intracellular cutinase 
concentrations, but also to show that the MUB secretion assay produced results which were 
concordant and therefore producing reliable results. In line with the MUB protein secretion 
assay result, cutinase was shown to be expressed and secreted in sufficient concentrations to 
be detectable through Western blot analysis with anti-FLAG-HRP antibody (Figure 5.). The 
MUB assay was not suitable for measuring intracellular cutinase; a trial run was carried out 
where cells were pelleted and resuspended in MUB, however results were similar for strains 
whether secreting cutinase or not. Although cells were not lysed here, the lack of negative 
control at this stage made it an undesirable line of investigation. 
In previous chapters a protein standard has been derived to quantify yields of both expressed 
and secreted protein. However this was not possible for cutinase; following overexpression in 
BL21 (DE3), sufficient cutinase was found in the soluble fraction, however when the 
purification protocol was carried out, cutinase did not bind to the Strep-trap column efficiently 
and the low concentration which was recovered quickly degraded. However as cutinase 
secretion was primarily investigated as a tool to measure relative changes in FT3SS protein 
secretion, it is not so essential to quantify exact concentrations. That said, it would still be 
beneficial, therefore expressing cutinase in a different protein expression strain would be 
desirable to see if any more cutinase could be recovered. Another option would be to attempt 
to purify cutinase on a column with affinity for the FLAG-tag. 
Steps were taken to ensure that the assay was fully optimised to account for substrate 
concentration (Figure 5.), time of reaction (Figure 5.) and the correct wavelength to measure 
fluorescent output (AU) following excitation (Figure 5. and Figure 5.8). pH was also 
investigated and pH 5 settled on due to reduced background fluorescence. While the optimal 
pH for the assay was not in line with the optimal pH for cutinase, it was evident that cutinase 
was still active in these conditions and as the assay measures relative fluorescence, the priority 
is for the assay to be accurate and reproducible, therefore it is not essential that cutinase is 
optimally functional. Initially the assay was carried out with the addition of quenching buffer 
and excitation at 365nm, however this produced results with high background fluorescence, 
which masked the true pattern of variation in the data (Figure 5.). As an alternative reaction 
mixtures were instead subject to excitation at the UV light range, at 302nm. At this excitation 
wavelength background fluorescence was both reduced and more uniform, it was observed 
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that the majority of this was due to the presence of LB in reaction mixes (Figure 5.). This effect 
may be reduced if cell cultures were grown in a minimal media (e.g. M9) to alleviate the 
contribution of LB to background fluorescence, however as this investigation concerns the 
secretion of protein in industrially relevant conditions, the data derived would not be 
applicable, as industry use rich media in cell culture. As LB was constant in all reaction 
mixtures, this was not a limitation and with excitation at 302nm the results from reaction 
mixes which contained cutinase were clearly pronounced from other reaction mixtures. 
Further to this the differences between ‘positive’ results were larger, this made data analysis 
and interpretation much simpler. Finally as pH quenching was not necessary, throughput was 
again improved.  
The image based MUB secretion assay (Appendix 5) was useful as an indicator of whether 
cutinase was present or absent, however not sensitive enough to distinguish between 
different concentrations of cutinase by eye. Densitometry was not possible due to the 
presence of shadows, so this could not be developed into a high throughput test, however 
there certainly is scope to utilise the image based assay to screen for presence or absence of 
secretion, for example when screening a transposon library.  
Once optimised the assay was utilised to demonstrate that cutinase secretion was directed 
through the modified FT3SS. This was confirmed by the the absence of cutinase in the 
supernatant of negative secretion strains (Figure 5.). It was essential that the assay did not 
report false positive results of cutinase secretion, so this was ideal. It was also demonstrated 
that the results of the MUB protein secretion assay were concordant with Western blot 
analysis. Higher fluorescent output (Figure 5.) and higher antibody signal (Figure 5.) are both 
indicative of a higher concentration of secreted cutinase. Both assays reported ∆CKL to secrete 
the least cutinase and that ∆CKL ∆clpX secreted twice as much. There was a slight mismatch in 
∆CKL ∆flgMN as the Western blot suggested around twice as much cutinase was secreted, 
compared to the MUB secretion assay which calculated it to be 1.53 fold higher. However the 
trend was still correct. The fact that negative control, sensitivity and accuracy have been 
achieved in the MUB secretion assay is essential to producing reliable results. Throughput was 
also greatly increased with the utilisation of this assay in comparison to Western blot analysis, 
however it was hoped that this could be extended by growing cell cultures in a 96 well plate 
and then centrifuging the plate to isolate cell culture supernatant. This could then be directly 
applied to MUB to carry out the assay. This modification to the assay was trailed in tandem 
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with 10mL cultures, however as it was evidently important to normalise culture supernatants 
with the addition of LB media to account for the variation in OD600 of cell cultures, therefore 
this method was not suitable for high throughput use, as this step hindered the process. As 
OD600 were generally within 10% of each other, this could be overlooked, however it was 
decided that this should be accounted for to improve accuracy. 
With the establishment that the MUB protein secretion assay enabled negative control and the 
distinction of differing concentrations of secreted cutinase, the assay was utilised for the 
investigation of secretion capacity of a number of strains and secretion construct variants.  
 
5.7.2. Combination of strain improvement strategies for increased 
FT3SS capacity 
 
Following on from confirmation in Chapters 3, 4 and 5 that four of the strategies (∆motAB, 
∆flgMN, ∆fliDST and ∆clpX) to improve the secretion capacity of the FT3SS were successful, it 
was desirable to combine these knockout mutations to investigate whether the improvements 
to secretion would be cumulative. Strains were generated through a combination of Lambda-
Red recombineering and P1 phage transduction. This resulted in the generation of eight new 
strains which carried a combination of knockout mutagenesis strategies which had been 
shown to increase protein secretion through the FT3SS. The growth curve of strains suggested 
that knockout mutations generally resulted in lower optical densities of cells compared to 
∆CKL, however it did not appear that any of the combinations of mutations were lethal or very 
detrimental to cell growth (Figure 5.). The effect of producing cutinase was negligible on cell 
growth for all strains (Figure 5.4); suggesting that overexpression of a recombinant enzyme 
had no negative effects on cell viability.  
Once cell viability was confirmed the collection of knockout mutants could be screened to 
ascertain the most effective secretors of cutinase. This involved testing the eight newly 
generated strains, the four previously tested secretion strains, the original ∆CKL strain and a 
negative control strain must also be included. To test the secretion capacity of 14 strains using 
the Western blot based secretion assay would have been extremely time consuming, and 
additionally limiting as not all of the experiments could be analysed in tandem, whereas all can 
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be screened on one 96 well plate. The concentration of intracellular cutinase produced in all 
strains was fairly similar –all were capable of expressing a sufficient amount with induction 
with 0.05mM IPTG (Figure 5. and Figure 5.). The variability of intracellular cutinase between 
biological repeats was high (Figure 5.6), this was due to the dependence on the concentration 
of intracellular cutinase in ∆CKL on results. As all results are normalised to this value, any 
fluctuations in the concentration of cutinase in ∆CKL has a large effect on all other results. In 
future a protein standard would be useful to reduce the variation, as values could be 
normalised to a constant concentration of cutinase. 
Despite the thorough optimisation of the MUB protein secretion assay, results for the 
concentration of secreted cutinase in all strains were variable (Figure 5.9). However the assay 
was able to uncover strains which secreted significantly higher cutinase than ∆CKL. Previously 
∆flgMN had been shown to secrete more cutinase than ∆CKL (Figure 5.); however this was not 
the case here, it is likely that this is the result of biological variation –as the results here are 
derived from three biological replicates, whereas previous reading were derived from one, this 
data is more reliable. In Figure 5.97, ∆flgMN did not contribute to increased secretion capacity 
with regard to cutinase secretion (in Chapter 3 and 4 E2 secretion in ∆flgMN was similar to 
∆CKL and for CH2 better Figure 3. and Figure 4.). ∆flgMN fluorescence was lower than ∆CKL 
alone and ∆motAB ∆flgMN and ∆clpX ∆flgMN was low, despite ∆motAB and ∆clpX being high. 
This suggests that ∆flgMN actually has a negative effect on cutinase secretion through the 
FT3SS. It has previously been shown that the removal of clpX results in increased secretion of 
FlgM (Guo et al. 2014). Therefore ∆clpX will already demonstrate some of the benefits of the 
strategy which is implemented by removing flgMN. This would explain why the combination of 
the two does not lead to increased secretion in comparison to the two individually, but not 
why it would be decreased.  
The strains which secreted significantly higher concentrations of cutinase were ∆motAB ∆fliDST 
and ∆clpX ∆motAB. ∆clpX and ∆motAB were both high capacity cutinase secretors individually, 
so it was anticipated that ∆clpX ∆motAB would secrete a high concentration of cutinase, 
however it is an incremental increase, not a cumulative increase. Suggesting that one of these 
mutations is limiting in terms of secretion capacity. Alone, ∆fliDST did not secrete a high 
concentration of cutinase, however when combined with ∆motAB it improved the secretion 
capacity over ∆motAB alone.  Interestingly the combination of these mutations did not result 
in improved secretion capacity of the FT3SS, as ∆clpX ∆motAB ∆fliDST secreted less than 
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∆motAB ∆fliDST and ∆clpX ∆motAB. If the three mutation strategies concerned flagella 
proteins, it might be theorised that only so many proteins can be removed before the 
structure or regulation is comprised, however ClpX is not a direct component of this. An 
alternative perspective is that there is a point where flhDC expression cannot be improved or 
that additional FlhD4C2 becomes detrimental to the cell. It was not possible to generate ∆fliC 
∆flgKL ∆motAB ∆flgMN ∆fliDST and ∆fliC ∆flgKL ∆motAB ∆flgMN ∆fliDST ∆clpX in the time of 
this project, however the poor secretion capacity of ∆flgMN ∆fliDST and ∆clpX ∆motAB ∆flgMN 
or ∆clpX ∆motAB ∆fliDST suggest that these strains would not have resulted in improved 
secretion capacity of the FT3SS. 
Of the 14 strains in the ∆CKL background, which carry additional gene knockouts, the two best 
strains (∆motAB ∆fliDST and ∆clpX ∆motAB) –as established by MUB secretion assay- were 
investigated more thoroughly to confirm the improvement in secretion capacity of cutinase by 
Western blot and to extend measurement of secretion capacity to additional protein 
substrates. Western blot analysis of the secreted fraction of these strains found that in 
comparison to ∆CKL, ∆motAB ∆fliDST secreted slightly more cutinase, whereas ∆clpX ∆motAB 
secreted around four times as much cutinase (Figure 5.10). These results were concordant in 
terms of ∆clpX ∆motAB with the MUB protein secretion assay (Figure 5.0), however ∆motAB 
∆fliDST had a higher fluorescent output that would be expected based on the Western blot. 
The rationale for the development of the MUB protein secretion assay was in part due to 
variable and potentially incorrect results obtained with Western blot analysis, therefore it is 
more likely that it is the Western blot which is giving inaccurate results. This is particularly 
relevant when protein abundance is high as lack of linearity in the chemiluminescent signal is 
more pronounced, leading to incorrect reporting of protein concentration (Gilda et al., 2015). 
This highlights a major issue when using Western blot analysis to screen unknown and high 
ranging quantities of protein, Western blots are better optimised by loading similar 
concentrations of antibody detected protein in each lane of the SDS-PAGE gel. However not 
only is this unknown, it is also unlikely in this kind of screening experiment. The MUB secretion 
assay is much better suited to detecting a wide range of concentration of secreted proteins of 
unknown and high ranging concentration.  
In general obtaining a satisfactory Western blot of secreted cutinase was often difficult and 
experimental failure due to lack of antibody chemiluminescent signal was commonplace; it is 
possible that cutinase is secreted into the supernatant in very low concentrations, which 
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hinders detection by antibody binding. An alternative is that the FLAG-tag is for some reason 
not always accessible or present for antibody binding, however this is unlikely as a the FLAG-
tag is detectable in some capacity, therefore must be present. While the overall aim of the 
work is to achieve a high yield of secreted protein, it is not a limitation if low concentrations of 
cutinase are secreted because the purpose of this assay is to screen FT3SS secretion capacity 
to assess improvements, to generate a high capacity platform strain for secretion. Whether the 
FT3SS has a low affinity for cutinase or whether cells generally express less cutinase than other 
secretion substrates (E2 and CH2) is hard to assess as a protein standard was not generated for 
cutinase, therefore an absolute concentration cannot be established. However based on 
comparison of the antibody signal derived from intracellular and secretion fractions, following 
loading of the same volume of sample from cutinase or CH2 expressing cells onto an SDS-PAGE 
gel, it would seem that cells express similar amounts, however less cutinase is secreted (i.e. 
Figure 4.). Many of the characteristics of CH2 are common to cutinase (i.e. non-native protein, 
lack of chaperone), therefore many reasons for this can be ruled out. As the secretion 
apparatus is evidently capable of secreting cutinase (and larger proteins), low secretion 
capacity is not due to size exclusion, instead it could be due to the characteristics such as 
hydrophobicity of cutinase residues. The fact that the inner channel of the FT3SS consists of 
mainly polar residues (Samatey et al., 2001), suggests that substrate hydrophobicity may have 
resulted in selective pressure, resulting in this evolutionary adaptation. So while substrate 
hydrophobicity is clearly important, it should not hinder secretion as the FT3SS is already 
adapted to overcome this.  
Secretion in the two most promising strains, ∆motAB ∆fliDST and ∆clpX ∆motAB was 
investigated with the E2 and CH2 secretion substrates, to investigate whether secretion 
capacity was substrate specific. It is known that E2 is both expressed in low quantities and 
absent in the supernatant of ∆fliDST mutants (Figure 3.), however some E2 was seen in the 
secreted fraction of ∆motAB ∆fliDST (Figure 5.). While it was still poor in comparison to ∆CKL 
this does suggest that the increased secretion capacity achieved with ∆motAB can somewhat 
compensate for the loss of FliS chaperone. Secretion was improved 3.75 fold in ∆clpX ∆motAB 
and while the concentration of E2 yielded was not very high (1.06µg L-1) in this biological 
replicate (Figure 5.2), there is potential for a very high yield to be achieved –for example a 3.75 
fold increase on the highest achieved yield of secreted E2 in ∆CKL grown in 10mL culture 
(14.674mg L-1), would result in a yield of 55.028 mg L-1 secreted E2 protein.  
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∆motAB ∆fliDST secreted CH2 very poorly in comparison to ∆CKL, as expression was also 
reduced this is likely to be the reason for this observation (Figure 5.). This suggests that the 
capacity of strains to express protein may be substrate specific, however as this is only based 
on two biological replicates and was not statistically significant; it may not be a true link. ∆clpX 
∆motAB both made and secreted more CH2 than ∆CKL. 86.76µg CH2 was secreted into a Litre 
of media which was high, but not the highest recorded yield (220µg L-1 in ∆flgMN), however as 
this was 2.56 fold higher than ∆CKL it clearly has a high capacity for CH2 secretion. For example 
this would extend the highest yield of secreted CH2 in ∆CKL from 94.27 µg L-1 to 241.33 µg L-1. 
Whether these yields could actually be achieved remains to be seen, but it does suggest 
promise for future yields of secreted protein in the ∆clpX ∆motAB strain. 
∆clpX ∆motAB is consistently efficient at secreting protein through secretion apparatus, 
whereas ∆motAB ∆fliDST was only effective at secreting cutinase. This does highlight a 
limitation of the cutinase secretion assay as results are not necessarily transferable to different 
substrates, this may result in investing time in strains when secretion capacity is not 
transferable to other substrates or conversely result in strains which are poor secretors of 
cutinase being overlooked, when they have potential to be efficient at secreting a different 
substrate. However as the MUB protein secretion assay did enable the fast screening of 15 
strains conclude that one (∆clpX ∆motAB) was very efficient at secreting a number of proteins, 
the assay is an excellent tool for investigating secretion apparatus capacity. With two strains 
identified which have a high capacity to secrete cutinase, focus shifted to modification of the 
secretion construct to improve protein secretion by that route. 
 
5.7.3. Modification of the synthetic modular secretion construct for 
increased FT3SS secretion  
 
Finally the MUB protein secretion assay was utilised to screen the effect of various features of 
the secretion construct on expression and secretion of cutinase through the FT3SS. The aim 
was to improve secretion by modifying the prototype secretion construct. Nine variations of 
the prototype secretion construct were constructed and expressed in ∆CKL -once again the 
MUB secretion assay was effective in quickly and accurately screening a large number of 
biological samples. In terms of expression it was found that the absence of the 3’ UTR resulted 
331 
 
in poor expression (Figure 5.). The role of the 3’ UTR in prokaryotes is not well understood. The 
stop codon is located here; however this was incorporated into the secretion construct by 
primer extension. While eukaryote translational control is mainly linked to the 3’ UTR, this is 
not the case in prokaryotes. However there is some evidence that the 3’ UTR protects the 
mRNA sequence from degradation by 3’ exonucleases (Belasco, 2010), so it would be logical so 
assume that the removal of the 3’ UTR results in less protein expression because there is 
reduced mRNA. Further investigation with RT-PCR would be very interesting so observe 
whether the concentration of secretion construct mRNA is lower in the absence of the 3’ UTR.  
The removal of the 5’ UTR and the 47 amino acid signal peptide resulted in a large increase in 
cutinase expression (SC8), however removal of the 5’ UTR alone (SC2) did not. The removal of 
the 47 amino acid signal peptide but with the 5’ UTR intact was not investigated, it would be 
informative to assess this in the future, to gain more information on the role of the 5’ UTR on 
secretion, especially as there is much in the literature to suggest that a secretion signal is also 
harboured in this region (Majander et al. 2005; Aldridge et al. 2006). However is seems 
possible that the presence of the 47 amino acid signal peptide either hinders expression or 
directs a high concentration of protein for secretion. If the latter is true then secreted protein 
degradation must be very high, as the relationship of intracellular to secreted protein is not in 
linear. Another explanation would be that the secretion signal peptide reduces the formation 
of inclusion bodies; therefore removal of the secretion signal results in a higher rate of 
formation of inclusion bodies, which are less susceptible to proteolysis, therefore more protein 
is present in the intracellular fraction. This was not seen in other studies which investigated 
the effect of the removal of the 5’ UTR and secretion signal, however this work was carried out 
in Salmonella (Végh et al., 2006). Other reasons could be that it improved RNA stability or 
translation efficiency.  
In terms of secreted cutinase, the majority of UTR variants secreted less cutinase than the 
original prototype secretion construct, aside from the secretion construct which was only 
defective of the 3’ UTR (SR1) (Figure 5.). Following the MUB protein secretion assay, 
fluorescence output was so low in the other UTR variants that is was more similar to that 
recorded for ∆CKL secreting empty vector than cutinase, suggesting that secretion was almost 
absent in these strains. This confirmed that in this secretion strain the entire 47 amino acid 
secretion signal (and not just residues 26-47) is essential for secretion of protein thought the 
FT3SS in this secretion platform strain, this is differing to what has been reported in the 
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literature for Salmonella (Végh et al., 2006; Dobó et al., 2010). Again in the future it would be 
interesting to investigate secretion in a secretion construct with the 5’ UTR only, as this has 
been reported to facilitate secretion despite the absence of the 47 amino acid secretion signal. 
The removal of the 3’ UTR alone (SC1) resulted in a large improvement to FT3SS secretion, 
despite resulting in low expression. This is unexpected as the protein structure of the secretion 
construct should be the same regardless of the presence or absence of the 3’ UTR, unless the 
absence of the 3’ UTR caused it to be degraded by 3’ exonucleases (Belasco, 2010). This may 
be evidence that secretion capacity is tuned to protein expression and is increased when the 
concentration of intracellular protein tagged for secretion is at a specific concentration (i.e. 
enough to secrete, not so much that secretion apparatus become ‘blocked’), however as the 
concentration of native protein for FT3SS in a wild type strain is dynamic, this is unlikely. An 
explanation may be linked to the evidence that overexpression of fliC mRNA results in reduced 
FlgM secretion, if this is due to the 3’ UTR region then this could explain improved secretion 
due to increased induction of late substrate secretion –including protein harbouring the FliC 
secretion signal (Guo et al. 2014). Interestingly expression of the prototype secretion construct 
resulted in the second best concentration of intracellular and secreted cutinase, after SC8 and 
SC1 respectively, suggesting that the prototype secretion construct which harbours both the 5’ 
and 47 amino acid secretion signal and the 3’ UTR perhaps results in a balance of the high 
levels of expression versus secretion. As the highest levels were observed in the absence of the 
5’ and 47 amino acid secretion signal and the 3’ UTR respectively. This may suggest that the 
two UTR regions and the 47 amino acid secretion signal act on expression and secretion 
respectively to form an equilibrium of secreted versus intracellular FliC protein in the cell. 
 
5.7.4. Combination of strain and secretion construct based strategies 
for improved FT3SS secretion 
 
The ultimate aim of this chapter was use the MUB protein secretion assay to screen many 
different strains and secretion constructs to locate the best performing of the two. This was 
achieved and the most efficient secretion strain (∆CKL ∆clpX ∆motAB) and secretion construct 
(SC1) have now been identified, leading to the designation of these as the mark 2 secretion 
platform strain and mark 2 secretion construct, with reference to the prototypes; these two 
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successful strategies to improve FT3SS were then combined to see it the observed effects 
would be cumulative and secretion capacity realty improved in comparison to the prototype 
secretion strain and secretion construct (ΔCKL). This was achieved as the combination of the 
∆clpX ∆motAB strain secreting the mark 2 secretion construct resulted in a 23.78 fold increase 
in secreted cutinase (Figure 5.). If this is true of other protein substrates this could result in a 
large yield of secreted protein and would give this secretion system a good standing in terms 
of industry standard. Altering the cargo of the mark 2 secretion construct to CH2, E2 and any 
other protein followed by expression in the mark 2 secretion strain would be very desirable to 
see if it resulted in a similar output. 
 
5.7.5. Future utilisation of the MUB secretion assay 
 
With the development of the MUB protein secretion assay there is much scope to investigate a 
number of other strategies to improve secretion through the FT3SS. Strategies can be wide 
ranging, so long as the implementation of it can be measured by change in secretion. These 
may improve further strain improvements, for example in terms of flagella gene regulation the 
flagella protein FliZ is reported to inhibit FlhD4C2 from binding to flagella class II promoters, 
thus reducing flagella gene expression (Wada et al., 2012). Other points of manipulation could 
involve the removal of the other class III genes, which are involved in chemotaxis in response 
to unfavourable environments and therefore not necessary in a shake flask with LB media; 
these include CheA-Z (mutants remained motile), Aer –which is linked to anaerobic respiration 
and also the Entner-Doudoroff pathway, which involves the conversion of sugar acids into 
energy and therefore should not be an issue in cultures grown in LB with mixing and finally Tar, 
Tap, Trg and Tsr, which are chemoreceptors for specific monosaccharides, amino acids or 
peptides (Prüss et al. 2003; Weerasuriya et al. 1998; Grebe & Stock, 1998; Parkinson, 1978). 
There is information in the literature that suggests that hook length alternation and 
straightening are possible. for example deletion of some of the C-terminal residues of flgE 
resulted in straight hooks in Salmonella (Kutsukake et al., 1979) -it would be interesting to see 
if this effected secretion capacity. It would also be interesting to see if increased expression of 
the ATPase complex (fliHIJ) would result in an increase in substrate sorting and secretion. 
Another option would be to implement a change in strategy and focus on secretion using an 
334 
 
alternative secretion signal -for example secretion of recombinant protein through the FT3SS 
with FlgM has previously been achieved (Singer et al. 2012). As FlgM secretion is required prior 
to FliC secretion, it may result in improved secretion. An alternative would be to engineer 
directed secretion in a hook-less secretion strain using early secretion substrates, this has been 
implemented using FlgD and FlgE secretion signal peptides and is also being investigated in this 
laboratory. Modification of the chromosome by insertion of DNA is another option, whether to 
implement flhDC promoter region modification or promoter replacement as discussed in 
Chapter 3, or to insert secretion construct DNA for more stable expression. 
There would also be merit to constructing a transposon library of mutants with a range of 
mutations, these could then be screened my MUB protein secretion assay to identify novel 
sources or combination of gene knockout to aid increased protein secretion. To date motility 
based assays been used to identify novel sources of either improved or reduced motility, 
however this could serve as a more high-throughput alternative (Girgis et al., 2007; Cameron 
et al., 2008). In the spirit of synthetic biology and reductionist biology (e.g. Synthia and Venter 
(Gibson et al. 2010; Hutchison et al. 2016)), it would also be interesting to investigate the 
‘minimal flagella’ required to mediate directed secretion. Not only would this be interesting 
but it could reveal unknown information about flagella protein function and essentiality. 
Another synthetic biology example would be to investigate if refactoring the flagella operons 
could aid secretion (Temme et al., 2012). This is based on the idea that the chromosome can 
be streamlined for more controlled and possibly improved expression. This involves taking a 
relevant operon and removing non-coding or regulatory genes, next each coding gene is 
recoded with different codons –in an effort to reduce all native regulation, these genes are 
then reordered and put under the control of synthetic promotors, ribosome binding sites and 
spacer sequences. The product is a refactored gene cluster organised into well characterised 
genetic parts with no native regulation. This results in greater control of gene expression and 
aid investigation into function of the individual components of the system –this may result in 
more efficient gene expression. A model predicted that the most efficient way of ordering the 
flagella operons was (predictably) from class I, to class II to class III (Kalir et al., 2001).  
The assay could be modified to gauge more information on protein secretion in terms of yield 
over time. Following culture of cells secreting cutinase (or any substrate if the MUB secretion 
assay isn’t being deployed), cells could be pelleted and supernatant removed for measurement 
of secreted protein. The cell pellet could then be resuspended in fresh media and incubated 
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for a further period of time, repetition of supernatant retrieval would allow secretion over 
time to be accurately assessed. The assay could also be deployed to investigate the effect of 
cell culture method protein secretion. For example the effect of temperature, agitation, 
culture size, different media on protein secretion. 
In summary with the advent of the MUB protein secretion assay there is huge scope to 
improve or just investigate FT3SS secretion further, with hope of producing a high capacity 
secretion strain suitable for use in industry or facilitating the furthering of knowledge on the 
FT3SS. 
Strain improvements could be based on further logical and informed strategies from the 
literature, this may relate to an extension of the ‘reduced metabolic burden’ strategy, for 
example removing the remaining chemotaxis linked class III genes (as in (Singer et al. 2012). 
Alternatively it could take a more engineering, synthetic biology based strategy, this has 
particular relevance when it is considered that a low percentage of total protein was secreted 
through the FT3SS. Steps could be taken in an attempt to improve this, for example increasing 
expression of the ATPase complex (fliHIJ) to see if substrate sorting and secretion could be 
increased or by investigating whether straight hooks could be implemented with deletion of 
some of the C-terminal residues of flgE as seen in Salmonella (Kutsukake et al., 1979). Another 
alternative would be to implement modelling to see if there are any bottlenecks occur, for 
example proton or sodium motive force could be investigated, to identify routes to improve 
secretion (Benedict et al., 2012). Proteomics could also be utilised to identify sources of 
improvement, for example an iTRAQ experiment of cells secreting the secretion construct and 
empty vector could infer routes for improvement. Finally a non-directed approach could be 
taken to identify mutant strains which are efficient at secreting protein. This could be carried 
out by generating a transposon library of mutants from the ∆CKL background and then 
screening secretion via a cutinase based MUB assay. This would generate strains with 
mutations throughout the chromosome, which is beneficial because favourable mutations may 
not actually be connected to flagella gene expression -for example they may result in the loss 
of a non-essential metabolically expensive function. In addition to improvements to the strain, 
further improvements may be valuable to the secretion construct. A secretion construct 
plasmid library could also be assembled and tested, this could include many combinations of 
secretion signals and UTRs from different flagella substrates, both in their entirety and in 
sections. It could also be expanded to investigate the effect on induction of the secretion 
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construct, as this was a theme throughout this thesis.  A range of promoter and RBS codons 
could be utilised from the BioBricks Catalogue for example –again the MUB –protein secretion 
assay would aid the investigation here.  
The MUB secretion assay could also be utilised to implement non-flagella gene related 
improvements, for example investigating whether more cutinase is secreted when co-
expressed with enzymes which have been shown to aid recombinant protein production. The 
effect of cell culture environment could also be screened, whether this is to investigate 
whether secretion is improved in various medias (relevant in terms of chemotaxis based gene 
expression) or induction protocols, but also in an effort to alter flagella hook structure, as 
certain pH, temperatures and salt concentrations have been shown to result in straight hooks, 
although it should be noted that as this was carried out in vitro it may not have the same effect 
on live cell culture (Kato et al., 1984; Hirano et al., 1994).  
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Chapter 6: 45kDa human collagen expression 
for FT3SS secretion 
There are two outlooks for developing profitable industrial biotechnology platforms; one is to 
produce a high yield of product and the other to produce valuable product.  In the previous 
results Chapters it was demonstrated that the FT3SS could potentially be modified into a high 
capacity secretion machine. Through this system it was shown that both native and 
recombinant proteins could be secreted into the extracellular media and that with 
improvements to both the strain and secretion construct almost 25 times the original secretion 
capacity could be achieved. If this was transferable to the yields seen prior to improvement 
this could result up to 55.028 mg L-1 E2 protein or 241.33 µg L-1 recombinant CH2 protein being 
secreted. The focus of this chapter will be to attempt to secrete a pharmaceutically relevant 
45kDa human pro α (I) collagen chain in the section platform strain. This was previously 
expressed in barley (Eskelin et al., 2009) and represents half of the full length chain, but retains 
many of the important collagen 1 cell adhesion properties. As explained in the introduction 
collagen has many therapeutic uses and is currently obtained from animal sources, however 
there is a drive to produce recombinant collagen as this would resolve issues of 
biocompatibility, safety and homogeneity (Olsen, 2003; Nuutila et al. 2015). Current 
recombinant sources include plants, animal cells and Pichia. The highest yield reported is 500 
mg L-1 in Pichia (Nokelainen et al., 2001) and the highest secreted 150 mg L-1 in HEK cells, but at 
a high cost/ yield ratio (Tillet et al. 1994). Secretion has only been reported in mammalian 
cells, therefore is would be beneficial to produce and secrete collagen in strains which harbour 
the modified FT3SS, as the helical nature of collagen 1 lends itself to potential flagella 
secretion as it has a diameter that easily fits within the 2nm pore of the secretion apparatus.  
While this would incur all of the benefits relating to E. coli based expression systems (low cost, 
fast growth etc.), there are some negatives surrounding post translational modifications 
however these can be partly overcome with the co-expression of prolyl-4-hydroxylase and 
lysyl-hydroxylase-3, which have been shown to effective in producing collagen with correct 
hydroxylation modifications of prolyl and lysyl residues (Figure 1.7). To date the only reports of 
expression of chains of human collagen reported in E. coli are for a 38kDa fragment of human 
pro α (III) collagen chain. When co-expressed with prolyl-4-hydroxylase and lysyl-hydroxylase-3 
a yield of 90mg L-1 intracellular COL3A1 collagen was achieved with a hydroxylation pattern 
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similar to the human form (Rutschmann et al., 2014). A 23kDa fragment of human pro α (I) 
collagen chain was also expressed to 10% of total cellular protein and was also highly 
hydroxylated with co-expression of prolyl-4-hydroxylase (Buechter et al., 2003). Collagen is a 
proline rich protein and while E. coli are able to produce proline autotrophically, production is 
limited by a negative feedback loop of proline on glutamate-5-kinase (Adams & Frank, 1980). 
This lack of intracellular proline is likely to limit the yield of recombinant collagen, therefore 
experimental design and strain improvements were designed to try and improve the 
concentration of intracellular proline, in an attempt to increase collagen expression. 
 
6.1. Production of collagen within the synthetic modular 
secretion construct 
 
The aim of this chapter was to express a 45kDa human pro α (I) collagen chain in the original 
secretion platform strain (∆CKL) in the first instance. This was partly chosen as the 45 KDa 
fragment is a similar size to flagellin (the most abundant substrate of the FT3SS) While 
expression would be impressive, secretion would also be desirable- as the idea of extruding 
collagen fibres from flagella export apparatus would be a great achievement.  In addition, as 
described in the last section, it would be the largest fragment of collagen to be produced in E. 
coli. The pro α (I) collagen chain was chosen as collagen I is the most abundant collagen 
protein, therefore the applications of recombinant collagen I would be wide- for example in 
tissue engineering -both in vitro (for cell culture) but also in vivo for aid in skin graft 
treatments. From herein the 45kDa pro α (I) collagen chain will be referred to as ‘COL1A1’. 
 
6.1.1. A synthetic collagen gene in the synthetic modular secretion 
construct 
 
Prior to the experimental work carried out in this thesis the sequence for the 45kDa human 
pro α (I) collagen chain or COL1A1 (accession number: NP000088) was obtained from the NCBI 
database. The gene was codon optimised for E.coli using the Genes® algorithm and then 
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incorporated into the prototype secretion construct sequence between the EcoRI and PstI 
restriction enzyme sites and consideration was taken to exclude any other restriction enzyme 
sites that are present in the secretion vector or constructs (NdeI, XhoI, EcoRI, PstI, XbaI, HindIII, 
BamHI). The resulting sequence was sent for synthesis by DNA 2.0. The gene was synthesised 
in an IPTG inducible pJexpress404 vector and the resulting genetic secretion construct and 
translated protein product is shown in Figure 5.. 
  
Figure 6.12: Genetic and protein schematic of the secretion construct harbouring COL1A1  
(A) Genetic schematic of pJexpress-FliC-COL1A1-FLAG-Strep, which resulted in the expression 
(B) of a FT3SS signal peptide COL1A1 flanked by FLAG and Strep tags and TEV protease sites  
 
 
6.1.2. Expression of the COL1A1 harbouring synthetic modular 
secretion construct: hyperosmotic shock 
 
The protein secretion assay was utilised to observe whether COL1A1 was expressed in the 
secretion system expression platform. As human collagen has proved difficult to express in E. 
coli it was not anticipated that secretion would necessarily occur, as yields were likely to be 
low. Initial investigation of COL1A1 expression was carried out in the original ∆CKL secretor 
strain. In preliminary work by M. Hicks (in our laboratory team) COL1A1 had been successfully 
expressed but at low levels in the MC1000 ∆CKL strain when cells were incubated overnight in 
liquid culture before induction with 1mM IPTG, however no secretion was observed. A priority 
is to increase the concentration of collagen in cells, as it has been observed throughout 
340 
 
experimentation in this thesis that the percentage of secreted protein in relation to total 
protein is consistently low (around 5% the maximum observed) in any variant of the secretion 
strain, therefore if the intracellular yield is low it is unlikely that collagen will be detectable in 
the secreted fraction. 
Proline is an osmoprotectant, it has previously been shown that supplementing the media with 
proline and applying osmotic shock has been shown to cause cells to uptake proline from the 
environment, leading to high internal proline levels (Buechter et al., 2003); this lead to the 
successful production of hydroxyproline. In E. coli hyperosmotic shock causes cells to 
upregulate ProU and ProP proline transporter expression, resulting in increased transport and 
therefore increased accumulation of intracellular proline (Wood, 1988). Therefore it was 
investigated whether this would aid intracellular collagen production. ∆CKL freshly 
transformed with either empty or COL1A1 harbouring secretion construct cells were incubated 
for 16 hours at 37°C with 180rpm agitation, cells underwent osmotic shock with 500mM NaCl 
(or dH20 as a negative control) and returned to the shaking incubator. After 30 minutes 
cultures were supplemented with 1mM IPTG and returned to the shaking incubator for 3 
hours. Cultures were then prepared for analysis by SDS-PAGE and Coomassie stain or Western 
blot analysis.  Following this procedure the OD600 of cultures was generally around OD600 3.5-4, 
with or without the application of osmotic shock. 
The Coomassie stained SDS-PAGE gels show that a low concentration of intracellular protein 
was seen in the supernatant of cells expressing empty secretion construct following 
hyperosmotic shock, however aside from that no other protein was visible (Figure 6.A). In the 
Western blot probed with the anti-FLAG-HRP antibody a band was detected in samples of cells 
expressing COL1A1, which was absent in cells expressing empty secretion construct, between 
72 and 55kDa at around 65kDa –as expected no FLAG was detected in the collagen standard 
(Figure 6.C). Likewise, in Figure 6.D anti-COL1A1 detected a band in these samples at around 
65kDa (indicated by an arrow) which is also absent in the negative control-empty vector lanes. 
The antibody binding pattern is slightly different in the standard, which was expected as the 
collagen is derived from a complex biological source from a different species (rat), however the 
collagen motif is evidently present in this sample, therefore it serves as a good positive control. 
Full length COL1A1 is a 45kDa protein, however with the secretion construct accessory 
peptides it is predicted to be 54.5kDa. Although it appears slightly larger than expected, the 
use of two antibodies and negative controls mean that it can be concluded that this is COL1A1 
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(N.B. this was also confirmed by M Hicks using MS/MS on Strep-tag purified COL1A1). In Figure 
6.C it is evident that hyperosmotic shock led to a reduced concentration of intracellular 
COL1A1 in comparison to without. Supernatant fractions were probed with anti-FLAG-HRP for 
the presence of COL1A1, however no FLAG tag was detected (not shown). 
 
Figure 6.2: Intracellular and secreted fractions of ∆CKL expressing either empty (-) or COL1A1 
(C) harbouring secretion construct following osmotic shock.  
E.coli ΔfliC ΔflgKL (∆CKL) harbouring either the plasmid pJexpress-FliC-COL1A1-FLAG-Strep (C) 
or pJexpress-FliC-empty-FLAG-Strep (-) were grown in LB overnight at 37°C, 180 rpm, following 
induction of hyperosmotic shock with 500mM NaCl or the same volume of dH20, cells were 
incubated for 30 minutes and then supplemented with IPTG. Cells were incubated for 3 hours 
and then harvested. 1 OD unit of cells were prepared for SDS-PAGE and the supernatant from 
1 OD unit of cells was precipitated with TCA (10% v/v) before SDS-PAGE and Western blot 
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analysis. A rat tail COL1 standard was loaded as a positive control. Coomassie stained SDS-
PAGE of the (A) supernatant and (B) intracellular fractions of cell cultures. Western blot of the 
intracellular fractions probed with (C) anti-FLAG-HRP and (D) anti-COL1A1 and appropriate 
secondary antibody. Osmotic shock (OS): + or -. 10µL sample loaded for each sample. 10µL rat 
tail COL1A1 on (D). Arrows denote presence of COL1A1. 
 
Following densitometry analysis of two biological replicates, the application of osmotic shock 
was shown to result in a reduction of COL1A1 expressed in cells (Figure 6.) –following osmotic 
shock cells expressed half the concentration of COL1A1 in comparison to controls. This was 
unexpected, although it is not known if this did relate to increased intracellular proline or not. 
 
Figure 6.3: Results following densitometry analysis of the intracellular samples of anti-FLAG-
HRP probed Western blots of the intracellular fractions of COL1A1 expressing cells following 
cell culture with or without osmotic shock.  
Following cell culture and initiation of osmotic shock if appropriate as in Figure 6., 
densitometry analysis was carried out on Western blots following probing with anti-FLAG-HRP. 
Results from two biological replicates, normalised to the result for COL1A1 without osmotic 
shock. No statistical significant found. 
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6.2. Strain improvements for increased intracellular 
proline 
 
An alternative strategy to improve intracellular proline and therefore possible COL1A1 
production is to make strain improvements to the expression strain. Strategies to implement 
this were identified by searching the literature and examining the metabolic network. The 
metabolic network for proline metabolism is shown in Figure 6.. There are three membrane 
transporters of proline Put, ProU and ProP. All transport proline into the cell. ProP is an ABC 
transporter and expressed through a wide range of osmolalities, ProU is a dual proline/betaine 
transporter and is transcriptionally regulated in response to high osmolality (Mellies et al., 
1994; Wood et al., 2001). PutP is very tightly regulated in response to PutA concentration, 
therefore not directly linked to osmolality (Dunlap & Csonka, 1985). Pyrroline-5-carboxylate 
synthase synthesises intracellular proline and several pathways result in the production of the 
proline precursor 1-pyrroline-5-carboxylate. Additionally PutA results in two enzymes products 
(proline dehydrogenase and 1-pyroline-5-carboxylate dehydrogenase) which result in proline 
and proline 1-pyrroline-5-carboxylate catabolism resulting in less proline. This demonstrates 
that the concentration of proline could be increased intracellularly by (1) increasing the 
amount of proline being transported into the cell (2) to increase the amount of proline 
produced by the cell’s metabolic pathways (3) to reduce proline catabolism. Strategies will be 
implemented by gene knock out mutagenesis or by changing promoters to cause stronger 
gene activity. Strategies 2 and 3 were implemented in this thesis and will be discussed in more 
detail in the next section, with support from the literature.  
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Figure 6.4: The proline metabolism network in E. coli 
Green arrows denote reactions which result in the production or transport of proline and its 
precursors, red arrows denote the opposite. Intracellular proline is both derived and used 
intracellularly and transported into the cell from the extracellular environment. Proteins of 
interest include: the transporters PROabc (ProU), PROt2r (ProP) and PutP. Proteins: PutA, ProB 
and metabolite: L-glutamate also shown which is metabolically relevant in other metabolic 
networks. Adapted from Reed et al. 2003 
 
6.2.1. Removal of feedback inhibition of proline accumulation: ProB  
 
 As described, E. coli are able to produce proline autotrophically , however production is 
limited by a negative feedback loop of proline on glutamate-5-kinase (Adams & Frank, 1980). 
Proline binds to glutamate kinase (ProB), changing the shape of the active site, causing 
inactivity of glutamate kinase. This is known as allosteric inhibition. Removal of feedback 
inhibition has been achieved on two occasions by two different point mutations in the proB 
gene, which encodes glutamate-5-kinase. These point mutations were implemented at codon 
107 (gat -> aat, D -> N) or codon 143 (gag -> gcg, E -> A). (Csonka et al., 1988; Rushlow et al., 
1985). Intracellular proline levels were not reported in the literature; however it is 
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hypothesised that this will occur, potentially resulting in increased COL1A1 expression. These 
two point substations will therefore be implemented in the ∆CKL strain using Lambda-Red 
recombinase based knockout mutagenesis followed by Lambda-Red recombinase based 
insertion of a PCR derived proB gene with the SNPs in situ. This strategy involves the 
production of ΔproB prior to the insertion of mutant proB genes. As a bonus this ΔproB mutant 
may also be useful in increasing internal E. coli proline. The ability of a proline auxotroph 
(ΔproB) to accumulate proline from the environment following hyperosmotic shock has also 
been demonstrated previously (Buechter et al., 2003). Although no value in osmotic shock was 
found here, complete removal of the proB gene may be of value; while production of proline 
via this metabolic route will be inhibited, it may have a positive consequence elsewhere if 
other pathways or transporters compensate for this. 
 
6.2.2. Removal of proline catabolism: PutA 
 
putA encodes a multifunctional enzyme which catalyses both of the proline catabolism 
reactions in the proline metabolic network (Ling et al., 1994). The two enzyme activities are 
proline dehydrogenase and P5C dehydrogenase. Introducing a putA knockout in a proline 
overproducing strain (proB  D107N)  was shown to increase intracellular proline levels further 
(Csonka, 1988). putA has also been shown to inhibit expression of the proline transporter putP 
which transports proline into the cell from the extracellular environment (Nakao et al. 1988; 
Falcioni et al. 2013) therefore its removal may increase proline transportation into the cell.  
 
6.2.3. Removal of proline catabolism for other metabolic processes: 
GdhA 
 
Following PutA initiated catabolism of proline and it’s metabolic precursor 1-pyrroline-5-
carboxylate, a source of metabolite flow is through the glutamate pathway via glutamate 
dehydrogenase (GdhA). There are two routes to the production of glutamate in E. coli and 
when nitrogen is abundant (as it would be in LB media) the glutamate dehydrogenase pathway 
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is implemented to yield glutamate. It would seem logical that loss of metabolites from this 
network into other cellular metabolic networks would not be conducive to the production of 
proline (Kumar et al., 2010). Furthermore as second route to glutamate production is present 
cells will not become glutamate autotrophs.  
 
6.2.4. Mutagenesis for increased intracellular proline: proB, putA, 
gdhA 
 
Once potential strain modifications had been identified which may result in an increase the 
amount of internal proline, these strategies were implemented by gene knock out or insertion 
mutagenesis. ∆CKL was used as the parent strain, so that COL1A1 secretion could be 
investigated throughout. These were ∆proB, proB D107N, proB E153A, ∆putA and ∆gdhA. 
Combination of these strategies was also implemented with P1 phage transduction which led 
to the generation of ∆putA ∆proB and ∆putA ∆gdhA. 
 
6.2.4.1. Knockout mutagenesis via the Lambda Red recombinase 
method: proB, putA, gdhA 
Primers were designed to amplify the FRT flanked resistance genes from the appropriate 
template plasmid. Successful PCR reactions were confirmed by the presence of product DNA 
which corresponded to the anticipated PCR product size (Table 6.).   
 
Table 6.12: PCR products for gene knockouts 
Gene knockout Antibiotic resistance Template plasmid Size of product (kbp) 
proB Km pKD4 1.6 
putA Km pKD13 1.4 
gdhA Km pKD13 1.4 
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Positive results for all PCR experiments were achieved (Figure 6.5) -bands of the correct size 
were cut out and DNA isolated. Product DNA comprises of FRT flanked antibiotic resistance 
cassettes, with homologous ends to the up- and downstream regions of chromosomal DNA of 
the gene selected for knockout mutagenesis. 
 
Figure 6.5: DNA gels of gene knockout construct PCR products.  
PCR reactions were carried out using the templates and primers in Appendix 2 with Phusion® 
High-Fidelity DNA Polymerase. PCR mixtures were analysed on a 1% TAE agarose DNA gel 
supplemented with a trace of ethidium bromide, visualised under UV light and inverted. 
Samples in A and C were run with GeneRuler™ 1kb DNA ladder; sample in B run with Quickload 
Purple 1kb ladder (NEB). PCR resulted in the formation of the gene knockout constructs 
harbouring antibiotic resistance cassettes (as listed in Table 6.). A. proB::Km, B. putA::Km, C. 
gdhA::Km.  
 
Once isolated, the linear PCR derived DNA was electroporated into ∆CKL parent strains 
expressing Lambda Red recombinase enzymes. Successful recombination events were 
screened by plating on agar plates supplemented with kanamycin. Positive colonies were 
observed for all recombination strains and following the curing of the Red recombinase 
plasmid so that no further recombination events occur, the deletion of chromosomal genes 
was confirmed with PCR. 
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6.2.4.2. PCR conformation of knockout mutagenesis: proB, putA, gdhA 
To confirm that the acquisition of antibiotic resistance was indicative of the removal of the 
gene targeted PCR reactions using combinations of primers which anneal either in the 
antibiotic resistance cassette or the region of chromosomal DNA either side of the target 
knockout gene. Either the size or the presence of the resulting PCR products allowed further 
confirmation of knockout mutagenesis.  
 
Table 6.13: PCR products for confirmation of knockout mutagenesis in ∆CKL. 
Positive results were obtained for the following knockout mutagenesis conformations. The size 
of PCR products which denote positive results is given along with the size of the PCR product (if 
relevant) expected if knockout mutagenesis was not successful. 
Gene knockout Antibiotic Resistance Size of product if 
positive (kbp) 
Size of product if 
negative (kbp) 
proB Km 1260 N/A 
putA Km 1465 4164 
gdhA Km 758 N/A 
 
The size of the PCR product which would arise for primer pairs following successful knockout 
mutagenesis was predicted (Table 6.). Following colony PCR or successful transformants, 
positive PCR results were achieved for all proline metabolism gene knockout mutants. 
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Figure 6.6: Agarose DNA gels of PCR products to confirm successful knockout mutagenesis.  
PCR reactions were carried out using chromosomal DNA templates and primers in Appendix 2 
with Phusion® High-Fidelity DNA Polymerase. PCR mixtures were analysed on a 1% TAE 
agarose DNA gel supplemented with a trace of ethidium bromide, visualised under UV light 
and inverted. Samples were run with GeneRuler™ 1kb DNA ladder. PCR resulted in the 
formation of products of the sizes listed in Table 6.. A. proB::Km, B. putA::Km, C. gdhA::Km. 
 
6.2.4.3. Knockout mutagenesis via the P1 phage transduction method 
While Lambda-Red recombineering is the preferred method for knockout mutagenesis (due to 
the absence of phage), the efficiency is poor and therefore it can take multiple attempts of the 
protocol to generate mutants- when necessary P1 phage transduction was carried out to 
achieve knockout mutants in a short space of time. This resulted in the successful generation 
of the combination strategy mutants (∆CKL) ∆putA ∆proB and ∆putA ∆gdhA from the ∆CKL 
∆putA parent strain following the removal of FRT linked antibiotic resistance using the Flp 
recombinase gene harbouring pCP20 plasmid. P1 phage lysates were derived from ∆CKL ∆proB 
and ∆CKL ∆gdhA. 
Once successful transformatants were obtained cells were passaged on sodium citrate plates, 
to eradicate phage. Growth was always normal in these strains, suggesting that phage was 
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eliminated from these strains. Care was taken to ensure that there was no possibility of 
existing genes knockouts in the parent strain being reinstated by chromosomal DNA packaged 
by the P1 phage during homologous recombination. The chromosomal location of genes 
targeted for knockout mutagenesis are listed in Table 5.. P1 phage is capable of packaging and 
initiating the homologous recombination of up to 100,000bp of donor chromosomal DNA into 
a parent strain. However proB and gdhA are not within this limit, therefore additional 
conformation of existing gene knockouts of the parent strain was not required. 
 
Table 6.3: Chromosomal location (bp) of genes which underwent knockout mutagenesis and 
existing gene knockouts. 
Gene Chromosomal location 
Start End 
∆fliC 2053401 2054069 
∆flgKL 1140598 1140943 
∆putA 1072681 1076643 
∆proB 242522 243625 
∆gdhA 1877223 1878566 
 
It was hoped that either Lambda-Red recombination or P1 phage transduction could be 
utilised to also produce (∆CKL) ∆proB ∆gdhA and (∆CKL) ∆putA ∆gdhA ∆proB however this was 
not successful in the time. 
 
6.2.4.4. Site directed mutagenesis  
To implement the D107N and E153A nucleotide substitutions, an extension of the Lambda Red 
recombinase method was implemented, to enable site directed mutagenesis. The proB gene 
was amplified from the genome of ∆CKL using primer pairs; one primer was homologous to the 
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region where the nucleotide substitution was to be made (i.e. residue 107 or 163). This primer 
contained an single nucleotide polymorphism to implement the following nucleotide alteration 
at: codon 107 (gat -> aat, D -> N) or codon 143 (gag -> gcg, E -> A). Overlap PCR was carried out 
with primers to yield a PCR product which harboured a chloramphenicol resistance cassette 
and the proB gene with the given SNP. As the proB gene knockout mutant in the ∆CKL 
background has been derived, this PCR construct was inserted into this parent background by a 
second round of Lambda-Red recombineering. This resulted in the excision of the kanamycin 
resistance gene and the insertion of the proB D107N::Cm or proB E153A::Cm cassette, which 
could be screened for by plating on chloramphenicol supplemented LB agar plates. The PCR 
reaction carried out are outlined in Figure 6..  
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Figure 6.7: Strategy to implement proB substitutions by overlap PCR. 
Schematic of site directed mutagenesis implemented by Lambda Red recombineering and 
overlap PCR. (A) proB knockout mutagenesis. A DNA construct which harbours the kanamycin 
resistance cassette (Km ARC) with ends homologous to chromosomal DNA up- and down-
stream of proB is produced by PCR with custom primers and pKD4 as a template. This 
construct was inserted into MC1000 ΔCKL chromosomal DNA by the Lambda Red 
recombineering method. (B) PCR reactions to create DNA fragments necessary for overlap PCR 
for site directed mutagenesis. Template was MC1000 ΔCKL for 1-2 and pKD3 for 3. D107A and 
E143A primers contained single nucleotide polymorphisms so that nucleotide substitutions 
would be implemented during extension (C) PCR products from B are the templates for C. (C 
4a) DNA templates from reactions B1a, B2a and B3 are assembled by overlap PCR. C 4b) DNA 
templates from reaction B1b, B2b and B3 are assembled by overlap PCR. D) The products of B 
are incorporated into the chromosomal DNA of MC1000 ΔCKL ΔproB by the Lambda Red 
recombineering method. NOTE: all primers and PCR reactions are listed in Appendix 2 and 4. 
Yellow boxes indicate non-antibiotic resistance coding sections of pKD3. ‘F’ indicates the flp 
recombinase target (FRT) site of this coding region.  
KD3 KD3 Cm ARCF F
Chromosomal DNA proB
Chromosomal DNA Km ARCF F
Chromosomal DNA D107  proB E143
Chromosomal DNA D107  proB E143
N107
D107  proB A143
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Chromosomal DNAN107  proB E143
Chromosomal DNAN107  proB E143 F
D107  proB A143
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D107  proB A143
Chromosomal DNA Km ARCF F
KD3 Cm ARCF F
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B.
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PROB US F
PROB KO R
PROB KO R
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PROB US F
D107N R
E153A R
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PROB US STOP F
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1b.
2a.
2b.
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To implement the D107N and E143A substitutions in ∆CKL ∆proB site directed mutagenesis 
was carried out. PCR reactions were carried out to produce the products shown in Figure 6.. 
PCR reactions were considered successful if bands of the sizes listed in ( 
 
 
 
 
Figure 6.C). Although bands at additional sizes were present the 2.2 kbp products were 
excised. The bands should be the DNA constructs of the proB gene with an SNP at either codon 
107 or 153, adjoined to a chloramphenicol cassette which is flanked by FRT sites. To ensure 
purity and to verify the identity of these bands, the 2.2 kbp bands, were excised, isolated, 
cloned into pJET2.1 and transformed into NEB 5-alpha Competent E. coli before sequencing –
both constructs proved to align to the predicted sequences, including the nucleotide 
substitutions.  
 
Table 6.4: Size of PCR products in overlap PCR to generate D107N and E143A proB 
substitutions 
PCR reaction PCR product (kbp) 
1A 380 
1B 489 
2A 830 
2B 725 
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Figure 6.8: DNA gels of DNA template PCR products for overlap PCR to implement single 
nucleotide substitutions. 
PCR reactions were carried out using the templates and primers in Appendix 4 with Phusion® 
High-Fidelity DNA Polymerase. PCR mixtures were analysed on a 1% TAE agarose DNA gel 
supplemented with a trace of ethidium bromide, visualised under UV light and inverted. 
Samples were run with GeneRuler™ 1kb DNA ladder. PCR resulted in the formation of all DNA 
templates for overlap PCR (1A-4B, see Table 6. for reference) 
 
Following conformation by sequencing, FRT-ABC-proB D107N/E153A-FRT was amplified from 
pJET2.1 with the primers used to generate the overlap product initially. This linear DNA was 
3 1099 
4A 2211 
4B 2211 
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then into electroporated into ∆CKL parent strains expressing Lambda Red recombinase 
enzymes. Successful recombination events were screened by plating on agar plates 
supplemented with chloramphenicol. Positive colonies were observed for all recombination 
strains and following the curing of the Red recombinase plasmid so that no further 
recombination events occur, loss of kanamycin resistance was confirmed in both strains and 
the insertion of the proB D107N or proB E153A genes was confirmed with PCR (Figure 6.) and 
sent for sequencing. As the product was so long, multiple sequencing reactions were carried 
out with different primers which annealed throughout the PCR product. Sequencing revealed 
that in the colonies isolated the D107N substitution has not been implemented, however the 
E153A substitution had. 
 
Figure 6.9: Chromosomal DNA amplified from the chromosome of proB D107N and proB 
E153A 
PCR reactions were carried out chromosomal DNA from single colonies of potential proB 
D107N and proB E153A mutants using Wizard® Genomic DNA Purification Kit. Primers in 
Appendix 2 with Phusion® High-Fidelity DNA Polymerase. PCR mixtures were analysed on a 1% 
TAE agarose DNA gel supplemented with a trace of ethidium bromide, visualised under UV 
light and inverted. Samples were run with GeneRuler™ 1kb DNA ladder. PCR resulted in the 
formation of 2488bp DNA for all reactions.  
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6.3. Collagen expression in strains with proline 
metabolism based improvements for increased 
intracellular proline 
 
With the strain improvements designed to result in increased intracellular proline confirmed 
COL1A1 expression was measured in all of the strains. As the hyperosmotic shock protocol was 
shown to have a negative effect of the expression of COL1A1, this strategy was not 
implemented in these strains. The intracellular fraction protein from cell cultures all looked 
uniform (Figure 6.A), no protein was detected in the supernatant fractions of cell cultures 
following Coomassie stain –not shown. The relative chemiluminescent signal detected for each 
sample following antibody probing with either anti-FLAG-HRP or anti-COL1A1 was very similar, 
suggesting both gave an accurate representation of the concentration of COL1A1 protein in 
each sample (Figure 6.B and C). No signal was detected in the cells of the ∆CKL strain 
expressing empty secretion construct. In was evident that COL1A1 was not expressed in ∆proB 
E153A or ∆putA. The strains which expressed the least COL1A1 were ∆CKL, ∆putA ∆gdhA and 
∆proB ∆putA. Both ∆proB and ∆gdhA expressed the highest concentration of COL1A1. 
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Figure 6.10: Intracellular and secreted fractions of ∆CKL expressing either empty or COL1A1 
harbouring secretion construct and proline metabolism mutant strains: ∆proB, proB E153A, 
∆putA, ∆gdhA, ∆putA ∆gdhA and ∆proB ∆putA 
E.coli ∆CKL harbouring either the plasmid pJexpress-FliC-COL1A1-FLAG-Strep or pJexpress-FliC-
empty-FLAG-Strep (empty) and (∆CKL) ∆proB, proB E153A, ∆putA, ∆gdhA, ∆putA ∆gdhA and 
∆proB ∆putA expressing pJexpress-FliC-COL1A1-FLAG-Strep were grown in LB overnight at 
37°C, 180 rpm, following induction with 1mM IPTG cells were incubated for three hours and 
then harvested. 1 OD unit of cells were prepared for SDS-PAGE and the supernatant from 1 OD 
unit of cells was precipitated with TCA (10% v/v) before SDS-PAGE and Western blot analysis. 
(A) Coomassie stained SDS-PAGE of the intracellular fractions of cell cultures, including one 
lane left blank. Western blot of the intracellular fractions probed with (B) anti-FLAG-HRP and 
(C) anti-COL1A1 and appropriate secondary antibody.  
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Densitometry analysis was carried out based on two biological replicates, probed with either 
anti-FLAG-HRP or anti-COL1A1. The reported relative densitometry for strains in comparison to 
that recorded for ∆CKL resulted in a similar pattern of results. ∆ghdA expressed the most 
collagen (1.47 and 1.70 fold more than ∆CKL respectively) followed by ∆proB. ∆CKL and ∆putA 
∆gdhA expressed similar concentration of COL1A1. When calculating using anti-FLAG-HRP it 
was show that ∆putA ∆proB did not express a high concentration of COL1A1, however with 
anti-COL1A1 it was calculated to result in 1.39 fold more intracellular collagen. As less 
variability was observed using the anti-COL1A1, these results may be more reliable. 
 
 
Figure 6.13: Results following densitometry analysis of the intracellular samples of anti-
FLAG-HRP and anti-COL1A1 probed Western blots of ∆CKL, ∆proB, ∆gdhA, ∆putA ∆gdhA and 
∆proB ∆putA COL1A1 expressing cells following cell culture  
Following cell culture and Western blot analysis as described in the figure legend of Figure 6., 
densitometry analysis was carried out on Western blots following probing with anti-FLAG-HRP 
or anti-COL1A1 and appropriate secondary antibody. Results from two biological replicates, 
normalised to the result for ∆CKL in each repeat. Strains which expressed no COL1A1 are not 
shown. One-way ANOVA: no significance. 
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6.4. Secretion of a bacterial collagen like protein in the 
FT3SS secretion strain 
 
Secretion of COL1A1 was not observed, however it was of interest to investigate the capacity 
of the prototype and mark 2 secretion strains to express and secrete a collagen like protein to 
establish whether it was amenable to secreting this kind of protein. As an alternative to the 
45kDA COL1A1 expression and secretion of the Streptococcus pyogenes collagen-like surface 
protein 2 (Scl2) was investigated. The protein harbours the Gly-X-X triplet amino acid motifs, 
characteristic of human collagen and has previously been expressed in E. coli with yields of 10g 
L-1 at high cell density - 0.3g L-1 at low- but not secreted (Chen et al., 2010; An et al., 2014; Peng 
et al., 2012). There is suggestion that these collagen-like proteins could also be used for 
therapeutic applications, for example it has been incorporated into a hydrogel and found to 
aid wound healing in rats (Cereceres et al., 2015). Prior to the work in this thesis, the Scl2 
protein (Accession: AY069936) was cloned into the prototype secretion construct with the 
EcoRI and PstI restriction enzyme sites as with COL1A1 in Figure 5.. Expression was induced 
with 0.05mM IPTG, which was in-keeping with the expression protocol in Chapter 4 and 5. The 
predicted size is 22.6 kDa for Scl2 or 32kDa in the secretion construct. Following expression in 
∆CKL and ∆CKL ∆clpX ∆motAB, no protein was seen in the Coomassie stained secreted fraction 
of cell cultures (Figure 6.14A). Western blot analysis with anti-FLAG-HRP found that Scl2 was 
both expressed and secreted in both strains; around twice the concentration of Scl2 was seen 
in the supernatant of ∆CKL ∆clpX ∆motAB cells (Figure 6.14B). The Scl2 protein ran at a slightly 
larger size in the supernatant as opposed to the intracellular fraction. The size of the band in 
the intracellular fraction was closer to the expected size. When stripped and probed with anti-
GroEL, similar concentrations of GroEL were seen in the secreted fractions of both strains. 
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Figure 6.14: Intracellular and secreted fractions of ∆CKL or ∆CKL ∆clpX ∆motAB expressing 
Scl2. 
E.coli ∆CKL (C) or ∆CKL ∆clpX ∆motAB (XM) harbouring pJexpress-FliC-Scl2-FLAG-Strep were 
grown in LB overnight at 37°C, 180 rpm, following induction with 0.05mM IPTG cells were until 
they reached OD 1.0. 1 OD unit of cells were prepared for SDS-PAGE and the supernatant from 
1 OD unit of cells was precipitated with TCA (10% v/v) before SDS-PAGE and Western blot 
analysis. (A) Coomassie stained SDS-PAGE of the secreted and intracellular fractions of cell 
cultures. Western blot of the intracellular fractions probed with (B) anti-FLAG-HRP and (C) anti-
GroEL and appropriate secondary antibody. Samples loaded: Supernatant: 20µL. Cells: 5µL or 
2µL for Coomassie and Western respectively 
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Densitometry analysis based on two biological replicated showed that on average cells from 
both strains expressed similar concentrations of intracellular Scl2, however ∆CKL ∆clpX 
∆motAB cell culture resulted in 1.49 times more Scl2 protein being secreted into the media 
(Figure 6.15). 
 
Figure 6.15: Results following densitometry analysis of the intracellular samples of anti-
FLAG-HRP probed Western blots of ∆CKL (C) and ∆CKL ∆clpX ∆motAB (XM) Scl2 expressing 
cells following cell culture  
Following cell culture and Western blot analysis as described in the figure legend of Figure 
6.14, densitometry analysis was carried out on Western blots following probing with anti-
FLAG-HRP. Results from two biological replicates, normalised to the result for ∆CKL in each 
repeat. One-way ANOVA: no significance. 
 
Although not attempted here it would be beneficial to attempt to purify either of these 
collagen based products using the Strep-tag and TEV cleavage sites. This would allow 
investigation as to whether the purified product would have any beneficial properties in terms 
of cell adhesion, if this was found steps could be taken to utilise the collagen product to 
investigate wound healing for example. 
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6.5. Discussion: Collagen expression for FT3SS  
 
Collagen has many important therapeutic applications and is currently obtained from animal 
sources, therefore there are issues with safety and biocompatibility (Olsen, 2003). This has led 
to the generation of expression strains to generate recombinant collagen for use in 
therapeutics (Nuutila et al., 2015). Most of these expression systems involve whole plants, 
animal cells or Pichia (which are not reported to secrete the collagen produced). An E.coli 
based system could improve many of the issues associated with production of collagen from 
animal sources or these cell lines. Previously this has been achieved with a 23 and 38kDa chain 
of human pro α (I) or (III) collagen chain fused to glutathione S-transferase (Buechter et al., 
2003; Rutschmann et al., 2014), however this thesis aimed to express and/or secrete a 45kDa 
chain of human pro α (I) chain. As collagen is a proline rich protein and E. coli do not 
accumulate proline, much emphasis was put on improving the concentration of intracellular 
proline.  
 
6.5.1. Expression of human COL1A1 in the FT3SS secretion strain 
 
Initially efforts to express COL1A1 were linked to investigating whether expression levels could 
be increased with hyperosmotic shock. This has previously been shown to increase the 
concentration of intracellular proline and also aid the production of a fragment of collagen 
(Buechter et al., 2003). While COL1A1 was expressed in both strains, the use of hyperosmotic 
shock led to a reduction in the concentration of COL1A1 seen in cells by around half (Figure 6.C 
and D and Figure 6.). This may have been due to the fact that the report in the literature was 
linked to a proline feedback mechanism knockout mutant (∆proB), therefore there may have 
been limited effect in a +proB strain as additional proline transported in the cell due to 
hyperosmotic shock may have been immediately led to feedback inhibition and therefore less 
intracellular proline. Alternatively the addition of NaCl may have caused the cells fitness to be 
reduced, however (slight) cell lysis was only observed in cells expressing the empty secretion 
construct following osmotic shock (Figure 6.A). Regardless of the effect of hyperosmotic shock, 
this result does represent the largest fragment of human collagen to be expressed in E. 
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coli.COL1A1 was not detected in the secreted fraction of cells, therefore steps were required 
to improve this. It was decided that first improving expression may aid this and that the best 
route to achieve this would be to increase intracellular proline concentration. 
 
6.5.2. Proline metabolism strain improvements  
 
The hyperosmotic shock method was not successful in improving intracellular COL1A1 
concentrations; therefore strategies to improve intracellular proline which was intrinsic to the 
cell metabolism were implemented. Mining the literature and surveying the proline metabolic 
network resulted in the generation of three strategies. This was to remove negative feedback 
of intracellular proline accumulation and could be implemented by removing proB or 
generating strains with an SNP in the proB gene (Buechter et al., 2003; Csonka et al., 1988; 
Rushlow et al., 1985). Another strategy involved the removal of the dual function putA gene 
which catalyses two reactions which catabolise proline or the proline precursor 1-pyrroline-5-
carboxylate. Removal of putA has been shown to increase intracellular proline levels and result 
in increased proline transporters, which move extracellular proline into the cell (Csonka 1988; 
Nakao et al. 1988). Finally it was hypothesised that the removal of gdhA would result in less 
proline precursor metabolites being directed to other metabolic processes. 
Aside from the proB D107N mutant all of these strains were generated and ∆putA ∆proB and 
∆putA ∆gdhA were successfully combined. It was shown that the ∆proB E153A and ∆putA 
mutants did not express COL1A1 (Figure 6.B and C). The intracellular protein fraction of these 
strains did not look altered compared to controls (Figure 6.A) and growth rates seemed to be 
unaffected- as observed by similar final OD600 – indicating these cells were not perturbed in 
their fitness in this media. However the other strains all produced COL1A1 (Figure 6. B and C). 
Results for densitometry was less variable when calculated based the Western bolts derived by 
the anti-COL1A1 antibody as opposed to anti-FLAG-HRP, furthermore as this was an antibody 
raised against a motif of residues which is present in the COL1A1, it is specific it also provides 
more evidence of quality control of COL1A1 production as the antibody was raised against an 
88 amino acid section of COL1A1, which is present in the N-terminus of the protein and 
therefore present in the 45kDa COL1A1 protein. For these reasons I will describe results based 
on the findings following anti-COL1A1 probing of the nitrocellulose membrane. The highest 
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increase in intracellular COL1A1 was observed in the gdhA knockout mutant, resulting in an 
average of 1.7 fold more expression. The next was in ∆proB, with a 1.5 fold increase ∆putA 
∆proB and ∆putA ∆gdhA were the next. All strain improvements to proline metabolism (which 
expressed COL1A1) resulted in increased intracellular COL1A1 –while it is not known if they 
actually resulted in an increase in intracellular proline, it does suggest potential. Without the 
full set of combinations or information on the intracellular proline concentrations of strains it 
is difficult to speculate on the effect of each knock out mutation strategy, however it would 
seem that the addition of ∆putA results in a reduced concentration of COL1A1 (i.e. ∆putA 
∆gdhA and ∆putA ∆proB, lower than ∆gdhA and ∆proB alone. This is surprising since the 
literature would predict that a putA mutant would accumulate excess proline (Csonka et al. 
1988; Nakao et al. 1988).  This may allude to the fact that intracellular proline levels do not 
alter COL1A1 expression at all –however as discussed more information is required to confirm 
this. 
As metabolic networks are complex it is difficult to pull apart the reasons for the success or 
failure of these strategies to result in increased COL1A1 production. A good starting point 
would be to see in these mutants did result in variation in intracellular proline levels. This 
could be achieved by GC-MS or more traditional methods, such as detection with ninhydrin. 
Ninhydrin reacts with free amines to yield a colour change, while it reacts with all amino acids, 
proline is the only amino acid to result in an absorption peak at 520nm (Paes et al., 2013). 
However if GC-MS was combined with an internal standard this could provide quantitative 
measurements of intracellular proline. GC-MS was attempted in this body of work, although 
results required further optimisation as results were ‘noisy’ and masked the presence of 
proline in biological samples, this could be improved with improved sample preparation i.e. 
more biological sample, use of minimal media, not LB. 
Although improvements were made in the concentration of COL1A1 found in cells, it was not 
detected in the secreted fractions of cell culture. This has not previously been an issue for 
other substrates and it is unclear whether FT3SS secretion of COL1A1 is ultimately not possible 
or whether induction conditions or secretion capacity could be modified to facilitate this. To 
gain an idea of whether the FT3SS is capable of secreting COL1A1 expression and secretion of a 
collagen-like protein was investigated. 
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6.5.3. Secretion of a collagen-like protein through the FT3SS  
 
Scl2 was successfully expressed and secreted in both the prototype and mark 2 secretion 
platform strains. Despite similar intracellular concentrations more was secreted in the mark 2 
strain suggesting the improved secretion capacity characteristics of the ∆clpX ∆motAB applied 
for this substrate. The size of the band in the intracellular fraction was smaller than the one 
observed in the extracellular fraction of protein. This may be due to proteolysis occurring to 
the protein in the cell, as this is commonly reported when recombinant protein is expressed in 
the cytoplasm. The use of mass spectrometry could aid investigation into whether this was the 
case. As an alternative, intracellular fractions could be extracted following a shorter period of 
time to investigate whether less small protein was detected with Western blotting.  
This experimental work demonstrates that the FT3SS is capable of secreting protein with the 
repeating Gly-X-X triplet amino acid motifs, characteristic of human collagen, therefore the 
most likely reasons for the absence of secreted protein is either the size of COL1A1 (45kDa, 
compared to 35.5kDa or that following the overnight induction protocol proteolytic enzymes 
accumulate in the supernatant and secreted COL1A1 is degraded (degradation was seen 
following overnight secretion of E2 enzyme in Chapter 3. It would be advantageous to alter the 
expression protocol for COL1A1 to observe whether secreted protein could be observed. 
Finally Scl2 is itself relevant in terms of therapeutics (An et al., 2014; Cereceres et al., 2015), 
therefore this demonstrates an additional use of the FT3SS to secrete an industrial 
biotechnology relevant protein. As stated previously is would be beneficial to purify collagen 
like proteins to investigate adhesive and healing properties and also to gather information on 
yield.  
 
6.5.4. Further improvements for collagen secretion through the FT3SS 
 
As discussed the use of GC-MS would be advantageous in terms of investigating whether 
intracellular proline is important in the expression of proline rich recombinant proteins. As it is 
not known if the mutants implemented in the strains which resulted in increased COL1A1 
expression resulted in increased proline or whether increased COL1A1 expression was as a 
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result of another factor. The use of GC-MS could elucidate this and although it could not 
confirm a direct link, the identification of a correlation for increased proline and increased 
COL1A1 would be compelling.  
In an effort to generate strains which could express (and ultimately) secrete COL1A1, it would 
be advantageous to produce the full set of mutants which were identified here. As knockout 
mutations resulted in improved expression it would be interesting to combine all three 
strategies and also to implement the ones which were not possible (proB D107N and ∆proB 
∆gdhA). It would be interesting to see whether proB D107N ∆proB resulted in an increase in 
COL1A1, as this strain was reported to produce high intracellular proline levels (Csonka, 1988). 
Although it is not known if increased proline increased COL1A1 production in this strain other 
strain improvements may include upregulating expression of the transporters in an effort to 
improve proline transport into the cell. An ideal target for this would be the tightly regulated 
PutP transporter. As it is known that PutA downregulates PutP, it would be advantageous to 
remove this gene and at the same time engineer a promoter replacement for a strong 
promoter upstream of putP. In addition to these strategies use of flux balance analysis would 
be helpful in both confirming the strategies already implemented and also identifying new 
routes to improving intracellular proline abundance. Flux balance analysis optimises the flow 
of metabolites through a system, based on an objective function. In the case of this work the 
objective function would be: maximisation of intracellular proline. Gene knockouts can be 
implemented and the change in flux through each reaction can be measured. This can be used 
to identify novel routes for metabolic network improvement which may not be in the literature 
and also identify any unforeseen cell consequences of initiating gene knockouts, which may 
affect cell fitness (objective function: biomass). Models do not necessarily represent the 
biology and this affects predictability, so care must be taken to ensure the model is as 
biologically representative as possible. For example the Reed genomic scale model (Reed et al., 
2003) allows proline transport into the extracellular space of all three proline transporters, 
however this is not the case, therefore the model should be adjusted.  
In terms of secreting COL1A1, as discussed in the previous section alteration of the expression 
protocol may result in the detection of COL1A1 in the supernatant. Furthermore integration of 
the knockout mutants which improve both secretion and intracellular COL1A1 expression 
could be combined (i.e. ∆CKL ∆clpX ∆motAB ∆gdhA), to see if secretion could be achieved. In 
terms of improving yields it may be beneficial to grow cells in richer media for a more 
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prolonged period of time. For example Peng et al. (2012) expressed 1g L-1 Scl2 when cells were 
grown to OD600 1.0, whereas around 10g L
-1 Scl2 was achieved following growth in excess of 
OD600 100. It would also be interesting to express COL1A1 in cells expressing prolyl-4-
hydroxylase and lysyl-hydroxylase-3, to investigate whether this would be an effective means 
of producing collagen with correct the correct hydroxylation modifications of prolyl and lysyl 
residues. 
Finally as a therapeutic use is the endpoint goal of expressing COL1A1 and to an extent Scl2, it 
would be beneficial to purify some of this protein and investigate functionality, as this is 
essential if the protein is to be used in a therapeutic setting. This could involve investigating 
whether isolated recombinant collagen proteins are able to associate with the extracellular 
matrix of mammalian cells –as collagen I does in vivo or whether it can improve wound healing 
in an animal model. Although collagen I formation requires COL1A2 in addition to COL1A1 to 
form a triple helix, COL1A1 will make trimeric helixes; these are resistant to proteolysis, 
therefore the formation of triple helixes can be assessed by challenging isolated COL1A1 with 
proteolytic enzymes, if it is resistant this is evidence that triple helixes formed (Buechter et al., 
2003; Howes et al., 2014).  
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Chapter Seven: Discussion and future 
prospects 
 
7.1. Summary of major findings 
 
The work carried out in this thesis describes attempts at generation of a high capacity FT3SS E. 
coli secretion machine for directed secretion of a number of proteins into the extracellular 
media of cell cultures. Modification of the FT3SS, coupled with the generation of secretion 
constructs allowed the potential of this secretion platform to begin to be explored. This 
secretion platform was developed due to the requirement of industrial biotechnology for 
processes which are low in both cost and time in terms of growth requirements and reduced 
downstream processing, yet result in high quality products. Downstream processing can 
account for up to 80% production costs; continuous culture systems which do not require cell 
lysis to retrieve product are attractive in terms of cost reduction, therefore secretion into the 
extracellular media is desirable (Walsh, 2014).  Furthermore when extruded from the cell 
cytoplasm protein product quality can be improved due to reduced proteolysis and correct 
protein folding (Baeshen et al., 2015).  Efforts to secrete protein are usually confined to the 
periplasm of cells, while the aforementioned beneficial characteristics are achieved here, this 
can be improved further with secretion to the extracellular space, while at the same time 
simplifying downstream processing (Choi & Lee, 2004). Secretion into the extracellular space 
has been achieved in a number or organisms and cell lines (including mammalian cell lines e.g. 
CHO and HEK, yeasts e.g. Pichia pastoris and Saccharomyces and bacteria e.g. Pseudomonas 
and Bacillus), however the use of E. coli would be favoured due to the low growth 
requirements, high growth rate and industry acceptability (Baeshen et al. 2014; Yoon et al. 
2010; Ferrer-Miralles & Villaverde, 2013). The caveat to this is that while secretion to the 
periplasm has been exploited in E. coli the implementation of extracellular secretion is poor. 
Therefore the basis of this thesis was to generate an E. coli based platform to implement 
extracellular secretion of protein; specifically this concerned the modification of the FT3SS into 
a high capacity secretion system. Drawing on reports of recombinant protein secretion 
through various FT3SS mutants (Majander et al. 2005; Singer et al. 2012; Végh et al. 2006), it 
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was hoped that modifying the native high capacity extracellular secretion system, would result 
in high yields of secreted recombinant protein of industrial biotechnological relevance. Once 
applied, efforts were then made to improve the platform secretion system in terms of both 
improved yield and range of secreted protein products. Strategies to enable the production of 
this secretion platform drew on traditional microbiology strain improvement methods and 
synthetic biology concepts. As a prelude to the final discussion the major findings of each 
chapter of this thesis are summarised here. 
 
7.1.1. Chapter Three: Strain improvements for increased secretion 
capacity of native substrates through the T3SS 
 
The main focus of this chapter was to identify a platform E. coli strain to form the basis of a 
secretion platform. Once established a protein secretion assay was developed and steps were 
taken to improve secretion capacity by the implementation of strain improvements. The major 
findings of this chapter were: 
 Using a plasmid based system, the expression and secretion of E2 (the native FT3SS 
substrate FliC with residues Δ191-280 removed) was investigated to establish that the 
HAPless secretion platform strain ∆fliC ∆flgKL (∆CKL) had the capacity to secrete 
around twice the concentration of E2 protein in comparison to the CAPless strain: 
∆fliCD. With the use of an E2 protein standard of known concentration, this was 
equated to 9.19mg L-1 secreted protein. While this was reasonably impressive 
compared to other efforts to secrete protein from the FT3SS, it was hoped that this 
could be improved to give this protein secretion platform a standing in industrial 
biotechnology applications.  
 The HAPless strain was used herein to investigate both the intracellular and secreted 
concentrations of E2 protein. A protein secretion assay was developed to measure this 
effectively and accurately, this was paired with a gene expression assay and growth 
curves; together this allowed a wealth of information on the expression and secretion 
capacity, growth phenotype and gene expression profile of cells. Coupled with 
measurements at different times, this allowed a dynamic and temporal perspective on 
these factors. 
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 Gene knockouts were implemented using Lambda-Red recombinase methods, to 
generate negative control strains, which were either void of FT3SS apparatus or locked 
in early substrate secretion (E2 is late). With these it was demonstrated that protein 
observed in the supernatant was a consequence of directed protein secretion and not 
cell lysis or membrane leakage. 
 Gene knockouts were then identified based on information reported in the literature 
with a view to improving the secretion capacity of the platform secretion strain. These 
were based on strategies to remove negative feedback of flagella gene expression or 
to reduce the metabolic burden. 
 Not all strategies resulted in increased protein secretion. The presence of an IS5 
mutation meant that lrhA was already ineffective at regulating flagella gene expression 
in the wildtype. The removal of dksA resulted in decreased protein secretion, 
presumably due to the fact that it is linked to the stringent response, which was not in 
effect here as experiments were carried out in minimal media 
 The removal of clpX resulted in improved secretion of flagella both in strains with 
functional flagella (improved motility and abundance of flagellin monomers) and in 
terms of secretion with 23.457 mg L-1 E2 being detected in the supernatant of cell 
culture.  
 Further knockout mutations also demonstrated promise in terms of improving 
secretion capacity, removal of motAB resulted in over twice as much E2 protein being 
secreted into the media. 
 It was also observed that protein secretion substrate is not insulated to the effects of 
the cells, as little E2 was expressed in the ∆CKL ∆fliDST strain in the absence of the FliC 
chaperone FliS. This, coupled with the desire to assess the secretion capacity of the 
platform secretion system with reference to industrially relevant proteins, drove the 
requirement to secrete non-native proteins in the secretion system. 
 Together these results demonstrated the great promise and potential of the FT3SS 
based secretion platform for extracellular protein secretion. 
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7.1.2. Chapter Four: Further development and testing of the engineered 
FT3SS system: non-native protein secretion and assay development 
 
This chapter focused on integrating a protein secretion construct into the secretion platform to 
aid production of a range of recombinant proteins and processing of secreted product. In this 
chapter the expression and secretion of the recombinant antibody fragment CH2 was 
investigated in a number of strains designed to demonstrate increased secretion capacity.  
Major findings of this chapter included: 
 The advent of an inducible secretion construct consisting of FT3SS motifs (the 5’ and 3’ 
UTRs and 47 amino acid secretion signal peptide) and features to allow detection, 
purification and isolation of cargo protein was effective and useful. 
 In combination with the modified FT3SS secretion platform strain it was possible to 
express and secrete the first recombinant protein (the antibody fragment -CH2) in this 
system.  
 True secretion was established by observing negative secretion in several control 
situations, i.e. strains lacking FT3SS or locked for early substrate specificity or secretion 
constructs without FT3SS signals. 
 The protein secretion assay was modified slightly to enable measurement of 
intracellular and secreted CH2 protein in a number of cell cultures grown in tandem; 
this improved experimental output. 
 Secretion capacity of CH2 harboured in the secretion construct was found to be 
around 1.5 times higher in all of the strains which had been designed to exhibit 
increased secretion: (∆CKL) ∆motAB, ∆flgMN, ∆fliDST, ∆clpX. 
  With the derivation of a CH2 protein standard of known concentration it was 
established that the best secreted yield was 219.66µg L-1 ∆CKL ∆flgMN. As a truly 
secreted protein from E. coli this was a reasonable yield, especially given the 
consideration that growth times and cell densities are much higher in industrial 
production of recombinant protein, thus skewing results.   
 These results highlighted the potential of strain improvement based strategies , it was 
hoped that these improvements in secretion capacity would cumulate if the knockout 
mutagenesis strategies for improved secretion were combined. However this would 
require a more high throughput test 
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7.1.3: Chapter Five: Development of a high-throughput assay for FT3SS 
secretion to screen a multitude of secretion strains and plasmids 
 
In this chapter a high throughput protein secretion assay was developed to improve the rate 
and accuracy at which secretion in the secretion platform could be assessed. This allowed 
screening of a large number of modifications to both the secretion platform strain and 
construct to be assessed, with the view of identifying a combination which would result in a 
high secretion capacity of the modified FT3SS. The main findings of this chapter included: 
 Development of an enzyme based secretion assay involved modification of the 
secretion construct protein cargo to permit the expression and secretion of a 
recombinant cutinase. The secretion of an active enzyme was of particular interest as 
it demonstrated that correct protein folding occurred following secretion through the 
FT3SS. 
 Development of a MUB based protein secretion assay was arduous; however rigorous 
optimisation and use of controls enabled an effective, accurate and high throughput 
fluorescent plate reader based secretion assay to be deployed. 
 A combination of Lambda-Red recombinase and P1 phage transduction methods 
resulted in a large panel of 15 secretion strains, with the potential to demonstrate 
much higher secretion capacities than the prototype ∆CKL secretion platform strain. 
This involved the combination of up to three of the knockout mutations which had 
previously been shown to lead to increased secretion of E2 or CH2 -∆motAB, ∆flgMN, 
∆fliDST and ∆clpX. 
 In conjunction the prototype secretion construct was modified to investigate whether 
the removal of any of the components of the E. coli derived secretion construct 
elements (5’ and 3’ UTR and the 47 amino acid secretion signal peptide) would 
improve expression of secretion. This required generation and testing of nine secretion 
construct variants.  
 Following screening of secretion capacity with the MUB protein secretion assay it was 
established that secretion capacity (quantified by fluorescence output) was improved 
around 8 fold in the ΔCKL ΔclpX ΔmotAB secretion strain. In addition while a variant of 
the secretion construct which harboured only the 3’ UTR expressed around 2.2 times 
more cutinase than the prototype secretion construct, the best output in terms of 
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improved secretion was observed in the absence of the 3’ UTR only –resulting in up to 
a 15 fold increase in secretion. Combined the ‘mark 2’ secretion strain and secretion 
construct, resulted in almost a 25-fold increase in secretion over the original prototype 
CKL strain.  
 Together this demonstrated the power of a high throughput secretion assay and that 
strategies to improve secretion capacity of the FT3SS could be combined. The mark 2 
secretor strain alone was also shown to result in increased E2 (3.75 fold) and CH2 (2.56 
fold) secretion compared to the prototype secretion strain. If this was combined with 
the mark 2 secretion construct the scope to secrete industrial biotechnology relevant 
concentrations of recombinant protein would be large  
 
7.1.4. Chapter Six: 45kDa human collagen expression for FT3SS 
secretion 
 
In the final chapter an effort was made to showcase the potential of the secretion platform for 
the production of a large eukaryotic protein with therapeutic applications: the 45kDa human 
pro α (I) collagen chain. Metabolic engineering was implemented to see if this could increase 
the yield of recombinant collagen expressed in the secretion platform. Major findings are given 
below: 
 The 45kDa human pro α (I) collagen chain (COL1A1) was expressed from the secretion 
construct in the original prototype secretion platform strain. Although not secreted, 
expression of this protein was still extremely impressive, as it is the largest fragment of 
a collagen I chain to be expressed in E. coli. 
 Efforts were made to increase the concentration of intracellular proline, in an effort to 
improve COL1A1 expression. While inducing osmotic shock was not effective, strain 
improvements were. Guided by the literature and the proline metabolic network, a 
number of knock out mutants were generated, the removal of glutamate hydrogenase 
(gdhA) from the metabolic network resulted in up to 1.5 times more collagen being 
expressed, however secreted COL1A1 was not detected. 
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 Finally to see if the modified FT3SS was capable of secreting a collagen-like protein, 
Scl2 was expressed in the mark 2 secretion strain; this resulted in a 1.5 fold 
improvement in comparison to the prototype secretion strain.  
 In combination these results show that in the near future a secretion and proline 
maximised secretion platform may be utilised to secrete full length COL1A1 for 
therapeutic application.  
 
In addition to the discussion points made in each chapter, the following themes emerged.  
 
7.2. Improved secretion capacity of the FT3SS 
 
The FT3SS had previously been modified to result in secretion of protein into the media with 
an industrial biotechnology goal in mind, however the work in this thesis is far more extensive 
in terms of modifying both strain and secretion construct than any work carried out previously 
(Majander et al. 2005; Singer et al. 2012; Widmaier et al. 2009). While the aforementioned 
studies investigated different secretion peptide signals, only one study modified a strain to 
enable increased secretion, which resulted in a 2 fold increase in secreted protein (Singer et al. 
2012), a value surpassed in this thesis by over tenfold. Furthermore aside from the Majander 
et al. (2005) study, which concerned E. coli, all of these investigations involved Salmonella, 
therefore work has greatly furthered the understanding of recombinant protein secretion 
through the FT3SS in an industrially relevant organism. The yield of secreted protein achieved 
in this work bettered those achieved in these studies and when incubation time and cell 
density were considered, it represented a substantial improvement. For examples the highest 
achieved secreted yield was 12mg L-1 and involved growing cells for 24 hours as opposed to 
around 6 hours in this study -although the OD600 reached was not reported, it can be assumed 
that this would exceed the OD600 of 1.0-1.5 used in this thesis (Majander et al., 2005). 
 Although the strain based improvements to secretion capacity were considerable in this study 
it would be beneficial to continue to investigate if this could be improved further. It is 
envisioned that this would be facilitated by the MUB protein secretion assay, because the 
scope for screening mutants once derived is large. These points were made in the discussion of 
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Chapter 5, but to reiterate, the MUB protein secretion assay could be used to investigate the 
secretion capacity of a wide range of mutant strains in the ∆CKL background. Mutations could 
be implemented in a direct manor based on ideas from the literature or informed by 
information derived from modelling or proteomic analysis, which could identify bottlenecks to 
FT3SS secretion apparatus or recombinant protein production. Additionally use of a 
transposon library would allow a huge range of mutants to be screened with the view to 
finding novel candidates for high capacity secretion strains. A modification of the secretion 
construct could allow multiple traits to be selected for, for example if the secretion construct 
was induced by expression of putP, a high level of cutinase secretion would suggest both 
increased proline transport and high secretion capacity. This strain could be selected to secrete 
proline rich proteins, such as collagen. Additionally a library of secretion construct plasmids 
could be generated to investigate variation in secretion based on modifications to genetic 
elements such as the promoter and RBS and also the secretion signal or 5’UTR (which was 
shown here to be important for efficient secretion). As it was observed that the presence and 
absence of tags (UTR, secretion signal peptide) effected both expression and secretion it would 
be beneficial to investigate optimum combinations of these to increase secretion. This may 
involve using sections of these components, varying combinations or utilising other secretion 
signals i.e. for FlgM. The assay could also be used to investigate optimum expression 
conditions for increased yields of secreted proteins, with focus on the potential that 
expression and secretion capacity must be equally matched for optimum secretion. In terms of 
investigating the most effective cell culture methods for secretion a range of medias, induction 
and incubation protocols could be assessed –for example growing to high cell density and then 
inducing, growing at low temperature or growing in bioreactors with aeration (Rosano & 
Ceccarelli, 2014; Soini et al. 2008). It would be beneficial to obtain use of a parallel bioreactor 
system so that multiple experimental set ups could be implemented in tandem to investigate 
these effects, this would have the added benefit of being more akin in terms of reactor design 
to industrial fermentation methods.  
It was evident in this thesis that not all proteins are secreted at the same capacity in all strains, 
therefore using a cutinase only secretion assay to screen for effective secretion, may not result 
in the best optimisation strategy for every protein. This could potentially be overcome, while 
still retaining the high throughput nature of the assay by modifying the secretion construct to 
harbour another enzyme such as sialidase which hydrolyzes terminal sialic acid residues on 
polysaccharide chains and can therefore be linked to a range of substrates –including  
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(Chokhawala et al., 2007) or reactive protein such as GFP or tetracysteine, which can be 
fluorescently labelled following secretion (DeLisa et al., 2002; Haitjema et al., 2014). 
Additionally different proteins could be secreted which are compatible with the optimised 
MUB assay, for example lipase (Roberts 1985). Lipase is also compatible with a large range of 
assays, including the tribuyrin and pNPB assays attempted here and also the precipitation of 
fatty acids from Tween or olive oil, or the interfacial tension experiments, where the change in 
shape of an enzyme-droplet is altered from a drop to a tear shape (Gupta et al., 2003; Eom et 
al., 2005). 
It may also be possible to harness the FT3SS to implement strain based improvements to 
secretion via selective pressure (ideally following a protocol to generate lots of mutants i.e. a 
transposon library). If mildly toxic proteins were inserted into the secretion construct, cells 
with higher secretion capacities are more likely to survive. For example investigation into the 
expression of toxic proteins in E. coli such as DNAase and ribonuclease has found that cells can 
withstand varying amounts of toxins (Saïda et al., 2006; Doherty et al., 1993), therefore this 
different intracellular concentrations of toxin would have a variable effect on cell survival; if 
the toxin was linked to a secretion signal and expression is tuned correctly, this could result in 
a population of cells which survive or die based on their ability to secrete a toxin.   
In reality it is likely that a combination of these strategies would be incorporated to result in a 
strain which is better designed to secrete protein through the FT3SS than the current mark 2 
secretor strain, however all the tools are in place to realise this. An improved secretor strain is 
likely to maintain the ∆CKL ∆clpX ∆motAB background as it is so efficient, but also be ‘stripped 
back’ in terms of non-essential, non-detrimental genes such as the class III flagella genes and 
also harbour some gene knockouts throughout the chromosome, which were found to result 
in increased secretion capacity during non-directed mutagenesis e.g. a transposon library. This 
could be teamed with a high performing secretion construct, which would carry a favourable 
combination of UTR and secretion signal peptide residues to ensure good expression and 
secretion. 
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7.3. The modified FT3SS as a tool  
 
The modified FT3SS was developed with the aim of secreting biotechnologically relevant 
protein; however in carrying out the work findings have also alluded to the novel insights on 
characteristics of the FT3SS –for example the role of the 5’ and 3’ UTR and 47 amino acid 
secretion signal on expression and secretion. With this in mind it would also be possible to 
utilise the FT3SS secretion platform developed here to further knowledge on the FT3SS. For 
example knockout mutagenesis of genes followed by measurement of protein secretion could 
be carried out to investigate the essentiality of components of the FT3SS or the effect of 
transcriptional regulators or environmental conditions. While the FT3SS is very well studied, as 
investigation is low throughput, the combinations of gene knockouts are generally logical, 
however this could be used to investigate a wide range of combinational FT3SS gene 
knockouts, increasing the potential to discover a new feature, function or interaction of 
proteins in the FT3SS. Furthermore as investigation into flagella phenotype is usually related to 
motility on motility agar plates, this may provide a more accurate representation of FT3SS 
activity of cells in liquid media. In addition to this, the necessity of regions of the 5’ and 3’ UTRs 
and secretion signals could also be investigated in a high throughput manner. A 5’ UTR 
harbouring secretion signal without the 47 amino acid secretion signal was not generated in 
this study and there would be great value in observing the effect of this on secretion, as the 
role of these elements is under debate (Majander et al. 2005; Végh et al. 2006; Bonifield & 
Hughes, 2003). Furthermore if the 47 amino acid secretion signal is found to be non-essential a 
minimal secretion construct could be assembled. The cutinase secretion assay could also be 
used to investigate the amount of protein secreted without the tag accessory proteins which 
are harboured in the secretion construct as this may well improve secretion. 
 
7.4. The role of the modified FT3SS in industrial 
biotechnology 
Work carried out in this thesis has demonstrated the suitability of the modified FT3SS for use 
in industrial biotechnology. It was possible to secrete the nearly native E2 protein to the match 
the yields seen in other FT3SS examples, the best achieved in the literature was 12 mg L-1 
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following high density culture, whereas I achieved around 23.5 mg L-1, when cells were grown 
to an OD600 of 1.5. While yields did not match those seen for secreted protein in the expression 
systems used in industry (e.g. Pichia up to 15g L-1 rodent collagen fragments (Werten et al., 
1999)) or for E. coli following secretion into the periplasm via the TAT system (60mg L-1 GFP in 
batch culture or 1g L-1 in fed batch high cell density culture (Matos et al., 2012)), there are 
many benefits to using an extracellular secretion E. coli based expression system which make 
this attractive for industrial use. In comparison to the other E. coli extracellular secretion 
system (T1SS) which has been investigated for industrial biotechnology use, the yields 
recorded in this work far surpassed them (reported at 2mg L-1 (Fernandez & de Lorenzo, 2001; 
Fernández 2004), demonstrating that the FT3SS is the most amenable secretion system to be 
utilised for technological purposes. Furthermore the design of the secretion construct means 
that the secretion platform could be adapted to fit industry specifications, both for the protein 
secreted, but also for the purification tag or protease cleavage site for example.  In fact to 
achieve a wider view of the range of industrially relevant protein which could be expressed 
and secreted in this platform, it would be advantageous to approach companies to see if they 
would collaborate in trying to secrete proteins which they routinely produce intracellularly. 
Both yield and quality of secreted protein could be assessed. In the near future it would be 
interesting to try and secrete some more biotechnology and synthetic biology proteins, in 
terms of biotechnology, the expression of human growth hormone, insulin and ScFvs in a 
range of expression systems is widely reported, therefore it would be of interest to measure 
how the FT3SS compares. In terms of a synthetic biology challenge, the expression of spider 
silk is a popular theme in the field and causes a particular challenge because the desired 
strength and flexibility of the silk is dependent on correct translation and assembly and lack of 
degradation –the latter of which could be overcome if secreted to the media. Spider silk is 
formed of protein subunits which assemble to form a silk thread. Silk monomers have been 
expressed in E. coli from gene constructs which comprise of up to 96 repeats of monomers to 
enable expression of a silk pseudo-polymer (Xia et al., 2010; Michalczechen-Lacerda et al., 
2014). Another strategy is to secrete spider silk as monomers either use them in this form or 
assemble them into polymers. As monomers have a tendency to self-assemble in cells, 
secretion would be beneficial and was previously achieved through the Salmonella TT3SS to 
yields of up to 70 no l−1 h−1 (Widmaier et al., 2009). It would be of interest to investigate what 
yield of secreted pseudo-polymers or monomers would be achievable in the E. coli FT3SS. 
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In general it would be desirable to gain more information on the quality of secreted protein in 
terms of fidelity to the anticipated residue sequence –this is relevant to both efficient 
transcription and translation and also in relation to proteolysis; this could be ascertained with 
mass spectrometry. Correct folding is required to ensure protein function and also low 
immunogenicity, therefore structural analysis. This was successfully demonstrated in the MUB 
cleavage assay which relies on functional enzyme, but could also include investigating whether 
therapeutic protein is functional. For example whether recombinant collagen can form links 
between mammalian cell lines with good extracellular membrane expression or its effect on 
wound healing models. Different culture methods could also result in novel products, for 
example the co-culture of strains expressing different proteins, to result in a multi protein 
secreted fraction. For example if cells were co-cultured which expressed either COL1A1 or 
COL1A2 this may enable the formation of trimeric full length type I collagen triple helixes. 
Another variation in culture method would be to grow secretion strains in biofilms, so that 
secreted protein may aggregate as a film or sheet of secreted protein based material, for 
example if collagen were used- enabling potential applications such as bacterial based 
production of collagen sheets (even by 3D printing) –previously Staphylococcus were 3D 
printed to produce a material, but it would be advantageous if these cells secreted therapeutic 
protein (Villar et al., 2013) 
Finally in order for this secretion platform to be cost effective in an industrial setting there are 
two requirements; firstly that yield is increased, while this can be achieved in bench scale 
experiments by the strain and secretion construct improvements explored here and by 
different incubation methods, a clear route to improving cell biomass and therefore -in theory- 
expressed and secreted protein per volume of media, is to grow cells in rich media to a high 
optical density –this is best achieved by use of fed batch fermentation. Care would have to be 
taken that cell lysis did not occur, however to a degree as long as it occurred to a low degree, 
this secretion expression platform could still be cost effective as the positive aspects of 
extracellular secretion would still largely be at play, however media would require some 
downstream processing to remove protein contaminants. The alternative method of this 
secretion platform being economically viable would be to express and secrete a protein which 
is high value, thus requiring lower concentrations of product. 
As discussed above yield can be improved by growing cells at high cell density –this is seen 
throughout the literature and skews the yields reported when compared to the results 
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achieved in this body of work. A worked example will be described to demonstrate this; for 
example secretion of GFP via TAT to the periplasm of E. coli in a small scale batch experiment 
resulted in a 60mg L-1 concentration of periplasmic derived protein. However cells were grown 
to OD600 20. Therefore per Litre of culture, there are 13 or 20 times more E. coli present than 
there are when cells are cultures for E2 or CH2 secretion respectively. Therefore if it is 
assumed that cells are just as efficient at secreting at high optical densities (there are some 
caveats to this, including increased likelihood of plasmid loss, pH and oxygen reduction leading 
to reduced expression (Sivashanmugam et al., 2009)) then the yields will be more impressive 
than initially reported. For example when calculated per OD unit, the 60mg L-1 concentration, 
equates to 3µg GFP per OD unit (60/1000/20). This is comparable to 15µg E2 per OD unit (23.5 
mg L-1/1000/1.5) and 219ng CH2 per OD unit (219 µg L-1/1000/1). Displaying results in this 
fashion highlights that the yields achieved in this work (in terms of E2) actually surpass those 
reported in this study. While CH2 yield was still lower that GFP, this data handling does reveal 
that only 13 (3000/219) times less efficient than that seen in TAT secretion, as opposed to the 
250 fold difference (60000/219 estimated previously. In fed batch fermentation the same 
study reported a 1g L-1 yield of GFP extracted from the periplasm, however the OD600 exceeded 
150, this would relate to 6.66mg GFP per OD unit (1000mg L-1/1000/150). This is a much higher 
yield than those reported in this work and for GFP grown in small batch fermentation, 
demonstrating the benefits of supplementing cells with rich media. It is reported that for 
industry to consider a new platform technology for protein secretion yield should be in the 10s 
of mg L-1 (personal communication, Ian Hodgson, Head of Molecular 
Biology, FUJIFILM Diosynth Biotechnologies). This was not achieved for the native E2 protein, 
but not the recombinant CH2 protein in the experiments carried out in this thesis, however the 
aforementioned calculations show that a weight per volume request is subject to cell density, 
therefore with the mark 2 secretor strain and improved fermentation procedures, perhaps the 
FT3SS could be productive enough. Investigation into biotechnological suitability would also 
require checking that the tags used are compliant with industry –the main driver being cost. 
Strep and FLAG resins are expensive (although are used), therefore the process may be more 
cost effective if a non-chromatographic tag was used, such as elastic-like polypeptide, which 
precipitates when certain temperatures of buffers are applied. Equally, although proteases are 
utilised to remove tags in industry, the incorporation of a self-cleaving tag may be more cost 
effective than use of TEV protease (Fong et al., 2010).  
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7.5. Conclusion 
 
The body of work in this thesis demonstrates the amenability of E. coli to both produce and 
secrete industrial biotechnology relevant protein products. Improvements were made to the 
secretion platform strain and secretion construct, which resulted in an increased yield of a 
range of protein products. As discussed, this represents a basic level of improvement in terms 
of the potential for future increases in secretion capacity. Through this thesis three iterations 
of the design process were carried out following generation of the initial secretion platform 
strain: (1) single strategy mutant generation, (2) combination of mutant strategies and (3) 
modification of the secretion construct. During these three iterations a 25 fold increase in the 
concentration of secreted protein was achieved. If applied to the highest yield achieved (23.5 
mg L-1), this could result in a yield of almost 600mg L-1. As described in the discussion, in 
comparison to the secretion capacity of other E. coli secretion systems the choice of the FT3SS 
is beneficial. The yields of extracellular protein secretion surpassed that observed through 
T1SS secretion by far; furthermore depending on how yields are interpreted, the FT3SS is 
competitive with periplasmic T2SS secretion. With regard to the T2SS, secretion through the 
FT3SS has the added benefit of resulting in extracellular secretion, which requires less 
downstream processing and is likely to result in improved product quality. While yields 
achieved in other expression systems (Pichia, Bacilus) may exceed the FT3SS, use of an E. coli 
expression system is also desirable due to the low costs associated with its fermentation. 
Furthermore while the yields achieved are impressive, it could be further improved upon with 
the utilisation of a range of tools, relating to techniques from traditional microbiology, 
synthetic biology and computational biology. With the integration of these techniques I have 
confidence that the FT3SS secretion platform system could be competitive in the field of 
industrial biotechnology.  
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Appendix 
Appendix 1: Flagella type III secretion genes proteins.  
Classified into operon class, cellular location, function, stoichiometry, assembly method and size of protein. Collated from Macnab 2003; Berg 2003; Stafford & Hughes 
2007; Raha et al. 1994; Pesavento & Hengge 2012; Mytelka and Chamberlin, 1996 
Protein Operon Class Cellular Location  Function  Stoichiometry Size (kDa) 
FlhA 2 Centre of MS ring Protein export component ~2 75 
FlhB 2 Centre of MS ring Protein export component ~2 42 
FlhC 1 Cytoplasm Master regulator of class 2 operons  22 
FlhD 1 Cytoplasm Master regulator of class 2 operons  14 
FlhE 2 Cell envelope protein Role in swarming motility  12 
FliA 2 Cytoplasm Sigma factor 28, for class 3 operons  27 
FliC 3 Cell exterior Filament (flagellin) 20000-30000 53 
FliD 3 Cell exterior  Filament cap 10 50 
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FliE 2 Periplasm Rod MS-ring junction, export gate ~9 11 
FliF 2 Cytoplasmic membrane MS-ring, mount for rotor switch and rod, housing for export apparatus 26 61 
FliG 2 Peripheral C ring, rotor/switch protein, torque generation, binds MS ring and 
MotA 
26 37 
FliH 2 Cytoplasm Negative regulator of FliI, Protein export, ATPase complex. Assosiates 
with FliM and FlhA. Assosiates with chaperones 
 26 
FliI 2 Cytoplasm Drives type III protein export. ATPase –unfolds late secretion 
substrates 
 49 
FliJ 2 Cytoplasm ATPase complex. Preference for rod and hook protein  17 
FliK 2 Cell exterior Hook-length control  39 
FliL 2  Assosiates with MotAB complex, MS ring (FliF) and C ring (FliG) weakly  17 
FliM 2 Peripheral C ring, rotor/switch protein 37 38 
FliN 2 Peripheral C ring, Switch component 110 38 
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FliO 2 Centre of MS ring Export component ~1 11 
FliP 2 Centre of MS ring Export component ~4 27 
FliQ 2 Centre of MS ring Export component ~1 10 
FliR 2 Centre of MS ring Export component ~1 29 
FliS 3 Cytoplasm FliC chaperone. Stabilises FlgM  15 
FliT 3 Cytoplasm FliD chaperone  14 
FliY 2 Cytoplasm Regulates class III transcription (?)   
FliZ 2 Cytoplasm σ70 antagonist   
FlgA 2 Periplasm Chaperone for P ring protein   
FlgB 2 Periplasm Rod protein 7  
FlgC 2 Periplasm Rod protein 6  
FlgD 2 Cell exterior Hook capping protein ~5  
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FlgE 2 Cell exterior  Hook protein 132  
FlgF 2 Periplasm Rod protein 6  
FlgG 2 Periplasm Distal rod protein 26  
FlgH 2 Outer membrane L-ring protein 28  
FlgI 2 Periplasm P-ring protein 24  
FlgJ 2 Periplasm Rod capping protein, degrades PG layer 5?  
FlgK 3 Cell exterior HAP1: hook filament junction protein 13  
FlgL 3 Cell exterior HAP2: hook filament junction protein ~10  
FlgM 3 Cytoplasm Anti - sigma factor 28   
FlgN 3 Cytoplasm FlgK, FlgL specific chaperone. Transcriptional activator of FlgM   
MotA 3 Cytoplasmic membrane Force generation, stator protein ~32 32 
MotB  3 Cytoplasmic membrane Force generation, stator protein, converts proton energy into torque ~16 34 
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Appendix 2: PCR primers used in the study:  
SDM: site directed mutagenesis 
Primer Nucleotide Sequence Function 
proB KO FOR GCTAAAACGTTCGTTTGATATCATTTTTCCTAAAATTGAATGGCAGAGAATC
GTGTAGGCTGGAGCTGCTTC 
Construction of gene knockout cassettes 
proB KO REV GTTGCGCTAATTTATACGAGGCTTGCTTCGCGGCAATGCCCATTTGTTCCAG
CATATGAATATCCTCCTTA 
Construction of gene knockout cassettes 
proB KO CONFO TGATTTTAATTAACGCGCGAATATTCAGCGGG Conformation of gene knockout 
proB US FOR CGTTTGATATCATTTTTCCTAAAATTGAATGGCAGAGAATC Construction of cassettes for SDM  
D107N REV 1A GCGTTCACGGTCTTCCATATTAGCACGGGTCAGCAGC Construction of cassettes for SDM 
D107N FOR 2A GCTGCTGACCCGTGCTAATATGGAAGACCGTGAACGC Construction of cassettes for SDM 
E143A REV 1B CGTTATCGCCGACCTTAATCGCTGCCGTAGCGACAGCATCG Construction of cassettes for SDM 
E143A FOR 2B CGATGCTGTCGCTACGGCAGCGATTAAGGTCGGCGATAACG 
 
Construction of cassettes for SDM 
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proB STOP FOR GCCGTTCACCGTGATGACATGATTACCCGTTCTGCTTCGAAGTTCC Construction of cassettes for SDM 
proB STOP REV GCCGTTCACCGTGATGACATGATTACCCGTTAAGTGTAGGCTGGAGCTGCT
TCGAAGTTCC 
Construction of cassettes for SDM 
K1 CAGTCATAGCCGAATAGCCT Conformation of gene knockout 
K2 CGGTGCCCTGAATGAACTGC Conformation of gene knockout 
C1 TTATACGCAAGGCGACAAGG Conformation of gene knockout 
C2 GATCTTCCGTCACAGGTAGG Conformation of gene knockout 
dksA KO FOR TTTTTCCCCCGAACATGGGGATCGATAGTGCGTGTTAAGGAGAAGCAACGT
GTAGGCTGGAGCTGCTTC 
Construction of gene knockout cassettes 
dksA KO REV CAAAAAATAAGGCGGGAGCATTTCCCGCCTGTGGTAAACGTGATGGAACG
GCTGTAACATATGAATATCCTCCTTA 
Construction of gene knockout cassettes 
dksA KO CONFO TTGTCAGAAGCTCAACAGAGGGGGGTAGAAATT Conformation of gene knockout 
lrhA KO FOR TGTTTGTGTGTGCACAGCATTAACCAGCTCAGTATGAGCCGCCAGTAAGTG
ATAATATTGTAGGCTGGAGCTGCTTC 
Construction of gene knockout cassettes 
lrhA KO REV AAACACCCCCAGCGGCTCGTTTTTTACACTATTGTCTCAGGAATTATCTATC Construction of gene knockout cassettes 
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GTCCGTCGATTCCGGGGATCCGTCGACC 
lrhA KO CONFO GAGTGAGTAACTTAATAGATATGCGATCCCTGAA Conformation of gene knockout 
motAB KO FOR GCCTGACGACTGAACATCCTGTCATGGTCAACAGTGGAAGGATGATGTCG
TGTAGGCTGGAGCTGCTTC 
Construction of gene knockout cassettes 
motAB KO REV TTCATCAAAAAATGTCTGATAAAAATCGCTTATATCCATGCTCACGCTGCAT
ATGAATATCCTCCTTA 
Construction of gene knockout cassettes 
motAB KO CONFO ATTTTATTACCCACGCTCACCAGCCTGTTGGC Conformation of gene knockout 
flgMN KO FOR CGATAAATAAGCAACACATGATAAAAGCGCCCTCAATGAGGAATAAACCG
TGTAGGCTGGAGCTGCTTC 
Construction of gene knockout cassettes 
flgMN KO REV GACGGTGTAACAATGCATTCCGGCCTGCAGTGCAGGCCGGAGATAATCTC
ATATGAATATCCTCCTTA 
Construction of gene knockout cassettes 
flgMN KO CONFO TAACCCAGTTTCGCCAGGCATGGCGGGTAAAA Conformation of gene knockout 
flgDE KO F AGCATGATGCTGAAAACCCTTACGCTCGGTCAATAAAGGAGAAAGCTGTG
TAGGCTGGAGCTGCTTC 
Construction of gene knockout cassettes 
flgDE KO R TCGCGGTATAAATTGCGTGATCCATTGAGCTATCCCGTCAGCGACATATGA
ATATCCTCCTTA 
Construction of gene knockout cassettes 
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flgDE KO CONFO ATTCCAGGTTAACGCTGCACCAGGTGCTGCGACAGGCGG Conformation of gene knockout 
gdhA KO F CAACATAAGCACAATCGTATTAATATATAAGGGTTTTATATCTGTGTAGGCT
GGAGCTGCTTC 
Construction of gene knockout cassettes 
gdhA KO R GCCCATTTGTAGGCCTGATAAGCGTAGCGCCATCAGGCATTTACAACATTC
CGGGGATCCGTCGAC 
Construction of gene knockout cassettes 
gdhA KO CONFO GCAATTAATGGAAATGCTAATACTACGGCGAACAATGC Conformation of gene knockout 
fliDST KO FOR CGATAACCCCGGTATTCGTTTTACGTGTCGAAAGATAAAAGGAAATCGCGT
GTAGGCTGGAGCTGCTTC 
Construction of gene knockout cassettes 
fliDST KO REV GAAGCGTAGCCGTAATCGGATTATTCGCGAGCCATCGACTCATTCAGATAT
TCCGGGGATCCGTCGAC 
Construction of gene knockout cassettes 
fliDST KO CONFO TGACTTGTGCCATGATTCGTTATCCTATATTG Conformation of gene knockout 
putA KO FOR TACCAACGTGTTTCAACGTTGTAGTACCTATAAAGTGCTATTGCAATTCAAC
GTGGAAAGTGAACAACAGGAGTAATGGCGTGTAGGCTGGAGCTGCTTC 
Construction of gene knockout cassettes 
putA KO REV ACAATTGACGGCGTCTCTTTTTCAGACTCAAT Construction of gene knockout cassettes 
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putA KO CONFO AAAACGTGCAGCGGATTATTATTGAGGGGATTCGACCACGTTAAAGTACG
GCCTCCTCCAACATTGTAGGAGGCCGATGGACACATATGAATATCCTCCTT 
Conformation of gene knockout 
pJex ins F CGAGCGTCTGTCTTCTGGCTTGCGTATTAACAG Colony PCR and sequencing of inserts in pJexpress  
pJex seq F AACGGTTTCCCTCTAGAAATAATTTTGTTT Colony PCR and sequencing of inserts in pJexpress 
pJex seq R TTCGCCCGGGCTAATTATGGGGTGTCGCCC Colony PCR and sequencing of inserts in pJexpress 
pJex seq alt F ATTCCACAACGGTTTCCCTCTAGAAATAATTTTG Colony PCR and sequencing of inserts in pJexpress 
5’ and 47aa present 
(5’ UTR 47aa F) 
CGGTACCATATGGCGGGAATAAGGGGCAGAG Construction of secretion construct variants 
No 5’, 47aa present 
(47aa F) 
CGGTGACATATGAAAGAGGAGAAATAGTCCATGGCACAAGTCATTAATAC
CAACAGCCTCTC 
Construction of secretion construct variants 
No 5’ or 47aa TTAACTTCATATGCTCGAGAGGATAACGAATCATGGAGAATCTGTATTTTC
AGGGCGAATCC 
Construction of secretion construct variants 
coli 26-47 F CGGTACCATATGAAAGAGGAGAAATAGTCCATGTCGAGTTCTATCGAGCG
TCTGTCTTCTGGCTTGCG 
Construction of secretion construct variants 
sal 26-47 F CGGTACCATATGAAAGAGGAGAAATAGTCCATGGGAACGGCAATCGAGC
GTCTGTCTTCTGGC 
Construction of secretion construct variants 
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3’ UTR present (3’ 
UTR R) 
TACAGAGGATCCCACGATAAACAGCCCTGCGTT Construction of secretion construct variants 
3’ UTR absent (no 3’) CGCAGTTTGAGAAATCTAGAAAGCTTTAAGGATCCCGTTAG Construction of secretion construct variants 
coli 26-47 F CGGTACCATATGAAAGAGGAGAAATAGTCCATGTCGAGTTCTATCGAGCG
TCTGTCTTCTGGCTTGCG 
Construction of secretion construct variants 
sal 26-47 F CGGTACCATATGAAAGAGGAGAAATAGTCCATGGGAACGGCAATCGAGC
GTCTGTCTTCTGGC 
Construction of secretion construct variants 
IS5 F CATCGAGCCGTTTTACCCCAAGGCTGGTAATGGC PCR and sequencing conformation of the IS5 element 
IS5 R GAGATCTCTCCCACTGACGTATCATTTGGTCC PCR and sequencing conformation of the IS5 element 
flhD R GGAATCTTGCGTCAACTGAGTAATCGTCTGGTGG PCR and sequencing conformation of the IS5 element 
IS5 top F CCTGTTTCATTTTTGCTTGCTAGCGTAGCG PCR and sequencing conformation of the IS5 element 
IS5 half F TACAAGGGGTTGCTGAAAAACGATAACCAACTGGCG PCR and sequencing conformation of the IS5 element 
flhD R shifted CGGAAGTGACAAACCAGTTGATTGGTTTCTGCCAGC PCR and sequencing conformation of the IS5 element 
pJET F CGACTCACTATAGGGAGAGCGGC Colony PCR and sequencing of inserts in pJET2.1 
pJET R AAGAACATCGATTTTCCATGGCAG Colony PCR and sequencing of inserts in pJET2.1 
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Appendix 3:  Templates, primers and strains for gene deletions  
Gene 
deletion(s) 
Template 
DNA 
Forward 
primer 
Reverse primer Resistance 
cassette 
Confirm deletion with 
k1/k2 c1/c2 and: 
proB KD4 proB KO FOR proB KO REV Km proB KO CONFO 
dksA KD4 dksA KO FOR dksA KO REV Km dksA KO CONFO 
lrhA KD13 lrha KO FOR lrhA KO REV Km lrhA KO CONFO 
putA KD13 putA KO FOR putA KO REV Km putA KO CONFO 
fliCD KD3 fliCD KO FOR fliCD KO REV Cm fliCD KO CONFO 
flgMN KD4 flgMN KO FOR flgMN KO REV Km flgMN KO CONFO 
motAB KD3 motAB KO FOR motAB KO REV Cm motAB KO CONFO 
fliDST KD13 fliDST KO FOR fliDST KO REV Km fliDST KO CONFO 
gdhA KD13 gdhA KO FOR gdhA KO REV Km gdhA KO OCNFO 
flgDE KD4 flgDE KO FOR flgDE KO REV Km flgDE KO CONFO 
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Appendix 4 Templates and primers to implement proB gene substitutions by overlap PCR 
PCR 
Reaction 
Template Forward Primer Reverse Primer 
1A MC1000 ΔCKL chromosomal DNA proB US FOR D107N REV 
1B MC1000 ΔCKL chromosomal DNA proB US FOR E143A REV 
2A MC1000 ΔCKL chromosomal DNA D107N FOR proB STOP REV 
2B MC1000 ΔCKL chromosomal DNA E143A FOR proB STOP REV 
3 KD3 proB STOP FOR proB KO REV 
4A PCR products from reactions 1A, 2A, 3 proB US FOR proB KO REV 
4B PCR products from reactions 1B, 2B, 3 proB US FOR proB US REV 
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Appendix 5: Images of the fluorescence output of reaction mixtures following incubation of MUB 
with the secreted fraction of CKL, ΔflhDC, ΔflgDE, ΔflgMN or ΔclpX cells secreting empty or 
cutinase harbouring secretion construct.  
E.coli ∆CKL (C), ΔflhDC (DC), ΔflgDE (DE), ΔflgMN (MN) or ΔclpX (X) containing either the plasmid 
pJexpress-FliC-cutinase-Flag-Strep (c) or pJexpress-FliC-empty-Flag-Strep (e) were induced with 
0.05mM IPTG (or 1mM for ΔflhDC and ΔflgDE) and grown in LB at 37°C with 180rpm agitation. Cells 
were harvested when cell culture reached OD600 1.0. The supernatant was obtained by 
centrifugation. Either LB media or cell supernatant (40µL) was added to 160µL 100µM MUB solution 
(0.05M phosphate citrate buffer, pH 5) and added to a 96 well plate. Following incubation at 30°C 
fluorescence was measured capturing an image during excitation by UV light in a G:BOX. The image 
was inverted. One biological replicate, two technical replicates for each reaction mixture 
combination. Images captured following 0, 1 and 16 Hours incubation 
